The role of post-translational modifications on the oligomerization, aggregation and toxicity of mutant huntingtin by Santos, Joana Margarida Marques Branco dos
UNIVERSIDADE DE LISBOA 
Faculdade de Medicina 
 
 
The Role of Post-Translational Modifications on the 
Oligomerization, Aggregation and Toxicity of Mutant 
Huntingtin 
 
 
Joana Margarida Marques Branco dos Santos 
 
 
Orientadores:    Doutor Federico Herrera Garcia 
Prof. Doutor Tiago Fleming de Oliveira Outeiro 
Prof. Doutor Flaviano Giorgini 
 
 
Tese especialmente elaborada para obtenção do grau de Doutor em 
Ciências Biomédicas, na especialidade de Neurociências 
 
2018 
! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSIDADE DE LISBOA 
Faculdade de Medicina 
 
The Role of Post-Translational Modifications on the Oligomerization, 
Aggregation and Toxicity of Mutant Huntingtin 
 
Joana Margarida Marques Branco dos Santos 
 
Orientadores:        Doutor Federico Herrera Garcia 
Prof. Doutor Tiago Fleming de Oliveira Outeiro 
Prof. Doutor Flaviano Giorgini 
 
Tese especialmente elaborada para obtenção do grau de Doutor em Ciências 
Biomédicas, na especialidade de Neurociências 
 
Júri 
Presidente: Professor Doutor José Luís Bliebernicht Ducla Soares, Professor Catedrático em 
regime de tenure e Vice-Presidente do Conselho Científico da Faculdade de Mecinina da 
Universidade de Lisboa. 
Vogais: 
- Prof. Dr. Ir. Nollen, Ellen Alexandra Adriënne, Professor of Faculty of Medical Sciences Aging 
 Biology, University of Groningen (Holanda), 
- Doutora Ana Cristina Carvalho Rego, Professora Auxiliar com Agregação da Faculdade de 
 Medicina da Universidade de Coimbra, 
- Doutora Cecília Maria Pereira Rodrigues, Professora Catedrática da Faculdade de Farmácia da 
 Universidade de Lisboa, 
- Doutor Cláudio Emanuel Moneira Gomes, Professor Associado com Agregação da Faculdade de 
 Ciências da Universidade de Lisboa, 
- Doutor Federico Herrera Garcia, Professor Auxiliar da Faculdade de Ciências da Universidade de 
 Lisboa (orientador), 
- Doutora Luísa Maria Vaqueiro Lopes, Professora Associada Convidada da Faculdade de 
 Medicina da Universidade de Lisboa. 
Instituição Financiadora: Fundação para a Ciência e Tecnologia (SFRH/BD/85275/2012) 
2018 
! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Todas as informações efectuadas no presente documento são da exclusiva 
responsabilidade da sua autora, não cabendo qualquer responsabilidade à 
Faculdade de Medicina da Universidade de Lisboa pelos conteúdos nele 
apresentados. 
 
A impressão desta tese foi aprovada pelo Conselho Científico da 
Faculdade de Medicina de Lisboa em reunião de 12 de Outubro 
de 2018. 
! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 I declare that this dissertation is based on work developed during my PhD research 
project, except where otherwise stated. Experimental work was performed mainly at 
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de 
Lisboa, in Oeiras, Portugal and the Department of Genetics and Genome Biology, 
University of Leicester, in Leicester, United Kingdom. The initial part of the work 
involving mammalian cell models (described in Chapter III, 3.1 and 3.3) was developed at 
Instituto de Medicina Molecular – Faculdade de Medicina, Universidade de Lisboa, in 
Lisbon, Portugal. Doctor Federico Herrera, Prof. Doctor Tiago Fleming Outeiro and Prof. 
Doctor Flaviano Giorgini supervised all work.  
 Financial support was provided by Fundação para a Ciência e a Tecnologia (FCT), 
Portugal, through the PhD fellowship SFRH/BD/85275/2012 and FCT/MCTES (Ref. 
CBQ/04612/ICL3535, to Doctor Federico Herrera and Doctor Pedro Domingos). Doctor 
Federico Herrera and Prof. Doctor Tiago Outeiro were supported by a seed grant from the 
European Huntington Disease Network (EHDN). Doctor Federico Herrera is currently 
supported by Project LISBOA-01-0145-FEDER-007660 (Cellular Structural and 
Molecular Microbiology) funded by FEDER funds through COMPETE2020 - Programa 
Operacional Competitividade e Internacionalização (POCI) and by national funds through 
FCT (Ref. IF/00094/2013). Prof. Doctor Tiago Outeiro is supported by the DFG Center for 
Nanoscale Microscopy and Molecular Physiology of the Brain. Prof. Doctor Flaviano 
Giorgini thanks the Medical Research Council (MRC) for infrastructure supporting this 
work. 
 
 
! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Aos meus pais. 
Ao meu irmão. 
 
 
 
 
 
 
 
 
 
 
 
 
“For pure joy, I look at a small painting by Arbit Blatas. An ocean liner is at 
the center of the composition, perhaps ready to depart. It holds the promise of 
discovery.” 
 
António Damásio, in “Self comes to mind”. 
! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! i 
Table&of&contents&!
Acknowledgements/Agradecimentos.............................................................................................................................iii 
Summary.................................................................................................................................................................................................v 
Resumo...................................................................................................................................................................................................ix 
List of thesis publications.....................................................................................................................................................xiii 
Publications...........................................................................................................................................................................xiii 
Communications in scientific meetings...........................................................................................................xiv 
List of abbreviations................................................................................................................................................................xvii 
I. Introduction                                                                                                                       1 
1.1. Protein misfolding and neurodegeneration........................................................................................................3 
Mechanisms of protein aggregation........................................................................................................................6 
Molecular basis of neurodegeneration................................................................................................................11 
1.2. Huntington’s disease........................................................................................................................................................17 
Etiology and clinical symptoms..............................................................................................................................17 
Huntingtin protein and molecular pathogenesis of HD.........................................................................19 
Cell and non-cell autonomous mechanisms of striatal degeneration in HD..........................30 
1.3. Model systems of Neurodegenerative diseases............................................................................................39 
Bimolecular fluorescence complementation: a cell-based assay for studying protein 
oligomerization....................................................................................................................................................................39 
Modeling HD in Drosophila melanogaster....................................................................................................42 
II. Aims                                                                                                                                49 
 
III. Results                                                                                                                           53 
A. Post-translational Modifications in Huntington’s disease: new insights into the 
mechanisms of mutant huntingtin aggregation and toxicity.........................................................................55 
3.1. The role of N-terminal phosphorylation and protein phosphatases on huntingtin 
oligomerization, aggregation and toxicity..................................................................................................................57 
Abstract......................................................................................................................................................................................57 
Introduction.............................................................................................................................................................................57 
Results.........................................................................................................................................................................................59 
Discussion................................................................................................................................................................................75 
Materials and methods I................................................................................................................................................79 
Acknowledgements...........................................................................................................................................................87 
Contribution............................................................................................................................................................................87 
3.2. Glycation modulates mutant huntingtin toxicity in Drosophila......................................................89 
Abstract......................................................................................................................................................................................89 
Introduction.............................................................................................................................................................................89 
Results.........................................................................................................................................................................................91 
!ii 
Discussion................................................................................................................................................................................95 
Materials and methods II..............................................................................................................................................97 
Acknowledgements........................................................................................................................................................100 
Contribution.........................................................................................................................................................................100 
B. Interplay between mutant huntintin and other aggregation-prone proteins for 
Huntington’s disease pathogenesis...............................................................................................................................101 
3.3. Co-aggregation between huntingtin and alpha-synuclein in living cells...............................103 
Abstract...................................................................................................................................................................................103 
Introduction..........................................................................................................................................................................103 
Results......................................................................................................................................................................................105 
Discussion.............................................................................................................................................................................112 
Materials and methods III.........................................................................................................................................116 
Acknowledgements........................................................................................................................................................117 
Contribution.........................................................................................................................................................................117 
3.4. Prion proteins modulate mutant huntingtin mediated neurotoxicity.........................................119 
Abstract...................................................................................................................................................................................119 
Introduction..........................................................................................................................................................................120 
Results......................................................................................................................................................................................122 
Discussion.............................................................................................................................................................................137 
Materials and methods IV.........................................................................................................................................141 
Acknowledgements........................................................................................................................................................148 
Contribution.........................................................................................................................................................................148 
IV. Conclusions and Future perspectives                                                                       149 
 
V. Appendix                                                                                                                      161 
Supplemental information I................................................................................................................................................163 
Supplemental information II..............................................................................................................................................175 
Supplemental information III............................................................................................................................................181 
Supplemental information IV...........................................................................................................................................183 
 
VI. References                                                                                                                   191 
 
VII. Facsimile of Published Articles                                                                               233 
! iii 
Acknowledgements/Agradecimentos 
&
 A PhD is a long journey of self discovery, yet a challenge that is hardly exceeded 
by oneself. This thesis represents not only my work, it was a group effort in which 
extraordinary researchers have participated and contributed, in one way or another, to the 
person I am today, both at scientific and personal levels. 
 My deepest gratitude goes to my supervisor Dr. Federico Herrera, who made this 
thesis a reality in every way possible. Our journey together started in 2011, when I joined 
Professor Tiago Outeiro lab (UNCM). Fede was determinant for my growth as a master 
student and now, as a PhD. I thank Fede for guiding me throughout my PhD, and for 
sharing with me his valuable scientific and technical knowledge. Fede taught me 
everything I know about scientific writing, being always very careful and going deeply 
through all details of the present thesis and other scientific publications. I am sincerely 
grateful to Fede for his patience and for giving me the time and space I needed to 
independently grow and develop my own scientific ideas/opinions. Mostly, I thank Fede 
for the constructive and fair criticism, which was sometimes hard to hear, but essential to 
get to the final stage of my PhD. Thank you for motivating me to finish this thesis, for all 
the support and advice in the critical and hard times of my PhD, and especially for all the 
precious time you have dedicated to discuss and supervise my work. 
 O meu profundo agradecimento ao Professor Dr. Tiago Outeiro, a quem devo o 
início da minha jornada neste maravilhoso mundo da ciência e, como tal, parte do meu 
percurso científico. O Tiago abriu-me as portas do seu laboratório oferecendo-me a 
possibilidade de trabalhar com investigadores excepcionais, num ambiente de sólida 
construção de conhecimento científico. Muito obrigado por toda a ajuda, disponibilidade e 
sábias diretrizes que em muito contribuíram para a minha investigação e para a 
consolidação deste trabalho.  
 I owe my sincere gratitude to Professor Dr. Flaviano Giorgini, who gave me the 
opportunity to work in his lab for two wonderful years (Leicester, UK), and probably the 
most productive times of my PhD. Flav is one of the rare supervisors who always have 
wise words to share and to guide his students in such a stressful and demanding period of 
ours science careers. I found in Flav an inspiring and rigorous scientist, who helped me to 
see the bright side of my work, even when I thought I had no results or new developments 
to discuss with him and my colleagues in Leicester. He helped to organize and develop my 
scientific thinking, to make rational sense of my results, and to reach quality in the 
!iv 
production of scientific data. I am deeply thankful to Flav for the meaningful scientific 
discussions, for trusting in my work, and for motivating me to never give up on 
accomplishing my goals. 
 Devo também um especial agradecimento ao Dr. Pedro Domingos pela preciosa 
colaboração e por proporcionar todo o apoio técnico e intelectual necessários ao meu 
trabalho com Drosophila. Obrigado por fazer parte do meu comité de tese e por me receber 
no seu laboratório ao longo destes dois últimos anos de PhD. Agradeço a disponibilidade 
em me ajudar e receber sempre que tive dúvidas. 
 Um sincero agradecimento à Dra Luísa Lopes e ao meu querido colega Dr. Hugo 
Vicente Miranda pelo tempo dispensado como membros do meu comité de tese. O 
excepcional input científico que me facultaram foi fundamental para o foco e desenrolar da 
minha investigação. Ao Hugo, muito obrigado por todo o apoio tanto a nível profissional 
como pessoal, é com muito carinho que guardo todos os conselhos que certamente me 
guiarão no futuro.   
 Aos colegas do grupo UNCM, a todos sem exceção, com quem tive a honra de 
trabalhar e que me proporcionaram momentos de constante inspiração e espírito de 
entreajuda. Devo também um agradecimento aos colegas do laboratório “Cell Structure 
and Dynamics”, no ITQB, dos quais teria que destacar o Ricardo Vilela e a Joana Ferreira 
pelo companheirismo, apoio e confidências. Ainda do ITQB, à Yolanda Pires, que 
contribuiu e ajudou em algumas das últimas experiências do meu PhD. Obrigado pela 
amizade e companhia nas longas horas de microscopia.  Um obrigado também à Cristiana 
Santos.  
 To my colleagues and friends in Leicester, who supported me in all possible ways. 
Special thanks to Carlo Breda, who introduced me to Drosophila and helped me to think 
and design experiments. To Ane, Usha, Marcela and Daniel for always making me feel at 
home.  
 I am grateful to all collaborators, whose names are mentioned in the results chapter 
of the present thesis. I would also like to thank the people from IMM and IGC facilities for 
the technical support with some of the experiments.&
 A toda a minha família, pela preocupação e interesse no meu trabalho. Por 
acreditarem nos meus sonhos e confiarem nas minhas escolhas. Ao meu irmão,  por todo o 
seu entusiasmo por ciência. À Inês e à Filipa, amigas e confidentes desde os tempos de 
mestrado. À Maria, por estar sempre presente e por vibrar com todos os meus sucessos.  
! v 
Summary&
&
 Neurodegenerative diseases (NDs) present major health and economic challenges 
to modern societies. No treatments can currently stop, delay or reverse the progression of 
such devastating disorders. The development of effective therapeutics is particularly 
complicated because the molecular underpinnings of NDs are still far from being 
understood. A possible clue could come from the fact that a large number of NDs display 
protein misfolding and aggregation as pathophysiological hallmarks. Understanding factors 
which modulate the aggregate formation process and the mechanisms by which protein 
intermediates exert cellular toxicity could advance our knowledge of disease pathogenesis 
and represents a possible intervention point in our search for effective therapies. Recent 
years have seen several rational targets for therapeutic development being generated from 
a combination of cell culture studies and analysis of genetically tractable animals. Here we 
used a cell model exploiting bimolecular fluorescence complementation (BiFC) and 
Drosophila models to study the molecular basis of Huntington’s disease (HD). 
 HD is a hereditary neurodegenerative disorder generally affecting individuals of 
40-50 years of age, although the most severe forms of the disease can appear in children 
and adolescents. HD causes death invariably 15-20 years after the first symptoms, with 
patients and their families experiencing incalculable pain and suffering throughout the 
course of the disease. The causative mutation encodes a polyglutamine expansion in the 
huntingtin (HTT) protein, which modulates its aggregation and cytotoxicity by still unclear 
mechanisms. Although HD is genetically well defined, unidentified genetic and/or 
environmental factors may also play a role in disease development and progression.  
 The present thesis aimed to (i) characterize the effect of specific post-translational 
modifications (PTMs) upon mutant HTT aggregation dynamics and toxicity, as well as (ii) 
investigate the putative regulatory role of protein phosphatases in these processes, and (iii) 
understand how interactions between mutant HTT and other aggregation-prone proteins 
may modulate disease pathogenesis.  
 We started by determining the relative contribution of each of the three 
phosphorylatable residues (T3, S13 and S16) in the N-terminal region of HTT towards its 
aggregation and toxicity. By using single phosphomimic (D) and phosphoresistant (A) 
BiFC mutants, we found that all of the D mutants completely abolished the formation of 
large insoluble species, while having little effect on oligomerization and toxicity. When 
combined with non-phosphorylated forms of mutant HTT, D mutants differentially 
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affected HTT aggregation dynamics in living cells, with T3 phosphorylation having the 
most dominant effect. Analyses of transgenic Drosophila mutants further supported T3 as 
a critical modulator of mutant HTT aggregation, with both larvae and adult fly tissues from 
T3D mutants exhibiting lower number of aggregates compared to non-mutated counterpart.  
 Since N-terminal phosphorylation strikingly prevented HTT aggregation, we 
investigated specific protein phosphatases as potential modulators of HTT aggregation and 
toxicity in both mammalian cells and Drosophila. An initial pharmacological screen in our 
BiFC cell model identified three phosphatase inhibitors (PP1, PP2A and Cdc25) as 
potential suppressors of HTT aggregation. Subsequent RNAi experiments in vivo showed 
that PP1 downregulation prevented the deposition of HTT inclusions in adult fly 
dopaminergic neurons, whereas both PP2 and Cdc25 knockdown did not produce overt 
phenotypes. Interestingly, downregulation of PP1 in flies caused severe age-dependent 
neurodegeneration. Together, these findings indicate that PP1 modulates HTT aggregation 
and toxicity in opposite ways, which further support the current notion that large inclusions 
are not the toxic factors in HD and other NDs. 
 The formation of advanced glycation-end products (AGEs) as result of the 
interaction between proteins and reducing sugars is referred to as protein glycation. Such 
irreversible PTM is found in various disease-associated proteins, and is thought to 
contribute to the pathogenesis of NDs. Here, we provide the first in vivo evidence on the 
deleterious impact of glycation on HTT biology and HD. Pharmacological or genetic 
modulation of protein glycation led to increased accumulation of AGEs in mutant HTT-
expressing flies and exacerbated phenotypes related to both early and late stages of HD. In 
particular, we showed that treatment with increasing doses of a potent glycation agent - 
methylglyoxal (MGO) - accelerated neuronal loss in adult animals and negatively affected 
the development of photoreceptor neurons. Genetic suppression of the MGO pathway 
resulted in impaired development, reduced lifespan and increased neurodegeneration of 
HD flies. In humans, increased blood glucose levels activate the MGO pathway, which 
would implicate altered glucose metabolism (e.g. diabetes) as an environment risk factor 
for HD development.  
 Aberrant protein-protein interactions can compromise normal cell function and 
contribute to cytotoxicity in NDs. Here, we explored the effects of mutant HTT 
interactions with other aggregation-prone proteins on each other’s behavior. We showed 
that mutant HTT interacts and co-aggregates with alpha-synuclein (α-syn), Tau and the 
Rnq1 prion protein in living human cells, altering their subcellular localization and 
! vii 
aggregation patterns. While in vivo α-syn and Tau studies were carried out by various 
collaborators, we set out to elucidate the interplay between the Rnq1 prion protein and 
mutant HTT. In yeast, the Q/N-rich Rnq1 prion protein is required for mutant HTT 
aggregation and toxicity. Because the human genome encodes multiple proteins enriched 
in Q/N domains, we hypothesized that they may function as modifiers of disease 
pathogenesis. Drosophila expressing Rnq1 showed a significant increase in age-dependent 
neuronal loss and motor dysfunction. Furthermore, as occurs in yeast, we found that Rnq1 
potentiates mutant HTT toxicity in Drosophila. Together, our results are consistent with 
the existence of two mechanisms for HTT toxicity, one related to toxicity of the 
aggregation process itself, and the other related to the sequestration of molecules required 
for normal cell function. 
 Overall, our findings provide new insights into HD pathology by uncovering novel 
aspects of mutant HTT aggregation and toxicity. We expect these studies to contribute to a 
better understanding of the mechanisms underlying the pathogenesis of HD and other 
human protein misfolding disorders, and thus lay the groundwork for effective therapeutic 
strategies for these devastating disorders.  
 
Keywords: Huntington’s disease, huntingtin, phosphorylation, glycation, prion proteins.
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Resumo&
&
 As doenças neurodegenerativas (DNs) apresentam grandes desafios económicos e 
para a saúde nas sociedades modernas. Atualmente, não existem tratamentos capazes de 
parar, atrasar ou reverter a progressão destas doenças devastadoras. Os fundamentos 
moleculares de DNs ainda estão longe de serem compreendidos, o que complica o 
desenvolvimento de terapias eficazes. Um grande número de DNs é caracterizada pela 
alteração da conformação normal de proteínas (misfolding) e sua acumulação em 
agregados proteicos (agregação). Assim, compreender quais os intervenientes no processo 
de formação de agregados, e os mecanismos pelos quais as espécies intermédias, 
resultantes do processo, exercem toxicidade celular, pode facultar avanços no nosso 
conhecimento sobre a patogénese de NDs e, representa um ponto de inflexão na nossa 
busca por terapias eficientes. Nos últimos anos têm surgido vários potenciais alvos 
terapêuticos através de estudos em culturas celulares e da análise de modelos animais de 
fácil manipulação genética. Neste trabalho, utilizámos modelos celulares, baseados no 
método de complementação biomolecular por fluorescência (BiFC), e modelos de 
Drosophila para estudar os mecanismos associados à doença de Huntington (DH). 
 A DH é uma doença neurodegenerativa hereditária que afeta geralmente indivíduos 
entre os 40-50 anos de idade, embora formas mais graves da doença possam surgir em 
crianças e adolescentes. Esta doença leva à morte 15-20 anos após o aparecimento dos 
primeiros sintomas, causando dor e sofrimento incalculáveis a pacientes e famílias ao 
longo de todo esse período. A mutação genética responsável pela DH resulta na expansão 
anormal de uma região rica em glutaminas na proteína huntingtina (HTT). Essa região 
modula a agregação e a toxicidade celular da proteína por mecanismos ainda não 
totalmente conhecidos. Apesar da DH ser uma doença de causa genética definida, outros 
factores genéticos e/ou ambientais podem afectar o seu desenvolvimento e progressão. 
 Esta tese teve como principais objectivos (i) caracterizar o efeito de modificações 
pós-traducionais específicas na dinâmica de agregação da HTT bem como na sua 
toxicidade, (ii) investigar o potencial papel regulador de fosfatases nesses processos, e (iii) 
compreender como interações entre a HTT e outras proteínas com propensão para agregar 
podem contribuir para a patogénese da doença. 
 Começámos por determinar o papel de cada um dos três resíduos fosforiláveis (T3, 
S13 e S16) da região N-terminal da HTT na agregação e toxicidade da proteína. Através da 
utilização de mutantes BiFC  que imitam o estado de fosforilação (D) ou não-fosforilação 
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(A) nos respectivos resíduos, verificou-se que a fosforilação constitutiva de qualquer um 
dos resíduos resultou na ausência total de grandes espécies insolúveis nas células. No 
entanto, estes mutantes produziram pouco efeito sobre a oligomerização e toxicidade da 
HTT. Estes resultados indicam que a fosforilação da região N-terminal da HTT 
desempenha um papel-chave na agregação da proteína. Combinações de mutantes 
fosforilados com mutantes resistentes à fosforilação levaram a alterações na dinâmica de 
agregação da HTT em células vivas, onde T3D exerceu um efeito dominante sobre todos 
os mutantes resistentes à fosforilação, impedindo assim a formação de agregados. Em 
Drosophila, mutantes T3D exibiram um menor número de agregados em relação ao 
controlo, evidenciando assim o resíduo T3 como um modulator crítico da agregação da 
HTT. 
 Uma vez que a fosforilação da região N-terminal da HTT produziu um efeito 
supressor notável sobre a agregação da proteína, procurámos de seguida identificar 
fosfatases específicas como potenciais reguladores da agregação e toxicidade da HTT em 
células de mamífero e Drosophila. Um screening farmacológico inicial permitiu-nos 
identificar três inibidores de fosfatases (PP1, PP2A e Cdc25) como possíveis supressores 
da agregação da HTT. Experiências subsequentes de interferência de RNA contra PP1 em 
Drosophila resultaram na diminuição de agregados em neurónios dopaminérgicos da 
mosca adulta, enquanto que, tanto a inibição de PP2 como Cdc25 não produziu qualquer 
alteração no fenótipo de agregação esperado da HTT. Curiosamente, a inibição de PP1 em 
Drosophila agravou severamente a perda neuronal dependente da idade. Estas novas 
descobertas indicam que PP1 modula de forma oposta a agregação e toxicidade da HTT, o 
que vai de encontro à hipótese atual de que grandes agregados proteicos não constituem os 
factores tóxicos na DH e noutras DNs. 
 A formação de produtos finais da glicação avançada (AGEs) como resultado da 
interação entre proteínas e açúcares redutores é conhecida como “glicação proteica”. Esta 
modificação pós-traducional irreversível ocorre em várias proteínas associadas a doenças, 
e pensa-se estar envolvida na patogénese de DNs. Nesta tese, oferecemos a primeira 
evidência in vivo sobre o impacto negativo da glicação na biologia da HTT e na DH. Ao 
manipular farmacologicamente ou geneticamente a glicação proteica observámos a 
acumulação de AGEs num modelo de Drosophila da DH, sendo que tanto fenótipos 
relacionados com estágios precoces e tardios da DH tiveram uma manifestação exacerbada 
nestes animais. Em particular, demonstrámos que o tratamento com doses crescentes de 
um potente agente de glicação, o metilglioxal (MGO), resultou na perda neuronal 
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prematura em animais adultos e afetou negativamente o desenvolvimento dos neurónios 
fotorreceptores. A estimulação genética da via do MGO prejudicou o desenvolvimento, a 
sobrevida e a integridade neuronal destes animais modelo da DH. Nos seres humanos, 
níveis aumentados de glicose no sangue levam à ativação da via do MGO, sugerindo que 
alterações no metabolismo da glicose (por exemplo, diabetes) podem constituir um factor 
de risco ambiental para o desenvolvimento da doença. 
 Interações proteicas aberrantes podem comprometer a função celular normal e 
contribuir para a toxicidade celular em DNs. Neste trabalho, explorámos os efeitos de 
interações entre a HTT e outras proteínas propensas à agregação no contexto celular e em 
modelos animais. Foi demonstrado que a HTT é capaz de interagir e co-agregar com as 
proteínas alfa-sinucleína (α-syn), Tau e a proteína prião Rnq1, alterando a sua localização 
e padrão de agregação em células vivas. Estudos in vivo da interação com α-syn ou Tau 
foram realizados por vários colaboradores, enquanto que o nosso trabalho focou-se na 
interação entre a HTT e a proteína prião Rnq1. Em levedura, este proteína rica em regiões 
Q/N é necessária para a agregação e toxicidade da HTT. Uma vez que, o nosso genoma 
codifica múltiplas proteínas enriquecidas em domínios Q/N, colocámos a hipótese de que 
estas proteínas poderiam eventualmente desempenhar um papel na patogénese da DH. 
Quando  expressa em Drosophila, Rnq1 provocou um aumento significativo da perda 
neuronal associada à idade, e disfunção motora. Além disso, como ocorre em levedura, 
também a expressão de Rnq1 em Drosophila resultou no aumento da toxicidade da HTT. 
Na sua totalidade, os nossos resultados são consistentes com a existência de dois 
mecanismos de toxicidade da HTT, um relacionado com a toxicidade do próprio processo 
de formação de agregados e, outro relacionado com o “sequestro” de moléculas essenciais 
à normal função celular. 
 O presente estudo põe a descoberto novos aspectos sobre a agregação e toxicidade 
da HTT, possibilitando deste modo um melhor conhecimento da patologia da DH. 
Esperamos que este trabalho possa contribuir para desvendar os mecanismos moleculares 
responsáveis pela patogénese da DH e de outras doenças humanas associadas ao 
misfolding de proteínas, e assim, estabelecer as bases para o desenvolvimento de 
estratégias terapêuticas eficientes contra estas doenças devastadoras. 
 
Palavras-chave: Doença de Huntington, huntingtina, fosforilação, glicação, proteínas 
prião.
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1.1.&Protein&Misfolding&and&Neurodegeneration&
 
 The correct folding of proteins into a unique three-dimensional structure is essential 
for normal function and stability. Protein folding starts at ribosomes, where proteins are 
synthesized as linear chains of amino acids that subsequently undergo various 
conformational changes to achieve native and functional state. Intermediate conformers are 
thermodynamically unstable due to the exposure of hydrophobic residues that are normally 
buried in the native structure. Such hydrophobic surfaces become the object of several off-
pathway interactions favoring protein aggregation, a highly dynamic process that starts 
with the association of two misfolded monomers (dimerization) and can progress towards 
the formation of a wide range of structures with variable size, stability and solubility 
(Balchin et al., 2016) (Figure 1). Under normal conditions, cells are capable of maintaining 
proteome homeostasis, i.e. proteostasis, via a complex quality-control system that acts 
either by refolding or degrading misfolded proteins (Figure 1). This system involves a tight 
cooperation between molecular chaperones, which mediate protein folding and 
conformational repair, and proteolytic pathways, which get rid of misfolded proteins when 
repair fails. However, once formed, higher ordered aggregate structures are extremely 
stable and highly resistant to degradation, while recruiting other proteins into the 
aggregation process. Although folding intermediates often aggregate in normal conditions, 
protein misfolding can increase in the presence of particular cellular stress conditions, 
leading to the exhaustion of the protein-quality control system. Accumulation of misfolded 
proteins and aggregates can have deleterious effects on cells (Sweeney et al., 2017, 
Tyedmers et al., 2010a). The maintenance of protein integrity is crucial for normal cell 
function and viability, and imbalance of the proteostasis network underlies many fatal 
diseases, including cancer, diabetes and neurodegenerative disorders. Proteome integrity 
declines with aging, which is also a major risk factor for a significant number of human 
diseases associated with protein misfolding and aggregation, commonly termed protein 
misfolding disorders (PMDs) (Balchin et al., 2016) (Table I).  
 Many neurodegenerative disorders are PMDs, including Alzheimer’s (AD), 
Parkinson’s (PD) or Huntington’s (HD) diseases. In these disorders, relatively specific 
proteins abnormally aggregate into β-sheet fibrils (amyloid) and deposit in particular 
regions of the brain. However, amyloid deposits are not exclusive to the central nervous 
system (CNS) and can also appear in peripheral tissues (Table I). The composition and 
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location of protein aggregates, as well as the neurons that are selectively killed and the 
clinical symptoms are characteristic of each disorder (Table I). For example, beta amyloid 
peptide (Aβ) plaques and Tau intracellular tangles in AD are found in the hippocampus, 
amygdala and cortex regions that regulate memory, emotions and thinking. Alpha-
synuclein (α-syn) is the primary component of Lewy bodies in PD, which is characterized 
by the loss of dopaminergic neurons in the Substantia nigra. Polyglutamine diseases such 
as HD and some spinocerebellar ataxias develop due to an abnormal expansion of 
polyglutamine amino acid sequences (polyQ) in the huntingtin (HTT) and ataxin proteins, 
respectively. Huntingtin aggregates are initially found in the striatum, while ataxin 
aggregates are found in the cerebellum, and degeneration of these regions is responsible 
for the motor symptoms that characterize these disorders. Rapid spongiform degeneration 
of brain tissue in prion disorders is thought to occur via the intracellular propagation of 
pathogenic conformers of the prion protein (PrPSc) (Kumar et al., 2016, Ross and Poirier, 
2004). 
  
Figure 1. Protein folding, misfolding and aggregation. Molecular chaperones promote de novo 
folding, assist the refolding and proteolytic degradation of misfolded proteins, and prevent harmful 
interactions with other cellular and molecular factors. Genetic and environmental stressors may accelerate 
protein misfolding and aggregation, resulting in the accumulation of potentially toxic species that can have a 
wide range of morphologies and physical-chemical features. In normal conditions, intermediate aggregate 
species are targeted for degradation via the ubiquitin-proteasome or the autophagic-lysosomal systems. 
However, when the concentration of misfolded and/or aggregated proteins exceeds the capacity of the 
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proteome quality-control system, proper functioning of multiple cellular processes become affected, which 
may ultimately result in premature cell death. Adapted from (Balchin et al., 2016). 
 
Table I. Protein misfolding diseases: histopathological features 
Neurodegenerative diseases 
Disease Location Aggregate types Major protein components References 
Parkinson’s Disease 
Substantia 
nigra, 
Cerebral cortex 
Cytoplasmic 
Lewy Bodies 
α-synuclein 
Ubiquitin 
LRRK2 
(Conway et al., 
1998, Forloni et al., 
2002, Nussbaum 
and 
Polymeropoulos, 
1997, Tan et al., 
2009, Zhu et al., 
2006) 
Alzheimer’s Disease Neocortex, Limbic region  
Extracellular 
amyloid plaques 
and intracellular 
Tau tangles 
β-amyloid 
HSP90 
Tau protein 
Ubiquitin 
(Agorogiannis et al., 
2004, Cataldo et al., 
2003, Forloni et al., 
2002, Liao et al., 
2004) 
Huntington’s Disease Striatal and cortical areas 
Nuclear and 
cytoplasmic 
aggregates 
Huntingtin 
Ubiquitin 
(Agorogiannis et al., 
2004, Arrasate et 
al., 2004, The 
Huntington's 
Disease 
Collaborative 
Research Group, 
1993) 
Spinocerebellar Ataxias 
Cerebellum, 
Spinal Cord 
and Brainstem 
Cytoplasmic or 
intranuclear 
inclusions 
Ataxins 
CACNA1A 
Tau protein  
TBP 
ATN1 
(Hayashi et al., 
2003, Houlden et al., 
2007, Huynh et al., 
1999, Zhuchenko et 
al., 1997) 
Friedrich Ataxia 
Dentate 
nucleus, 
Dorsal root 
ganglia 
Cytoplasmatic 
inclusions in 
neurons 
Frataxin 
 (Koeppen, 2011) 
Amyotrophic lateral 
sclerosis Motor neurons 
Cytoplasmatic 
aggregates in 
neurons and 
astrocytes 
SOD I 
TDP-43 
FUS/TLS 
Ubiquitin 
(Arai et al., 2006, 
Kwiatkowski et al., 
2009, Niwa et al., 
2002) 
Alexander’s Disease Astrocytes  Rosenthal fibers  
GFAP 
CRYAB 
HSP27 
Plectin 
(Brenner et al., 
2001, Iwaki et al., 
1993, Tian et al., 
2006) 
Fragile X Syndrome Neocortex,  Hippocampus  
Intranuclear 
inclusions 
FMRP 
Ubiquitin 
(Koukoui and 
Chaudhuri, 2007) 
Transmissible 
spongiform 
encephalopathies 
(TSEs) or prion diseases 
Cerebral cortex Fibrillar amyloid deposits 
Prion protein 
(PrP)  
MAP2 
α-synuclein 
β-amyloid 
Tau protein  
(Ben-Gedalya et al., 
2011, Haik et al., 
2002, Kovacs et al., 
2017, Miyazono et 
al., 1992, Zhang and 
Dong, 2012) 
Familial amyloid 
polyneuropathy 
Sensory and 
motor nerve 
fibers, 
Autonomic 
ganglions 
Amyloid deposits Transthyretin (Fong and Vieira, 2013) 
Prolactinomas Pituitary gland Amyloid deposits Prolactin (Hinton et al., 1997) 
 (Continued) 
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Table I. Protein misfolding diseases: histopathological features (cont.) 
Peripheral diseases 
Disease Location Aggregate types Composition References 
Aortic medial amyloid Circulatory 
System 
Amyloid deposits Medin (Madine and 
Middleton, 2010) 
Atherosclerosis 
Circulatory 
System Amyloid deposits Apolipoprotein A1 (Teoh et al., 2011) 
Cardiac arrhythmias, 
Isolated atrial 
amyloidosis 
Circulatory 
System 
Atrial amyloid 
deposits 
Atrial natriuretic 
factor 
(Steiner and 
Hajkova, 2006) 
Cerebral amyloid 
angiopathy 
Circulatory 
System Amyloid deposits 
β-amyloid, 
Cystatin (Revesz et al., 2009) 
Diabetes mellitus 
type 2 
Pancreas Amyloid deposits Amylin (Tomita, 2012) 
Dialysis related 
amyloidosis 
Systemic 
Amyloid deposits 
in osteoarticular 
structures 
β2-microglobulin (Heegaard, 2009) 
Finnish amyloidosis Systemic Amyloid deposits Gelsolin 
(Solomon et al., 
2012) 
Hereditary non-
neuropathic systemic 
amyloidosis 
Systemic Amyloid deposits Lysozyme (Pepys et al., 1993) 
Lattice corneal dystrophy Eye Amyloid deposits Keratoepithelin (Ozawa et al., 2011) 
Medullary carcinoma of 
the thyroid 
Thyroid gland 
Nuclear, 
cytoplasmic and 
extracellular 
amyloid deposits 
Calcitonin 
(Stamatakos et al., 
2011) 
Rheumatoid arthritis 
Bones and 
joints 
B and T cell 
aggregates Serum amyloid A (Weyand, 2007) 
Sporadic Inclusion Body 
Myositis Muscle 
Multiprotein 
aggregates: Aβ42, 
Tau, α-synuclein 
S-IBM 
(Askanas et al., 
2012) 
Systemic AL amyloidosis Systemic Amyloid deposits 
Immunoglobulin 
light chain AL (Merlini et al., 2011) 
 
Mechanisms of protein aggregation 
 
Amyloid fibril formation 
 Protein aggregation occurs via a complex seeding-nucleation mechanism involving 
the formation of small oligomers, amorphous aggregates of various sizes, protofibrils and 
mature fibrils organized as cross-β-sheet amyloid structures. The initial step of aggregation 
involves the formation of a nucleus typically consisting in misfolded monomers that self-
associate to form soluble oligomeric species of different sizes and structures. The process 
evolves through the addition of intermediate species that further accumulate as a globular 
oligomeric structure or protofibril. The formation of such structures increases 
thermodynamic stability and marks the rate-limiting step of the aggregation process. Once 
a nucleus is formed, fibrils grow exponentially by elongation reactions ultimately resulting 
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in higher-order aggregates, including amyloid fibrils, in which β-sheets run perpendicular 
to the long fibril axis. These cross-β-sheet aggregates can then seed polymerization by 
inducing conformational conversion of proximal monomers into amyloid structures in a 
process similar to that occurring during prion propagation. Fibril fragmentation results in 
the release of fibril ends which enables the formation of secondary nucleation sites, and 
can therefore accelerate aggregation (Eisele et al., 2015, Knowles et al., 2014) (Figure 2). 
Thus, the conversion of a soluble molecule into an amyloid conformation can be triggered 
by two mechanisms that can act independently and complement each other – nucleation or 
seeding from preformed aggregates. The latter might constitute an important step for 
spreading of amyloid species within and between cells and is currently thought to 
contribute to the progression of pathology in neurodegenerative diseases. Indeed, such a 
prion-like phenomenon was first observed with the PrPSc conformer in transmissible 
spongiform encephalopathies (TSEs), but it has recently been extended to non-infectious 
disease-associated proteins, including Aβ, Tau, α-syn, SOD1, TDP-43 and mutant HTT 
(Costanzo and Zurzolo, 2013, Brundin et al., 2010, Stopschinski and Diamond, 2017). 
 
Causes of protein misfolding and aggregation 
 Despite the fact that the cross-β-sheet is a common structure of aggregates formed 
by several disease-associated proteins (Table I), the initial trigger of protein misfolding 
remains unclear in most cases. Internal conditions that have been identified to drive protein 
misfolding include mutations, translational errors and covalent modifications of proteins 
due to proteolytic cleavage, posttranslational modifications (PTMs) and oxidative stress.  
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Figure 2. Aggregate formation process. Amyloid formation may occur via nucleated and/or seeded 
polymerization. Nucleated polymerization involves the formation of an aggregation nucleus consisting in β-
sheet rich intermediates, typically soluble oligomers or protofibrils. This primary nucleation event is 
characterized by slow assembly kinetics, being highly dependent on protein concentration. However, once 
misfolded species are converted into more stable intermediates, rapid fibril growth can take place through the 
recruitment of soluble monomers. The growing fibril has an intrinsic tendency to further assemble into an 
amyloid-like structure, in which β-strands are rearranged in a perpendicular orientation to the axis of the 
fiber, giving rise to larger insoluble species (cross-β aggregates). Protein aggregation may imply secondary 
processes that greatly increase the size and number of aggregates. Such processes are primarily catalyzed by 
proteolytic reactions involving the formation of new aggregation nuclei (secondary nucleation), and the 
generation of seeds that induce the misfolding and incorporation of native molecules into β-sheet 
conformations (seeding). Adapted from (Brundin et al., 2010). 
 
 The probability of protein aggregation increases with increasing protein 
concentration, whether it is caused by increased gene expression or by decreased protein 
degradation and recycling. For example, duplications and triplications of the genes 
encoding α-syn or amyloid precursor protein (APP) cause early deposition of Aβ plaques 
and α-syn intracellular inclusions, respectively (Cataldo et al., 2003, Chartier-Harlin et al., 
2004, Lemere et al., 1996). In Down’s syndrome (DS), the triplication of APP on 
chromosome 21 is widely accepted as the underlying mechanism through which DS 
individuals progressively develop Aβ deposits and other features of AD (Wiseman et al., 
2015). The abnormal expansion of a triplet cytosine-adenine-guanine (CAG) repeat in the 
coding regions of at least 9 unrelated genes leads to the production of polyQ-expanded 
proteins with high aggregation propensities. Such mutated proteins are the causative agents 
of a group of neurodegenerative disorders termed as polyglutaminopathies. To date, this 
family of diseases include one recessive inherited disorder, the X-linked spinal and bulbar 
muscular atrophy (SBMA), and eight dominantly inherited disorders: six spinocerebellar 
ataxias (SCA) types 1, 2, 3 (also known as Machado-Joseph disease) 6, 7 and 17; 
dentatorubral pallidoluysian atrophy (DRPLA); and HD (Fan et al., 2014). HD is caused 
by the expansion of a CAG repeat in the first exon of the HTT gene, also known as IT15 
(The Huntington's Disease Collaborative Research Group, 1993). The CAG expansion size 
in all diseases correlates with the age of onset, extent of protein aggregation and disease 
severity (Fan et al., 2014). Moreover, single-point mutations in SNCA, Parkin, and 
LRRK2, among a few other genes, lead invariably to protein misfolding and aggregation in 
cell and animal models of PD (Conway et al., 1998, Forloni et al., 2002, Hattori and 
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Mizuno, 2004, Nussbaum and Polymeropoulos, 1997). Presenilin mutations are associated 
with extracellular amyloid deposits in familial AD (De Strooper, 2007). Mutations in 
superoxide dismutase, TDP-43 or FUS induce the aggregation and toxicity of these 
proteins in familial amyotrophic lateral sclerosis (ALS) (Durham et al., 1997, 
Kwiatkowski et al., 2009, Liscic et al., 2008). Although prion diseases are typically 
sporadic or acquired by infection, over 60 mutations in the PRNP gene are now recognized 
to cause premature PrP truncation and accumulation of the pathogenic conformer (PrPSc) 
(Mead and Reilly, 2015). The generation of aggregation-prone peptides can also result 
from proteolytic degradation of larger precursor proteins. Amyloid fibrils are known to be 
composed of relatively short peptides or proteolytic fragments. The role of proteolysis is 
well established in AD pathogenesis, being the toxic Aβ peptide generated from APP via 
successive aspartyl protease-mediated cleavage (Esler and Wolfe, 2001). Proteolytic 
cleavage promotes the aggregation of other disease-related proteins, such as α-syn, Tau 
and HTT, by liberating fragments that are more prone to misfold and can then seed 
aggregation of the full-length protein (Graham et al., 2006, Li et al., 2005, Wellington et 
al., 2002, Yin and Kuret, 2006).  
Protein aggregation is also influenced by phosphorylation and other PTMs. While 
neurofibrillary tangles and Lewy bodies are mostly composed of hyperphosphorylated Tau 
and serine-129-phosphorylated α-syn, respectively (Tenreiro et al., 2014), phosphorylation 
of mutant HTT on its N-terminal region prevents the formation of large inclusions in 
different cell and animal models (Branco-Santos et al., 2017, Gu et al., 2009). 
Phosphorylation may also serve as a recognition signal for further modifications, such as 
catalytic cleavage and ubiquitination (Thompson et al., 2009). Likewise, oxidation leads to 
irreversible modifications of protein residues, being also implicated in modulating 
aggregation of disease-associated proteins (Rochet, 2007, Tyedmers et al., 2010a).  
 Environmental factors such as aging and diet may also potentiate aberrant protein 
covalent modifications, and decrease the ability of the cell to clear misfolded proteins 
(Balchin et al., 2016). Cellular defense mechanisms against protein accumulation primarily 
involve the ubiquitin-proteasome system (UPS), whereby abnormal proteins are 
ubiquitinated and transported to the proteasome for their degradation (Figure 3). 
Alternatively, misfolded proteins are processed by chaperone-mediated autophagy, a 
clearance mechanism in which targeted proteins are translocated into the lysosome with 
the assistance of molecular chaperones, such as the heat shock cognate protein (Hsc70) 
(Kuiper et al., 2017, Rochet, 2007, Taylor et al., 2002) (Figure 3). The autophagy-
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lysosome system comprises another two mechanisms capable of removing cytosolic 
components: micro- and macroautophagy. In microautophagy, non-degraded proteins are 
directly sequestered by engulfment of the lysosomal membrane. When degradation and 
primary clearance mechanisms fail, protein aggregates are deposited in a specific cellular 
compartment located near the nucleus, known as aggresome in mammalian cells or IPOD 
in yeast cells (Tyedmers et al., 2010a) (Figure 3). The formation of such transient deposits 
or inclusion bodies is thought to constitute an attempt of the cell to avoid potential toxic 
interactions between protein aggregates and other cytosolic proteins or organelles until 
they can be cleared (Balchin et al., 2016, Tyedmers et al., 2010a). Although proteasomes 
can be stimulated to degrade large inclusions (Myeku et al., 2016), they are normally 
cleared by macroautophagy in a process involving the formation of double-membrane 
vesicular bodies termed autophagosomes that scavenge protein aggregates along with 
damaged organelles and other cellular debris (Rochet, 2007). Examples of aggregated 
proteins that may be processed via aggresome formation and macroautophagy are α-syn 
and polyQ-containing proteins (Tanaka et al., 2004b, Taylor et al., 2003). It has been 
hypothesized that the impairment of cellular proteostasis pathways is both a cause and a 
consequence of protein aggregation, thereby creating a vicious cycle that ultimately leads 
to cell death. Support for this idea comes from the observation that cytosolic aggregates 
compromise protein folding and degradation by sequestering components of the chaperone 
network and proteasome subunits (Hipp et al., 2014, Park et al., 2013). On the other hand, 
the presence of ubiquitinated aggregates in PMDs suggests that they are targeted for 
degradation but the UPS is unable to function, resulting in their accumulation (Hipp et al., 
2012).  
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Figure 3. Cellular defense mechanisms against protein accumulation. Molecular chaperones and 
the ubiquitin-proteasome system are the primary routes of protein turnover, being responsible for refolding 
processes and degradation of unfolded proteins, respectively. Proteasome degradation can occur in the 
cytoplasm or in the nucleus. Misfolded proteins retained in the ER and/or other organelles can be stabilized 
by chaperones (e.g., CHIP) and transported to the cytoplasm for proteasome degradation. When a protein 
does not turnover rapidly, molecular chaperones are called into action to assist in its delivering to the 
lysosome, a clearance mechanism known as chaperone-mediated autophagy. If all this fails and misfolded 
proteins start to accumulate in the cytoplasm, they can be sequestered by microtubule-mediated transport and 
deposited near the centriole forming an aggresome, where they remain until the cell can discard them through 
macroautophagy. Obtained from (Ross and Poirier, 2005). 
 
Molecular basis of neurodegeneration 
 
 The fact that large proteinaceous deposits can be easily observed in affected patient 
tissues led to the initial assumption that these species are the causative agents of 
neurodegeneration. However, neuronal death does not always correlate with the presence 
of amyloid fibrils (Saudou et al., 1998, Slow et al., 2005, Tsvetkov et al., 2013). There is 
now increasing evidence suggesting that some intracellular inclusions are formed as a part 
of a physiological response to excess misfolded protein, being neuroprotective rather than 
neurotoxic (Arrasate et al., 2004, Bodner et al., 2006, Winner et al., 2011). While large 
aggregates occupy specific cellular sites and do not move substantially, oligomeric species 
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are able to move more freely within cells and across membranes. Their solubility and 
dynamic properties should, in theory, allow them to interfere with biological processes 
more effectively than larger, more static protein inclusions. In fact, intermediate species 
expose sticky hydrophobic surfaces and form intermolecular hydrogen bonds, which 
increase their propensity to engage in aberrant interactions with proteins, lipids, nucleic 
acids and carbohydrates (Eisele et al., 2015). Protein misfolding and aggregation 
compromise important cellular processes for normal brain function and neuronal survival, 
including transcription, synaptic signaling, vesicular trafficking and mitochondrial function 
(Chiti and Dobson, 2006, Sweeney et al., 2017, Taylor et al., 2002). In addition, 
accumulation of misfolded proteins can lead to the extracellular release of reactive oxygen 
species (ROS) and induce stress response pathways. Chronic microglia and astrocyte 
activation promotes the production of chemokines and pro-inflammatory cytokines that 
generally lead to death of nearby neurons (Ben Haim et al., 2015, Gentleman, 2013), hence 
contributing to spreading neurodegeneration and disease progression. On the other hand, 
extracellular aggregates have been shown to directly bind glial cells and impair the 
microglial M2 phenotype, considered to be neuroprotective owing to release of 
neurotrophic and growth factors (Heppner et al., 2015). 
 Although aggregation-prone proteins appear to act primarily by toxic gain-of-
function, in some cases, loss-of-function events may also contribute to disease 
pathogenesis. According to this hypothesis, neuronal dysfunction can be caused by the loss 
of normal activity of aggregation-prone proteins upon self-assembly and/or depletion of 
vital regulatory and signaling proteins that get sequestered into the inclusions. 
Experimental support in this regard is provided by knockout studies, in which deletion of 
genes encoding disease-related proteins results in premature death or accelerates 
neurodegenerative phenotypes of disease-model organisms. Knockout of endogenous HTT 
leads to early embryonic lethality in mice (Duyao et al., 1995, Nasir et al., 1995, Zeitlin et 
al., 1995), and exacerbates brain degeneration and motor deficits in adult HD flies (Zhang 
et al., 2009). Loss-of-function effects are also observed for the cellular prion protein (PrPC) 
(Sakudo and Onodera, 2014), APP (Senechal et al., 2008), SOD1 (Reaume et al., 1996) 
and three syn isoforms (Greten-Harrison et al., 2010). Interestingly, diffusion of human α-
syn fibrils to different brain regions occurs more readily in α-syn null mice, suggesting that 
loss of the endogenous protein influences interneuronal transfer of oligomeric α-syn and 
leads to advanced brain pathology (Helwig et al., 2016). Altogether, these observations 
raise the possibility that loss of normal protein function may be involved not only in 
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disease development but also in its progression. 
 
Spreading of protein aggregation in neurodegeneration 
 As mentioned above, transneuronal propagation of toxicity may occur through a 
seeding mechanism in which soluble oligomeric species are capable of crossing cellular 
membranes and act as seeds for the generation of amyloid-like aggregates in different areas 
of the brain. This concept of prion-like aggregation has been hypothesized to have an 
important role in driving pathogenesis of many PMDs (Brundin et al., 2010), but remains a 
matter of intense debate. On one hand, there is currently no evidence that more common 
neurodegenerative disorders are transmissible between individuals (Irwin et al., 2013, 
Stopschinski and Diamond, 2017). On the other hand, pathophysiological studies of AD, 
PD, ALS and HD patient brains reveal unique but stereotypical patterns of pathology 
spread between interconnected brain regions, suggesting a similar mechanism of disease 
progression based on non-cell autonomous dissemination of protein aggregates 
(Brettschneider et al., 2015, Pecho-Vrieseling et al., 2014). Experimental evidence for 
prion-like seeding and spreading of toxic aggregates comes mainly from animal models. In 
AD transgenic mice, intracerebral injection of either in vitro purified fibrils or disease-
affected brain homogenates can induce progressive spread of Aβ or Tau aggregation 
(Clavaguera et al., 2009, Clavaguera et al., 2013, Kane et al., 2000). Similarly, α-syn was 
shown to propagate from neurons to other neurons (Desplats et al., 2009) and glial cells 
(Lee et al., 2010), following a PD-like cascade of neuropathology that evolves along 
specific neuronal networks to neighboring anatomical structures (Luk et al., 2012, Rey et 
al., 2016). While pathological protein propagation in AD and PD is relatively well 
documented, evidence for prion-like spreading of mutant HTT (Babcock and Ganetzky, 
2015, Herrera et al., 2011, Pearce et al., 2015), SOD1 (Ayers et al., 2016) and other 
disease-causing proteins has only recently begun to emerge. The intercellular processes 
underlying spreading of protein aggregates are still under investigation, although common 
mechanisms of release and uptake of biomolecules, such as endocytosis, exocytosis and 
receptor-mediated phagocytosis, are likely to be involved (Pearce, 2017). In addition, 
misfolded proteins can be transferred directly by cell-to-cell contact via tunneling 
nanotubes (TNTs) (Gousset et al., 2009, Wang et al., 2011) or be internalized by passive 
diffusion across lipid membranes (Cecchi and Stefani, 2013, Ren et al., 2009, van Rooijen 
et al., 2009). Extracellular aggregates of Aβ (Resenberger et al., 2011) and α-syn (Ferreira 
et al., 2017) were recently found to physically interact with PrPc at the cell membrane, 
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initiating a cascade of toxic events that leads to synaptic dysfunction and subsequent 
neuronal death. These exciting findings may suggest the existence of a cell receptor-
mediated mechanism for neurotoxicity spread that could explain, at least in part, why some 
neurons are more vulnerable to toxic extracellular species.  
 Seeding and aggregation typically occurs for the same type of aggregation-prone 
protein (Rajan et al., 2001). However, several studies have shown that misfolding of one 
disease-causing protein can induce misfolding an aggregation of other aggregation-prone 
proteins (Guo et al., 2013, Katorcha et al., 2017, Vasconcelos et al., 2016). Such cross-
seeding properties can contribute to neuropathology and are implicated as one possible 
reason for the heterogeneity of neurodegenerative diseases. Indeed, aggregates of different 
proteins can be observed in patients with!overlapped symptoms (Galpern and Lang, 2006, 
Miyazono et al., 1992, Vital et al., 2007). Furthermore, we and others have found that co-
aggregation of otherwise unrelated proteins alters protein subcellular localization and 
aggregation patterns (Blum et al., 2015, Herrera and Outeiro, 2012), and potentiates 
cytotoxicity and neurodegeneration (Pocas et al., 2015, Sajjad et al., 2014).  
 
 Over the last decade, researchers have focused on developing therapeutic strategies 
targeting protein aggregation, but very few have shown significant benefits in clinical trials 
(Eisele et al., 2015, Sweeney et al., 2017). This is in part because we still lack deep 
understanding of the processes underlying disease pathogenesis. A major challenge would 
be to determine which species are toxic to which cells and under which conditions. Protein 
aggregates exist in a wide variety of structures that show different levels of neurotoxicity 
and afflict different neuronal populations. Despite the fact that oligomeric species are 
currently considered to be at the core of proteotoxic interactions and seeding mechanisms, 
amyloid-β structures represent a more readily accessible target for novel therapeutic 
intervention due partly to the absence, until recently, of suitable experimental models for 
the study and detection of soluble intermediate species in living cells (Goncalves et al., 
2010, Herrera et al., 2014). The availability of such models should contribute to a better 
understanding of the initial events triggering aggregation of aberrant proteins, and is 
expected to prove useful in our search for promising disease-modifying candidates that 
could be modulated before irreversible spreading of protein pathology and neuronal loss. 
Furthermore, although neurodegenerative disorders share common histopathological 
features, the cellular pathways and molecular mechanisms involved in neurotoxicity may 
differ. Thus, because selective neuronal vulnerability is likely dependent on specific 
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protein-protein interactions (Yang and Hu, 2016), identifying molecular partners of 
disease-causing proteins and understanding how such interactions are modulated by 
environmental changes could provide new insights into the pathogenesis of 
neurodegenerative disorders. In the scope of the present thesis, current understanding of 
HD pathogenesis is detailed bellow, with particular emphasis on post-translational 
modifications and aberrant protein-protein interactions underlying mutant HTT 
aggregation and toxicity.  
 
 
 
 
 
 
 
 
 
 
 !
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1.2.&Huntington’s&Disease&
&
Etiology and clinical symptoms 
 
 HD was first described in 1872 by George Huntington as a choreiform movement 
disorder (Huntington, 1872). Although rare, HD is the most common inherited 
neurodegenerative disorder affecting 5 to 10 individuals per 100,000 in western 
populations, with many more people at risk of developing symptoms (Bates et al., 2015, 
Labbadia and Morimoto, 2013). HD has an autosomal dominant pattern of inheritance, and 
men and women have the same probability of developing the disease. The most prominent 
clinical feature is the inability to control muscles, which manifests early in the course of 
the disease as involuntary movements, giving the patient characteristic irregular “dance-
like movements” known as chorea. As HD progresses, chorea stabilizes and fine motor 
impairment (dystonia, bradykinesia and rigidity) starts to appear. Such motor symptoms 
are correlated with progressive neuronal loss in the striatum and related basal ganglia 
structures, although other regions of the brain are also affected (Bates et al., 2015, Ross et 
al., 2014) (Figure 4A). Imaging studies suggest that neurodegeneration initiates in the 
cerebral cortex and extends to subcortical regions involved in sensory signals and 
regulatory functions (Brundin et al., 2010), which could explain the appearance of 
cognitive and neuropsychiatric disturbances years before the motor symptoms (Stout et al., 
2011). Changes in cognition and behavior generally include personality changes often 
accompanied by social disengagement and!disinhibition, irritability, apathy, sleep problems 
and depression. Learning can also be impaired but language and episodic memory are not 
affected, in contrast to AD. Most HD patients also experience peripheral symptoms such as 
extreme fatigue and weight loss (Carroll et al., 2015, van der Burg et al., 2009). These 
symptoms are generally associated with changes in muscular, circulatory and digestive 
systems that affect quality of life and, in some cases, constitute the primary cause of death. 
Indeed, more than half of the HD population dies from aspiration pneumonia followed by 
cardiovascular disease (Heemskerk and Roos, 2012, Sorensen and Fenger, 1992). Non-
neurological complications of HD may also include gastrointestinal dysfunction (van der 
Burg et al., 2011), skeletal-muscle atrophy (Lodi et al., 2000, Ribchester et al., 2004) and 
osteoporosis (Goodman and Barker, 2011). Moreover, HD patients are at higher risk of 
developing diabetes mellitus and hyperglycemia (Farrer, 1985). These peripheral 
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abnormalities are presumably caused by HTT-induced defects as intranuclear inclusions 
alongside with a decline in glucose tolerance and decreased insulin production are seen in 
pancreatic islet cells of HD mice (Andreassen et al., 2002, Hurlbert et al., 1999). Due to 
the nonspecific nature of these early-stage features, HD can be initially confounded with 
other CNS disorders. Patients and their families are frequently left without proper medical 
follow-up and counseling until the time of diagnosis, that typically occurs when motor 
difficulties begin. In the future, studies on peripheral pathology might pave the way for 
early diagnosis in HD and new markers to monitor disease progression.  
 HD is caused by abnormal expansion of a CAG repeat located in the beginning of 
the HTT gene, located on the short arm of chromosome 4 (4p16.3). The size of expanded 
CAG has a strong inverse correlation with the age of disease onset (Figure 4B), and can 
also influence disease progression and severity (Rosenblatt et al., 2012). Healthy 
individuals carry between 16 and 27 CAG repeats, while 36 repeats or more are associated 
with manifested HD. However, repeats of 36-40 CAG are incompletely penantrant which 
often leads to uncertainty in clinical diagnosis. Full penetrance is observed when CAG 
length is expanded over 40 repeats with mutation carriers invariably developing motor 
signs of HD. Disease onset occurs most frequently in midlife, approximately at 40 years of 
age, while juvenile cases have been reported with CAG lengths over 55 repeats (Bates et 
al., 2015, Rubinsztein, 2002). Individuals with 27 to 35 CAG repeats are essentially 
asymptomatic, although the disease can appear in future generations owing to meiotic 
instability of such intermediate alleles. However, there is a large part of the interindividual 
variability that is not explained by differences in CAG repeat extension between patients, 
and that may be due to genetic, epigenetic or environmental factors, such as sport or 
nutrition (Gusella and MacDonald, 2009). 
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Figure 4. Clinical and histopathological hallmarks of HD. (A) HD is characterized by the 
accumulation of mutant HTT associated with neurotoxicity in specific brain regions. The medium spiny 
neurons of the basal ganglia are particularly vulnerable to mutant HTT toxicity (darkest green). However, 
cortical degeneration appears to precede neuronal loss in the striatum and might be observed 15 years before 
first symptoms emerge. Neurodegeneration progresses gradually throughout the brain affecting subcortical 
regions, although to a lesser extent (lighter green). The specific pattern of spreading of neurodegeneration 
gives HD a combination of motor, cognitive and behavioral features that have some similarity with other 
disorders involving corticostriatal atrophy, such as dementia and PD. Extracted from (Brundin et al., 2010). 
(B) HD is caused by an abnormal expansion of a CAG repeat in an autosomal dominant gene, with longer 
expansions causing greater HTT aggregation and earlier onset of pathology. Despite the strong correlation 
between CAG repeat number and disease onset, wide variation in age of onset can be observed for the same 
CAG repeat length. Such differences have been attributed to genetic and/or environmental factors that may 
modulate disease pathogenesis. Median value for each repeat size is indicated as a white line; Interval of 95% 
confidence is indicated as the black box; Range is indicated by brackets; Outliers are indicated by black lines. 
Extracted from (Rubinsztein, 2002). 
 
 HD is a fatal disorder, with patients having 15 to 20 years of life expectancy after 
the first signs of motor dysfunction (Foroud et al., 1999). Currently, there is no effective 
treatment for this devastating disease, and existing drugs only alleviate symptoms (Kim 
and Kim, 2014, Ross et al., 2014). Drugs aiming at modifying disease pathogenesis should 
be considered for therapeutic strategies against HD. Thus, research on the mechanisms 
underlying HD may lay the groundwork for the development of novel therapies that can 
alter the course of HD. 
 
Huntingtin protein and molecular pathogenesis of HD 
 
Huntingtin structure, function and pathobiology  
 The HTT gene is extremely large and consists of 67 exons and 180 kb, encoding for 
a large protein of 3144 amino acids (~350 kDa). The pathogenic CAG expansion, located 
in the first exon of the gene, is translated as an abnormally elongated polyglutamine 
(polyQ) tract in the HTT protein. HTT is widely expressed throughout all body tissues, 
although its expression is particularly high in the brain. At the cellular level, normal HTT 
is mostly found in the cytoplasm as a soluble unfolded monomer (Bates et al., 2015, The 
Huntington's Disease Collaborative Research Group, 1993). However, the existence of a 
nuclear export signal in its C-terminal indicates that HTT can shuttle between the nucleus 
and cytoplasm under certain conditions (Xia et al., 2003). While some biochemical and 
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mechanistic roles of wild-type HTT have been uncovered, its specific cellular function 
remains elusive. This is mainly due to the large size of the protein, that makes isolation and 
analysis very difficult, and to the large number of HTT interacting partners (Table II).  
 
Table II. Selected HTT interactors and modifiers of HTT aggregation and toxicity 
Interactor/ 
modifier Function 
Secondary 
partners 
PolyQ length 
dependence 
HTT 
aggregation 
HTT 
toxicity References 
α-Adaptin 
C/HYP-J Endocytosis  Yes n.d. n.d. 
(Faber et al., 
1998) 
α-syn Unknown   n.d. enhancer enhancer 
(Charles et al., 
2000, Herrera and 
Outeiro, 2012, 
Pocas et al., 2015, 
Tomas-Zapico et 
al., 2012) 
ADMR1 Ubiquitin receptor, proteasome activity  Yes suppressor suppressor 
(Huang and Her, 
2016) 
AIFM1 
Mitochondrial 
apoptosis-inducing 
factor 
 No n.d. enhancer (Ratovitski et al., 2012) 
Arfaptin 2 Cytoskeletal remodeling 
Ras-related 
GTPases n.d. enhancer enhancer 
(Peters et al., 
2002, Rangone et 
al., 2005) 
CA150 Transcription co-activator  No suppressor suppressor 
(Arango et al., 
2006, Holbert et 
al., 2001) 
Calmodulin Calcium-binding protein TG2 Yes enhancer enhancer 
(Bao et al., 1996, 
Dudek et al., 2008, 
Zainelli et al., 
2004) 
Caprin-1 
RNA-binding 
translational 
repressor, stress 
granule-associated 
protein 
G3BP No n.d. n.d. (Ratovitski et al., 2012) 
Caspase-3 Pro-apoptotic   Yes n.d. enhancer (Zhang et al., 2006) 
CBP Transcription co-activator  Yes  n.d. n.d. 
(Cong et al., 2005, 
Steffan et al., 
2000) 
CBS Generation of cystein  No n.d. n.d. 
(Boutell et al., 
1998) 
CIP4 Signal transduction  Yes n.d. (-) (Holbert et al., 2003) 
CtBP Transcription co-repressor  Yes n.d. n.d. (Kegel et al., 2002) 
DNAJB1 HSP40 molecular chaperone HSP70 n.d. n.d. suppressor 
(Kuo et al., 2013, 
Park et al., 2013) 
DNAJB6, 
DNAJB8 
HSP40 molecular 
chaperones HDAC4 n.d. suppressor suppressor 
(Gillis et al., 2013, 
Hageman et al., 
2010, Mansson et 
al., 2014) 
E2-25K/HIP2 Ubiquitin-conjugating enzyme  No enhancer enhancer 
(de Pril et al., 
2007, Kalchman et 
al., 1996) 
FIP2 Cell morphogenesis Rab8 n.d. n.d. n.d. 
(Hattula and 
Peranen, 2000, 
Qin et al., 2004) 
FUS/TLS RNA/DNA-binding protein  No (-) suppressor 
(Doi et al., 2010, 
Kino et al., 2016) 
GIT1 G protein-coupled receptor kinase  n.d. enhancer n.d. 
(Goehler et al., 
2004) 
GRB2 
Epidermal growth 
factor receptor-
binding protein 
Foxd3 Yes suppressor n.d. (Baksi et al., 2013, Liu et al., 1997) 
(Continued) 
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Table II. Selected HTT interactors and modifiers of HTT aggregation and toxicity (cont.) 
Interactor/ 
modifier Function 
Secondary 
partners 
PolyQ length 
dependence 
HTT 
aggregation 
HTT 
toxicity References 
HAP1 
Membrane 
trafficking, 
autophagy 
dynactin  Yes n.d. n.d. 
(Li et al., 1995, 
Wong and 
Holzbaur, 2014) 
HAP40 Endosome motility  Rab5 n.d. enhancer enhancer 
(Guo et al., 2018, 
Huang and Her, 
2016, Pal et al., 
2006) 
HIP1 Endocytosis, pro-apoptotic  Yes (-) enhancer 
(Gervais et al., 
2002, Kalchman et 
al., 1997, Qin et 
al., 2004, Wanker 
et al., 1997) 
HIP14/HYP-H 
palmitoyl 
transferase, traffic, 
endocytosis 
 Yes suppressor suppressor 
(Faber et al., 1998, 
Singaraja et al., 
2002, Yanai et al., 
2006) 
HYPA/FBP11 RNA splicing  MeCP2 Yes  n.d. n.d. (Faber et al., 1998) 
HYPB/SETD
2 
Lysine 
methyltransferase, 
RNA splicing 
 n.d. n.d. n.d. (Gao et al., 2014) 
HYPK Chaperone-like activity  No suppressor suppressor 
(Raychaudhuri et 
al., 2008) 
HSP70 
Molecular 
chaperone involved 
in endocytosis and 
apoptosis 
Clathrin No suppressor suppressor 
(Monsellier et al., 
2015, Yu et al., 
2014) 
InsP3R1 
Calcium release 
channel  HAP1A Yes n.d. n.d. (Tang et al., 2003) 
ITSN Endocytosis, signal transduction JNK  No enhancer enhancer 
(Scappini et al., 
2007) 
MLF1, MLF2 Myeloid leukemia factors  Yes  suppressor suppressor 
(Banerjee et al., 
2017) 
mSin3a Transcription co-repressor  Yes n.d. n.d. 
(Boutell et al., 
1999, Steffan et 
al., 2000) 
N-CoR Nuclear receptor co-repressor  Yes n.d. n.d. 
(Boutell et al., 
1999) 
NF-Y Transcription factor  Yes n.d. n.d. (Yamanaka et al., 2008) 
NFκ B Transcription factor  n.d. n.d. n.d. (Takano and Gusella, 2002) 
p53 
Transcription factor, 
pro-apoptotic (tumor 
suppressor) 
 No (-) enhancer 
(Bae et al., 2005, 
Steffan et al., 
2000) 
PAK1, PAK2 
Cytoskeleton 
dynamics, anti-
apoptotic 
 Yes enhancer enhancer 
(Luo et al., 2008, 
Luo and 
Rubinsztein, 2009) 
PACSIN1 Endocytosis, cell morphogenesis  Yes n.d. n.d. 
(Modregger et al., 
2002) 
PFN2 Actin-binding protein, endocytosis 
Dynamin 1, 
Clathrin, 
Synapsin, 
Rock2 
NAP1 
NSF/Sec18 
Yes  suppressor suppressor 
(Burnett et al., 
2008, Goehler et 
al., 2004, Posey et 
al., 2018) 
PrPC Unknown   n.d. suppressor suppressor (Lee et al., 2007) 
PSD-95 Synaptic scaffolding protein  Yes n.d. suppressor (Sun et al., 2001) 
Rab5 Autophagosome formation  n.d. suppressor suppressor 
(Ravikumar et al., 
2008) 
RasGAP Ras GTPase activating protein  n.d. n.d. n.d. (Liu et al., 1997) 
REST/NRSF Transcription repressor NRSE Yes n.d. n.d. 
(Zuccato et al., 
2003) 
SH3GL3/end
ophilin-A3 
Vesicle trafficking, 
endocytosis   Yes enhancer n.d. 
(Qin et al., 2004, 
Sittler et al., 1998) 
(Continued) 
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Table II. Selected HTT interactors and modifiers of HTT aggregation and toxicity (cont.) 
Interactor/ 
modifier Function 
Secondary 
partners 
PolyQ length 
dependence 
HTT 
aggregation 
HTT 
toxicity References 
SP1 Transcription activator NGFR Yes suppressor suppressor 
(Dunah et al., 
2002, Li et al., 
2002b) 
TAFII-130 Transcription co-activator  No n.d. suppressor 
(Dunah et al., 
2002) 
TATA-binding 
protein Transcription factor  Yes n.d. n.d. 
(Huang et al., 
1998, van Roon-
Mom et al., 2002) 
Tau Microtubule-associated protein  Yes suppressor enhancer 
(Blum et al., 2015, 
Fernandez-
Nogales et al., 
2014, Vuono et al., 
2015) 
TDP-43 RNA/DNA-binding protein PGNR n.d. n.d. enhancer 
(Fuentealba et al., 
2010, Schwab et 
al., 2008, 
Tauffenberger et 
al., 2013) 
Tpr Nuclear export protein  Yes n.d. n.d. 
(Cornett et al., 
2005) 
TRiC Chaperonin, de novo folding,   No suppressor suppressor 
(Darrow et al., 
2015, 
Shahmoradian et 
al., 2013, Tam et 
al., 2006, Tam et 
al., 2009) 
tTG Tissue transglutaminase  Yes (-) enhancer 
(Bailey and 
Johnson, 2005, 
Chun et al., 2001a, 
Chun et al., 
2001b) 
USP19 Deubiquitinating enzyme HSP90 No enhancer n.d. (He et al., 2017) 
Adapted and completed from (Borrell-Pages et al., 2006, Giorgini and Muchowski, 2005, Harjes and 
Wanker, 2003, Yang and Hu, 2016, Zuchner and Brundin, 2008). n.d., not determined; (-), no effect. 
 
 Normal HTT protein is implicated as a scaffold in various cellular processes, 
including vesicular trafficking (Li et al., 1995, Strehlow et al., 2007) and gene 
transcription (Zuccato et al., 2003). Furthermore, the critical role of HTT in CNS 
development (Duyao et al., 1995, Henshall et al., 2009, Nasir et al., 1995, Zeitlin et al., 
1995) is likely to be associated to its ability in inhibiting apoptosis, acting as a 
neuroprotective agent (Gervais et al., 2002, Leavitt et al., 2006, Luo and Rubinsztein, 
2009, Zhang et al., 2006). Depletion of wild-type HTT in mice leads to embryonic lethality 
(Duyao et al., 1995, Nasir et al., 1995, Zeitlin et al., 1995), while a reduction of 50% in its 
levels of expression results in abnormal brain development (Auerbach et al., 2001, White 
et al., 1997). A subsequent study using zebrafish further suggests a role for HTT in the 
formation of the CNS, with morphological defects being evident in specific nerve cells 
(Henshall et al., 2009). Further investigation on the underlying mechanisms responsible for 
such deleterious phenotypes point at an anti-apoptotic function of HTT (Zeitlin et al., 
1995). This anti-apoptotic function is independent of the polyQ length (Ho et al., 2001, 
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Leavitt et al., 2001) and possibly related to HTT´s ability to sequester pro-apoptotic 
proteins (Gervais et al., 2002) and/or inhibit specific caspases (Zhang et al., 2006). The 
huntingtin interacting protein 1 (Hip1) is a pro-apoptotic protein capable of inducing 
caspase-3-mediated cell death and activating the pro-caspase 8 apoptotic pathway (Gervais 
et al., 2002, Hackam et al., 2000). Hip-1 activity is dependent on its interaction with Hippi 
(Hip-1 protein interactor). However, wild-type HTT sequesters Hip-1, reducing its 
availability to form pro-apoptotic complexes (Gervais et al., 2002). Furthermore, wild-type 
HTT physically interacts with caspase-3 in vitro, while its overexpression in vivo is 
concomitant with a decrease in caspase-3 activity and ameliorated neurodegenerative 
phenotypes (Zhang et al., 2006). Wild-type HTT could also prevent neuronal death by 
promoting specific pro-survival pathways. HTT protects against stress damage by 
preventing caspase-mediated cleavage of p21-activated kinase 2 (Pak2). Full-length Pak2 
stimulates cell survival and growth, but it can be converted into a pro-apoptotic factor 
under particular stress conditions, via activation by caspase-3 and -8. Wilt-type HTT 
specifically binds to Pak2, interfering with its cleavage (Luo and Rubinsztein, 2009). 
 Structurally, HTT is composed of multiple regions of HEAT repeats that consist of 
40 or more amino acids assembling into a hydrophobic α-helical conformation (Figure 5). 
The role of these domains in HTT biology is not clear, although they have been suggested 
as binding motifs for protein-protein interactions. Intrinsically disordered regions found to 
have a large number of PTM sites intercalate with the clusters of HEAT repeats. Of 
particular interest is the N-terminus segment encoded by exon 1 (HTTex1). This region 
contains a sequence of 17 amino acids (N17) preceding the polyQ tract and a proline-rich 
domain (PRD) of 51 amino acids after the polyQ tract (Figure 5). The importance of 
HTTex1 lies on the observation that expression of expanded polyQ-containing HTTex1 is 
sufficient to cause HD-like phenotypes in animal models (Bates et al., 1998, Mangiarini et 
al., 1996). Moreover, small N-terminal fragments of mutant HTT have been found in 
human post-mortem brains (Kim et al., 2001, Lunkes et al., 2002), suggesting that the 
generation of N-terminal fragments containing HTTex1 is a key step in HD pathogenesis. 
Although aberrant RNA splicing of mutant HTT can give rise to a truncated form of about 
100 amino acids (Sathasivam et al., 2013), the generation of toxic fragments containing 
HTTex1 generally occurs through protease-mediated cleavage. HTT can be cleaved at 
arginine-167 and aspartate-586 by caspase-6 and at aspartates 513 and 552 by caspase-3. 
Caspase-2 and -8 were also found to target aspartates 552 or 586, respectively. In addition, 
three calpain cleavage sites are predicted at leucine-437, threonine-469 and serine-536. 
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Both wild-type and mutant HTT can undergo proteolytic cleavage (Goffredo et al., 2002, 
Kim et al., 2001). However, such modification appears to be more relevant in a disease 
context since mutant HTT aggregation is facilitated by its cleavage. In a mouse model of 
HD, proteolysis of full-length mutant HTT into HTTex1-containing fragments promotes 
protein aggregation and occurs prior to detection of behavioral deficits (Landles et al., 
2010). Furthermore, such cleavage events may also promote toxic effects since N-terminal 
fragments are likely more toxic than full-length mutant HTT (Graham et al., 2006). 
Pharmacological inhibition of caspase-6 decreases intracellular levels of HTT proteolytic 
fragments and prevents mutant HTT-induced toxicity in both cells and animals (Aharony 
et al., 2015). However, such approach is unlikely to prove effective in HD treatment as 
other caspases may function as alternate enzymes and liberate similar toxic fragments, in 
the absence of caspase-6 (Wong et al., 2015a).   
 
 Figure 5. Schematic representation of HTT and its post-translational modification sites. HTT 
has a polyQ stretch at the N-terminus that is flanked by its first 17 amino acids (N17) and by a proline-rich 
domain (PRD). This region (HTTex1) corresponds to exon 1 and is followed by a series of clusters of highly 
repeated sequences, known as HEAT domains, which confer an intrinsic disorderly nature to the protein. 
Between these HEAT repeats are a number of cleavage sites and several other PTMs. Predicted cleavage 
sites are marked by inverted triangles. Caspase-2, -3, -6 and -8 sites are indicated in grey, green, purple and 
dark blue, respectively. Calpain cleavage sites are shown in brown. SUMO-1 and ubiquitin enzymes compete 
for the same lysine (K) sites, indicated in blue oval. Lysine residues are also putative targets for protein 
glycation (orange diamond). Additional PTMs include phosphorylation (yellow circles), acetylation (green 
oval) and palmitoylation (purple hexagon). To date, seven specific kinases responsible for HTT 
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phosphorylation have been identified (in black), while only two families of phosphatases are demonstrated to 
target HTT at serine (S)-421 (in red). 
 
 Although abnormally expanded polyQ is pointed as the major responsible for HTT 
aggregation (DiFiglia et al., 1997, Li and Li, 1998, Scherzinger et al., 1999), several lines 
of evidence indicate that the amino acid sequences flanking the polyQ tract (N17 and 
PRD) may also play a role in this process. N17 and PRD seem to affect HTT aggregation 
in opposite ways (Chen and Wolynes, 2017, Crick et al., 2013). Synthetic polyQ peptides 
lacking the N17 domain show slower aggregation kinetics, whereas PRD deletion results in 
increased aggregation propensity (Tam et al., 2009, Thakur et al., 2009). It has been 
hypothesized that the N17 domain triggers the initial steps of polyQ aggregation by 
facilitating primary nucleation events. The N17 domain features an amphipathic α-helix 
with a characteristic coiled-coil structure (Rossetti et al., 2011). However, when the polyQ 
tract is expanded, N17 can undergo conformational changes and self-associate into α-
helix-rich tetramers that may act as a nucleus for fibril formation (Fiumara et al., 2010, 
Jayaraman et al., 2012). Such self-association process would expose the hydrophobic face 
of N17 and shorten the distance between the adjacent polyQ tract thus favoring inter-
domain interactions and accelerating polyQ aggregation (Kelley et al., 2009, Liebman and 
Meredith, 2010, Williamson et al., 2010). N17 generally stands at the edge of the amyloid 
structure (Hoop et al., 2014, Sivanandam et al., 2011), which in theory could allow it to 
sequester truncated monomers for fibril elongation and/or to participate in secondary 
nucleation events (Jayaraman et al., 2012). Initial steps of HTT aggregation can be 
suppressed by several chaperones found to directly bind the N17 domain, further 
supporting a role for N17 in HTT aggregate formation (Monsellier et al., 2015, Tam et al., 
2009). In contrast, PRD stabilizes aggregation-prone conformations adopted by the polyQ 
stretch (Bhattacharyya et al., 2006, Darnell et al., 2007). Although the PRD is thought to 
inhibit N17 nucleation when at a proximal position (Caron et al., 2013), this positive effect 
is minimized by the loss of flexibility of expanded polyQ repeats, which prevents possible 
interactions between the PRD and N17.  
 Compelling evidence suggest that regions flanking the polyQ stretch may also 
modulate HTT toxicity (Dehay and Bertolotti, 2006, Duennwald et al., 2006b, Lin et al., 
2017). Deletion of PRD leads to the conversion of benign large aggregates into smaller 
toxic species (Dehay and Bertolotti, 2006). Those smaller aggregates often display 
undefined boundaries, which would favor polyQ interactions with other proteins in the 
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cellular environment (Duennwald et al., 2006b). In agreement with the idea that PRD may 
function to attenuate HTT toxicity is the fact that this sequence recruits protein interactors 
that are associated with increased proteasomal degradation of mutant HTT and reduced 
neuronal loss (Southwell et al., 2008). Conversely, N17 has been shown to target HTT 
aggregates to lipid membranes, setting the basis for potential toxic interactions between 
cellular compartments (Burke et al., 2013a, Kegel et al., 2005, Rockabrand et al., 2007). 
Such a role for N17 is attributed to its amphipathic α-helix, which confers lipid-binding 
properties to the protein (Kegel et al., 2005). N17 also contains a functionally active 
nuclear export signal (NES) being suggested to modulate HTT cellular localization and 
trafficking (Cornett et al., 2005, Zheng et al., 2013). Abnormal expansion of the polyQ or 
specific mutations within the N17 domain lead to HTT nuclear accumulation and 
cytotoxicity (Atwal et al., 2007, Cornett et al., 2005, Zheng et al., 2013). Despite the high 
degree of sequence conservation throughout mammalian evolution, polyQ-flanking regions 
do not seem to be required for normal HTT function (Andre et al., 2017, Gu et al., 2015, 
Neveklovska et al., 2012). They might have rather evolved along with polyQ stretches to 
modulate their pathogenicity as suggested by their significant role in mutant HTT 
aggregation and toxicity.  
  
Huntingtin post-translational modifications  
 In addition to proteolytic cleavage (mention above), HTT can be modified by 
several other PTMs, including phosphorylation, acetylation, ubiquitination, SUMOylation, 
palmitoylation, glycosylation, transglutamination and protein glycation (Figure 5). Known 
phosphorylation sites at HTTex1 include one threonine and two serine residues (threonine-
3, serine-13 and -16), but several other phopho-serine sites are found beyond HTTex1, 
including serine-419, -421, -434, -536, -1181, -1201, -2076, -2653 and -2657. The IκB 
kinase (IKK) phosphorylates the three phospho-residues contained in HTTex1 
(Bustamante et al., 2015, Thompson et al., 2009). Casein kinase 2 (CK2) (Atwal et al., 
2011) and GM1 ganglioside (Di Pardo et al., 2012) are also suggested as HTTex1 serine-
specific kinases. Downstream of HTTex1, both Akt1 (Humbert et al., 2002) and the serum 
and glucocorticoid-induced kinase (SGK) (Rangone et al., 2004) target phosphorylation of 
serine-421, whereas its dephosphorylation is catalyzed by phosphatases of the PPP family 
(PP1 and PP2A) (Metzler et al., 2010) or by metal-dependent phosphatases of the PPM 
family (PP2C) (Marion et al., 2014). Other kinases such as the cyclin-dependent kinase 5 
(Cdk5) (Anne et al., 2007, Luo et al., 2005) and a kinase of the mitogen-activated protein 
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kinase (MAPK) family, the ERK1 (Schilling et al., 2006), have also been implicated in 
HTT phosphorylation. Most HTT phosphorylation events are thought to have a 
neuroprotective effect, although this assumption is still controversial (Ehrnhoefer et al., 
2011). Lysine-444 is the best characterized site for acetylation that, similar to 
phosphorylation, is suggested to confer neuroprotection against mutant HTT toxicity 
(Cong et al., 2011, Jeong et al., 2009). In addition, HTTex1 contains other potential 
acetylation sites that are also targeted by SUMO or ubiquitin E3 ligases (Kalchman et al., 
1996, Subramaniam et al., 2009). The covalent attachment of fatty acids is catalyzed by 
palmitoyl transferases at cysteine-214. While diminished palmitoylation is associated with 
increased mutant HTT aggregation and toxicity (Yanai et al., 2006), suppression of HTT 
glycosylation results in decreased neuronal loss and enhanced clearance of protein 
aggregates via autophagy (Kumar et al., 2014). Likewise, increased levels of 
transglutaminases are found in particular HD brain regions, suggesting a potential 
enzymatic imbalance accounting for selective neuronal vulnerability to mutant HTT 
(Kahlem et al., 1998). 
 
N17 PTMs as key modulators of HD pathogenesis 
 The reversible covalent addition of a functional group to a protein can modulate its 
biological function and its interaction with other molecules. Therefore, PTMs play a 
critical role in maintaining normal cell biology, but also influence pathological processes 
in many neurodegenerative diseases. 
 The N17 domain provides multiple sites of regulatory PTMs (Figure 5) that can 
modify HTT conformation and affect protein stability, modulating the propensity of 
misfolded HTT to form aggregates as well as its subcellular localization, clearance and 
toxicity. Phosphorylation is a major PTM occurring on N17, where threonine-3 (T3), 
serine-13 (S13) and serine-16 (S16) were found to be phosphorylated in vivo (Aiken et al., 
2009, Di Pardo et al., 2012, Thompson et al., 2009). These events seem to be less 
predominant in a disease context, as expanded HTTex1 shows lower levels of N17 
phosphorylation than normal HTTex1 (Aiken et al., 2009, Atwal et al., 2011, Cariulo et 
al., 2017a). Mounting evidence suggests that N17 phosphorylation is associated with 
reduced HTT accumulation and neurotoxicity (Atwal et al., 2011, Cariulo et al., 2017a, 
Chiki et al., 2017, Di Pardo et al., 2012, Mishra et al., 2012, Thompson et al., 2009). 
Phosphorylation of N17 serine residues by IKK promotes proteasome- and lysosome-
mediated turnover of wild-type HTT fragments. However, mutant HTT molecules are 
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inefficiently targeted for degradation, a process that was related with lower IKK activity 
(Thompson et al., 2009). Impairment of such IKK-dependent cleavage mechanisms would 
result in increased accumulation of mutant HTT and ultimately lead to the loss of striatal 
neurons observed in mutant HTTex1 transfected mice (Thompson et al., 2009). 
Experimental support for this hypothesis comes from a later study showing that IKK 
inhibition increases the accumulation of amyloid fibrils in striatal neurons expressing 
expanded HTTex1 (Caron et al., 2014). A very recent report indicates that T3 can also be 
targeted by IKK (Bustamante et al., 2015), although this finding has not been confirmed in 
vivo. Other kinases have been suggested to regulate N17 phosphorylation at S13 and S16 
(Atwal et al., 2011, Di Pardo et al., 2012). Pharmacological inhibition of CK2 leads to 
diminished N17 phosphorylation and greater mutant HTT toxicity, suggesting a protective 
role of S13/S16 phosphorylation (Atwal et al., 2011). GM1 ganglioside induces 
phosphorylation of both S13 and S16 while normalizing levels of a neurotransmission-
associated factor and restoring motor function in a mouse HD model (Di Pardo et al., 
2012). 
Additional evidence for the neuroprotective function of N17 phosphorylation is 
provided by experiments using animal models carrying phosphomimetic (E/D) or 
phosphoresistant (A) mutations in either full-length HTT (Gu et al., 2009) or HTTex1 
(Aiken et al., 2009, Gu et al., 2009, Thompson et al., 2009). Serine to aspartate (S→D) 
substitutions in a mouse HD model based on bacterial artificial chromosome (BAC) 
expression reverted motor and psychiatric disease-related phenotypes to that of healthy 
controls (Gu et al., 2009). Constitutive double S13/S16 phosphorylation also prevented the 
accumulation of mutant HTT aggregates and associated neuropathology in striatum and 
cortical layers of the brain (Gu et al., 2009). Marsh and colleagues showed that mimicking 
T3 phosphorylation ameliorates polyQ-mediated toxicity in a Drosophila HD model, but 
increases the amount of insoluble HTTex1 species (Aiken et al., 2009). This is consistent 
with the emerging view that not all aggregates are toxic, and differential effects of distinct 
aggregates may depend on the molecular context, including factors that are either intrinsic 
or extrinsic to the HTT protein. Recent studies on HTTex1 peptides demonstrated that 
inducing phosphorylation (Arndt et al., 2015, Bustamante et al., 2015, Cariulo et al., 
2017a), or adding a negative charge (D) (Chiki et al., 2017) to the T3 residue disrupts the 
N17 amphipathic α-helical structure leading to a decreased ability to form α-helix-rich 
tetramers that are required for amyloid nucleation and fibril elongation. However, the 
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inhibitory effect of T3D on mutant HTT aggregation propensity can be reversed by 
modifications in adjacent N17 residues (Chiki et al., 2017). Similarly, phosphomimetic 
mutations at S13 and S16 diminish the α-helical content of mutant HTTex1 (Atwal et al., 
2011, Mishra et al., 2012) and stabilize inter-domain interactions between N17 and PRD 
(Caron et al., 2013). The slower aggregation kinetics observed for phospho-serine HTT 
peptides (Caron et al., 2013, Gu et al., 2009, Mishra et al., 2012) seem to be due to 
reduced stability of transient oligomers rather than changes in monomer conformations, 
indicating that N17 phosphorylation may inflict a kinetic and/or thermodynamic barrier to 
the initial phases of oligomerization (Mishra et al., 2012). 
 Phosphorylation can regulate secondary modifications such as acetylation, 
ubiquitination and SUMOylation. For example, IKK-mediated phosphorylation of N17 
serine residues reduces HTTex1 poly-ubiquitination while promoting its poly-
SUMOylation and acetylation (Thompson et al., 2009). SUMO-1 (small ubiquitin-like 
modifier) or ubiquitin can modify HTT at identical lysine residues (K6, K9 and K15). 
SUMOylation stabilizes HTTex1, reduces its aggregation and increases its toxicity (Steffan 
et al., 2004), whereas ubiquitination enhances aggregation and reduces toxicity by 
targeting soluble HTT molecules for proteasomal degradation (Jana et al., 2005, Zucchelli 
et al., 2011). Analysis of wild-type HTT purified peptides by mass spectrometry showed 
that acetylation of K9 can occur concomitantly with Ser13 phosphorylation (Thompson et 
al., 2009). Acetylation of K9 does not seem to directly affect HTT aggregation (Chiki et 
al., 2017), and its role on HD pathogenesis remains poorly understood. Acetylation can 
also occur beyond HTTex1 as the acetyltransferase CREB-binding protein (CBP) was 
found to target K444, promoting the autophagic clearance of mutant HTT and preventing 
its toxicity in vivo (Jeong et al., 2009). Because acetylation is emerging as an important 
regulatory cellular mechanism for protein stability and turnover in health and disease 
(Glozak et al., 2005, Ravikumar et al., 2004, Yamamoto et al., 2006), one may speculate a 
similar role for N17 acetylation. In agreement with this idea, IKK is found to directly 
interact with CBP in the nucleus suggesting a possible link between IKK-mediated 
phosphorylation of N17 and CBP activity (Verma et al., 2004). N17 serine 
phosphorylation is indeed associated with increased HTTex1 nuclear accumulation (Atwal 
et al., 2011, Havel et al., 2011), which would in turn allow CBP-mediated acetylation, 
facilitating HTT traffic into autophagosomes (Jeong et al., 2009).  
 In summary, current evidence indicates that PTMs occurring within the N17 region 
are critical players in HD pathogenesis. Because PTMs are catalyzed by enzymes, they 
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may hold great potential as druggable targets for therapeutic interventions. However, many 
questions remain to be answered. For example, it is not yet clear whether altered pathway-
modifying PTMs are a cause or a consequence of mutant HTT misfolding and subsequent 
toxicity. We also still lack evidence about what protein phosphatases, if any, may modulate 
N17 phosphorylation and whether they would affect its aggregation and toxicity. 
Understanding how N17 PTMs impact on HTT behavior and modulate each other, as well 
as identifying molecular pathways involved in these processes, will provide deeper insight 
into HD pathogenesis and may therefore open novel avenues for treatment of this 
devastating disorder. 
 
Cell and non-cell autonomous mechanisms of striatal degeneration in HD 
 
 Despite the ubiquitous expression of HTT, selective striatal degeneration accounts 
for up to 95% of the cell loss observed within the brain of patients and animal models of 
HD. Such striatal vulnerability to mutant HTT-induced toxicity is attributed to particular 
biochemical and structural characteristics of the medium spiny neurons (MSNs) and/or to 
their functional connectivity within the complex neuronal networks of the striatum. These 
neurons are GABAergic cells that project to the Globus pallidus and Substantia nigra, and 
receive glutamatergic and dopaminergic input from the cortex and Substantia nigra, 
respectively (Ehrlich, 2012, Ross and Tabrizi, 2011). Various cell autonomous and non-
cell-autonomous mechanisms for MSN-preferential degeneration have been suggested, 
including reduced availability of neuronal survival factors such as neurotrophins and heat-
shock proteins, glutamatergic excitotoxicity, and MSN-specific SUMOylation of HTT 
mediated by a Ras homologue enriched in the Striatum (Rhes) (Figure 6). 
 
Loss of neuronal survival factors  
 In HD, loss of the brain-derived neurotrophic factor (BDNF) underlies synaptic 
dysfunction and impaired survival of MSNs. BDNF is produced in the cortex and 
anterogradely transported along the cortico-striatal tract to the MSNs, with the wild-type 
HTT playing an important role in mRNA synthesis and vesicular transport of BDNF 
(Gauthier et al., 2004, Zuccato et al., 2003). However, when the polyQ tract is abnormally 
expanded, HTT loses the ability to sequester the repressor element-1 silencing 
transcription factor/neuron-restrictive silencer factor (REST/NRSF) complex in the 
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cytoplasm, which is then translocated into the nucleus thereby leading to transcriptional 
repression of BDNF and other neuronal genes (Zuccato et al., 2001). Furthermore, axonal 
transport and release of BDNF from cortical neurons to their terminals within the striatum 
is also impaired in HD due to aberrant mutant HTT interactions with the huntingtin-
associated protein 1 (HAP1). HAP1 and dynactin are part of an important motor protein 
complex for intracellular trafficking in neuronal cells. Sequestration of HAP1 into mutant 
HTT inclusions leads to disruption of the HAP1/dynactin complex, disturbing the transport 
of BDNF vesicles along microtubules (Gauthier et al., 2004). Notably, BDNF vesicle 
traffic deficits appear to be a specific pathogenic mechanism of HD, since proteins 
involved in other neurodegenerative disorders do not affect BDNF transport (Gauthier et 
al., 2004). In support of this, mimicking phosphorylation of mutant HTT on S421 restores 
the binding of molecular motors to microtubules, which may indicate the existence of an 
upstream HTT-related signaling pathway for controlling BDNF transport (Colin et al., 
2008). Conversely, lower levels of BDNF in the synaptic cleft may induce the expression 
of particular caspases in striatal neurons, thereby contributing to the generation of 
cytotoxic HTT fragments, and ultimately, cell death (Hermel et al., 2004). Ellerby et al. 
showed that removal of BDNF from the extracellular medium of primary striatal cultures 
leads to enhanced caspase-2 gene transcription by a still unknown mechanism. Caspase-2 
expression is indeed increased in striatal and cortical post-mortem HD tissues from both 
patients and transgenic mice (Hermel et al., 2004). Furthermore, caspase-2 associates with 
full-length mutant HTT promoting its cleavage and hence modulating HTT cytotoxicity 
(Hermel et al., 2004). This study also suggests a mutual relation between mutant HTT and 
BDNF loss, and implicates caspase-2 in HD-mediated striatal cell death. This is consistent 
with the preferential accumulation of mutant HTT cytotoxic fragments in striatal neurons 
(Li et al., 2000). 
 Additional neurotrophic agents may also play significant roles for MSN survival by 
conferring neuroprotection against oxidative stress (Maksimovic et al., 2001, Maksimovic 
et al., 2002) and glutamate-induced excitotoxicity (Freese et al., 1992, Frim et al., 1993, 
Nakao et al., 1996, Schumacher et al., 1991). Neural implants of either nerve growth factor 
(NGF)- or basic fibroblast growth factor (bFGF)-producing cells prevented striatal loss in 
adult rats subjected to excitotoxic insults, whereas grafting of BDNF-secreting cells 
showed no protection in this model (Frim et al., 1993). Furthermore, treatment of striatal 
cultures with NGF and bFGF can regulate the levels of wild-type HTT in a dose-dependent 
manner, suggesting a gain-of-function mechanism of neuroprotection (Haque and Isacson, 
Huntington’s!disease!
!32 
2000). 
 
 
Figure 6.  Mechanisms underlying striatal vulnerability in HD. Given the diversity of HTT 
molecular interactions, its misfolding and aggregation can culminate with the disruption of essential cellular 
processes, such as transcription, intracellular signaling, mitochondrial activity, autophagy and proteasomal 
function. Although mutant HTT is likely to contribute predominantly to neuronal pathology, other cells 
might also become affected thereby triggering a cascade of pathological events that lead to dysfunctional 
cell-to-cell interaction mechanisms and ultimately neuronal death. These non-cell autonomous pathogenic 
mechanisms include excitotoxicity, dysregulation of the kynurenine pathway, neuroinflammation and spread 
of mutant HTT toxic species in a prion-like fashion. Adapted from (Bates et al., 2015). 
 
Heat-shock proteins in HD 
 Heat-shock proteins (HSPs) play important roles in the maintenance of protein 
homeostasis essential for cell survival in both health and disease (Hartl et al., 2011, 
Sakahira et al., 2002). In the HD context, heat-shock proteins HSP70 and HSP40 prevent 
the formation of HTT aggregates (Muchowski et al., 2000, Wacker et al., 2004) via direct 
interaction with the N17 domain (Monsellier et al., 2015). HSP70/40 specifically binds to 
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N17 acting as a shield in pro-aggregation interactions between N17 and flanking regions 
(Monsellier et al., 2015). In addition, it alters structural conformations of pre-formed HTT 
fibrils, rendering them less toxic (Monsellier et al., 2015). Reduced levels of HSP70 and 
co-chaperones of the DNAJ/HSP40 family are associated with increased HTT aggregation 
and toxicity (Hageman et al., 2010, Tagawa et al., 2007), while their overexpression 
prevents toxicity (Jana et al., 2000) and neurodegenerative phenotypes in Drosophila 
models of HD (Chan et al., 2000, Kazemi-Esfarjani and Benzer, 2000). Interestingly, 
HSP70 is upregulated in rat brain-derived cells found to be particularly resistant to HD 
pathology, but not in cortical and striatal neurons (Tagawa et al., 2007). The underlying 
mechanism seems to involve a positive feedback loop between mutant HTT and p53 gene 
expression (Bae et al., 2005, Feng et al., 2006, Tagawa et al., 2007) which in turn inhibits 
the transcriptional regulation of HSP70 in vulnerable neurons (Tagawa et al., 2007). 
However, this might not be exclusive since mutant HTT may also interfere with HSP70 
expression via sequestration of the NF-Y transcriptional factor (Yamanaka et al., 2008). 
The consequences of HSP70 loss in striatal neurons may also involve impaired endocytosis 
(Yu et al., 2014) and increased caspase-3-mediated cell death (Zhou et al., 2001). It is 
important to note that downregulation of striatal HSP70 levels and its co-chaperones may 
also occur during normal aging (Gleixner et al., 2014). This could explain, in part, the age-
dependent enhanced sensitivity of striatal neurons to mutant HTT.  
 
Glutamatergic excitotoxicity 
 Impairment of cortico-striatal synapses has also been linked to excitotoxicity. 
Glutamate is a major component of the CNS, serving as the primary excitatory 
neurotransmitter for synaptic plasticity stimulation and thereby being associated with 
learning and memory functions. Such biological processes depend on glutamate binding 
and activation of NMDA receptors (NMDAR). NMDARs mediate calcium influx to the 
cell, triggering a cascade of downstream regulatory events involved in mitochondrial 
activity, transcription, cellular responses to oxidative stress and programmed cell death 
pathways. Overstimulation of NMDAR or stimulation of extrasynaptic NMDAR due to 
excessive glutamate levels can lead to excitotoxic cell death, in a mechanism thought to be 
central to many neurodegenerative disorders (Labbadia and Morimoto, 2013, Roze et al., 
2011, Zuccato et al., 2010). There are increased levels of glutamate in the HD striatum due 
to reduced glial glutamate uptake (Behrens et al., 2002, Hassel et al., 2008, Lievens et al., 
2001, Miller et al., 2008). Mutant HTT accumulates in the nucleus of astrocytes and 
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downregulates the glutamate transporter GLT1 from their surface (Shin et al., 2005) by 
blocking the association of its promoter with the Sp1 transcription factor (Bradford et al., 
2009). This culminates with a deficient glutamate uptake and increased excitotoxicity in 
cell and animal models of HD (Shin et al., 2005). Altered levels of GLT1 mRNA in mice 
occur after the appearance of HTT aggregates in astrocytes (Lievens et al., 2001), 
suggesting that excitotoxicity might not be a cause but a consequence of HD pathology. 
Notably, mRNA levels of GLT1 are also found to be decreased in the striatum from HD 
patients (Arzberger et al., 1997). 
 
The quinolinic acid hypothesis  
 MSNs express higher levels of NMDAR relative to spared interneurons, which 
could also contribute to excitotoxicity and may account for the preferential loss of MSNs 
in HD (Raymond et al., 2011). NMDAR trafficking is increased in HD-striatal neurons as 
a consequence of aberrant interaction between mutant HTT and post-synaptic proteins 
required for NMDAR stability (Fan et al., 2009). Secondary metabolites derived from the 
kynurenine pathway (KP) of tryptophan degradation can also affect NMDAR activity 
(Figure 7). Altered tryptophan metabolism has been implicated in HD and other 
neurodegenerative disorders, with elevated levels of neurotoxic KP metabolites being 
correlated with increased oxidative stress and excitotoxicity (Maddison and Giorgini, 
2015). The mechanisms underlying KP activation in HD are not completely understood. 
However, it was recently demonstrated that expression of mutant HTT stimulates the 
transcription and release of proinflammatory cytokines in microglial cells (Crotti et al., 
2014, Kierdorf et al., 2013). Therefore, microglial activation could lead to increased levels 
of downstream KP metabolites, in particular quinolinic acid (QUIN), a strong agonist of 
NMDAR. Furthermore, induction of proinflammatory cell response can influence the 
enzymatic activity of kynurenine 3-monooxygenase (KMO) (Giorgini et al., 2008), which 
determines the balance between neurotoxic and neuroprotective KP metabolites (Giorgini 
et al., 2005). Strikingly, treatment with KMO inhibitors can prevent the toxic effects of 
mutant HTT in vivo, revealing KMO as a promising potential target for HD therapy 
(Campesan et al., 2011, Giorgini et al., 2005, Zwilling et al., 2011).  
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Figure 7. Schematic representation of the kynurenine pathway in mammals. The KP serves as 
the primary route of L-TRP degradation in mammals. This route ultimately leads to the synthesis of NAD+, a 
vital coenzyme for the maintenance of cellular energy homeostasis. The KP contains four neuroactive 
compounds derived from L-KYN. Both KAT and KMO enzymes can metabolize L-KYN, resulting in the 
production of neuroprotective (KYNA, highlighted in green) or neurotoxic (3-HK, 3-HANA and QUIN, 
highlighted in red) metabolites, respectively. While the mechanistic chemistry behind 3-HK and 3-HANA 
neurotoxicity is still poorly understood, QUIN and KYNA metabolites have been hypothesized to play a role 
in excitotoxicity via regulation of NMDAR activity. QUIN selectively activates NMDARs whereas KYNA 
acts as an antagonist of the receptor by blocking its glycine co-agonist site. Image from (Maddison and 
Giorgini, 2015). 
 
Altered striatal signaling pathways in HD 
 The small GTP binding protein Rhes is highly expressed in the striatum, where it 
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preferentially binds to mutant HTT acting as a SUMO E3 ligase, thereby inducing HTT 
SUMOylation while reducing its ubiquitination. Ultimately, Rhes leads to disaggregation 
of non-toxic aggregates of mutant HTT and reduces proteasomal degradation of soluble 
neurotoxic species (Subramaniam et al., 2009). Experimental evidence suggests that Rhes 
activity is controlled by extrasynaptic NMDARs, which once blocked cause 
downregulation of Rhes and decrease the levels of non-toxic HTT inclusions in cultured 
striatal cells (Okamoto et al., 2009). The same study further proposes a possible link 
between extrasynaptic NMDARs, mutant HTT and mitochondria-mediated cell death. In 
physiological conditions, NMDAR-mediated calcium influx activates MAPK signaling 
along with the protein phosphatase MSK1, which targets cyclic AMP (cAMP)-response 
element binding protein (CREB). CREB is a critical factor for mitochondrial gene 
transcription, thus playing an essential role in mitochondrial biogenesis and function (Roze 
et al., 2011). Excessive extrasynaptic NMDAR activity in mutant HTT-expressing neurons 
leads to inhibition of MAPK signaling, CREB phosphorylation and increased cell death 
(Okamoto et al., 2009).  
  Remarkably, interrelated signaling pathways resulting in HTTex1 phosphorylation 
are specifically altered in the striatum, which may also contribute to the spatial distribution 
of toxicity observed in HD. Compelling evidence indicates that regulation of dopaminergic 
and cAMP-regulated phosphoprotein (DARPP-32) activity in the striatum provides an 
indirect modulatory mechanism of HTTex1 phosphorylation (Di Pardo et al., 2012, 
Metzler et al., 2010). DARPP-32 has been identified as a key integrator of glutamate and 
dopamine signaling in MSNs, serving as a neuroprotective agent against NMDA-induced 
excitotoxicity by acting as a potent inhibitor of PP1 (Svenningsson et al., 2004). The loss 
of DARPP-32 expression in a mouse HD model correlates with increased PP1 activity and 
decreased S421 HTT phosphorylation, which in turn confers enhanced striatal vulnerability 
to excitotoxicity (Metzler et al., 2010). Interestingly, normal levels of DARPP-32 striatal 
expression can be restored by GM1-mediated phosphorylation of N17 (Di Pardo et al., 
2012), suggesting a bidirectional relation between DARPP-32 and HTT. Finally, the 
protein kinase C and casein kinase 2 substrate in neurons (PACSIN1), also known as 
syndapin 1, has been shown to overlap with molecular mechanisms of synaptic 
transmission known to be affected in HD, such as NMDAR recycling, neuronal spine 
formation and microtubule organization (Zuccato et al., 2010). Moreover, PACSIN1 is 
required for HTT structural stability via direct interactions with the N17 and PRD domains 
(Caron et al., 2013). However, such interactions are affected by increased length of the 
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polyQ stretch and/or by decreased overall phosphorylation levels via treatment with CK2 
inhibitors. Given that both N17 and PACSIN1 are substrates for CK2 (Plomann et al., 
1998), it has been hypothesized that PACSIN1 may affect HTT conformation and stability, 
and potentially its aggregation and toxicity, in conjugation with striatal-specific signaling 
events (Atwal et al., 2011, Caron et al., 2013). 
  
Intercellular transmission of mutant huntingtin 
  Current studies indicate that spatiotemporal patterns of neurodegenerative disease 
progression are highly selective, which may imply a role for neuronal connection-mediated 
propagation of protein misfolding in pathology. In the particular case of HD, there is 
increasing consensus that mutant HTT is able to spread between cells in several different 
ways, which may underlie non-cell autonomous mechanisms of striatal vulnerability. First 
evidence came from post-mortem human studies. Neuronal grafts of striatal tissue 
transplanted intracerebrally into HD patients about a decade before death exhibited 
markers of inflammation and excitotoxicity, as well as disease-like degeneration with 
preferential loss of projection neurons in comparison to interneurons (Cicchetti et al., 
2009). Later work from the same authors confirmed the presence of mutant HTT 
aggregates within the transplanted tissue, suggesting a potential mechanism of intercellular 
transfer between host cells and grafted neurons (Cicchetti et al., 2014). Studies in cell and 
animal models further indicate that the spread of mutant HTT from one cell to another 
might take place in HD (Babcock and Ganetzky, 2015, Pearce et al., 2015, Pecho-
Vrieseling et al., 2014). Although synaptic transfer and lysosomal exocytosis have been 
implicated in transmission of Aβ, Tau and α-syn aggregates, this seems not to be the case 
of HTT in HD (Costanzo and Zurzolo, 2013, Victoria and Zurzolo, 2017). Unlike other 
aggregation-prone proteins, mutant HTT does not appear to associate with membrane 
vesicles upon cellular internalization, which precludes potential exo- and endocytic 
mechanisms of transfer (Ren et al., 2009). Instead, extracellular mutant HTT aggregates 
can directly bind to the cell surface, being readily taken up into the cytosol and 
subsequently gaining access to the nucleus and other cellular compartments. Internalized 
aggregates can be transmitted across dividing cells and persist in culture for over 80 
generations, although the fraction of cells exhibiting this phenotype remained low (Ren et 
al., 2009). Similarly, experiments in living cells showed low rate movement of mutant 
HTT between cells (Herrera et al., 2011). Nonetheless, this phenomenon can be further 
accelerated upon selective lysis of the donor cells (Ren et al., 2009), which could suggest a 
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possible link between cell death and widespread HTT aggregation in the brain. Another 
proposed mechanism for interneuronal transmission of mutant HTT aggregates is the 
formation of TNTs (Costanzo et al., 2013). These structures are long thin actin-containing 
bridges that allow cell-to-cell contacts for the exchange of molecules and organelles under 
both physiological and pathological conditions (Victoria and Zurzolo, 2017). An increase 
in TNT formation can occur as a result of oxidative stress (Wang et al., 2011) and 
accumulation of HTT aggregates (Costanzo et al., 2013). TNT formation might be induced 
as a cell attempt to get rid of aggregated toxic species, presumably via activation of ROS-
induced stress pathways (Victoria and Zurzolo, 2017). In Drosophila, phagocytic uptake of 
neuronal HTT is followed by its accumulation and aggregation in the glial cytoplasm 
(Pearce et al., 2015). This process is hypothesized as a neuroprotective clearance 
mechanism against the spread of mutant HTT toxicity (Pearce et al., 2015, Pearce, 2017). 
However, another hypothesis would be that phagocytic glia might serve as an alternative 
route for spreading of HTT aggregates hence accounting for non-cell autonomous-
associated toxicity (Victoria and Zurzolo, 2017). This is supported by the observation that 
selective expression of mutant HTT in astrocytes induces early neuronal dysfunction 
(Meunier et al., 2016) and increased gliosis (Bradford et al., 2009), being sufficient for 
causing HD-related phenotypes in mice (Bradford et al., 2009). Moreover, mice with both 
neuronal and glial expression of mutant HTT develop HTT aggregates in their astroglial 
brain cells (Bradford et al., 2010, Lievens et al., 2001) prior to astrocyte dysfunction and 
excitotoxicity (Lievens et al., 2001). Thus, suggesting a positive feed-forward loop 
between HTT aggregation and glia-related neurotoxicity that may accelerate disease 
progression (Bradford et al., 2010). !
&
&
&
&
&
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1.3.&Model&Systems&of&Neurodegenerative&Diseases&
&
 Neurodegeneration can result from a variety of environmental and genetic factors. 
Although common neurodegenerative disorders appear to occur mostly sporadically, the 
identification of causative gene mutations through human genome-wide association studies 
has facilitated a better understanding of molecular mechanisms underlying these disorders. 
Indeed, the discovery of APP, SNCA, HTT and TDP-43 gene mutations has been 
instrumental in developing experimental models of AD, PD, HD and ALS, respectively. 
These disease models range from yeast and C. elegans (nematode) to mammals and human 
cell culture systems, typically exhibiting many features of familial forms of the human 
disease, clinically very similar to sporadic cases. However, none of the existing models 
fully recapitulates the human disease and the choice of a particular model may depend on 
the question under investigation. As such, the use of different models as complementary 
tools for dissecting the pathogenesis of disease should be considered if results are to be 
extrapolated or generalized to humans (Narayan et al., 2014). In this section, the 
bimolecular fluorescence complementation assay and its application to the study of 
aberrant protein oligomerization in neurodegenerative disorders is discussed, as well as the 
use of Drosophila melanogaster as a model organism to study neurodegenerative and 
motor disorders such as HD. 
 
Bimolecular fluorescence complementation: a cell-based assay for 
studying protein oligomerization 
 
 Since its discovery in 1958 by Frederic M Richards (Richards, 1958), protein 
complementation has been widely used for the development of biological assays 
(Shekhawat and Ghosh, 2011). Such assays rely on the principle that most proteins can be 
digested into two or more fragments without activity once isolated, but that recover 
activity when they are mixed together in certain conditions (Kerppola, 2008). 
Complementation properties of fluorescent proteins were first described in the beginning 
of this century. The green fluorescent protein (GFP) was used to develop a protein 
reassembly system based on antiparallel leucine zipper heterodimer formation for the 
detection of artificial protein-protein interactions in bacteria (Ghosh et al., 2000). Kerppola 
and colleagues then used fluorescence complementation for the analysis of protein-protein 
Modeling!neurodegenerative!disorders!
!40 
interactions in mammalian cells and named the method bimolecular fluorescence 
complementation (BiFC) assay (Hu et al., 2002). This assay involves the fusion of two 
non-fluorescent fragments of a reporter protein to the proteins of interest which, when 
interacting, form a fluorescence complex by bringing the reporter fragments back together 
and reconstituting the activity of the reporter protein (Figure 8A). In the following decade, 
BiFC systems evolved considerably. There are currently BiFC systems with virtually every 
fluorescent protein in the spectrum, and their advantages and disadvantages have been 
extensively analyzed. Probably the greatest advantage of BiFC assays over other 
complementation assays is the fact that they enable the direct visualization of protein 
interactions in living cells, without the need for staining with exogenous molecules (Chen 
et al., 2006a, Kerppola, 2008). However, the formation of fluorescent protein complexes is 
fundamentally irreversible and does not occur instantly, requiring a maturation period in 
the range of minutes. Such features complicate the visualization of dynamic reversible 
interactions, but they can be useful for trapping and visualization of rare complexes. For 
example, in the context of neurodegenerative diseases, the stabilization of certain protein-
protein interactions facilitates the study of transient species forming during the aggregation 
process, such as dimers and/or small oligomers (Herrera et al., 2011, Outeiro et al., 2008). 
Another potential limitation of some fluorescent proteins is that their activity is restored 
more efficiently at temperatures below 30ºC, which is not ideal for mammalian cell 
studies. This disadvantage is now overcome with the availability of third generation-
fluorescent proteins, such as Venus or Cerulean (Nagai et al., 2002). These variants are 
brighter and able to efficiently reconstitute the fluorophore at 37ºC. Finally, original BiFC 
systems were limited to the study of the interaction between two proteins, but current 
multicolor BiFC systems allow the analysis of multiple protein-protein interactions 
simultaneously (Hu and Kerppola, 2003). Multicolor BiFC is based on the fact that N-
terminal fragments from different GFP-derived proteins have different excitation/emission 
spectra when combined with the same C-terminal fragment. As such, each protein 
interaction produces a different type of fluorescence that can be measured simultaneously 
in the same cell. Alternatively, BiFC systems can be combined with other methods, in 
particular FRET/FLIM, to analyze the interaction between more than two proteins 
simultaneously (Shyu et al., 2008). 
 As mentioned above, the BiFC system has also proven useful as a cellular model of 
neurodegenerative disorders. We and others have developed BiFC models for the 
visualization of toxic aggregation-prone proteins in living cells, including α-syn (Outeiro 
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et al., 2008), HTT (Herrera et al., 2011, Lajoie and Snapp, 2010), APP (Chen et al., 2006a) 
and Tau (Blum et al., 2015, Chun et al., 2011). Besides their feasibility, and in contrast 
with other techniques, these systems make it possible to monitor closely the first steps of 
aggregation, i.e. oligomerization, owing to the fact that monomers, soluble oligomeric 
species and large inclusion bodies are visually distinguishable (Figure 8B). Monomers are 
not fluorescent and only dimers, oligomers and larger inclusions produce fluorescence. 
Fluorescence from dimers and oligomers is homogeneously distributed, while large 
inclusions are foci of concentrated, intense fluorescence. This allows the determination of 
the number, size and subcellular location of large inclusions and the assessment of the 
dynamics of oligomeric species and inclusions of different sizes over time, for example. 
Because dimers and oligomers cannot be distinguished by this method, further toxicity and 
biochemical assays should complement the initial BiFC results, in order to characterize 
both the nature and toxicity of oligomeric species and the levels of expression of the 
constructs. If insoluble aggregates are formed, Triton-X-soluble and -insoluble fractions, 
sucrose gradients or filter trap assays can be used to more accurately characterize larger 
inclusions (Goncalves et al., 2010, Herrera et al., 2011).  
 
 
Figure 8. BiFC models of neurodegenerative disorders. (A) The non-fluorescent halves of a reporter 
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protein are fused to two proteins of interest (green bars). If the proteins dimerize, the non-fluorescent 
fragments are close enough to each other to reconstitute the fluorophore. The resulted fluorescence is then 
directly proportional to the amount of dimers/oligomers within cells and can be easily measured by 
conventional methods such as flow cytometry, western blotting and fluorescence microscopy. (B) While 
monomers do not show fluorescence, dimers and oligomers show a homogeneously distributed fluorescence 
in the subcellular compartment where they are formed; larger inclusions are observed as brighter regions with 
different morphologies that ‘scavenge’ fluorescence from the rest of the cell. The localization of oligomers 
and aggregates depends on the protein of interest and the particular experimental conditions. In the HTT-
Venus BiFC model, fluorescence is mostly restricted to the cytoplasm and aggregates are very frequent. 
Scale bar: 20 μm. Obtained from (Herrera et al., 2014). 
 
 Another possible use for the BiFC system in the study of neurodegenerative 
disorders is the characterization of aberrant interactions between different disease-related 
proteins. Using this method, we found that both α-syn (Herrera and Outeiro, 2012, Pocas 
et al., 2015), Tau (Blum et al., 2015) and DJ-1 (Sajjad et al., 2014) co-aggregate with 
mutant HTT and alter its aggregation pattern in living cells, suggesting that alterations of 
these proteins may also contribute to HD pathogenesis. We have also used successfully our 
HTT-Venus BiFC system to show cell-to-cell transmission of mutant HTT in living cells 
by flow cytometry (Herrera et al., 2011). In that study, two independent populations of 
cells were transfected with each of the BiFC constructs. When these cell populations were 
isolated, they did not display fluorescence, as determined by flow cytometry. However, 
when cell populations were mixed, some fluorescent cells appeared, demonstrating the 
traffic of mutant HTT between cells.  
 In summary, the use of BiFC along with other complementary methodologies 
provides a promising approach for the search of novel molecular targets involved protein 
misfolding and aggregation. Moreover, the BiFC assay constitutes a simple and easy tool 
for performing high-throughput genetic and pharmacological screens in a predictable, 
timely and cost-effective manner (Amaral et al., 2013). !
Modeling HD in Drosophila melanogaster 
 
 The fact that HD has a monogenic origin has enabled the development of reliable 
models for exploring different aspects of HTT aggregation and toxicity. Bioinformatic 
analyses and the cloning of the HD gene from ancient organisms have revealed a strong 
homology of the HTT sequence across evolution.  Similarities can be found among 
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mammals, but also in more distant relatives such as Drosophila melanogaster. In contrast 
to mammals, the fruit fly offers great advantages in terms of rapid generation and low cost 
maintenance, and it is therefore being extensively used to model HD and other human 
neurodegenerative disorders. Remarkably, more than 75% of genes identified in human 
diseases have counterparts in Drosophila (Chien et al., 2002), and fundamental cellular 
processes related to neurobiology are similar between Drosophila and humans, including 
synaptic transmission, synaptogenesis, subcellular trafficking and age-related cell death. 
Moreover, critical signalling pathways involved in brain development are also conserved 
due to a common evolutionary origin for the CNS of invertebrates and vertebrates (Hirth 
and Reichert, 1999). Despite its simpler nervous system as compared to humans, the fruit 
fly is capable of performing multiple tasks involving learning and memory functions, and 
show complex sleep and motor behaviours (Ambegaokar et al., 2010, Lessing and Bonini, 
2009). Additional features of Drosophila make it an attractive organism for use in genetic 
and pharmacological screenings of potential modifiers of neurodegeneration. First, it has a 
life cycle of only 2-weeks and relatively short lifespan, although one single cross may give 
rise to a large number of genetically identical individuals (Hirth, 2010). This allows the 
study of disease development and progression within the same population, in a statistically 
significant manner. Second, its well-known anatomy displays unique features such as 
compound eyes that enable rapid and detailed experimentation in the search of phenotypic 
suppressors or enhancers (Hirth, 2010). Flies also feature both blood-brain and blood-
retinal barriers established by septate junctions formed between glial cells or between cone 
and pigment cells, respectively, which prevent passive entrance of small molecules to their 
CNS, including endogenous factors, environmental toxins and drugs (Pinsonneault et al., 
2011). This characteristic offers the possibility of accurately assessing efficacy of 
candidate drugs for brain pathologies. Finally, the simplicity and manipulability of the fly 
genome - comprised in only four pairs of chromosomes - have allowed the development of 
powerful genetic tools for dissecting disease mechanisms. Indeed, the ease of creating gene 
deletions, insertions, knock-downs or transgenics, in comparison to mammals, is probably 
the most important reason for the successful use of Drosophila to model and study human 
neurodegenerative diseases (Venken et al., 2011). 
 The GAL4/UAS (upstream activating sequence) system provides an efficient way 
to spatially and temporally control the expression of transgenes in Drosophila (Figure 9). 
This binary approach requires two transgenic lines: the driver line that expresses GAL4, a 
transcriptional activator protein from yeast, in a specific tissue (i.e. under the control of a 
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tissue- or cell-specific promoter), and a second line containing a UAS-dependent 
transgene. The generation of UAS lines has been achieved by taking advantage of the 
naturally found transposable element in Drosophila, the P-element. P-elements can be 
engineered to carry foreign sequences thus allowing for integration of a single UAS-
dependent transgene at random locations in the fly genome. Although this system favours 
the creation of several independent transgenic lines harbouring the same UAS construct, 
one should be aware that expression levels of the transgene and consequent severity of a 
degenerative phenotype might vary between lines due to chromatin position effects. The 
development of a new high-efficient genomic integration system based on phiC31 
integrase-mediated DNA recombination has made it possible to overcome disadvantages of 
the former system by allowing site-specific insertions in the genome, and thereby 
providing a particular expression profile of the transgene. Once the UAS line carrying the 
transgene of interest is established, it can then be crossed together with a driver GAL4 line 
to induce transgene expression. GAL4 specifically bind to UAS activating the transcription 
of the reporter gene, which is expressed in the progeny, in a tissue-specific manner. 
Ubiquitous expression of polyQ-expanded HTTex1 by actinGAL4 or tubulinGAL4 drivers 
is extremely toxic causing almost complete pre-adult fly lethality (Green and Giorgini, 
2012). To overcome potential deleterious effects of the transgenes, tissue-specific drivers 
can be employed. This also confers a particular advantage in the study of 
neurodegenerative disease owing to the possibility of addressing cell-type specific toxicity 
of disease-associated proteins. In addition, the temperature-sensitivity of the GAL4/UAS 
system provided by the TARGET (temporal and regional gene expression targeting) 
method allows the temporal control of transgene expression. This method relies on the 
antagonistic action of a yeast temperature-sensitive protein, the GAL80, over GAL4 
expression. When combined with GAL4/UAS constructs at temperatures above 29ºC, 
GAL80 is inactivated resulting in derepression of GAL4 activity and consequent onset of 
the UAS-dependent transgene expression (Elliott and Brand, 2008). The strength of this 
technique is illustrated in a study showing that polyQ-containing proteins being expressed 
in old flies are more prone to form toxic amyloids than those from younger individuals, 
suggesting that different protein aggregation patterns may be related to age. These 
observations have led to the conclusion that age-related changes in aggregate 
characteristics may help to explain the late-onset nature of HD and other polyglutamine 
diseases (Tonoki et al., 2011).  
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 Besides its utility in mis-expression studies, the GAL4/UAS system also applies to 
RNA interference (RNAi) knockdown studies, in which expression of the Drosophila 
homologue of a certain human gene is reduced allowing loss-of-function analyses (Duffy, 
2002). Indeed, the use of similar approaches in Drosophila has provided hints to the 
physiological role of the HTT protein. For example, it has been shown that null mutants for 
the Drosophila HD gene (dhtt) display no obvious developmental defects, but their 
mobility is strongly compromised later in life and they have significantly lower longevity 
(Zhang et al., 2009).  Dhtt knockout phenotypes may result from disruption of normal 
synaptic function and axonal trafficking in the absence of HTT (Zhang et al., 2009). 
Following the same approach, recent studies have also implied HTT as a scaffold for 
selective autophagy (Rui et al., 2015) and as an epigenetic modulator for chromatin 
organization during development (Dietz et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Modeling human neurodegenerative disease in Drosophila. The GAL4/UAS binary 
system allows the ectopic expression of any given sequence, including a protein coding sequence from a 
human disease-associated gene or a noncoding RNA. This system is based upon crossing two independent 
transgenic lines, one line expressing a tissue-specific GAL4 promoter [e.g., elav (embryonic lethal, abnormal 
visual), GMR (glass multiple reporter) and Rh (rhodopsin)], and another line carrying a transgene of interest 
under the control of several copies of the UAS sequence. In the latter, the transgene of interest is inserted in a 
pUAST vector downstream of the UAS, and then injected into Drosophila embryos by well-established 
techniques. Because transcription of the transgene requires the presence of GAL4, the two components are 
brought together in the progeny of a simple genetic cross, whereby triggering the expression of the transgene 
in a tissue-specific manner. Obtained from (Elliott and Brand, 2008). 
 
 Although the HTT gene is well conserved throughout evolution, the Drosophila 
homolog does not contain a sequence of CAG repeats (Li et al., 1999). As such, and 
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because HD is thought to be caused primarily by toxic dominant gain-of-function 
mechanisms, the simple expression of the human polyQ-expanded HTT protein has been 
used as a strategy to accurately model the disease in this organism (Green and Giorgini, 
2012, Krench and Littleton, 2013). Most common drivers used to model HD in Drosophila 
include elavGAL4, GMRGAL4 and the rhabdomere-specific driver Rhodopsin (RhGAL4). 
The elavGAL4 driver is broadly expressed throughout the nervous system in both neurons 
and glial cells from embryogenesis onward (Berger et al., 2007). Pan-neuronal expression 
of mutant HTT by the elavGAL4 driver causes pronounced neurodegenerative phenotypes 
in the eye or CNS, including degeneration of photoreceptor neurons often accompanied by 
developmental defects and reduced lifespan. The Drosophila eye is a compound structure 
in which about 750 units, called ommatidia, are arranged in a highly regular pattern. Each 
ommatidium contains eight light-sensitive neurons (rhabdomeres) composed of rhodopsin 
molecules, seven of which are visible under the light microscope (Green and Giorgini, 
2012). Flies expressing HTTex1 containing 93Q under the control of the elavGAL4 driver 
exhibit progressive rhabdomere loss that can be easily quantified using the well-established 
pseudopupil assay (Figure 10). The GMRGAL4 and RhGAL4 drivers can also be employed 
to assess neurodegeneration in the Drosophila compound eye. Given their eye-specific 
expression, these drivers allow the study of highly toxic constructs that would be lethal if 
they were more broadly expressed. Furthermore, GMRGAL4-driven mutant HTT flies 
yield a typically “rough” eye phenotype that can be readily observed without the need for 
quantitative measurements, thereby providing an appropriate model for genetic 
enhancer/suppressor screens (Marsh et al., 2003, Pocas et al., 2015). 
Larva eye imaginal discs preparations are another advantage of the model, allowing 
imaging of fluorescent-tagged proteins in vivo (Branco-Santos et al., 2017, Pocas et al., 
2015). Development of photoreceptor cells begins in the third larva stage, where the eye 
imaginal discs complete their growth (Marsh et al., 2003). By using transgenic Drosophila 
lines encoding mCherry-tagged wild-type or mutant versions of HTTex1, we recently 
showed that GMR-driven expression of polyQ-expanded HTTex1 produced a large 
number of aggregates within larval eye imaginal discs. On the contrary, no inclusion 
bodies were observed in wild-type HTT expressing larvae, although its diffused pattern of 
expression was suggestive of the presence of soluble oligomeric species. Such phenotypes 
are similar to those seen in human cells (Branco-Santos et al., 2017, Herrera et al., 2011), 
which further indicate that Drosophila may share common mechanisms of polyQ 
pathogenesis. Other tissue-specific drivers may prove useful in mimicking behavioral 
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aspects of HD in Drosophila. This is the case of the c164GAL4, a motor neuron-specific 
driver widely used to study motor dysfunction in Drosophila models of HD and other 
diseases affecting fine control of movements. Motor performance in Drosophila can be 
assayed by standardized behavioral testing of adult negative geotactic responses or larval 
crawling activity. While adult HD flies exhibit progressive loss of normal motor function 
as evidenced by their inefficient ability to climb or fly to the top a tube in a specified 
amount of time (Branco-Santos et al., unpublished work), HD larvae perform greater 
crawling activity but weaker exploratory behavior of the surrounding environment relative 
to controls (Steinert et al., 2012) (Figure 11). Although apparently contradictory, both 
phenotypes denote altered innate behaviors indicative of extensive cellular toxicity and/or 
changes in metabolism. Larval crawling assays are particularly useful when expression or 
deletion of a gene causes lethality in pupal or adult stages and they allow to screen directly 
for chemical compounds that may act on early stages of the disease. 
 
Figure 10. Assaying neurodegeneration in Drosophila HD models. The light microscopy-based 
pseudopupil assay enables the quantification of photoreceptor neurons in the adult fly eye, being frequently 
used to assess polyQ-mediated neurotoxicity in Drosophila. (A) Representative images from wild-type (WT) 
and elav-driven HTTex1 flies carrying 93Q (HTT93Q). Images obtained from (Green and Giorgini, 2012). 
(B) Quantification of mean rhabdomeres (± SEM) per ommatidium. A normal fly (WT) typically has 7 
visible photoreceptors in each ommatidia, whereas HD flies exhibit an average of 5 rhabdomeres at one day 
of age, with that number being significantly reduced over time, in an age-dependent manner. Statistical 
analysis by two-way ANOVA, n=30 flies per genotype, *p<0.0001.  
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Figure 11. Larval crawling behavior defects in a Drosophila model of HD. (A) Representative 
pattern of crawling behavior in control (c164GAL4) and larvae overexpressing HTT93Q in motor neurons, 
via the c164 promoter. HTT93Q larvae typically exhibit a weaker exploratory behavior when compared to 
HTT20Q as observed by a significant decrease in number of turns (C) and a correlated significant increase in 
distance travelled (B). Greater crawling activity of HD larvae is demonstrated by a significant increase in 
distance/turn in comparison to control larvae (D). Data are mean ± SEM. *significant versus HTT20Q, 
p<0.05. Scale bar, 10 mm. (Branco-Santos et al., unpublished work). 
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The most common histopathological hallmark of HD is the presence of intracellular 
HTT aggregates associated with neuronal loss in the striatum and deep layers of the cortex. 
These inclusions are generated by the misfolding and subsequent aggregation and 
intracellular accumulation of mutant HTT. Although the precise molecular mechanisms 
underlying HD pathogenesis are still not clear, a suite of intramolecular and intermolecular 
factors have been identified and associated with HTT aggregation and toxicity. Current 
evidence indicates that PTMs and specific protein-protein interactions play a key role in 
HD pathogenesis. Identifying the intracellular pathways involved in HTT PTMs and 
understanding how these modifications and/or other proteins modulate HTT aggregation 
and toxicity may provide further insight into the molecular basis of this devastating 
disorder. Thus, by taking advantage of a series of BiFC systems and Drosophila models of 
HD, the aims of the present PhD work were to: 
 
1) Explore the role of specific PTMs on mutant HTT oligomerization, aggregation and 
toxicity (Chapter III, section A) 
! Characterize single HTT N-terminal phosphomutants in vitro and in vivo; 
! Identify specific protein phosphatases involved in mutant HTT N-terminal 
phosphorylation, aggregation and toxicity in vitro and in vivo; 
! Determine the effect of protein glycation on mutant HTT toxicity in vivo. 
 
2) Understand how aberrant protein-protein interactions may modulate HD pathogenesis 
(Chapter III, section B) 
! Study the effect of aggregation-prone proteins upon mutant HTT aggregation and 
toxicity; 
! Unravel molecular pathways involved in mutant HTT toxicity mediated by prion-
like proteins.  
 !
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Abstract 
 
 Huntington’s disease (HD) is an incurable and fatal neurodegenerative disorder 
characterized by the accumulation of mutant huntingtin protein (HTT) into intracellular 
proteinaceous inclusions in specific brain tissues. The first 17 amino acids of the 
huntingtin protein (N17) undergo several post-translational modifications that modulate the 
propensity of huntingtin to form aggregates, and alter its subcellular localization, clearance 
and toxicity.  In this study, our aim was to understand how single phosphorylation events 
in N17 regulate huntingtin oligomerization, aggregation and toxicity, and to identify 
protein phosphatases that could be involved in these processes. Using a bimolecular 
fluorescence complementation (BiFC) assay, we showed that expression of single 
phosphomimic mutations within N17 phosphorylatable residues (T3, S13 or S16) 
completely abolished HTT aggregation in human cells. In Drosophila, mimicking 
phosphorylation at T3 decreased HTT aggregation in larvae and adult dopaminergic 
neurons. Interestingly, pharmacological or genetic inhibition of protein phosphatase 1 
(PP1) prevented HTT aggregation in both human cells and Drosophila while increasing 
neurotoxicity in flies. In summary, our findings provide novel insights into the role of N17 
phosphorylation in HD pathogenesis. 
 
Introduction 
 
 Huntington’s disease (HD) is characterized by the loss of medium spiny neurons in 
the striatum. The main histopathological hallmark of HD is the misfolding and subsequent 
intracellular aggregation of a mutant form of huntingtin (HTT) (Rochet, 2007). HTT is a 
very large protein (~350 kDa), but expression of exon 1 is sufficient to produce HD-like 
features in various cellular and animal models (Bates et al., 1998, Bates et al., 2015, 
Mangiarini et al., 1996). HTT exon 1 (HTTex1) contains a polyglutamine (polyQ) tract 
that, in normal conditions, is constituted by 6 to 35 glutamine residues. An expansion of 
Huntingtin!N<terminal!phosphorylation!
!58 
the polyQ tract beyond 35 glutamines induces the misfolding and aggregation of mutant 
HTT and causes HD (Ambrose CM and Hummerich H, 1994, The Huntington's Disease 
Collaborative Research Group, 1993). Mutant HTT with longer polyQ expansions is more 
prone to aggregate, and leads to earlier onset of the disease (Bates et al., 2015, DiFiglia et 
al., 1997, Krobitsch and Lindquist, 2000). 
The polyQ tract is preceded by an N-terminal sequence of 17 amino acids (N17 
domain) that is highly conserved, suggesting that this domain plays an important role in the 
function of HTT (Atwal et al., 2007, Burke et al., 2013b, Cornett et al., 2005, Kuiper et 
al., 2017, Michalek et al., 2013, Rockabrand et al., 2007, Xia et al., 2003). The N17 
domain plays a key role in the aggregation pathway of HTT, where the protein associates 
first into alpha-helical oligomers and acts as a seed to concentrate and facilitate the 
formation of larger aggregates and fibrils (Crick et al., 2013, Jayaraman et al., 2012, 
Thakur et al., 2009, Wetzel, 2006, Williamson et al., 2010). Deletion or posttranslational 
modifications, such as phosphorylation, ubiquitination and SUMOylation, in the N17 
produce striking effects in the stability and aggregation of HTT, as well as in cell viability 
(Aiken et al., 2009, Choudhury and Bhattacharyya, 2015, Gu et al., 2009, Gu et al., 2015, 
Havel et al., 2011, Jana et al., 2005, Maiuri et al., 2013, Mishra et al., 2012, Steffan et al., 
2001, Steffan et al., 2004, Thompson et al., 2009, Veldman et al., 2015, Zheng et al., 
2013, Zucchelli et al., 2011). The N17 domain has 3 phosphorylatable amino acid residues 
– threonine at position 3 (T3), and serine residues at positions 13 and 16 (S13 and S16). 
Constitutive phosphorylation of T3 enhances mutant HTT aggregation, but its role in HTT 
toxicity remains unclear (Aiken et al., 2009). Previous studies have focused on double 
S13/S16 phosphorylation (Atwal et al., 2011, Caron et al., 2014, Di Pardo et al., 2012, Gu 
et al., 2009, Khoshnan et al., 2004, Thompson et al., 2009), despite the fact that double 
S13/S16 phosphorylation is less frequent than single T3 or S13 phosphorylation 
(Bustamante et al., 2015, Huang et al., 2015), and that overexpression of particular kinases 
is required in order to achieve double S13/S16 phosphorylation (Thompson et al., 2009). 
Single phosphorylation and phosphomimetic modifications in S13 or S16 modulates 
the formation of HTT fibrils and reduces the oligomerization rate in cell-free systems, just 
as the double S13/S16 phosphorylation does in vitro and in vivo (Gu et al., 2009, Havel et 
al., 2011, Mishra et al., 2012, Thompson et al., 2009). Casein Kinase 2 (CK2) inhibitors 
reduce S13/S16 phosphorylation and enhance toxicity (Atwal et al., 2011), while GM1 
ganglioside induces S13/S16 phosphorylation and restores motor and molecular deficits in 
HD mice (Di Pardo et al., 2012). IKK, a kinase involved in inflammatory responses, also 
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regulates T3 and S13/S16 phosphorylation and modulates HTT aggregation (Atwal et al., 
2011, Bustamante et al., 2015, Caron et al., 2013, Thompson et al., 2009). While several 
protein phosphatases control HTT dephosphorylation beyond exon 1 and modulate its 
toxicity (Ermak et al., 2009, Marion et al., 2014, Pardo et al., 2006, Pineda et al., 2009, 
Rosenstock et al., 2011), it is not known which protein phosphatases, if any, regulate 
phosphorylation of the N17 domain. 
 Here, we elucidate the contribution of single N17 phosphorylation events towards 
HTTex1 oligomerization, aggregation and toxicity in cell cultures and a Drosophila HS 
model. We screened a collection of protein phosphatase chemical inhibitors to identify 
modulators of HTTex1 oligomerization, aggregation and toxicity. Inhibition of PP1 
prevents HTTex1 aggregation but not oligomerization in human cells. In addition, 
downregulation of PP1 in Drosophila neurons reduces HTTex1 aggregation and increases 
its toxicity. In total, our findings point to a critical role of T3 phosphorylation in HTTex1 
aggregation and support the targeting of PP1 for therapeutic interventions in HD. 
 
Results 
 
Single N-terminal phosphomutants modulate mutant huntingtin aggregation in human 
cells 
 In order to investigate the contribution of each phosphorylatable residue (T3, S13 
and S16) within the N17 towards HTTex1 aggregation, we first interrogated whether single 
N17 phosphorylation events modulate aggregate formation. We employed our HTTex1-
Venus BiFC system for the visualization of both oligomeric species and inclusion bodies 
of HTTex1 in living cells, which we have previously described (Herrera et al., 2011). 
Using the 97QHTTex1-Venus constructs as templates, we introduced point mutations in 
each of the phosphorylatable residues within the N17, changing these amino acids to either 
alanine or aspartic acid (Figure 12A). Mutations to alanine (A, phosphoresistant) resemble 
biophysical properties of a constitutive unphosphorylated state, and mutations to aspartate 
(D, phosphomimic) confer a negative charge to the residue, mimicking phosphorylation. 
Importantly, these phosphomutants behave like phosphorylated peptides in terms of their 
intramolecular conformation and aggregation in cell-free systems and primary neuronal 
cultures (Caron et al., 2013, Chiki et al., 2017, Havel et al., 2011, Mishra et al., 2012).  
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 As described in Chapter I, expanded (97Q) HTTex1 BiFC pairs produce more 
oligomers and inclusion bodies than wild-type (19Q) HTTex1 BiFC pairs (Figure 12B). In 
accordance, HTTex1 is known to exist as tetramers but not monomers (Sahoo et al., 2016). 
These phenotypes were further confirmed by protein immunoblot and dot blot analysis 
(Figure 12D), where 97QHTTex1 appears as large SDS-insoluble aggregates (filter trap, 
FT) and oligomeric species of variable sizes (Native-PAGE), and 19QHTTex1 
accumulates essentially as single-size oligomers. The aggregation pattern of non-mutated 
97QHTTex1 was compared with that of phosphoresistant (T3A, S13A, S16A) or 
phosphomimic (T3D, S13D, S16D) mutant forms of 97QHTTex1 (Figure 12B-D and 
Figure S1, Supplemental information I). While phosphoresistant mutants (T3A, S13A and 
S16A) showed essentially the same aggregation pattern as non-mutated 97QHTTex1, 
phosphomimic mutants (T3D, S13D and S16D) completely abolished the formation of 
97QHTTex1 aggregates. However, the absence of aggregates was accompanied by the 
formation of intermediate species in similar levels to the non-mutated 97QHTTex1 BiFC 
pair as determined by flow cytometry analysis (Figure S2, Supplemental information I), 
suggesting that N17 phosphorylation redirects aggregation down to a different assembly 
pathway. Consistent with this, previous reports show that N17 phosphorylation alters 
aggregate morphologies, resulting in both reduced aggregation kinetics and increased 
susceptibility for degradation (Arndt et al., 2015, Chiki et al., 2017, Mishra et al., 2012, 
Thompson et al., 2009). 
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Figure 12. Single N17 phosphomimic mutations modulate 97QHTTex1 aggregation but not 
oligomerization in human H4 glioma cells. (A) HTTex1 (gray bars) was fused to two non-fluorescent 
halves of the Venus protein. When HTTex1 dimerizes, Venus recovers fluorescence. The three N17 
phosphorylatable residues were mutated to mimic phosphorylation or dephosphorylation. (B) Cells 
transfected with phosphoresistant BiFC pairs resemble the non-mutated 97QHTTex1 phenotype in terms of 
aggregation, while phosphomimic pairs showed a total absence of aggregates. (C) Quantitative analyses of 
microscopy pictures. *significant versus 97Q/97Q, p<0.05. (D) Filter trap assays (FT) were consistent with 
microscopy results. Phosphomimic pairs did not produce insoluble aggregates (FT), but showed similar 
levels of oligomeric species (Native-PAGE) comparing to non-mutated 97QHTTex1. Expression levels of 
each pair were evaluated by SDS-PAGE. Scale bar, 20 µm. 
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Threonine-3 is a critical modulator of mutant huntingtin aggregation  
 Phosphorylation is a dynamic process that could differently affect various 
subpopulations of any given protein within a cell. Thus, we predicted that, in normal 
conditions, mixed pools of phosphorylated and unphosphorylated HTT may co-exist in 
cells. Taking advantage of the unique features of our BiFC system, we asked whether 
different combinations of phosphomimic and phosphoresistant mutants could interact and 
affect 97QHTTex1 aggregation. We transfected H4 cells with all possible pairwise 
combinations of phosphomutants and non-mutated counterparts (Table III).  
 Strikingly, combinations of different phosphomimic pairs did not produce any 
inclusions, independently of the mutated residues (Table III). On the other hand, 
combinations of phosphomimics with phosphoresistant (Table III) or non-mutated versions 
(Table III and Figure S3, Supplemental information I) resulted in intermediate patterns of 
aggregation that were dependent on the residue mutated. Importantly, combinations 
containing T3D resulted in total absence (0%) of cells with inclusions, whereas 
combinations with S13D or S16D resulted in 14.1-17.1% or 19.8-29.1% of cells with 
inclusions, respectively, which was significantly less than that of the non-mutated 
97QHTTex1 pair (36.1%). Further analysis of cells expressing these combinations showed 
that the S13D/97Q combination decreased the number of inclusions per cell (Figure S3C 
and D, Supplemental information I) but had no effect on inclusion diameter (Figure S3E, 
Supplemental information I). No differences were observed in the number or size of 
S16D/97Q inclusions (Figure S3C-E, Supplemental information I). In addition, analysis of 
total cell fluorescence showed that all combinations of phosphomimic with non-mutated 
97QHTTex1 oligomerized and produced similar levels of oligomeric species as those 
formed solely by non-mutated 97QHTTex1 (Figure S4, Supplemental information I). 
These results strongly suggest that mixed phospho-HTTex1 molecules interact and co-
aggregate in living cells at different extents, depending on the phosphorylated residue, 
being T3D the most restrictive modification for preventing HTTex1 aggregation. 
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Table III. Percentage of cells containing HTTex1 inclusions (average±SEM) when transfected 
with different combinations of HTTex1-Venus BiFC constructs.  
  Venus 2 
  
T3D S13D S16D T3A S13A S16A 97Q 
Ve
nu
s 1
 
T3D 0 0 0 0 0 0 0 
S13D   0 0 22.0±3.4 17.1±2.3 14.5±1.2 14.1±1.3 
S16D     0 27.5±1.5 29.1±3.6 19.8±3.0 22.9±1.0 
T3A       46.4±1.3 43.5±3.6 45.9±2.5 34.5±2.2 
S13A         48.5±1.3 35.3±2.4 37.8±1.9 
S16A           48.2±2.6 36.6±6.1 
97Q             36.1±2.2 
  
 While combinations of phosphoresistant mutants with non-mutated 97QHTTex1 
did not modify inclusion body formation, combinations of different phosphoresistant pairs 
generally resulted in increased percentage of cells displaying inclusions (43.5-48.5%) 
versus the non-mutated 97QHTTex1 pair, with the exception of the S13A/S16A 
combination (35.3%) (Table III). Interestingly, pairs of BiFC plasmids containing T3A and 
S13A mutations (double mutant) resulted in 49% of cells with inclusions (data not shown), 
similar to T3A (46.4%) or S13A (48.5%) pairs, indicating that additional 
dephosphorylation events on these residues do not enhance aggregation.  
 N17 phosphorylation has been shown to modulate neurotoxicity in several HD 
models by preventing HTT aggregation (Gu et al., 2009, Khoshnan et al., 2004), although 
this finding remains controversial (Aiken et al., 2009, Atwal et al., 2011, Thompson et al., 
2009). Given that we demonstrated that N17 phosphomutants modulate HTTex1 
aggregation in our cell model, we next evaluated whether N17 phosphomutants affected 
HTTex1 cytotoxicity. We assessed cytotoxicity by measuring the levels of lactate 
dehydrogenase (LDH) release from cells as an indicator of cell membrane integrity (Figure 
13 and Figure S5, Supplemental information I). Only T3D pairs decreased significantly 
97QHTTex1 cytotoxicity at 24 h post-transfection (Figure 13A). The levels of LDH 
activity produced by T3D pairs were further measured at 48 h and 72 h after transfection, 
which revealed a trend towards a decrease in 97QHTTex1 cytotoxicity, although no 
significant differences were detected (Figure S5, Supplemental information I). S13 and 
S16 phosphomutants had no effect on HTTex1 cytotoxicity at 24 h (Figure 13A), 48 h or 
72 h post-transfection (data not shown). Interestingly, T3D was no longer able to prevent 
HTTex1 cytotoxicity when combined with unphosphorylated molecules of 97QHTTex1 
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(Figure 13B). No differences were observed when S13D or S16D was co-expressed with 
non-mutated 97QHTTex1 (Figure 13B). 
Figure 13. T3 phosphomimic prevents 97QHTTex1 cytotoxicity. Cytotoxicity produced by 
phosphomutants BiFC pairs (A) or combinations of phosphomimic mutants with non-mutated 97QHTTex1 
(B), measured at 24 h post-transfection. Levels of released LDH activity were normalized versus the 
19Q/19Q control. *significant versus 97Q/97Q, p<0.05. 
 
 These observations reinforce the significance of T3 residue for HD pathogenesis 
and indicate that, in our cell model, HTTex1 cytotoxicity is not directly associated with its 
oligomerization or aggregation, since changes in N17’s phosphorylation state had striking 
effects on aggregation but very limited or no effects on cytotoxicity. 
 
Serine-13 or -16 phosphorylation modifies the dynamics of mutant huntingtin 
aggregates  
 As mentioned above, N17 phosphorylation can influence the morphology of HTT 
aggregates (Gu et al., 2009, Mishra et al., 2012) as well as the rate of inclusion body 
formation (Caron et al., 2014). To further investigate the properties of the different 
97QHTTex1 inclusions in our cell model, we used fluorescence recovery after 
photobleaching (FRAP) analysis. This microscopy-based approach assesses protein 
kinetics properties in living cells by measuring the movement of unbleached fluorescent 
proteins into a small region of interest (ROI) that was irreversibly photobleached with 
high-intensity light (Lippincott-Schwartz et al., 2001). Thus, fluorescence intensity after 
photobleaching is directly proportional to dynamics of protein assemblies and/or exchange 
of proteins between ROI and its surrounding area. Using this technique, we compared the 
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dynamics of inclusions formed exclusively by non-mutated 97QHTTex1 and 
phosphomimic- or phosphoresistant-containing inclusions (Figure 14). Fluorescence 
recovery of 97QHTTex1 inclusions containing S13D or S16D mutants occurred rapidly 
relative to inclusions formed solely by non-mutated 97QHTTex1 (Figure 14A and B), 
indicating a higher exchange of HTTex1 molecules. In contrast, inclusions formed by non-
mutated 97QHTTex1 and phosphoresistant mutants showed significantly slower 
fluorescence recovery, with the exception of the S16A/97Q combination (Figure 14C). 
Interestingly, phosphomimic-containing inclusions mostly displayed a fluid-like behavior, 
appearing rather continuous with the cytosolic fluorescence (Figure 14D), as opposed to 
the more rigid behavior of the inclusions formed by combinations containing 
phosphoresistant mutants or non-mutated 97QHTTex1 BiFC pairs (data not shown).  
 Expanded HTTex1 enters a multistep aggregation pathway where globular 
intermediates self-associate to form more tightly packed inclusions (Duim et al., 2014). 
These two types of inclusions differ in their dynamic properties, being globular 
intermediates highly mobile and constantly exchanged between soluble phases (Caron et 
al., 2014, Thakur et al., 2009). Our results suggest that phosphomimic-containing 
inclusions are more similar to large dynamic oligomers than to mature aggregates, and 
support the idea that aggregates may be mainly composed of unphosphorylated HTT 
molecules, consistent with data indicating that disease-causing HTT is hypophosphorylated 
in the N17 region (Aiken et al., 2009, Atwal et al., 2011). 
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Figure 14. Phosphomimic-containing inclusions of 97QHTTex1 are more dynamic. (A) Time 
lapse of FRAP experiments on aggregates containing non-mutated 97QHTTex1 alone or in combination with 
phosphomimic mutant in H4 glioma cells. T3D mutants produced no aggregates under any circumstance. (B) 
Aggregates containing S13D or S16D mutants recovered significantly faster than the non-mutated 
97QHTTex1 pair. (C) Aggregates combining non-mutated 97QHTTex1 with T3A or S13A recovered more 
slowly than aggregates made only of non-mutated 97QHTTex1, with the exception of the S16A/97Q 
combination. (D) Time lapse of aggregates formed by non-mutated 97QHTTex1 and S13D. Aggregates 
containing phosphomimic versions are highly dynamic and flexible, and move (arrow indicates moving 
aggregate in each frame) through the cell with more freedom than aggregates formed by non-mutated 
97QHTTex1 pair (data not shown). Scale bars, 20 µm. 
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N-terminal phosphorylation modulates mutant huntingtin aggregation in Drosophila 
 To further explore the role of N17 phosphorylation on HTTex1 aggregation, we 
tested how single phosphoresistant or phosphomimic mutants modulate the formation of 
inclusion bodies in Drosophila. We generated flies expressing either wild-type (19Q), non-
mutated (97Q) control or different phosphomutant versions of 97QHTTex1 fused to 
mCherry in adult dopaminergic neurons, under the control of THGAL4 (Figure 15A-G), or 
in larval imaginal discs using the eye-specific GMRGAL4 driver (Figure S6, Supplemental 
information). Wild-type 19QHTTex1-mCherry produced a diffuse pattern of distribution in 
both larval eye imaginal discs (Figure S6A, Supplemental information) and adult 
dopaminergic neurons (data not shown), indicating the presence of soluble oligomeric 
species. On the other hand, Non-mutated 97QHTTex1-mCherry accumulated mostly as 
large inclusion bodies, showing a high number of inclusions in both larval and fly tissues 
(Figure 15A and Figure S6B, Supplemental information I). This is consistent with our 
results in human cell lines. Surprisingly, all phosphomutants produced inclusion bodies 
that varied substantially in their number, morphology and localization, depending on tissue 
specificity. In the larval eye imaginal discs, all phosphomutants showed fewer inclusion 
bodies than non-mutated 97QHTTex1 (Figure S6, Supplemental information I), with the 
exception of S13D mutant that increased aggregation (Figure S6F and I, Supplemental 
information I). In adult dopaminergic neurons, both T3A (Figure 15B) and T3D (Figure 
15E) mutants generated lower number of inclusions versus non-mutated 97QHTTex1 
(Figure 15O), which was also accompanied by wider expression of intermediate species. In 
contrast, S13D (Figure 15F) and S16D (Figure 15G) showed a significantly higher number 
of aggregates (Figure 15O), with S13D also displaying larger inclusions in comparison to 
those formed by the non-mutated counterpart. Inclusions formed by S16D mutant were 
also localized in cell nuclei, in agreement with previous studies suggesting that S16 
phosphorylation promotes nuclear translocation of HTTex1 (Atwal et al., 2011, Havel et 
al., 2011). S13A (Figure 15C) and S16A (Figure 15D) mutants produced as many 
inclusions as non-mutated 97QHTTex1 (Figure 15O). 
Together with our results in cells, these findings further indicate that single N17 
phosphorylation modulates 97QHTTex1 aggregation, although the final outcome can 
depend on the biological context. 
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Figure 15. PP1 knockdown prevents 97QHTTex1 aggregation in Drosophila. Confocal 
microscopy images of dopaminergic neurons in adult Drosophila brains expressing non-mutated 
97QHTTex1-mCherry or the different phosphomutants (A-G) under the control of THGAL4. (H-N) Co-
expression of PP1α-96A RNAi with non-mutated 97QHTTex1-mCherry or phosphomutants. 97HTTex1-
mCherry is shown in red (column 1 and 4), and dopaminergic cells (column 2 and 5, anti-TH) are shown in 
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blue. Any mutation at T3 residue prevented 97HTTex1 aggregation (B and E), while phosphomimic 
mutations at S13 or S16 produced a significant increase of 97HTTex1 inclusion bodies (F and G). PP1α-96A 
RNAi decreased the number of 97HTTex1 inclusions, with the exception of T3A (I), where no change was 
observed, and T3D (L) expressing flies that showed a significant increase in 97HTTex1 aggregation, all in 
comparison to the respective no RNAi expressing genotype. (O) Quantification of average number of 
aggregates (±SEM) in each brain. *significant versus THGAL4>UAS-97QHTTex1-mCherry, #significant 
versus the correspondent “no RNAi” transgenic control (white bars), †significant versus THGAL4>UAS-
97QHTTex1-mCherry/UAS-PP1α-96A RNAi, p<0.05. Scale bar, 10 µm. 
 
Protein phosphatase inhibitors regulate mutant huntingtin aggregation and toxicity  
 We next aimed at characterizing the molecular pathways involved in HTTex1 
oligomerization, aggregation and toxicity. Others have identified several kinases that 
modulate N17 phosphorylation and hence HTTex1 aggregation and toxicity (Atwal et al., 
2011, Bustamante et al., 2015, Thompson et al., 2009). However, the protein phosphatases 
that could be involved in these processes remain unknown. To address this question, we 
screened a library of 33 phosphatase chemical inhibitors in our BiFC cellular model for 
their effect on 97QHTTex1 aggregation and oligomerization, by means of filter trap assays 
and flow cytometry, respectively (Figure 16 and Table S1, Supplemental information I). 
We identified three groups of phosphatases (PP1/PP2A, CD45 and Cdc25) which 
inhibition decreased 97QHTTex1 aggregation in human cells when compared to controls 
treated with DMSO (Figure 16A, B01, B02, B07, B08, C04 and C05). Furthermore, these 
compounds were validated by fluorescence microscopy analyses, where a consistent 
decrease in the number of cells forming inclusions was observed (Figure 16B). 
Interestingly, cells treated with the three selected inhibitors also showed a slight reduction 
in average fluorescence, indicating a decrease towards the production of oligomeric 
species, although the formation of large aggregates was affected to a greater degree (Figure 
16A, B01, B02, B07, B08 and C04). We also observed an overall reduction in fluorescence 
levels for 28 out of the 33 inhibitors assayed. However, the few exceptions where a 
striking decrease was observed (C06, D01 and D03) were due to a reduction in HTTex1 
expression or toxicity of the compound (Table S1 and Figure S7, Supplemental 
information I). CD45 inhibitors resulted in decreased levels of HTTex1 expression and 
were lately excluded from our study. PP1/PP2A and Cdc25 inhibitors did not decrease cell 
viability or HTTex1 protein levels (Table S1 and Figure S7, Supplemental information I). 
 To further characterize PP1/PP2A and Cdc25 inhibitors, we tested the effect of 
those compounds in adult compound eye of Drosophila expressing pan-neuronally 
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93QHTTex1 under the control of elavGAL4. The Drosophila eye is composed by 
photoreceptor neurons, known as rhabdomeres, which are regularly arranged in clusters of 
eight to form highly organized individual structures called ommatidia. Seven rhabdomeres 
per ommatidia are visible in cross-section, and can then be scored using the light 
microscopy-based pseudopupil assay (Green and Giorgini, 2012). We assessed 
neurodegeneration of treated or non-treated HD flies, by scoring degeneration of 
rhabdomeres (Figure 16C). When expressed in the fly nervous system, 93QHTTex1 causes 
progressive photoreceptor loss. Interestingly, while Cdc25 inhibition enhanced 
neurodegeneration in our Drosophila HD model, PP1/PP2A inhibitor treatment 
ameliorated 93QHTTex1 neurotoxicity in a dose-dependent manner, being able to 
completely reversed this phenotype (Figure 16C, 93QHTTex1 Day 7 treated with 100 μM 
of B02 compound versus 93QHTTex1 Day 0 non-treated). However, we also observed that 
treatment with PP1/PP2A inhibitors strongly compromised the survival of our HD flies 
(data not shown), so we cannot exclude the possibility of an artifact or compensatory 
mechanism responses. 
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Figure 16. Protein phosphatase inhibitors regulate HTTex1 aggregation in human cells and 
neurotoxicity in Drosophila. (A) Representative filter trap of protein extracts from H4 cells transfected 
with non-mutated 97QHTTex1 BiFC constructs and treated with chemical inhibitors of protein phosphatases. 
The graph shows oligomerization levels as determined by flow cytometry (black bars) and aggregation levels 
as determined by optic density of filter trap dots (white bars). The names of phosphatase inhibitors (Enzo 
Life Sciences) and the concentrations used are described in Table S1. (B) Selected inhibitors PP1/PP2A (B01 
and B02) and Cdc25 (C04 and C05) also reduced the percentage of H4 cells with large 97QHTTex1 
inclusions as determined by quantitative analyses of microscopy pictures. (C) Quantification of mean 
rhabdomeres (±SEM) in adult flies expressing 93QHTTex1 pan-neuronally after 7 days of treatment with 
increasing concentrations of a PP1/PP2A inhibitor (B02) or with a single-dose of 100 μM of a Cdc25 
inhibitor (C05). PP1/PP2A inhibition prevented HTTex1 neurotoxicity in a dose-response manner, while 
Cdc25 inhibition potentiated neuronal loss as it decreased the number of rhabdomeres comparing to 
93QHTTex1 flies treated with DMSO. *significant versus DMSO treated flies, p<0.05; n.s., not significant. 
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Protein phosphatase 1 modulates mutant huntingtin aggregation and neurotoxicity in 
Drosophila 
 Next, we assessed whether genetic inhibition of the selected protein phosphatases 
regulate HTTex1 aggregation in Drosophila. We used an RNAi knockdown approach to 
downregulate homologues of PP1, PP2A or Cdc25 in flies expressing 97QHTTex1-
mCherry in dopaminergic neurons (Figure 15, columns 4-6, and Figure S8, Supplemental 
information I). Downregulation of string, the fly homologue for Cdc25, or PP2A had no 
effect on 97QHTTex1 aggregation (Figure S8, Supplemental information I), while PP1 
knockdown flies (Figure 15H and O) showed significantly fewer aggregates per brain 
when compared to 97QHTTex1 no RNAi control (Figure 15A and O). In order to exclude 
the possibility that suppression of aggregation upon PP1 silencing was due to titration of 
GAL4/UAS activity, we compared single UAS-97QHTTex1-mCherry expressing flies 
versus flies carrying double UAS constructs. As expected, the titration control expressing 
both UAS-97QHTTex1-mCherry and UAS-lacZ constructs displayed similar aggregation 
phenotype to single UAS-97QHTTex1-mCherry expressing flies (Figure S9, Supplemental 
information I). Strikingly, PP1 downregulation in phosphomutant backgrounds (Figure 
15J, K, M and N) also resulted in decreased 97QHTTex1 aggregation, with the exception 
of T3A (Figure 15I) and T3D (Figure 15L). When co-expressed with T3A, PP1 RNAi did 
not cause significant changes in the number of aggregates (Figure 15O), which could 
indicate that PP1 modulates HTTex1 aggregation by targeting T3 dephosphorylation. On 
the other hand, PP1 knockdown increased aggregation in T3D mutants relative to its no 
RNAi counterpart. Interestingly, the aggregation levels observed in T3D background upon 
PP1 inhibition were also significantly higher than those seen in PP1 knockdown brains 
expressing non-mutated 97QHTTex1. Since HTTex1 does not contain any 
phosphorylatable residue beyond N17 domain, these results denote a potential cumulative 
effect of PP1 RNAi on 97QHTTex1 aggregation concomitant with S13 and/or S16 
phosphorylation. 
 We further explored the effects of PP1 silencing in our Drosophila model by 
assaying neurodegeneration of photoreceptor neurons in living animals (Figure 17). 
Importantly, genetic inhibition of PP1 did not compromise rhabdomere viability in flies 
expressing wild-type (19Q) HTTex1 under the control of Rh1GAL4 (Figure 17A, column 
4 and D), but significantly enhanced 97QHTTex1 neurotoxicity, further reducing the 
number of rhabdomeres in an age-dependent manner (Figure 17A-C, column 5 and D). 
This is consistent with the toxicity of PP1 pharmacological inhibitors that we observed in 
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flies. PP2A or string RNAi had no effect in the number of rhabdomeres upon co-
expression with either 19QHTTex1 or 97QHTTex1 (Figure S8, Supplemental information 
I).  
 In total, our data suggest that PP1 has a role in modulating the formation of 
HTTex1 aggregates in both cell and Drosophila models of HD, which may be mostly 
mediated by T3 phosphorylation state. Furthermore, PP1 seems to regulate Drosophila 
neuronal loss but only in a disease context, suggesting that 97QHTTex1 aggregation and 
neurotoxicity may be related in our HD fly model. 
Huntingtin!N<terminal!phosphorylation!
!74 
 
Figure 17. Downregulation of PP1 potentiates 97QHTTex1 neurotoxicity in adult 
photoreceptor neurons. (A-C) Representative pictures of photoreceptors observed by water immersion 
live imaging of the retinas. Wild-type flies, HD flies and flies expressing PP1α-87B RNAi together with 
19QHTTex1 or 97QHTTex1 were analyzed at day 1, 8 and 15 post-eclosion. Wild-type and 19QHTTex1 
expressing flies showed normal retinal morphology as the 6 outer photoreceptors were visible per 
ommatidium (columns 1 and 2). Flies expressing 97QHTTex1 exhibited age-dependent neurodegeneration 
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with progressive loss of rhabdomeres from 8 to 15 days after eclosion (B and C, column 3). PP1α-87B 
downregulation caused increased neurotoxicity in flies expressing 97QHTTex1 (B and C, column 5) and did 
not affect photoreceptor integrity of 19QHTTex1 flies (column 4). Visualization of the rhabdomeres was 
performed using Rh1Gal4>UAS-GFPninaC, as described in methods section. (D) Quantification of mean 
rhabdomeres (±SEM) per ommatidium. *significant versus Rh1GAL4>UAS-GFPninaC/UAS-97QHTTex1-
mCherry, #significant versus Rh1GAL4>UAS-GFPninaC/UAS-97QHTTex1-mCherry at day 1 and day 8, 
p<0.05. Scale bar, 10 µm. 
 
Discussion 
 
Protein misfolding and aggregation are intimately involved in the pathogenesis of 
HD and other neurodegenerative disorders. Despite extensive research in the field, the 
precise molecular mechanisms by which misfolded proteins aggregate and form toxic 
species remain elusive. Increasing evidence suggests that targeting phosphorylation events 
in the N17 domain of mutant HTT can influence the pathological behavior of the protein 
(Atwal et al., 2011, Di Pardo et al., 2012, Havel et al., 2011, Khoshnan et al., 2004, 
Thompson et al., 2009). However, the significance of single N17 phosphorylation events 
in HTT oligomerization, aggregation and toxicity is still poorly understood. 
Here, we report that single N17 phosphorylation can prevent HTTex1 aggregation, 
but not oligomerization. We propose that each residue has a different “strength” in 
modulating HTTex1 aggregation. Importantly, we found that PP1 can control HTTex1 
aggregation and toxicity, suggesting that N17 phosphorylation might be regulated by this 
protein phosphatase. The fact that single N17 phosphorylation events are sufficient to 
abolish HTTex1 aggregation could be very important from an HD therapeutic perspective, 
since a single N17 phosphorylation could provide a simpler molecular target than double 
phosphorylation. 
We showed that single phosphomimic mutations at T3, S13 or S16 allow 
97QHTTex1 to oligomerize but not to form large inclusions in human cells (Figure 12 and 
Figure S2, Supplemental information I). Double S13/S16 phosphorylation prevents 
aggregation both in vitro and in vivo, and toxicity in vivo (Gu et al., 2015, Mishra et al., 
2012). However, double S13/S16 phosphorylation is less abundant than single 
phosphorylation events (Bustamante et al., 2015), and may require the overexpression of 
specific kinases (Thompson et al., 2009), which may confound therapeutic efforts based on 
this approach. Although some studies reported on the effect of single S13 or S16 
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phosphorylation events on HTTex1 intracellular localization, they did not focus on 
HTTex1 oligomerization, aggregation or toxicity (Atwal et al., 2011, Havel et al., 2011). 
Results from cell-free systems indicate that single S13- or S16-phosphorylated HTTex1 
behave similarly to double S13/S16-phosphorylated HTTex1 in terms of aggregation, 
being unable to form mature fibrils (Mishra et al., 2012). Our findings in living human 
cells provide additional biological support for those in vitro studies.  
The unique properties of our BiFC cellular model allowed us to analyze the relative 
contribution of each phosphorylatable residue towards HTTex1 oligomerization and 
aggregation. We found that T3D completely abolished 97QHTTex1 aggregation in the 
presence of any other phosphomutant or non-mutated 97QHTTex1 molecules, while S13D 
or S16D only had a partial reduction effect (Table III and Figure S3, Supplemental 
information I). Our results are consistent with a recent report showing that bona-fide T3 
phosphorylation decreases the aggregation propensity of mutant HTT (Cariulo et al., 
2017a). Interestingly, HD samples display low levels of T3 phosphorylation (Cariulo et al., 
2017a), while higher abundance of T3-phosphorylated pools is detected in normal contexts 
(Bustamante et al., 2015, Huang et al., 2015). Altogether, these findings highlight the 
relevance of this residue in modulating the aggregation of HTTex1, and strongly support 
T3 as a promising target for HD intervention (Aiken et al., 2009). Our results also suggest 
that HTTex1 might be predominantly unphosphorylated under pathological conditions 
(Aiken et al., 2009, Atwal et al., 2011), as phosphoresistant combinations behave more 
similarly to the non-mutated 97QHTTex1 pair than to the phosphomimics in terms of 
aggregation (Figure 12 and Table III).  
Previous in vitro studies demonstrate that N17 phosphorylation inhibits β-sheet 
conformation of mutant HTTex1 and suppresses its fibrillization, stabilizing the α-helical 
structure of the N17 domain which could lead to altered aggregation dynamics (Caron et 
al., 2013, Chiki et al., 2017). In FRAP experiments, we show that combinations of 
phosphomimic and non-mutated 97QHTTex1 induced the formation of inclusions that 
were more dynamic, diffuse and fluid than regular 97QHTTex1 aggregates, resembling an 
intermediate stage between oligomers and mature inclusions (Figure 14). Additionally, 
non-mutated 97QHTTex1 pairs did not aggregate to the same extent as the 
phosphoresistant combinations (Figure 12C and Table III). Thus, we propose a model 
where unphosphorylated HTTex1 fragments oligomerize and form inclusions that grow 
into mature fibrils until enough phosphorylated HTTex1 molecules are intercalated in the 
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structure to interfere with the process, acting as a ‘brake’. This could explain the existence 
of aggregates of various sizes and morphologies.  
Genetic and pharmacological inhibition of PP1 resulted in lower 97QHTTex1 
aggregation and increased toxicity (Figure 15-17). Protein phosphatases PP2B/3 
(Calcineurin), PP2C and PP1/PP2A have been also shown to regulate HTT 
phosphorylation at several residues beyond exon 1, as well as HTT toxicity (Ermak et al., 
2009, Marion et al., 2014, Pardo et al., 2006, Pineda et al., 2009, Rosenstock et al., 2011). 
It is important to note that HTTex1 does not contain any phosphorylatable residue beyond 
the N17 domain and, therefore, any direct effect of protein phosphatases should happen on 
T3, S13 or S16. Our results indicate that PP1 affects 97QHTTex1 aggregation by 
regulating T3 phosphorylation. In Drosophila dopaminergic neurons, PP1 knockdown in 
serine-phosphomutant backgrounds leads to a decrease in 97QHTTex1 aggregation, 
regardless the type of mutation – phosphomimic or phosphoresistant - on these residues 
(Figure 15O). Moreover, PP1 RNAi does not cause any further reduction of 97QHTTex1 
aggregation when co-expressed with T3A mutant. Together, these data suggest that the 
effect of PP1 inhibition on HTTex1 aggregation is primarily mediated by T3 
phosphorylation. However, an increase in 97QHTTex1 aggregation is observed when PP1 
RNAi is co-expressed with T3D mutant (Figure 15L and O), indicating that S13 and S16 
might also be target for PP1 regulation. Since S13D or S16D increase 97QHTTex1 
aggregation (Figure 15F, G and O), we hypothesize that PP1 modulates S13 or S16 
phosphorylation upon T3 phosphorylation. In fact, it is likely that different N17 mutations 
may contribute to subsequent phosphorylation events in other residues. For example, IKK-
mediated S16 phosphorylation is facilitated by previous phosphorylation of S13 
(Thompson et al., 2009), and we have observed that phosphomimic T3D mutation 
completely blocks S13/S16 phosphoryation.  
Interestingly, the striking decrease in 97QHTTex1 aggregation observed when PP1 
RNAi was co-expressed with S13D or S16D mutants versus S13D or S16D alone (no 
RNAi) (Figure 15O) suggests that T3 phosphorylation is dominant over S13 or S16 
phosphorylation. Our human cell data also supports this hypothesis, since S13D or S16D 
BiFC combinations with non-mutated 97QHTTex1 still shows aggregates, while T3D 
BiFC combinations with any other mutant completely abolishes aggregation (Table III and 
Figure S3, Supplemental information I).  
Huntingtin N17 phosphorylation modulates neurotoxicity in several HD models by 
preventing HTT aggregation (Gu et al., 2009). However, this finding is still under intense 
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debate (Aiken et al., 2009, Atwal et al., 2011, Thompson et al., 2009). Currently, there is 
still debate on whether large, insoluble aggregates are the cause of neuropathology or a by-
product of accumulated misfolded HTT. Though these aggregates were originally thought 
to be neurotoxic, accumulating evidence suggests that the formation of large aggregates 
might be part of a protective cellular mechanism to sequester soluble toxic species 
(Arrasate et al., 2004, Bodner et al., 2006, Kuemmerle et al., 1999, Slow et al., 2005). Our 
data here suggest that modulation of HTTex1 neurotoxicity by N17 phosphorylation and 
the appearance of large aggregates are not necessarily related. Interestingly, polyQ-
dependent toxicity varies widely depending on the cellular environment and cell-type 
specificity, indicating that additional factors may contribute to HTTex1 toxicity (Tsvetkov 
et al., 2013). Moreover, studies on other post-translational modifications in the N17 region 
reveal a complex cross-talk among them in modulating aggregation, and suggest that 
neurotoxicity may be due to different mechanisms dependent upon the modifier site 
(Steffan et al., 2004, Thompson et al., 2009).  
Altered PP1 activity has been linked to a variety of diseases, including several 
neurodegenerative disorders, such as AD and PD (Braithwaite et al., 2012, Gong et al., 
1995, Lobbestael et al., 2013). In fact, PP1 is normally highly expressed in the brain, and 
is particularly abundant in medium spiny neurons, known to be significantly affected in 
HD (da Cruz e Silva et al., 1995b). Based on these findings, it is possible that PP1 
malfunction increases the susceptibility of certain types of neurons to mutant HTTex1-
induced degeneration. Not surprisingly, inhibition of PP1 resulted in increased age-
dependent neuronal loss in our Drosophila HD model, suggesting that PP1 activity 
imbalance might precede HTTex1 neurotoxicity. Despite considerable efforts to develop 
specific chemical activators of PP1 (Chatterjee et al., 2012, Tappan and Chamberlin, 
2008), further investigations will be necessary to clarify the relationship between PP1 
activity impairment, aggregation and neurotoxicity in the context of HD and other polyQ 
misfolding disorders.  
In summary, our results support a strong role for single N17 phosphorylation events 
on HTTex1 aggregation, dynamics and toxicity, and uncover the regulatory role of PP1 in 
these events. Ultimately, our study opens novel avenues for the therapeutic targeting of 
PP1 and N17 phosphorylation in HD.   
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Materials and methods I 
 
In vitro experiments 
Cell cultures, plasmids and treatments 
Human H4 glioma cells (ATCC HTB-148, LGC Standards, Barcelona, Spain) were 
maintained in OPTI-MEM I culture medium (Gibco, TermoFisher Scientific, Carlsbad, 
CA, USA) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) and 1% (w/v) of a 
penicillin/streptomycin commercial antibiotic mixture (Gibco, TermoFisher Scientific, 
Carlsbad, CA, USA), under controlled conditions of temperature and humidity (37ºC, 5% 
CO2). Different types of cell culture dishes were used for cell seeding depending on the 
application. For flow cytometry and toxicity assays, cells were grown on 6-well plates (35 
mm diameter, Techno Plastic Cultures AG, Switzerland). For microscopy, cells were 
seeded on glass-bottom 35 mm dishes (10 mm glass surface diameter, MatTek 
Corporation, Ashland, MA, USA). And for protein extraction (PAGE and filter trap 
assays) cells were seeded on 100 mm dishes (Techno Plastic Cultures AG, Switzerland). 
For all experiments, cells were counted and seeded at a density of 10,000 cells/cm2 
regardless dish size. Generation of 19QHTTex1- and 97QHTTex1-Venus BiFC constructs 
was described elsewhere (Herrera et al., 2011). Phosphomimic (T3, S13 or S16 mutated to 
Aspartic acid) and phosphoresistant (T3, S13 or S16 mutated to Alanine) constructs were 
produced by PCR-based site-directed mutagenesis using 97QHTTex1-Venus plasmids as 
templates. Plasmid transfection was performed by means of the X-tremeGene 9 reagent 
(Roche diagnostics, Mannheim, Germany), following manufacturer’s instructions. Twenty-
four hours after transfection, cells were collected and analyzed for oligomerization, 
aggregation and toxicity as described below. Pharmacological inhibition of protein 
phosphatases was performed using a phosphatase inhibitor library (Enzo Life Sciences, 
Lausen, Switzerland). Briefly, cells were treated with 33 different phosphatase inhibitors 
upon transfection of 97QHTTex1 BiFC constructs. Phosphatase inhibitors were dissolved 
in DMSO and added to culture medium at variable concentrations, according to the IC50s 
described in manufacturer’s instructions (Table S1, Supplemental information I). 
 
Flow cytometry 
Transfection efficiency and fluorescence levels were determined by flow cytometry 
analyses. Cells were washed with Ca2+ and Mg2+ free phosphate buffer saline (PBS) 
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(Gibco, TermoFisher Scientific, Carlsbad, CA, USA) and collected by trypsinization 
(0.05% w/v trypsin, 5 min, 37ºC) into BD Falcon Round-Bottom tubes (BD Biosciences, 
San Jose, CA, USA). Cell pellets were resuspended in PBS and analyzed by means of a 
LSR Fortessa flow cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA). Ten 
thousand cells were examined per experimental group. The FlowJo software (Tree Star 
Inc., Ashland, OR, USA) was used for data analysis and representation. 
 
Fluorescence microscopy and FRAP experiments 
 The visualization of intracellular BiFC fluorescent aggregates was accessed in 
living cell cultures using an Axiovert 200M widefield fluorescence microscope equipped 
with a CCD camera (Carl Zeiss MicroImaging GmbH, Germany). Pictures of a total of 
100-150 cells per sample were scored for aggregate quantification. FRAP experiments 
were performed using a META LSM 510 confocal microscope. Briefly, protein aggregates 
were focused at the central focal plane and adjusted to avoid pixel saturation. Experiments 
lasted for 70-150 s, taking one picture every second. After establishing the basal signal, 
aggregates were bleached using the 488 nm laser line at 100% laser transmission on a 
circular region of interest (ROI) with a diameter of 30 pixels (1.31 µm radius) for 5 s (10 
iterations). Fluorescence recovery was then monitored for 60-140 s with LSM software. 
Data analyses were carried out using the ImageJ free software (http://rsbweb.nih.gov/ij/). 
 
Protein extraction and Immunoblotting 
Total protein levels and formation of oligomeric species were measured by means of 
SDS- or Native-PAGE immunoblotting, respectively. Proteins were extracted in native or 
denaturing conditions according to the requirements of each technique. Briefly, cells were 
washed with PBS 1X and collected by scraping. Cells were incubated with lysis buffer and 
sonicated for 10 sec at 5 mA using a Soniprep 150 sonicator (Albra, Milano, Italy). For 
denaturalizing conditions, the lysis buffer was 1% Triton X-100, 150 mM NaCl, 50 mM 
Tris pH 7.4, supplemented with a protease inhibitor cocktail (Roche diagnostics, 
Mannheim, Germany). For native conditions, the lysis buffer was 173 mM NaCl, 50 mM 
Tris pH 7.4, 5 mM EDTA, also supplemented with protease inhibitor cocktail. Proteins 
were collected after cell lysate centrifugation at 10,000xg for 10 min at 4ºC and quantified 
by means of the BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA, USA), 
following manufacturer’s instructions. For SDS- or Native-PAGE immunoblotting, 15 μg 
of total protein extracts were prepared and separated by electrophoresis using a 12% SDS-
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polyacrylamide gel or a 5% SDS-free-polyacrylamide gel, respectively. For denaturing 
conditions, samples were boiled in standard loading buffer (200 mM Tris-HCl pH 6.8, 8% 
SDS, 40% glycerol, 6.3% β-mercaptoethanol, 0.4% bromophenol blue) for 5 min at 95ºC. 
For native conditions, extracts were mixed with SDS- and mercaptoethanol free loading 
buffer (200 mM Tris-HCl pH 6.8; 40% glycerol; 0.4% bromophenol blue) and the boiling 
step was omitted. Proteins were transferred onto PVDF membranes and blocked with 5% 
(w/v) non-fat dry milk in Tris-HCl buffer saline-Tween solution (TBS-T) (150 mM NaCl, 
50 mM Tris pH 7.4, 0.5% Tween-20) for 1 h at room temperature. Membranes were 
incubated with primary antibodies against HTT (1:500, Millipore, Billerica, MA, USA) 
and GAPDH (1:30000, Ambion, Austin, TX, USA) as specified. A secondary mouse IgG 
Horseradish Peroxidase-linked antibody (1:10000, GE Healthcare Life Sciences, Uppsala, 
Sweden) was used for 1 h incubation at room temperature. Immunoblots were developed 
with enhanced chemiluminescence reagents (Millipore, Billerica, MA, USA) and exposed 
to X-ray films. The relative intensities of protein bands were measured using the Image J 
software. Protein expression levels were calculated by densitometry analyses and 
normalized to the GAPDH loading control.  
 
Filter trap assays 
 Cells were pelleted by centrifugation at 700xg for 10 min and cell lysates collected 
in native conditions as described above. One hundred μg of native protein extracts were 
mixed with SDS to a final concentration of 0.4% (w/v). Samples were loaded on a dot-
blotting device and filtered by vacuum through cellulose acetate membranes (0.22 μm 
pore; GE Water & Process Technologies, Fairfield, CT, USA), previously incubated with 
1% (w/v) SDS solution in PBS. After filtration, membranes were washed twice and 
processed for immublotting detection of HTT, as described above. In these conditions, 
only large SDS-insoluble aggregates are retained in the filter and therefore HTT signal is 
proportional to the presence of large insoluble species. Analyses and quantification of blots 
signal were performed using ImageJ software. 
 
Toxicity assays 
Cell toxicity was assayed by measuring the release of lactate dehydrogenase (LDH) 
from damaged cells into extracellular medium using the LDH Cytotoxicity Detection Kit 
(Clontech Laboratories Inc., Mountain View, CA, USA), following manufacturer’s 
instructions. Briefly, 5 μl of cell culture medium was collected and extracellular levels of 
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LDH measured at 492 nm using an Infinite M200 plate reader (Tecan, Männedorf, 
Switzerland). For statistical analysis, absorbance values were obtained in triplicate for all 
the different experimental groups and normalized versus the 19Q/19Q control.  
 
Drosophila experiments 
Drosophila stocks, genetics and crosses 
Flies were maintained at 25ºC and raised on standard cornmeal medium in a 
light/dark cycle of 12 hours. We generated eight constructs encoding for different versions 
of HTTex1 fused to mCherry: a wild-type version with a polyQ tail containing 19 
glutamines, a mutant version with 97 glutamines, and six constructs encoding 
phosphomutant versions (T3A/D, S13A/D and S16A/D) with 97 glutamines. To establish 
transgenic UAS-HTTex1-mCherry lines, our constructs were cloned into pWalium10-roe 
by the Gateway cloning technology (ThermoFisher Scientific, Waltham, MA, USA), and 
then injected into y1w1118 embryos using phiC31 integrase-mediated DNA recombination 
(BestGene strain #9723, attP landing site located at the 2L-28E7 genomic region). The 
UAS-93QHTTex1 line (P463) was a gift from J. Lawrence Marsh and Leslie Thompson 
(University of California, Irvine) (Steffan et al., 2001). For genetic knockdown 
experiments in Drosophila, we employed UAS-RNAi-targeted lines of four different fly 
genes encoding specific phosphatases: string (homolog of cdc25 phosphatase, BL34831, 
HMS00146), PP1α -87B (alpha-2 isoform of PP1 catalytic subunit, BL32414, 
HMS00409), PP1α-96A (alpha-1 isoform of PP1 catalytic subunit, BL42641, HMS02477) 
and PP2A-29B (different isoforms of PP2A regulatory subunit, BL43283, HMS01921). 
RNAi stocks were obtained from the TRiP (Transgenic RNAi Project) library (Ni et al., 
2011, Perkins et al., 2015), courtesy of the Bloomington Drosophila Stock Center (Indiana 
University, Bloomington, IN, USA). TRiP transgenic fly strains were generated by 
phiC31-targeted site-specific integration of shRNA Valium20 vectors at genomic attP40 or 
attP2 landing sites on the second and third chromosomes, respectively (strain BL42641, 
attp40 (2L-25C6); strains BL34831, BL32414 and BL43283, attP2 (3L-68A4)). Four 
different driver lines were used: THGAL4 (active in DA neurons, under the control of the 
tyrosine hydroxylase promoter), elavGAL4 (c155) (transiently active in the nervous 
system), GMRGAL4 (active in the eye) and Rh1GAL4 (active in the photoreceptors R1-R6, 
under the control of rhodopsin1 promoter). To analyze the effect RNAi downregulation of 
specific phosphatases upon HTTex1 aggregation in adult brains, UAS-97QHTTex1-
mCherry/CyO;Sb/TM6B and Sco/CyO;THGAL4/TM6B were established and crossed 
III.!A!|!Results!
! 83 
together to generate UAS-97QHTTex1-mCherry/CyO;THGAL4/TM6B progeny, then 
crossed with UAS-RNAi-targeted lines. Adult flies carrying UAS-97QHTTex1-
mCherry/+;THGAL4/UAS-stringRNAi, UAS-97QHTTex1-mCherry/+;THGAL4/UAS-
PP1-87BRNAi, UAS-97QHTTex1-mCherry/UAS-PP1α-96A;THGAL4/+ and UAS-
97QHTTex1-mCherry/+;THGAL4/UAS-PP2A-29BRNAi were selected and analyzed 
(Figure 18A). Unless specified otherwise, flies carrying UAS-lacZ targeted to the same 
location were used as controls. For deep pseudopupil (DPP) analysis, Rh1GAL4;UAS-
GFPninaC/UAS-19QHTTex1-mCherry;UAS-PP1-87BRNAi/+ and Rh1GAL4;UAS-
GFPninaC/UAS-97QHTTex1-mCherry;UAS-PP1-87BRNAi/+ adult flies were obtained by 
crossing the Rh1GAL4;UAS-GFPninaC with UAS-19QHTTex1-mCherry/CyO;UAS-PP1-
87BRNAi or UAS-97QHTTex1-mCherry/CyO;UAS-PP1-87BRNAi established stocks, 
respectively (Figure 18B). Rh1GAL4;UAS-GFPninaC, Rh1GAL4;UAS-GFPninaC/UAS-
19QHTTex1-mCherry;UAS-GFP and Rh1GAL4;UAS-GFPninaC/UAS-97QHTTex1-
mCherry;UAS-GFP were used as controls.  
(Continue in the next page) 
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Figure 18. Drosophila crossing schemes for screen for phosphatases as regulators of mutant 
HTT aggregation and toxicity. (A) Female virgins from a double balancer stock are crossed to original 
TH driver and UAS-97QHTTex1-mCherry lines in order to establish balanced stocks of those lines. 
Balancing original lines is a common practice in Drosophila laboratories. The use of balancer chromosomes 
prevents crossing-over events during meiosis thereby allowing for the maintenance of mutant fly stocks 
without the risk of losing the transgene over time, through successive generations. Once established, flies 
from the two different stocks are crossed together to generate a final stock-expressing mutant HTT via the 
GAL4/UAS system. Virgins are then collected and used in a series of 4 independent crosses with UAS-RNAi 
targeted lines, ensuring the knockdown of a specific phosphatase in fly dopaminergic neurons where mutant 
HTT is being expressed. The effect of phosphatase knockdown on mutant HTT aggregation was evaluated by 
means of immunohistochemistry. (B) In this scheme, a stock carrying both mutant HTT and an RNAi-
targeted phosphatase construct is established. Expression of both UAS-dependent transgenes is induced upon 
crossing with an Rh1GAL4 driver carrying also a GFPninaC construct, which allows fluorescence visualization 
of rhabdomeres. Flies from the resulting F1 progeny expressing the three UAS-dependent transgenes are 
selected and subsequently used for deep pseudopupil analyses of rhabdomere loss. Sco (Scutoid), dominant 
marker manifested in a specific pattern of loss of bristles from the head and thorax of the adult fly. CyO 
(Curly “O”, Oster 1956), second balancer chromosome carrying a dominant mutation, which causes curly 
wings. Sb (Stubble), dominant marker for shorter bristles. TM6B (Third multiply-inverted 6B), third balancer 
chromosome carrying the dominant mutation Tubby (Tb), which is manifested as physically shortened pupae 
and 3rd instar larvae phenotypes. X, chromosome X. 
 
Immunohistochemistry and Confocal microscopy 
 For confocal imaging of adult brains, 10-days-old flies were dissected and brains 
prepared as previously described (Wu and Luo, 2006). Briefly, adult flies were 
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anesthetized with CO2 and brains isolated in PBS 1X from the head cuticles before being 
fixed in 4% paraformaldehyde-containing PBS. Dopaminergic neurons were stained by 
incubation for 48 h at 4°C with mouse anti-TH antibody (1:100, Immunostar, Hudson, WI, 
USA) in PBST (1X PBS, 0.3% Triton X-100) containing 5% (v/v) normal goat serum. 
Samples were washed three times for 15 min in PBST. Mouse anti-Cy5 (1:200, Jackson 
ImmunoResearch, West Grove, PA, USA) was diluted in PBST with 5% (v/v) normal goat 
serum and used as secondary antibody by incubation for 24 h at 4ºC. For 
immunohistochemistry in larvae, eye imaginal discs of 3rd instar larvae were dissected in 
PBS 1X and fixed for 1 h in 4% paraformaldehyde as described elsewhere (Purves and 
Brachmann, 2007). Samples were then washed three times for 15 min in PBST and 
incubated overnight at 4ºC with rat anti-Elav antibody (1:100, Developmental Studies 
Hybridoma Bank, University of Iowa, USA). Imaginal discs were washed three times for 
15 min in PBST and incubated for 2 h with rat anti-Cy5 secondary antibody (1:200, 
Jackson ImmunoResearch, West Grove, PA, USA). Finally, all samples were subjected to 
a last step of washing and mounted in 80% glycerol PBS solution, followed by confocal 
microscopy analysis. Z-stack images were acquired using a LSM 710 Meta Zeiss confocal 
microscope (resolution of 1024 × 1024, slice thickness of 1 µm, frame average of 2). Z-
projections were generated and merged using ImageJ free software and images were 
prepared for publication on Adobe Photoshop CS6 (Adobe Systems Incorporated, San 
Jose, CA, USA). For quantification of aggregates, mCherry Z-stack images were analyzed 
by means of the Fiji software (Schindelin et al., 2012) and aggregation was measured 
using the 3D Objects Counter plugin (Bolte and Cordelieres, 2006). Briefly, the minimum 
threshold value was defined as 0.144 µm3 to exclude signal from soluble HTT in the count. 
The volume (µm3) occupied per each aggregate, the average number of aggregates and the 
corresponding standard deviations were calculated for at least 5 imaginal discs or adult 
brains per genotype.  
 
Live Imaging of adult Drosophila eye 
DPP analysis was performed in living animals as previously described (Pichaud 
and Desplan, 2001, Pocas et al., 2015). Briefly, flies at age of 1, 8 or 15 days were 
anaesthetized with CO2 and then placed on a 50 mm petri dish, previously poured with 2% 
agarose at 40ºC. Once the agarose was solidified, the anesthetized flies were covered with 
cool water to keep anaesthetic conditions. Adult compound eye integrity of at least 5 flies 
per genotype was examined by fluorescence microscopy with a water immersion objective 
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(HC APO L40X/0.80W U-V-I, Leica Microsystems, Wetzlar, Germany). Images were 
obtained using a Leica DM5500 B microscope (Leica Microsystems, Wetzlar, Germany) 
and an Andor Luca R DL-604M camera (Andor Technology Ltd., Belfast, UK). For 
quantitative analysis, images were analyzed using Image J free software and number of 
fluorescing rhabdomeres was scored for >15 ommatidia per fly.   
 
Phosphatase Inhibitors Treatment and Pseudopupil analysis 
Adult flies expressing 93QHTTex1 in the nervous system were collected upon 
eclosion and transferred to fresh vials of food previously supplemented with different 
concentrations of a PP2A inhibitor (compound B2, Table S1, Supplemental information I) 
(10, 30 or 100 μM) or a Cdc25 inhibitor (compound C5, Table S1, Supplemental 
information I) (100 μM). Briefly, compounds were dissolved in DMSO (0.1% final) and 
added to standard maize media at required doses. Flies were introduced to the media after 
eclosion and moved daily onto new vials containing freshly made food with appropriate 
concentrations of the compound. Pseudopupil analysis was performed after 7 days of 
treatment with PP2A or Cdc25 inhibitors as previously described (Campesan et al., 2011). 
Newly emerged untreated flies (0 day-old) and 7 day-old untreated or 0.1% DMSO treated 
flies were also analyzed for changes in rhabdomere number. Briefly, fly heads were 
carefully removed and fixed to glass slides using fingernail polish and rhabdomeres were 
analyzed at 500x magnification using an Olympus BH2 microscope. The number of visible 
rhabdomeres was scored for >50 ommatidia per fly, and at least 15 flies were examined per 
condition.  
 
Statistics 
 GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA) or Sigmaplot 
software (Systat Software, Inc., San Jose, CA, USA) were used to perform the statistical 
analysis and graphical representation of data. In vitro results are shown as the average ± 
standard deviation (SD) of at least 3 independent experiments and Drosophila results as 
the average ± standard error (SEM), unless specified otherwise. Cell culture data was 
analyzed by means of a one-way ANOVA followed by a post-hoc Tukey test for average 
comparison. Aggregate quantification and pseudopupil assays in Drosophila were 
analyzed by means of a one-way ANOVA followed by a Student-Newman-Keuls post-hoc 
test. DPP assays were analyzed by means of a two-way ANOVA followed by a Bonferroni 
post-hoc test. Results were in all cases considered significant only when p<0.05. 
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3.2.&Glycation&modulates&mutant&huntingtin&toxicity&in&Drosophila&
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Abstract 
 
 Protein glycation is an age-dependent post-translational modification associated 
with several neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. 
This non-enzymatic reaction occurring between reducing sugars and free amino-groups 
from proteins interferes with the folding and the aggregation process of proteins such as 
amyloid-beta and alpha-synuclein. As methylglyoxal (MGO) is the most important 
glycation agent, being present in all cell types, we asked whether MGO-mediated glycation 
might also play a role in huntingtin (HTT) biology, the causative protein in Huntington’s 
disease (HD). We have previously observed that glycation increased the aggregation of 
mutant HTT exon 1 (HTTex1) fragments associated with HD, in yeast and mammalian cell 
models. Here, we studied the effect of glycation on mutant HTT neurotoxicity in fruit flies. 
Notably, treatment of flies expressing a mutant version of HTTex1 (93QHTTex1) with 
MGO enhanced neuronal loss in a dose-dependent manner. Furthermore, increased 
glycation levels resulted in compromised viability during both developmental and adult 
stages of the fruit fly, impairing eclosion and decreasing lifespan. Overall, our study 
provides evidence that glycation modulates mutant HTTex1-related toxicity, and suggests 
it may constitute a novel target for therapeutic intervention in HD. 
 
Introduction 
 
 The formation of advanced glycation-end products (AGEs) has been implicated in 
several pathological conditions as well as in physiological aging. AGEs result from a non-
enzymatic reaction between reducing sugars and proteins, named Maillard’s reaction also 
known as glycation. This process is reported to have deleterious effects on proteins, being 
associated with loss of protein activity and aggregation (Kulkarni et al., 2013). Indeed, 
various proteins and enzymes of clinical significance are found to be glycated in patients, 
including those linked to neurodegenerative diseases such as Aβ, α-syn, Tau and prions 
(Vicente Miranda and Outeiro, 2010, Vicente Miranda et al., 2016a). In AD and PD, 
glycation interferes with normal biology of Aβ (Chen et al., 2006b, Li et al., 2013) and α-
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syn (Vicente Miranda et al., 2017), respectively, leading to increased protein accumulation 
and concomitant cytotoxicity. Moreover, glycation could induce aberrant signaling via a 
specific membrane receptor for AGEs (RAGE), resulting in increased oxidative stress and 
inflammation through the formation of ROS. Aβ itself is a ligand of RAGE, forming a 
positive feedback loop to augment oxidative damage in the brain (Chen et al., 2007). 
Importantly, RAGE-specific inhibitors have been shown to reduce Aβ-mediated toxicity in 
models of AD (Crunkhorn, 2012). Therefore, pharmacological interventions targeting 
glycation may emerge as valuable approaches for the treatment of AD and potentially, 
other neurodegenerative conditions. 
 Methylglyoxal (MGO) is an unavoidable by-product of glycolysis and the most 
reactive glycation agent. It is mainly produced by the non-enzymatic decomposition of the 
phosphate group of the triose phosphates (glyceraldeyde 3-phosphate and 
dihydroxyacetone phosphate) (Figure 19) (Vicente Miranda et al., 2016a). MGO can also 
arise from the interconversion between glyceraldeyde 3-phosphate and dihydroxyacetone 
phosphate by the triose phosphate isomerase (Tpi), where the enediolate intermediate may 
leak from the active site of Tpi in a paracatalytical reaction (Richard, 1991). Moreover, 
decreased Tpi activity results in an accumulation of dihydroxyacetone phosphate and 
MGO (Guix et al., 2009, Orosz et al., 2009). MGO is detoxified by the glyoxalase system, 
involving the enzymes glyoxalases I (Glo1) and II (Glo2), and by aldose reductases 
(Vicente Miranda et al., 2013). Previous reports showed that Glo1 inactivation induces a 
strong increase in MGO levels in yeast (Gomes et al., 2005). TPI deficiency increases the 
levels of dihydroxyacetone phosphate (Ciriacy and Breitenbach, 1979) and, consequently, 
increases the levels of MGO (Hollan et al., 1993, Phillips and Thornalley, 1993). TPI 
deficiency in humans results in increased levels of MGO (Ahmed et al., 2003).  
 Although no direct correlation between glycation and the pathogenesis of HD has 
been established thus far, levels of RAGE are increased in HD brains (Ma and Nicholson, 
2004) and in mouse models (Anzilotti et al., 2012). In addition, we found that glycation 
promotes aggregation and cytotoxicity in yeast and mammalian cell models expressing 
mutant HTT exon 1 fragments (HTTex1) (Vicente Miranda et al., 2016b). Here, we further 
investigate the role of protein glycation on mutant HTT toxicity in vivo, using a 
Drosophila HD model. 
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Figure 19. Methylglyoxal pathway. The 
methylglyoxal (MGO) pathway is an 
alternative metabolic route of glycolysis, 
where pyruvate is formed and subsequently 
catalyzed in mitochondria via the Krebs cycle 
for energy production. The excessive intake 
of glucose by a cell is the most important 
process for activation of the MGO pathway, 
although MGO can also be generated by lipid 
peroxidation and amino acid catabolism. 
MGO is a highly reactive dycarbonyl 
compound that binds to free amino-groups of 
proteins such as lysine, arginine and cysteine, 
thereby inducing the formation of an unstable 
Schiff’s base. This modification is reversible, 
although the Schiff’s base undergoes further 
intramolecular rearrangements and reactions, 
giving rise to irreversibly bounded compounds, the so-called AGEs. Notably, MGO is one of the substrates 
of the glyoxalase system that functions to protect cells from dicarbonyl-mediated AGE formation. TPI, triose 
phosphate isomerase. MGS, methylglyoxal synthase. GLO, glyoxalase enzymes. GSH, glutathione. DLDH, 
D-lactate dehydrogenase. Extracted from (Sousa Silva et al., 2013). 
 
Results 
 
MGO treatment exarcerbates neurodegeneration in a Drosophila model of HD  
 Using a versatile yeast model of HD and a human neuroglioma cell line (H4 cells), 
we recently observed that pharmacological or genetic modulation of the MGO pathway 
affects mutant HTT aggregation and toxicity (Vicente Miranda et al., 2016b). Deletion of 
genes encoding for enzymes involved in MGO metabolism, Glo1 or Tpi, induced HTT 
intracellular accumulation and formation of inclusion bodies in yeast cells (Vicente 
Miranda et al., 2016b). Importantly, Glo1 and Tpi knockout yeast strains are known to 
produce higher amounts of MGO and to accumulate AGEs (Gomes et al., 2005, Hollan et 
al., 1993, Phillips and Thornalley, 1993). These findings were further validated in human 
H4 cells, in which MGO treatment potentiated mutant HTT aggregation, an effect that was 
accompanied by defective autophagic clearance of HTT and enhanced cytotoxicity 
(Vicente Miranda et al., 2016b). To determine the effects of MGO-mediated glycation in 
vivo, we employed a Drosophila model of HD, described above (see Chapter I and Chapter 
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III, 3.1). This model is based upon the pan-neuronal expression of HTTex1 containing 
either normal (20QHTTex1) or expanded (93QHTTex1) polyQ stretches via the 
GAL4/UAS system (Steffan et al., 2001). Flies expressing 93QHTTex1 under the control 
of elavGAL4 exhibit a variety of HD-relevant phenotypes, including degeneration of the 
photoreceptor neurons (rhabdomeres), locomotor defects, decreased lifespan, and impaired 
emergence of the adult fly from the pupal case (eclosion) (Breda et al., 2016, Campesan et 
al., 2011, Green and Giorgini, 2012, Mason et al., 2013). Moreover, elavGAL4 drives 
expression of HTT at all developmental and adult fly stages (Berger et al., 2007), allowing 
for the assessment of MGO effects on early and late disease-like changes. Thus, we 
interrogated whether MGO-mediated glycation could contribute to mutant HTT-related 
neurotoxicity in different stages of the fly life cycle. For that purpose, both larvae and adult 
HD flies were treated with increasing concentrations of MGO. Flies expressing 
93QHTTex1 pan-neuronally display severe age-dependent neurodegeneration, with some 
neuronal loss being evident already upon eclosion (day 0) (Figure 20). After treatment with 
increasing concentrations of MGO during 7 days post-eclosion, HD adult flies showed 
greater reduction in the number of rhabdomeres per ommatidium in comparison to their 
untreated counterparts (Figure 20A). Notably, this effect was dependent on the dose of 
MGO added to the fly food (see Material and methods II for details), which indicates a 
successful administration of MGO through feeding. In addition, treatment of 93QHTTex1 
larvae also resulted in a dose-dependent reduction in the number of rhabdomeres upon 
eclosion (Figure 20B). Notably, MGO was toxic only in disease context, as treatment of 
control fly lines did not produce any effect (Figure S10, Supplemental information II). 
 
 
Figure 20. MGO treatment exacerbates neurodegeneration in HD transgenic flies. MGO 
significantly increases neuronal loss in adult (A) and developing flies (B) with pan-neuronal expression of 
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93QHTTex1, in a dose-response manner. Quantification of mean rhabdomeres (±SEM) per ommatidium. 
*Significance of differences versus untreated 7 day-old flies (A) or newly emerged flies (B), p<0.05. 
 
Genetic modulation of the MGO pathway alters mutant huntingtin-induced defects in 
vivo  
 Next, we asked whether genetic modulation of glycation via knockdown of Glo1 or 
Tpi altered 93QHTTex1-induced defects in vivo. We employed an RNAi approach to 
downregulate Glo1 or Tpi in Drosophila. The Glo1 knockdown line was generated using 
the phiC31 integrase system to insert an RNAi sequence into specific attP target sites in the 
genome (Groth et al., 2004), whereas Tpi knockdown was engineered via traditional P-
element-mediated mutagenesis, where the RNAi construct is inserted randomly into the 
genome. As such, two independent Tpi knowdown lines (Tpia and Tpib) were used in 
order to discard off-target effects or other artifacts. We first confirmed that silencing of Tpi 
or Glo1 increased overall glycation levels in 93QHTTex1-expressing flies (Figure S11, 
Supplemental information II). Moreover, a consistent increase in the levels of AGEs was 
detected in HTT protein by immunoprecipitation (Figure S11, Supplemental information 
II). Downregulation of either Glo1 or Tpi in WT background flies did not cause 
neurotoxicity as measured by the pseudopupil assay (Figure S12, Supplemental 
information II). However, when Glo1 or Tpi was knocked down in flies expressing 
93QHTTex1, a significant increase in neuronal loss was observed at both 0 and 7 days 
post-eclosion, in comparison to their relative titration controls (Figure 21A and B). 
Downregulation of Glo1 or Tpi also affects development and survival of HD flies (Figure 
21C-F). In this Drosophila HD model, pan-neuronal expression of normal polyQ stretches 
(20QHTTex1) causes a fly to live for up to 80 days, while 93QHTTex1 flies suffer a 
striking reduction of ~60 days in their lifespan (Figure S13, Supplemental information II). 
Downregulation of Glo1, but not Tpi, caused a further reduction in the lifespan of flies 
expressing 93QHTTex1 (Figure 21C and D). To assess viability in 93QHTTex1 
developing flies under glycation conditions, we measured the eclosion ratio between pupa-
emerging flies expressing both 93QHTTex and Glo1 or Tpi RNAi and their non-
expressing siblings (see Materials and methods II for details). Pre-eclosion lethality of 
93QHTTex1 flies was significantly increased when either Glo1 (Figure 21E) or Tpi 
(Figure 21F) was knocked down. 
 Overall, the results strongly suggest that glycation can act as an important 
environmental modifier of HTT toxicity, and thus influence HD onset and/or progression. 
Protein!glycation!in!HD!
!94 
 
 
 
Figure 21. Downregulation of Glo1 or Tpi potentiates mutant HTT toxicity in Drosophila. 
Flies expressing 93QHTTex1 pan-neuronally and knocked down for Glo1 or Tpi were assayed for 
neurodegeneration (A, B), longevity (C, D) and eclosion rates (E, F). HD flies carrying either Glo1 RNAi (A) 
or Tpi RNAi (B) showed increased neuronal loss in comparison to respective controls. Number of 
rhabdomeres per ommatidium was evaluated at day 0 and day 7 post-eclosion. Survival rate was evaluated in 
flies with pan-neuronal knockdown of Glo1 (C) or Tpi (D) in mutant HTT backgrounds. Mean survival in 
days: 93QHTTex1 + 3M = 12; 93QHTTex1 + Glo1 RNAi = 6; 93QHTTex1 + GFP = 13; 93QHTTex1 + 
Tpia RNAi = 12; 93QHTTex1 + Tpib RNAi = 11.5. RNAi silencing of Glo1 (E) or Tpi (F) caused a 
reduction in the percentage of flies emerging from the pupal case. Flies carrying a single copy of the driver 
(elavGAL4) or, two copies of UAS constructs (UAS) in the absence of GAL4, are shown as controls. For all 
experiments, 93QHTTex1 + 3M or 93QHTTex1 + GFP flies were used as titration controls for Glo1 and Tpi 
silencing lines, respectively. Data in all panels are mean ± SEM. *Significant versus the respective titration 
control, p<0.05. 
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Discussion 
 
 The precise mechanisms through which HTT mutations cause HD are still 
unknown. However, accumulation of HTT plays an important role in the disease and 
strategies aimed at reducing its levels constitute attractive strategies for therapeutic 
intervention and are currently being explored in ongoing clinical trials (Wild and Tabrizi, 
2014). Different post-translational modifications (PTMs) are known to modulate the levels, 
aggregation propensity and clearance of HTT, and could thereby play a role in HD 
pathogenesis (Ehrnhoefer et al., 2011, Krainc, 2010, Saudou and Humbert, 2016). For 
example, phosphorylation of HTT on Ser13 and Ser16 is protective in mouse models of 
HD (Gu et al., 2009), enhancing the clearance of HTT via the proteasome and chaperone-
mediated autophagy (Thompson et al., 2009). Acetylation of Lys9 and Lys444 promotes 
HTT clearance via the autophagy lysosome pathway (ALP) (Jeong et al., 2009). On the 
other hand, SUMOylation leads to HTT accumulation and translocation into the nucleus 
(Steffan et al., 2004).  
 We have previously found that both pharmacological and genetic induction of 
glycation plays a deleterious role in yeast and mammalian cell models of HD by 
decreasing HTT clearance, increasing the intracellular levels of HTT and enhancing its 
aggregation and toxicity, either directly or indirectly (through the increase in the levels of 
HTT) (Vicente Miranda et al., 2016b). Impaired clearance of HTT via the proteasome was 
previously associated with HD (Labbadia and Morimoto, 2013). Interestingly, our previous 
results in mammalian cells point for opposite effects of glycation on normal (25Q) versus 
mutant (104Q) HTTex1 variants. While glycation impairs the activation of the ALP system 
in cells expressing 25Q HTTex1, the ALP system is highly induced in the presence of 
glycated mutant HTTex1 (Vicente Miranda et al., 2016b). This increased ALP activation 
suggests a compensatory mechanism for the cell to cope with aggregated HTT that is 
normally cleared via the ALP system (Nixon, 2013, Yamamoto et al., 2006). 
 Although activation of autophagy could clear aggregated proteins and is considered 
an important therapeutic approach for several neurodegenerative disorders (Rubinsztein et 
al., 2012), it could also lead to neuronal death in certain conditions (Puyal et al., 2012). It 
is therefore possible that increasing levels of glycation could contribute to mutant HTT 
cytotoxicity via overactivation of the ALP (Vicente Miranda et al., 2016b). Interestingly, 
in this previous study we also observed that glycation reduces the extracellular release of 
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mutant HTT, which may account for its intracellular accumulation, increased aggregation 
and toxicity.  
 Diabetes is a risk factor for neurodegenerative diseases such as AD and PD 
(Vicente Miranda and Outeiro, 2010, Vicente Miranda et al., 2016a). A major consequence 
of diabetes is glucose metabolism imbalance and consequent hyperglycemia. Glucose and 
its byproducts have the ability to react with amino groups, forming AGEs that can impact 
the function of target proteins. Glycation exacerbates the accumulation, aggregation and 
toxicity of Aβ and α-syn (Li et al., 2013, Vicente Miranda et al., 2017). Glycation could 
therefore constitute a common mechanism contributing to the development of 
neurodegenerative diseases by acting as a “second hit” that tips the proteostasis balance of 
cells, causing dysfunction of multiple essential cellular pathways, and leading to premature 
death. Consistently with this hypothesis, antidiabetic drugs have been shown to be 
protective in HD pre-clinical trials. For example, metformin was shown to prolong the 
survival of HD male mice (Ma et al., 2007); and exendin-4 decreased HTT aggregation, 
suppressed cellular pathology in both brain and pancreas, improved motor function, and 
extended survival in a mouse model of HD (Martin et al., 2009). The prevalence of 
diabetes is higher in HD patients (Farrer, 1985, Podolsky et al., 1972), HD brains 
differentially express several proteins linked to type-2 diabetes (Schonberger et al., 2013), 
and mouse models of HD develop hyperglycemia (Hurlbert et al., 1999, Jenkins et al., 
2000), possibly due to the accumulation of intranuclear HTT inclusions in pancreatic β 
cells that produce insulin (Andreassen et al., 2002, Bjorkqvist et al., 2005). However, 
whether diabetes is a contributing factor or a consequence of HD is still unclear, as is the 
role of HTT glycation. 
 In this study, we demonstrate for the first time that glycation potentiates mutant 
HTT toxicity in vivo, as shown by the worsening of several disease-relevant phenotypes in 
a Drosophila model of HD (Figure 20 and 21). Feeding of mutant HTTex1-expressing flies 
with MGO reduced the number of rhabdomeres per omatidium, demonstrating a dose-
dependent and selective effect. Such deleterious effect was also observed upon eclosion, 
suggesting that glycation exacerbates HTT toxicity during development. Importantly, 
genetic manipulation of pathways controlling MGO levels, through Glo1 or Tpi1 
knockdown, also resulted in increased neurotoxicity and reduced survival. In Tpi RNAi 
flies, we observed a significant reduction in eclosion, and in Glo1 RNAi flies we observed 
a significant reduction in both eclosion and survival rate. Altogether, our results suggest 
that hyperglycemia, and the subsequent glycation of proteins including HTT, could not 
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only be a consequence but also a contributing factor in HD pathogenesis. 
 Interestingly, we recently showed that DJ-1 overexpression protects against HTT 
toxicity in yeast and fruit flies (Sajjad et al., 2014). Although mutations in the DJ-1 gene 
are associated with recessive forms of PD, DJ-1 was also described as an anti-MGO 
enzyme with glyoxalase activity (Lee et al., 2012). Moreover, DJ-1 is suggested to act as a 
protein deglycase that repairs MGO-glycated proteins (Richarme et al., 2015), although 
this finding remains controversial, as loss of Drosophila DJ-1 does not further contribute to 
MGO-induced AGE accumulation (Pfaff et al., 2017). Our studies are consistent with a 
potential protective role of human DJ-1, further supporting a connection between protein 
glycation and HD.  
 In summary, the present data obtained in flies serve as a strong complement to our 
previous findings in yeast and mammalian cell models of HD, further suggesting that 
protein glycation could contribute to HTT dysfunction and that its modulation may 
constitute a novel target for therapeutic intervention in HD. 
 
Materials and methods II 
 
Drosophila lines  
 Flies were raised on standard maize media at 25ºC in l2 h light/dark cycle. The 
UAS-20QHTT and UAS-93QHTT exon 1 flies were kindly provided by J. Lawrence 
Marsh and Leslie Thompson (University of California, Irvine) (Steffan et al., 2001). RNAi 
transgenic lines were obtained from the Vienna Drosophila Resource Center (VDRC, 
Vienna, Austria) for genetic silencing of glyoxalase I (Glo1) or triose phosphatase 
isomerase (Tpi). The Glo1 knockdown line (v101560, KK109109) was generated using the 
phiC31-integrase system, which target the RNAi transgene to a specific landing site on the 
second chromosome (P{attP,y+,w3'}VIE-260B (2L:22019296)) (Dietzl et al., 2007). For 
Tpi silencing, we employed two lines from the GD library, Tpia (v25643, GD10138) and 
Tpib (v25644, GD10138) (Mummery-Widmer et al., 2009), where the RNAi construct is 
inserted randomly into the genome via traditional P-element-mediated mutagenesis. The 
elavGAL4 driver (c155) and the UAS-eGFP (BL5431) stocks were obtained from the 
Bloomington Drosophila Stock Center (Indiana University, Bloomington, IN, USA). Flies 
carrying UAS-3M (empty vector located in the KK site) and UAS-eGFP were used as 
titration controls for the RNAi knockdown experiments.  
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Immunoprecipitation and immunoblot analysis 
 Total glycation levels and formation of AGEs in Glo1 or Tpi knockdown HD flies 
were measured by standard western blotting or immunoprecipitation (IP), respectively. 
One hundred heads of 7 days-old flies were isolated as described in (Campesan et al., 
2011), with minor modifications. Flies were frozen in liquid nitrogen and heads separated 
by vigorous vortexing. Heads were collected into new eppendorfs and homogenized using 
a sterile plastic pestle (Sigma-Aldrich, St. Louis, MO, USA) in NP40 buffer (0.5% NP40, 
10 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA) containing protease inhibitors 
(Complete Mini, Roche diagnostics, Mannheim, Germany). Total protein lysates were 
obtained by centrifugation at 2000 rpm, for 1 min at 4ºC and quantified by means of the 
BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA, USA), following 
manufacturer’s instructions. For IP experiments, 93QHTTex1 was pulled down from 750 
μg of total protein extracts as we previously described (Guerreiro et al., 2013), and 
immunoprecipitated with 10 μl of anti-HTT antibody (Millipore, Billerica, MA, USA). 
Total protein lysates and IP samples were analyzed by immunoblotting using the following 
antibodies: anti-AGEs (1:500, Cosmo Bio, Tokyo, Japan), anti-HTT (1:1000, Millipore, 
Billerica, MA, USA) and anti-α-tubulin (1:15000, Sigma-Aldrich, St. Louis, MO, USA). 
 
MGO treatment 
 To access glycation-mediated effects in different stages of Drosophila HD 
development, both larva and adult flies were treated with increasing concentrations of 
MGO. MGO was purified as previously described (Gomes et al., 2005), dissolved in H2O 
and added to maize media at the required doses (10, 30, 100 or 300 μM). For treatment 
during development, parental lines were crossed and flies were grown on maize media 
previously supplemented with different concentrations of MGO. F1 progeny was collected 
upon eclosion and analyzed for eclosion ratio and photoreceptor loss as described above. 
Adult feeding experiments were performed as described in Materials and methods I. 
Briefly, newly emerged flies were transferred to MGO-supplemented food and moved 
daily to new vials with appropriate MGO concentration. Rhabdomere number was scored 
after 7 days of treatment.  
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Pseudopupil analysis 
 Neurodegeneration was assayed by measuring the number of visible rabdomeres 
per ommatidium as described above (see Materials and methods I), and at least twelve flies 
were examined per condition at day 0 or 7 post-eclosion. 
 
Eclosion and longevity assays 
 Fruit fly viability was determined by measuring the percentage of eclosion, as 
previously described (Breda et al., 2016). For RNAi knockdown experiments, males 
carrying the sex-linked elavGAL4 driver were crossed to virgin females carrying UAS-
Glo1RNAi; UAS-93QHTTex1 or UAS-TpiRNAi; UAS-93QHTTex1 in order to generate 
female expressing the desired genotype and wild-type control males in the progeny. For 
MGO feeding experiments, the elavGAL4 males were crossed to virgin females 
homozygous for the UAS-20QHTTex1 or the UAS-93QHTTex1 transgene, and flies were 
allowed to lay eggs on vials with or without treatment. At least ten independent crosses 
were set up per condition and parental flies were removed 5 days after mating. The number 
of female or male flies emerging in the F1 generation was scored over 10 days post-
eclosion and eclosion percent per vial was calculated using the following ratio: (number of 
female/number of male flies)*100. For longevity analysis, one hundred newly emerged 
female flies were collected per genotype and kept in groups of 10 in separate vials. Flies 
were moved to fresh food every 2-3 days and the number of living flies was scored daily. 
 
Statistics 
 Statistical analysis was performed using Prism 6 (GraphPad Software Inc., La Jolla, 
CA, USA). For eclosion and rhabdomere quantification, analyses were carried out using 
ANOVA with the Newman-Keuls post-hoc test. For longevity, survival curves were 
generated and analyzed using the Kaplan-Meier method and log-rank statistics. All data is 
represented as the average ± standard error (SEM), and results were considered significant 
only when p<0.05. 
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Abstract 
 
 Protein misfolding and aggregation underlies the pathogenesis of several 
neurodegenerative disorders. Although the proteins causing these diseases are unique, 
growing evidence indicates that they can co-aggregate and modify one another’s behavior, 
suggesting this process may contribute to the overlap in clinical symptoms across different 
neurodegenerative disorders. Unraveling how such interactions occur and interfere with 
protein aggregate properties may provide opportunities for developing therapies. Here, we 
used a bimolecular fluorescence complementation (BiFC) assay to study interactions 
between a toxic huntingtin fragment (97QHTTex1), which causes Huntington’s disease, 
and other aggregation-prone proteins, in living human cells. We showed that 97QHTTex1 
interacts and co-aggregates with both alpha-synuclein (α-syn) and Tau, whose 
abnormalities were originally thought to be exclusively related with Parkinson’s and 
Alzheimer’s disease, respectively. Interactions of either α-syn or Tau with 97QHTTex1 
altered its pattern of aggregation and cellular distribution, although toxicity of the resulting 
aggregates was not further increased. Strikingly, we found that N-terminal phosphorylation 
of HTTex1 can prevent co-aggregation between 97QHTTex1 and α-syn, but not their 
ability to form hetero-dimers or higher oligomeric species. Altogether, our results further 
support that co-aggregation of otherwise unrelated disease-causing proteins might 
contribute to the development of mixed neuropathologies, pointing for a critical role of 
post-translational modifications in modulating these processes.  
 
Introduction 
  
 Neurodegenerative disorders such AD, PD or HD are generally characterized by 
the gradual loss of motor and/or cognitive functions, attributed to the death of specific 
neurons in the central nervous system. While an AD patient typically exhibits severe 
hippocampal degeneration accompanied by cognitive impairment and dementia, PD and 
HD are disorders of the basal ganglia characterized by behavior and motor defects. 
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Interestingly, clinical observations have reported a substantial overlap among 
neurodegenerative disorders, with some patients showing co-occurrence of symptoms 
characteristic of more than one disease (Rahimi and Kovacs, 2014).  Additionally, there 
seems to be a cross-talk between different diseases. For example, PD and HD patients are 
at increased risk of developing dementia (Leverenz et al., 2009, Tyebji and Hannan, 2017), 
and individuals primarily diagnosed with dementia may also develop parkinsonism 
(Horvath et al., 2014). Despite intensive research in the field, the complexity and 
heterogeneity of neurodegenerative disorders are still poorly understood. 
 The presence of amyloid-like proteinaceous inclusions is a common feature among 
several neurodegenerative diseases, which have been histopatologically classified 
according to the nature and localization of these inclusions in the brain. In HD, 
cytoplasmic and intranuclear aggregates containing an abnormal expanded polyQ protein 
(HTT) are typically found in medium spiny neurons of the striatum. AD can be classified 
as an amyloidopathy as well as a tauopathy, being characterized by the formation of both 
Aβ extracellular plaques and intracellular inclusions composed of hyperphosphorylated 
Tau in the form of neurofibrillary tangles (NFTs). The accumulation of α-syn into Lewy 
bodies is one of the hallmarks of PD hence belonging to a group of neuropathologies 
termed as synucleinopathies. Nevertheless, Tau positive inclusions are also described in 
synucleinopathies and vice-versa, suggesting that the presence of mixed proteinaceous 
inclusions may contribute to clinical heterogeneity, and perhaps, disease development and 
progression (Kotzbauer et al., 2004). In particular, the co-occurrence of Tau and α-syn 
deposits has been found in patients with Dementia with Lewy bodies (DLB) (Colom-
Cadena et al., 2013, Ishizawa et al., 2003), whereas α-syn localizes to NFTs of AD (Marui 
et al., 2000, Takeda et al., 2000).  
 Relevant findings have also emerged from in vitro and in vivo studies. The direct 
interaction between α-syn and Tau is first described in a report from 1999, where the 
researchers show that α-syn co-localizes with Tau in axons promoting its phosphorylation 
via activation of the protein kinase A (Jensen et al., 1999). Moreover, α-syn is shown to 
contain a specific binding site for Tau at its C-terminus, further suggesting that these 
proteins may work together on mechanisms of neurodegeneration (Jensen et al., 1999). 
Consistently, co-aggregation of α-syn and Tau is associated with increased toxicity in 
cellular and Drosophila models of disease (Badiola et al., 2011, Roy and Jackson, 2014).  
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 Importantly, α-syn interactions are not restricted to Tau, and may also occur 
between other aggregation-prone proteins, including HTT (Charles et al., 2000, Furlong et 
al., 2000, Herrera and Outeiro, 2012, Masliah et al., 2001, Zondler et al., 2014). 
Immunohistochemical analysis of tissues from both cortex and striatum of patients and 
mouse models of HD revealed α-syn as a component of polyglutamine aggregates (Charles 
et al., 2000). Intriguingly, overexpression of α-syn potentiates the formation of mutant 
HTT aggregates in cultured human cells, even when co-aggregation does not occur 
(Furlong et al., 2000). Notably, we showed that α-syn interacts and co-aggregates with 
HTT in living human cells, resulting in an altered HTT aggregation pattern (Herrera and 
Outeiro, 2012). 
 In the last decade, evidence linking Tau aggregation and HD neuropathology has 
also begun to emerge (Gratuze et al., 2016). A post-mortem study has reported co-
localization of Tau and HTT aggregates in the striatum of an HD patient (Caparros-
Lefebvre et al., 2009). At the cellular level, we recently showed that HTT directly interacts 
with Tau enhancing its phosphorylation, and that these interactions change the aggregation 
profile of HTT (Blum et al., 2015). Likewise, we found that Tau is hyperphosphorylated in 
a mouse model of HD (Blum et al., 2015), what is also observed by a similar study from 
other laboratory (Gratuze et al., 2015). 
  Altogether, these observations indicate that neurodegenerative diseases involve co-
aggregation of different protein species, which may also include post-translational 
modified species. PTMs can alter protein structure and could, in theory, play a role in co-
aggregation processes. Given that we found that PTMs modulate HTT aggregation 
(Chapter III, section A), we postulated that it might also interfere in HTT ability to interact 
and co-aggregate with other aggregation-prone proteins. Here, we investigated the effects 
of single phosphorylation events in the N-terminal region of HTTex1 upon mutant HTT 
interactions with both α-syn and Tau.  
 
Results 
 
Alpha-synuclein modifies mutant huntingtin aggregation pattern 
 We started by characterizing the effect of α-syn upon mutant HTT oligomerization, 
aggregation and toxicity in mammalian cells. By employing a Venus-based BiFC 
approach, a pair of constructs encoding either a wild-type (19Q) or a mutant (97Q) 
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HTTex1 fragment, or α-syn fused to non-fluorescence halves of the Venus protein was 
transfected into H4 human glioma cells (Figure S14A, Supplemental information III). In 
this system, HTTex1 is located at the N-terminus of both Venus halves (V1 and V2), 
whereas α-syn is located at the C-terminus of V1 or at the N-terminus of V2. The Syn-V1 
construct also contains a serine/glycine linker between V1 and α-syn in order to improve 
the flexibility of the fusion protein. As described in Chapter I, interaction between proteins 
of interest would bring the two Venus halves together, reconstituting the functional 
fluorophore and thereby emitting fluorescence. Importantly, these combinations of 
plasmids were previously generated and tested in our laboratory for production of 
fluorescence and dimerization efficiency (Herrera et al., 2011, Herrera and Outeiro, 2012). 
Flow cytometry analyses showed that transfection of all Venus BiFC pairs produced 
fluorescence (Figure S14B and C, Supplemental information III), indicating the formation 
of dimers/oligomers. This was further confirmed by microscopy, whereby HTTex1 BiFC 
pairs are visualized mostly in the cytoplasm (Figure 22A, 19Q/19Q and 97Q/97Q) and α-
syn spreading both through nucleus and cytosol (Figure 22A, Syn/Syn). While mutant 
HTT forms oligomeric species and large inclusions (Figure 22A, 97Q/97Q), α-syn 
accumulates as dimers and/or oligomers, with no aggregates being formed (Figure 22A, 
Syn/Syn). Consistently, filter trap assays indicated the presence of SDS-insoluble 
aggregates in 97Q/97Q cells, but not in cells transfected with the α-syn BiFC pair (Figure 
22F, FT). In addition, oligomeric species of variable size were detected in both mutant 
HTT and α-syn expressing cells (Figure 22F, Native-PAGE).  
 Co-transfection of α-syn-V2 with either 19QHTTex1-V1 or 97QHTTex1-V1 
plasmid produced fluorescence as determined by flow cytometry (Figure S14B and C, 
Supplemental information III). This suggests that α-syn can interact directly with both 
wild-type and mutant HTTex1, although it appears more prone to form dimers/oligomers 
with the mutant version (Figure S14B and C, Supplemental information III). Interestingly, 
when combined with mutant HTT, α-syn loses its nuclear location (Figure 22A, 97Q/Syn). 
This could be explained by the existence of a cytoplasmatic location-related domain in 
HTTex1 (Yan et al., 2011), which once interacting with α-syn would sequester it in the 
cytosol. Notably, combination of mutant HTT and α-syn BiFC constructs also resulted in 
the occurrence of large inclusions (Figure 22A, 97Q/Syn). However, further analysis of 
microscopy pictures revealed a change in the pattern of mutant HTT aggregation (Figure 
22B-D), with significantly fewer but larger aggregates being generated in the presence of 
α-syn. Filter trap assays showed a reduction in the formation of large aggregates 
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containing HTTex1 in 97Q/Syn cells versus 97Q/97Q cells (Figure 22F, FT), which was 
accompanied by a slight increase in the amount of HTTex1 oligomers (Figure 22F, Native-
PAGE). Moreover, α-syn co-expression with mutant HTT led to decreased levels of α-syn 
oligomeric species in comparison to the α-syn BiFC pair (Figure 22F, Native-PAGE).  
 Since, in our cellular model, α-syn and HTT interact modifying each other’s 
patterns of oligomerization and aggregation, we next asked whether such cellular 
phenotypic changes would correlate with altered cytotoxicity levels. We used the LDH 
assay (described in Chapter III, 3.1) to measure the cytotoxicity levels produced by H4 
cells after 24h of being transfected with different combinations of BiFC constructs (Figure 
22E). As previously reported, transfection of the 97QHTTex1 BiFC pair significantly 
increase cytotoxicity versus the wild-type counterpart (Herrera et al., 2011). A significant 
increase in cytotoxicity was also observed in cells transfected with the α-syn BiFC pair 
(Figure 22E). However, and in spite of the clear changes induced by α-syn on mutant HTT 
aggregation pattern and vice-versa, no changes were observed on cell viability when these 
two proteins were expressed together, even at 72 after transfection (data not shown). 
 Overall, the results are consistent with a previous report from our laboratory 
(Herrera and Outeiro, 2012), further suggesting HTT and α-syn as interplayers in 
mechanisms of neurodegenerative disease. 
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Figure 22. α-syn co-aggregates with mutant HTT and alters its aggregation pattern. (A) Cells 
transfected with 19QHTTex1-Venus BiFC pair of plasmids (19Q/19Q) show homogeneous fluorescence 
indicative of oligomeric species, while 97QHTTex1-Venus BiFC pair (97Q/97Q) produces both oligomeric 
species and large intracellular fluorescent aggregates with variable size and morphology. HTT location is 
primarily cytosolic. α-syn-Venus BiFC pair (Syn/Syn) produces homogeneous fluorescence distributed 
throughout all cellular compartments, including the nucleus. When α-syn and 97QHTTex1 BiFC constructs 
were combined, there is a change in the aggregation pattern of both proteins, quantified in B-D. Co-
transfection of 97QHTTex1 with α-syn BiFC constructs decreases the average number of aggregates per cell 
(B, C), and increases the average size of aggregates (D). (E) The α-syn pair or the 97QHTTex1 pair are more 
toxic than the wild-type HTTex1 pair (19Q/19Q) and combining α-syn with 97QHTTex1 does not enhance 
toxicity in this model. *significant versus 97Q/97Q, #significant versus 19Q/19Q, p<0.05. Scale bar, 20 μm. 
AU, arbitrary units. (F) Filter trap (FT) assays showed that both 97Q/97Q and 97Q/Syn produced SDS-
insoluble aggregates. Immunoblotting of total protein extracts under native conditions (Native-PAGE) 
indicated the generation of oligomeric species of variable size. Expression levels of each construct were 
evaluated by SDS-PAGE and GAPDH used as loading control. 
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Co-aggregation between huntingtin and alpha-synuclein is dependent on N-terminal 
phosphorylation state 
 In Chapter III, section A we demonstrated that single phosphorylation events in N-
terminal region comprising the first 17 amino acids of HTTex1 (N17) modulate protein 
aggregation. In particular, by employing HTTex1-Venus BiFC plasmids carrying single 
phosphomimic mutations within the 3 phosphorylatable residues of N17 (T3, S13, S16), 
we showed that phospho-HTTex1 molecules interact and co-aggregate with 
unphosphorylated HTTex1, depending on the residue mutated (Figure S3, Supplemental 
information I). To investigate the influence of HTTex1 phosphorylation on its interactions 
with α-syn, we transfected H4 cells with different combinations of phosphomimic mutants 
and α-syn (Figure 23). We observed that phosphorylated HTTex1 interacted with α-syn to 
the same extent as non-phosphorylated HTTex1 molecules (97Q/Syn combination), 
producing similar levels of fluorescence (flow cytometry assays, data not shown). 
However, co-expression of different phosphomimic mutants with α-syn resulted in mixed 
patterns of aggregation (Figure 23A), with a residue-dependent reduction in the percentage 
of cells with inclusions being shown (Figure 23B). Notably, such aggregation profiles 
resembled that of cells co-transfected with the correspondent phosphomimic mutant and 
non-mutated 97QHTTex1 BiFC constructs (Figure S3, Supplemental information I). This 
suggests that, in addition to regulating the formation of pure HTTex1 aggregates, N17 
phosphorylation may also play a role in co-aggregation processes occurring between HTT 
and other aggregation-prone proteins. 
 To further test the above hypothesis, we asked whether the modulatory effect of 
HTTex1 phosphomutants on aggregate formation could be extended to the Tau protein. 
Tau is an abundant neuronal protein, known to function as a microtubule stabilizer, thus 
being frequently found to localize to microtubule and actin networks (Elie et al., 2015). 
We have previously shown that mutant HTT interacts with Tau affecting its normal 
cellular distribution (Blum et al., 2015). In particular, using BiFC-based cellular models, 
we observed that, when co-expressed with Tau, mutant HTTex1 is recruited to the 
microtubules inducing Tau aggregation (Blum et al., 2015) (Figure 23A, 97Q/Tau). 
Concomitantly, mutant HTTex1 aggregation pattern was also altered, often leading to the 
formation of one single inclusion per cell (Blum et al., 2015) (Figure 23A, 97Q/Tau). 
Interestingly, most HTT/Tau inclusions were morphologically distinct from pure HTTex1 
aggregates, assembling into a ring-like structure (Blum et al., 2015) (Figure 23A, 
T3D/Tau). While the 97QHTTex1 BiFC pair induces the formation of inclusions in 30-
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40% of transfected cells (Herrera et al., 2011) (Figure 23B), 97Q/Tau inclusions are found 
in 15-17% of co-transfected cells (Blum et al., 2015) (Figure 23C). Strikingly, no changes 
in the percentage of cells showing large inclusions were observed when Tau was combined 
with the different phosphomimic mutants of HTTex1 (Figure 23C). 
 In summary, these observations further support a role for N17 phosphorylation in 
modulating HTTex1 aggregation, and suggest that it might also modulate HTTex1 protein-
protein interactions. Furthermore, our results strongly indicate that T3 phosphorylation is 
particularly important in preventing the formation, not only of pure HTTex1 aggregates, 
but also mixed aggregates containing HTTex1 and α-syn. Nevertheless, this effect appears 
to be protein-specific, as N17 phosphorylation did not affect interactions between Tau and 
HTTex1. 
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Figure 23. N17 phosphorylation interferes with mutant HTT and α-syn co-aggregation. (A) 
Combinations of 97QHTTex1-Venus BiFC contructs with α-syn revealed different co-aggregation responses 
to phosphomimic constructs, with T3D being the most restrictive in reducing aggregation. On the other hand, 
Tau co-aggregated with 97QHTTex1 regardless of the N17 mutation. B and C, Percentage of cells containing 
large inclusions as determined by quantitative analysis of microscopy pictures. *significant versus 97Q/Syn, 
p<0.05. Scale bar, 20 μm. 
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Discussion 
 
 Most neurodegenerative disorders are typically characterized by the aggregation of 
one or two specific proteins in the brain. In AD, PD and HD, much of the aggregated 
protein consist of Aβ, α-syn or HTT, respectively. However, accumulating evidence 
indicates that aggregation-prone proteins can co-aggregate increasing the possibility for 
neurotoxicity and disease (Badiola et al., 2011, Clinton et al., 2010, Corrochano et al., 
2012a, Pocas et al., 2015, Roy and Jackson, 2014, Tomas-Zapico et al., 2012). Indeed, 
since no protein acts in isolation, the interplay of diverse aggregation-prone proteins may 
influence disease onset, progression and severity, and is implicated as one possible reason 
for the heterogeneity of neurodegenerative diseases.  
 Interactions between particular aggregation-prone proteins can influence 
aggregation propensity and its outcomes, resulting in the formation of morphologically 
distinct intermediates that may differ in their ability to cause cell dysfunction and thus 
affect neurodegenerative processes (Morales et al., 2013, Sarell et al., 2013).  In the 
present study, we further discuss the consequences of HTT interactions with either α-syn 
or Tau upon the properties of the resulting aggregates, including their morphology and 
solubility, subcellular localization, and toxicity. In addition, we provide evidence for a 
modulatory role of N17 phosphorylation on mutant HTT co-aggregation propensity.  
 Both α-syn and Tau are expressed predominantly in the brain, more abundantly 
within nerve terminals, being involved in similar neuronal processes such as synaptic 
transmission and plasticity (Guo et al., 2017, Si et al., 2017). At a cellular and molecular 
level, endogenous α-syn is mostly present in the cytoplasm as an unfolded monomer, but it 
can also exist as a tetramer (Bartels et al., 2011, Dettmer et al., 2013). Tau is a 
microtubule-associated protein that promptly forms intracellular fibril structures when 
hyperphosphorylated (Guo et al., 2017). The fact that these two proteins share similar 
locations and functions suggests that interactions between them may be relevant for 
neuropathology. Moreover, the presence of aggregation-prone proteins within the same 
cellular compartments or in functionally connected brain areas may facilitate the 
occurrence of cross-seeding events (Morales et al., 2013, Sarell et al., 2013). Indeed, the 
aggregation potential of Tau is greatly enhanced in the presence of α-syn oligomers 
(Giasson et al., 2003, Kotzbauer et al., 2004, Waxman and Giasson, 2011). Similarly, 
when at low concentrations, α-syn requires Tau to initiate fibril formation (Giasson et al., 
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2003). Additional evidence for a significant role of α-syn/Tau interactions in 
neurodegeneration comes from experiments in different animal models (Emmer et al., 
2011, Roy and Jackson, 2014). Following the same line of thought, and considering that 
HTT is also a cytoplasmic protein, it is possible that HTT directly interacts with α-syn 
and/or Tau, and interferes with their normal cellular functions by cross-seeding their 
aggregation and/or recruiting them into HTT inclusions. Our study supports this idea by 
showing that co-expression of mutant HTT with either α-syn or Tau in human living cells 
leads to the formation of mixed cytosolic inclusions and altered patterns of protein 
subcellular distribution. In contrast with a report showing that mutant HTT aggregation is 
accelerated in the presence of overexpressed α-syn (Furlong et al., 2000), our results 
indicate that although α-syn can alter the aggregation profile of mutant HTT, no further 
HTT aggregation is observed when the two proteins are co-expressed at similar levels 
(Figure 22). However, while more HTT oligomeric species were formed, α-syn 
oligomerization was diminished, suggesting a dynamic system, where mutant HTT readily 
aggregates with α-syn becoming less available to form pure HTT aggregates. Indeed, cells 
expressing only mutant HTT produced similar levels of oligomerization versus cells 
expressing both mutant HTT and α-syn (Figure S14, Supplemental information III), 
indicating that mutant HTT molecules are as likely to interact with α-syn as with each 
other. These results might have clinical relevance as it suggest that a HD patient with no 
mutations in the SNCA gene affecting α-syn expression could also be at risk of developing 
α-syn pathology.  
 In mammalian neurons, endogenous α-syn is primarily located in the cytoplasm 
(Huang et al., 2011). However, its existence has also been reported in the nucleus (Li et 
al., 2002a, Zhong et al., 2010), where α-syn is thought to promote toxicity independent of 
its aggregation (Goers et al., 2003, Kontopoulos et al., 2006). In our BiFC-based cell 
model, α-syn oligomerizes in the nucleus and produces cytotoxicity, while no inclusion 
bodies are formed (Figure 22). When co-expressed with mutant HTT, α-syn changed its 
subcellular distribution being sequestered in the cytosol. This could suggest that cross-
seeding events between these two proteins preferentially occur in the cytoplasm. 
Consistent with this idea, the formation of HTT aggregates is greatly dependent on its 
cytosolic localization, with less aggregates being formed when HTT is localized to other 
cellular compartments (Yan et al., 2011).  
 Strikingly, no changes in cytotoxicity were observed when mutant HTT was 
combined with α-syn (Figure 22E). Given that oligomeric species are likely more toxic 
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than large insoluble species (Arrasate et al., 2004, Bodner et al., 2006, Eisele et al., 2015, 
Winner et al., 2011), it would be expected that higher levels of HTT oligomerization, 
observed in the presence of α-syn (Figure 22F), would lead to increased cytotoxicity. 
However, there are other cellular events occurring simultaneously that may be acting 
against such an expected outcome. In particular, the presence of α-syn oligomers in the 
nucleus was abolished as well as their overall levels decreased (Figure 22A and F). Other 
possible explanations may include the idea that, in our BiFC-based cell model, HTT 
oligomerization and cytotoxicity may not be necessary related (Chapter III, 3.1), and not 
least, because co-aggregation of HTT and α-syn may affect the stability of forming 
intermediates, resulting in a prolonged lifetime of potential toxic species, that would be 
difficult to catch in such early assays. Interestingly, in vitro studies show that mixed 
oligomeric species are more stable than homo-oligomers being incapable of further 
assembly, hence accumulating in a time-dependent manner (Fung et al., 2004, Lashuel et 
al., 2003). This enrichment of potential toxic species over time may be responsible for 
accelerating disease progression in patients with mixed neuropathologies (Tsigelny et al., 
2008). Subsequent experiments in Drosophila revealed a synergistic worsening of HD- and 
PD-related phenotypes in flies co-expressing α-syn and mutant HTT (Pocas et al., 2015). 
In this study, we established new Drosophila lines carrying UAS transgenes encoding 
either α-syn-EGFP or a mCherry-tagged mutant HTTex1 fragment. Immunohistochemistry 
analyses of different Drosophila tissues demonstrated that mutant HTT co-localizes with 
α-syn in adult fly dopaminergic neurons, and axonal projections of photoreceptor neurons 
in larval brains. Such physical interactions between these two proteins resulted in the 
generation of both soluble and insoluble species. Moreover, flies with neuronal expression 
of both mutant HTT and α-syn exhibited early motor impairment, decreased lifespan and 
premature neuronal loss (Pocas et al., 2015). Whether such deleterious phenotypes are a 
direct consequence of cross-seeding events resulting in a gradual accumulation of 
intermediate toxic species, or the result of a loss of normal α-syn function that becomes 
sequestered within HTT aggregates, remains to be clarified. Previous studies using mouse 
models of HD show that α-syn depletion ameliorates disease-relevant phenotypes while 
decreasing the number of inclusions in the brain (Corrochano et al., 2012a, Tomas-Zapico 
et al., 2012). At a cellular level, these animals display increased number of 
autophagosomes in comparison to HD animals expressing normal levels of endogenous α-
syn (Corrochano et al., 2012a, Corrochano et al., 2012b). These observations could 
suggest that the presence of both α-syn and mutant HTT triggers the occurrence of cross-
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seeding events thereby accelerating protein misfolding and aggregation, which would 
ultimately result in saturation of the autophagy-lysosome system with a consequent 
increase in cellular stress and toxicity. 
 Notably, a previous study from our laboratory provides the first evidence for a 
direct interaction between HTT and Tau in living cells (Blum et al., 2015). Co-expression 
of mutant HTT and Tau leads to slower aggregation rate, with less cells showing inclusions 
as well as less aggregates being formed per cell (Blum et al., 2015) (Figure 23). These 
inclusions are dynamically and morphologically distinct from pure HTT aggregates, 
appearing as static ring-like structures (Blum et al., 2015). Although the biological 
significance of such structural changes remains unclear, it has been hypothesized that 
increased cytotoxicity may arise when the rearrangement of globular species into ring-like 
structures exceed a certain threshold (Pires et al., 2012). Importantly, in the presence of 
mutant HTT, Tau displays increased levels of phosphorylation, which is probably related 
to a deregulation of protein phosphatase/kinase activity (Blum et al., 2015, Gratuze et al., 
2015). These observations indicate that both direct and indirect mechanisms of protein 
aggregation might be involved in the formation of Tau inclusions observed in HD.  
 Further support for the existence of indirect processes in the cross-talk between 
aggregation-prone proteins comes from studies on Aβ interactions with Tau. Although the 
ability of Aβ to induce Tau neuropathology is clearly demonstrated in vivo (Clinton et al., 
2010, Gotz et al., 2001, Vasconcelos et al., 2016), it seems that Tau aggregates do not have 
the same effect over Aβ (Gotz et al., 2001, Lewis et al., 2001). It has been hypothesized 
that Aβ deposition occurring prior to Tau pathology can trigger the activation of certain 
kinases responsible for Tau phosphorylation, which in turn, induces misfolding and 
aggregation of this protein (Ferrer, 2004, Guo et al., 2006, Oddo et al., 2004). Together 
with the existence of a spatial dissociation between Aβ and Tau inclusions in AD, these 
findings suggest that, in some cases, the formation of different proteinaceous inclusions in 
the brain may be mediated by altered signaling pathways rather than cross-seeding events. 
 On the other hand, Tau phosphorylation may also affect its ability to co-aggregate 
(Guo et al., 2006, Nubling et al., 2012). McGeer and colleagues show that Aβ binds to 
non-phosphorylated Tau forming soluble oligomers in vitro (Guo et al., 2006). Such 
Aβ/Tau interactions induce GSK3β-mediated Tau phosphorylation, that then decreases Aβ 
binding affinity, and prevents further assembly of Aβ/Tau oligomers into larger species 
(Guo et al., 2006). Remarkably, prior phosphorylation of Tau in specific threonine and 
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serine residues inhibits Aβ/Tau interactions, suggesting that initial steps of co-aggregation 
may be mediated by particular Tau phosphorylation events (Guo et al., 2006). On the 
contrary, Tau phosphorylation enhances co-aggregation of Tau and α-syn (Nubling et al., 
2012). Thus, it seems that PTMs can be crucial in determining the propensity of a protein 
to cross-seed and form mixed aggregates. Another striking example is the existence of 
prion (PrPc) strains with different glycosylation patterns that differ in their ability to initiate 
its own conformation conversion to infectious prion (PrPSc) (Collinge, 2001). The present 
study provides further evidence for an important role of specific PTMs in modulating co-
aggregation processes, although the outcome may vary depending on the interacting 
proteins. In particular, we propose that single N-terminal phosphorylation of HTT 
modulates its co-aggregation with α-syn but not Tau (Figure 23). Moreover, our results 
indicate common mechanisms of both HTT aggregation and HTT cross-seeding 
interactions with α-syn, whereby T3 phosphorylation plays an inhibitory role. Since a 
significant amount of HTT molecules are found in an unphosphorylated state in HD (Aiken 
et al., 2009, Atwal et al., 2011), this might help to explain the high propensity of mutant 
HTT to interact with α-syn (Figure S14, Supplemental information III), and the 
coincidence of HTT and α-syn in HD brain deposits (Charles et al., 2000). Such a 
mechanism would not exclude a direct association between increased levels of a certain 
aggregation-prone protein, in the cellular environment, and the likelihood of co-
aggregation occurring (Sarell et al., 2013).  
 In summary, our results support that HTT interactions with α-syn (and Tau) might 
contribute to the development and spreading of neurodegeneration in HD, and that HTT 
phosphorylation state might determine the efficiency of such cross-seeding events.  
 
Materials and methods III 
 
Cell culture and plasmids 
 Human H4 glioma cells (ATCC HTB-148, LGC Standards, Barcelona, Spain) were 
maintained and seeded as described in Materials and methods I. Generation of HTTex1- 
and Tau-Venus BiFC constructs was described in detail elsewhere (Blum et al., 2015, 
Herrera et al., 2011). α-syn-Venus BiFC plasmids were a kind gift from Pamela J. McLean 
(Department of Neurology, Alzheimer’s Disease Research Unit, Massachusetts General 
Hospital, MA, USA). Mutagenesis experiments for creating phosphomimic point 
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mutations within HTTex1-Venus plasmids are detailed in Materials and methods I. Cells 
were co-transfected with the different combinations of plasmids using X-tremeGene 9 
reagent (Roche diagnostics, Mannheim, Germany), and 24 h later, prepared for flow 
cytometry, miscroscopy, toxicity or immunoblotting. 
 Protein interaction, oligomerization and aggregation were determined by flow 
cytometry, fluorescence microscopy, immunoblotting and filter trap assays as described in 
Materials and methods I. Toxicity assays were carried out also as described above (see 
Materials and methods I). 
 
Statistics 
 Statistical analyses were performed using the GraphPad Prism 5 software 
(GraphPad Software Inc., La Jolla, CA, USA). All graphs show the average ± standard 
deviation (SD) of at least 3 independent experiments. Differences between mean values 
were determined by one-way ANOVA followed by a Tukey post-hoc test. Statistical 
significance was accepted when p<0.05. 
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3.4.& Prion& proteins& modulate& mutant& huntingtin& mediated&
neurotoxicity&
&
Abstract 
 
 Several studies have shown that misfolding of one disease-causing protein can 
induce misfolding an aggregation of other aggregation-prone proteins. Such cross-seeding 
properties can contribute to neuropathology and disease progression. Therefore, 
understanding how interactions between different types of aggregation-prone proteins may 
influence toxicity will be crucial for a deeper understanding of the molecular mechanisms 
underlying the pathogenesis of neurodegenerative disorders. In yeast, a suite of 
aggregation-prone proteins modulates the toxicity of mutant huntingtin (HTT). In 
particular, the Rnq1 protein (which forms the [PIN+] prion) is required for maximal mutant 
HTT toxicity and aggregation. Here, we investigated the effects of Rnq1 on mutant HTT-
dependent phenotypes using Drosophila and mammalian cell models of Huntington’s 
disease (HD). We found that Rnq1 exacerbates several disease-relevant phenotypes in a 
Drosophila HD model. Similar results were observed with co-expression of mutant HTT 
and either wild-type or disease-associated P101L mouse prion protein (MoPrP). 
Furthermore, we found that Rnq1 physically interacts with mutant HTT in mammalian 
cells, dramatically increasing its aggregation. As humans express many proteins with 
prion-like domains, these data suggest that prion-like proteins may play a critical role in 
HD pathogenesis and that of other neurodegenerative disorders.  
 Our past work has found that modulating levels of neuroactive kynurenine pathway 
metabolites via inhibition of kynurenine 3-monooxygenase (KMO) ameliorates disease-
relevant phenotypes in flies expressing HTT, alpha-synuclein, and amyloid-beta. We find 
here that KMO inhibition is also protective against Rnq1-mediated toxicity in flies, 
suggesting convergent mechanisms contributing to cellular toxicity in these models of 
protein misfolding. Altogether, our findings provide new insights into HD pathology and 
further support KMO as a promising therapeutic target for human protein misfolding 
disorders.  
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Introduction 
 
 The progressive accumulation of protein aggregates in the brain is a common 
hallmark of fatal neurodegenerative disorders including AD, PD and HD. Growing 
evidence suggest that these aggregates are able to seed protein misfolding in a process 
similar to the spreading of prion proteins in transmissible prion disorders (Stopschinski and 
Diamond, 2017). However, the events leading to the formation of toxic species and their 
propagation in brain cells remain elusive. Intriguingly, the co-existence of aggregated 
forms of distinct disease-associated proteins in patient brains have been observed (Rahimi 
and Kovacs, 2014), suggesting that cross-seeding interactions among various aggregation-
prone proteins might contribute to the pathogenesis and progression of different 
neurodegenerative disorders. In fact, prion-like proteins have been reported to mediate 
toxicity and propagation of Aβ aggregates (Kostylev et al., 2015, Salazar and Strittmatter, 
2017), and to interact with α-syn, thereby inducing synaptic dysfunction in transgenic PD 
mice (Ferreira et al., 2017). Conversely, α-syn is capable of cross-seeding prion protein 
aggregation and pathology (Katorcha et al., 2017). Identifying molecular factors involved 
in these cross-seeding processes is essential to better understanding the pathogenesis of 
these devastating disorders.  
Prion proteins are infectious amyloids, capable of converting natively folded 
proteins into prion-like conformers that can self-propagate between cells and among 
individuals of the same or different species (Colby and Prusiner, 2011, Aguzzi and 
Rajendran, 2009). Recent studies have found a suite of aggregation-prone proteins 
containing yeast prion-like domains that can modulate polyQ toxicity (Duennwald et al., 
2006a, Duennwald et al., 2006b, Kantcheva et al., 2014, Kayatekin et al., 2014, Mason et 
al., 2013, Ripaud et al., 2014). Prion-like domains are typically enriched for glutamine (Q) 
and asparagine (N) residues (King et al., 2012) that are essential for prion-like propagation 
and amyloid formation (Bruce and Chernoff, 2011, Wickner et al., 2008). However, 
different combinations of Q/N-rich proteins may determine different polyQ pathobiology 
(Sabate et al., 2015, Toombs et al., 2010). Deletion of genes encoding Q-rich proteins 
abolishes polyQ toxicity and their overexpression can convert nontoxic HTT species into 
toxic species (Duennwald et al., 2006a). Intriguingly, overexpression of other Q-rich 
peptides can also suppress polyQ toxicity (Ripaud et al., 2014). Furthermore, N-rich 
domains enhance polyQ aggregation and toxicity whereas the association of Q-rich 
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proteins with mutant HTT alters physical properties of HTT aggregates (Kayatekin et al., 
2014), which may reduce their ability to sequester nuclear proteins and other aggregation-
prone factors (Ripaud et al., 2014).  
The Rnq1 protein is a transferable epigenetic modifier of protein function in yeast, 
which contains a Q/N-rich region in its C-terminal region (residues 153-405) (Bruce and 
Chernoff, 2011, Perrett and Jones, 2008, Sondheimer and Lindquist, 2000). Despite the 
fact that the physiological function of the soluble protein is not known, the prion state of 
Rnq1 ([PIN+]) is required for de novo formation and propagation of other yeast prion 
proteins (Derkatch et al., 1997, Derkatch et al., 2000, Derkatch et al., 2001, Derkatch et 
al., 2004, Osherovich and Weissman, 2001, Resende et al., 2003). Strikingly, mounting 
evidence suggests a role for Rnq1 in yeast cell toxicity mediated by misfolded proteins 
(Duennwald et al., 2006a, Meriin et al., 2002). For example, in the yeast model of HD, 
downregulation of the RNQ1 gene suppresses HTT aggregation and toxicity (Meriin et al., 
2002), and the effect of other Q-rich proteins upon polyQ aggregation and toxicity require 
Rnq1 in its [PIN+] prion conformation (Duennwald et al., 2006a). Although no orthologue 
of Rnq1 is present in higher eukaryotes, hundreds of genes containing yeast prion-like 
regions have been identified in the human genome (Alberti et al., 2009, King et al., 2012), 
and therefore may serve as a simple model for understanding how prion-like proteins may 
modulate mutant HTT aggregation and toxicity.  
The fruit fly has been widely exploited for the study of many protein-misfolding 
disorders, including polyQ-related disorders such as HD (Campesan et al., 2011, Green et 
al., 2012, Gunawardena et al., 2003, Jackson et al., 1998, Lee et al., 2004, Steffan et al., 
2001, Steinert et al., 2012) and prion disorders (Choi et al., 2010, Deleault et al., 2003, 
Fernandez-Funez et al., 2010, Gavin et al., 2006, Murali et al., 2014, Robinson et al., 
2014, Steinert et al., 2012). These Drosophila models resemble aspects of the 
corresponding human diseases and provide multiple experimental advantages that have 
allowed the identification of new molecular pathways underling disease pathogenesis. 
Unlike yeast models, fruit flies yield the multifactorial and age-dependent components thus 
serving as a better model to investigate the role of prion-like proteins on HD and other 
human protein misfolding disorders. In the present study, we generated a transgenic 
Drosophila model expressing Rnq1 to determine the effects of prion-like proteins during 
normal aging, and to elucidate further its contribution towards expanded polyQ-related 
toxicity. In addition, we employed the bimolecular fluorescence complementation (BiFC) 
assay (Herrera et al., 2011) to study the interaction between Rnq1 and mutant HTT in 
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living cells. Our results highlight prion-like proteins as probable players in the complex 
and dynamic network of protein-protein interactions that regulate mutant HTT misfolding, 
and thereby HD pathogenesis, and further support the potential therapeutic value of 
kynurenine 3-monooxygenase (KMO) inhibition in HD and other human pathologies 
involving protein misfolding and aggregation. 
 
Results 
 
Rnq1 exhibits prion-like properties in transgenic flies 
 In order to investigate whether previous observations in yeast involving Rnq1 
(Bruce and Chernoff, 2011, Duennwald et al., 2006a, Kantcheva et al., 2014, Meriin et al., 
2002, Ripaud et al., 2014, Wickner et al., 2008) are relevant in animal models, we 
generated transgenic flies carrying UAS-RNQ1 and initially placed it under the control of 
the ubiquitously expressed daGal4 driver using the GAL4/UAS system (see Materials and 
methods IV) (Brand and Perrimon, 1993). We confirmed Rnq1 expression in the 1M and 
6M lines via QPCR (Figure S15, Supplemental information IV). To test whether the RNQ1 
transgenic flies produce Rnq1 with prion-inducing properties, we employed an adaptation 
of a prion-based in vivo transformation assay in yeast (Tanaka et al., 2004a). This assay 
exploits the [PIN+] prion requirement for the de novo formation of the Sup35-based [PSI+] 
prion that can in turn be induced by overexpression of Sup35 or its prion-forming region 
NM (Derkatch et al., 1997). The presence of the [PSI+] prion can be detected by 
suppression of a nonsense mutation (ade1-14) in the ADE1 gene that promotes phenotypic 
change in color (red to white; Ade- to Ade+) in prion-containing [PSI+] cells. Cells lacking 
the [PSI+] prion are therefore unable to grow on a medium lacking adenine and appear red 
due to efficient translation termination at the premature UGA stop codon in the ade1-14 
allele. In contrast, aggregation of Sup35 into its [PSI+]-aggregated form often leads to 
read-through of the ade1-14 mutation detectable as growth of white/pink colonies on 
defined medium lacking adenine. 
Brain homogenates were prepared from 56 day-old Rnq1-expressing and control 
elavGAL4 flies and added to prion-free [pin-][psi-] cells along with the URA3-based 
plasmid p6442 that allows for overexpression of the Sup35NM domain. After selecting 
p6442 Ura+ transformed cells, those that concomitantly acquire the [PIN+] prion from the 
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protein extract show induction of the [PSI+] prion when the Sup35 prion-forming domain 
(Sup35NM) is overexpressed (Sideri et al., 2011).   
 Forty-eight independent Ura+ transformed colonies were isolated in each 
experiment and the de novo prion formation was scored as the number of Ura+ colonies 
able to give rise to guanidine hydrochloride (GdnHCl)-curable [PSI+] colonies (Figure 
24A). GdnHCl is a reversible inhibitor of the Hsp104 chaperone that prevents continued 
[PSI+] propagation leading to the generation of red [psi-] colonies (Derkatch et al., 2000, 
Tuite et al., 1981). p6442-induced formation  [PSI+] was detected in less than 10% of 
control  [pin-] [psi-] cells, a figure comparable to previous reported frequencies (Sideri et 
al., 2011). Co-transformation with protein lysates prepared from a [PIN+] yeast strain 
increased the frequency of [PSI+] colonies up to 20.1% confirming that the de novo 
formation of [PSI+] is induced by [PIN+] infection (Patel and Liebman, 2007). A high 
molecular weight pellet fraction prepared from Rnq1-expressing fly extracts, yielded the 
highest frequency of [PSI+]-generating cells (34.4%), with similar infectivity observed for 
the crude fraction of the same fly lysate (31.9%). Notably, extracts prepared from flies not 
expressing Rnq1 (i.e. elavGAL4) gave a lower number of [PSI+]-forming cells than those 
expressing Rnq1 (18.2% vs 33.2%). It is interesting to note, however, that transformation 
with crude and pellet extracts from elavGAL4 driver control flies resulted in modest prion 
induction independent of Rnq1 expression (19.4% and 17%, respectively) (Figure 24A), 
suggesting the existence of an intrinsic activity in the fly that can drive the formation of the 
[PSI+] prion. 
 To further explore the infectivity of fly produced Rnq1 molecules, Rnq1-induced 
[PSI+] events were normalized to the elavGAL4 background (Figure 24B). We observed a 
trend (p=0.0624) towards increased [PSI+] conversion upon transformation using high 
molecular weight Rnq1 pellet over background. Notably, [PSI+] formation was 
significantly elevated ~2-fold when total Rnq1-dependent (crude plus pellet) [PSI+] events 
were considered (Rnq1 total). These data suggest that Rnq1 molecules synthesized in flies 
can seed the formation of the [PSI+] prion, possibly by contributing to [PSI+] propagation 
to the same extent as higher-order Rnq1 assemblies. This further supports the role of Rnq1 
as an infectious agent with the ability to self-propagate between different species, acting as 
a seed for the de novo formation of misfolded prion-like proteins. 
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Figure 24. Brain extracts from Rnq1 expressing flies increase de novo formation of the [PSI+] 
prion in yeast. (A) The infection potential of the fly-expressed Rnq1 was assayed in yeast cells by means 
of yeast prion transformation (95). Protein extracts from aged Rnq1 expressing flies were introduced into 
sphaeroplasts prepared from an ura3 [pin-][psi-] yeast strain by co-transformation with the plasmid p6442 
(pCUP1-SUP35NM-URA3). Following a period of overexpression of Sup35NM to induce the formation of 
the [PSI+] prion, colonies formed from [PSI+] cells were scored using a nonsense suppressible ade1-14 allele 
by growth on medium lacking adenine and confirmed by loss of the white [PSI+] phenotype following 
growth in the presence of 4 mM GdnHCl. “Total” represents grouped measurements of pellet and crude 
samples from the same fly brain lysates. Average % infectivity refers to the frequency (%) of [PSI+] cells 
formed per 48 Ura+ transformants analyzed. (B) Total Rnq1 was significantly more infectious in comparison 
to protein Total elavGAL4 flies not expressing Rnq1. For each condition, the number of [PSI+] colonies 
arising in controls (e.g. None, elavGAL4) was subtracted from the experimental colonies (e.g. [PIN+], Rnq1) 
in order to eliminate background effects, and a one sample t test was employed for analyses (see Materials 
and methods IV). The data illustrate the three independent assay values upon normalization and their mean ± 
SD. *p<0.05; #p=0.0624. 
 
Rnq1 expression induces age-dependent neurodegeneration and causes motor 
dysfunction in Drosophila 
 The presence of misfolded prion proteins in humans is associated with a range of 
brain pathologies (Mead and Reilly, 2015, Rahimi and Kovacs, 2014), although the 
importance of the physiological role of the prion protein has not yet been fully established.  
In yeast, prions can confer phenotypic benefits to the host, and are thought to play a role as 
functional amyloidogenic proteins in certain conditions (Eaglestone et al., 1999, Stein and 
True, 2011, True and Lindquist, 2000, True et al., 2004), while in other paradigms 
overexpression can lead to severe toxicity (Douglas et al., 2008). To investigate the effect 
of Rnq1 expression in Drosophila, we drove expression of Rnq1 pan-neuronally with the 
elavGAL4 driver or in motor neurons using the c164GAL4 driver, and assayed for 
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neurodegenerative phenotypes and behavior impairments in adult flies and larvae (Figure 
25 and 26). We assessed neurodegeneration of Rnq1-expressing flies by scoring 
degeneration of adult rhabdomeres at different time-points, from day 1 to day 56. When 
expressed under the control of elavGAL4, Rnq1 caused photoreceptor loss in an age-
dependent manner (Figure 25A). A significant decrease in rhabdomere number was 
observed in RNQ1-1M flies at 21 days, and neuronal loss progressively increased in older 
flies (genotype x age interaction, p<0.05, Figure 25A). We found a similar trend in RNQ1-
6M flies, although these decreases were only significant at 56 days of age (Figure 25A). 
This is consistent with Drosophila models of PD (Feany and Bender, 2000) and prion 
diseases (Fernandez-Funez et al., 2010), where neurodegeneration is observed only in 
aging animals. 
 While young control flies exhibit strong negative geotactic responses manifested by 
their ability to rapidly climb to the top of a vial, a decline in motor performance is 
observed as they age (Figure 25B) (Breda et al., 2015, Breda et al., 2016). We found that 
both RNQ1-1M and RNQ1-6M transgenic flies developed premature motor dysfunction, 
showing a decline in climbing ability relative to controls at every time point tested (Figure 
25B). Furthermore, Rnq1-related degenerative changes were not restricted to the brain, as 
analysis of total motor activity in c164GAL4-driven Rnq1 flies revealed a reduction of 
~21-36% in movement compared to driver and UAS controls (Figure 25C). Interestingly, a 
significant decrease in activity in the dark was observed for the Rnq1 flies versus controls 
(Figure 25D), which was accompanied by greater sleep-like behavior (Figure S16, 
Supplemental information IV).  
 Next, we asked whether Rnq1 expression could compromise behavior during early 
developmental stages. Third instar larvae display innate crawling behavior characterized 
by periods of movements in a specific direction followed by pauses during which the 
surrounding area is explored and direction may be altered (turns) (Wang et al., 1997). 
Expression of Rnq1 either in the nervous system (Figure 26A-D) or specifically in motor 
neurons (Figure 26E-G) resulted in abnormal larval crawling behavior. Interestingly, our 
Rnq1 expressing larvae displayed nearly identical crawling phenotypes to those previously 
observed in HD larvae (Steinert et al., 2012) (Figure 26B, C, E and F), which resulted in 
fewer turns and greater crawling activity relative to controls (Figure 26D and G).  
 Together with our prion infectivity observations, these results suggest that although 
Rnq1 has no detrimental effects on fruit fly viability and survival (Figure S17, 
Supplemental information IV), it promotes neuronal dysfunction during development, 
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suggesting the occurrence of early prion-like protein misfolding events that precede 
neuronal loss in older individuals. 
 
Figure 25. RNQ1 transgenic flies exhibit age-dependent neurodegeneration and early motor 
dysfunction. (A) Neuronal loss caused by Rnq1 pan-neuronal expression was assessed in aged RNQ1-1M 
or RNQ1-6M Drosophila lines at different time-points (1, 7, 14, 21, 28, 42 or 56 days post-eclosion). (B) 
Climbing activity of Rnq1 expressing flies under the control of elavGAL4. Fifty flies from each group were 
examined in 10 consecutive climbing assay tests at day 7, 14 or 28 post-eclosion. Values on the Y-axis 
represent the percentage of flies that successfully climbed above the threshold line of 8 cm within 10 s. (C, 
D) Total locomotor activity was assayed in new-emerged flies, using Trikinetics Drosophila monitors. Flies 
expressing Rnq1 in the motor neurons showed reduced overall activity in comparison to controls (C). 
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Analysis of mean activity levels during 12 h light/dark cycles reveals that decreased activity levels occur 
during the dark phase (D). Locomotor activity is represented as the average number of infrared beam 
crossings per 30 min of recording interval over 7 days in 12 h light/dark cycles. Comparisons are versus 
elavGAL4 or c164GAL4 and respective UAS controls, *p<0.05. All data are shown as the mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Rnq1 expression induces abnormal larval crawling. (A) Representative crawling 
behavior produced by elavGAL4 control and pan-neuronal RNQ1-1M or RNQ1-6M expression in third instar 
larvae. Larva crawling activity was manually monitored for 2 min in a temperature controlled room and 
expressed as crawling distance travelled (mm) (B, E), number of turns (C, F) and distance/turns (D, G) in 
larvae expressing Rnq1 driven to all nervous system (B-D) or specifically to motor neurons (E-G) by the elav 
or the c164 promoter, respectively. Comparisons are versus elavGAL4 or c164GAL4 and respective UAS 
controls, *p<0.05. Data are mean ± SEM. 
 
Prion-like proteins exacerbate disease-relevant phenotypes in a Drosophila model of HD  
 Since Rnq1 increases mutant HTT toxicity in yeast (Meriin et al., 2002), we sought 
to extend these findings by using a well-characterized Drosophila model of HD, in which 
the expression of a mutant HTT exon 1 encoding fragment (93QHTTex1) is directed to the 
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nervous system of the fruit fly using elavGAL4 (Steffan et al., 2001) (also described in 
Chapter I and III, section A). We found that Rnq1 expression potentiated 93QHTTex1 
phenotypes in Drosophila (Figure 27). Co-expression of Rnq1 with 93QHTTex1 resulted 
in a significant increase in neuronal loss at day 1 (Figure 27A) and day 7 post-eclosion 
(Figure 27A and B). We also observed a 3-day reduction in the lifespan of flies expressing 
both 93QHTTex1 and RNQ1-1M transgenes versus the UAS titration control (GFP + 
HTT) (Figure 27C), while RNQ1-6M + HTT co-expressing flies exhibited a modest 
reduction in lifespan relative to control flies (Figure 27D). Moreover, the eclosion of 
93QHTTex1 expressing flies was significantly decreased in the presence of Rnq1 (Figure 
27E and F), indicating that Rnq1 promotes developmental defects during late 
metamorphosis that further compromise the emergence of adult HD flies. Rnq1-induced 
toxic effects on viability of HD flies appear to reflect potentiation of mutant HTT toxicity 
and not solely additive effects, as Rnq1 expression did not affect eclosion or survival in 
wild-type backgrounds (Figure S17, Supplemental information IV). In order to investigate 
Rnq1 effects upon 93QHTTex1 toxicity during early developmental stages, we assessed 
the motor behavior of third instar larvae. Specific expression of Rnq1 in motor neurons 
using the c164GAL4 driver led to significant defects in locomotion in comparison to 
controls, and a modest enhancement of motor impairments in HD larvae (Figure 28). These 
data provide additional evidence supporting Rnq1 as a modulator of mutant HTT toxicity, 
and suggest a potential role for prion-like proteins in HD pathology.  
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Figure 27. Rnq1 expression potentiates mutant HTT toxicity in Drosophila. Transgenic fly lines 
exhibiting pan-neuronal expression of 93QHTTex1 and RNQ1  (RNQ1-1M + HTT, left panels; RNQ1-6M + 
HTT, right panels) were analyzed for photoreceptor number (A, B), survival (C, D) and viability (E, F). (A, 
B) Quantification of mean rhabdomeres (±SEM) per ommatidium at day 1 or day 7 after eclosion. Rnq1 and 
93QHTTex1 co-expressing flies showed significantly increased neurotoxicity when compared to GFP + HTT 
flies. (C, D) Rnq1 expression reduces lifespan of HD transgenic flies. Values on the Y-axis represent the 
percentage of flies alive at each time point analyzed. The mean values indicate the number of days it took for 
half of the flies to die (50% survival): GFP + HTT (mean = 13 days, left panel, C; mean = 6 days, right panel, 
D), RNQ1-1M + HTT (mean = 10 days), RNQ1-6M + HTT (mean = 4.5 days). (E, F) Percentage of eclosion 
(mean ratio of female/male flies ± SEM per vial). Female progeny express 93QHTTex1 pan-neuronally, 
whereas male progeny are wild-type. The ratio of female/male flies per vial (expected ratio 1:1) emerging 
over a 10 day period reveals a substantial deficit of 93QHTTex1 expressing females relative to male controls. 
The eclosion deficit caused by 93QHTTex1 expression is significantly enhanced by the presence of Rnq1. 
Comparisons are versus GFP + HTT, *p<0.05. 
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Figure 28. Rnq1 expression enhances defective locomotor behavior of HD third instar larvae. 
(A) Representative crawling traces of control (c164GAL4) and larvae expressing GFP + HTT, RNQ1-1M + 
HTT or RNQ1-6M + HTT in motor neurons via the c164GAL4 driver. (B, C) Co-expression of Rnq1 and 
93QHTTex1 induce greater larval crawling activity as observed by a significant increase in distance travelled 
(mm) in comparison to GFP + HTT (left panel). Data are mean distance/turn (mm) ± SEM. Comparisons are 
versus both c164GAL4 and respective UAS-RNQ1 control, *p<0.05. Scale bar, 10 mm.  
 
 To further support these findings, we interrogated whether the murine prion protein 
(MoPrP) could induce similar neuropathology in our Drosophila HD model. Mammalian 
prions are associated with transmissible spongiform encephalopathies (Colby and Prusiner, 
2011) and are found to co-exist with other aggregation-prone proteins in neurodegenerative 
disease-affected brains (Adjou et al., 2007, Haik et al., 2002, Miyazono et al., 1992, 
Rahimi and Kovacs, 2014). Consistent with a previous study showing that MoPrP 
exacerbates expanded polyQ-dependent morphological defects in Drosophila eyes (Park et 
al., 2011), we found that both the wild-type version of MoPrP (WT PrP), as well as MoPrP 
containing a human prion disease-associated mutation (P101L PrP), enhanced rhabdomere 
degeneration in 93QHTTex1 flies (Figure 29A). However, WT PrP had no effect on 
survival (Figure 29B) or eclosion (Figure 29C), while P101L PrP expression significantly 
impaired lifespan (Figure 29B) and development (Figure 29D) of HD flies. The differences 
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in viability outcome measures could be explained by the low propensity of WT PrP to 
accumulate in Drosophila brain neurons (Deleault et al., 2003). In contrast, P101L PrP 
rapidly accumulates as misfolded prion-like conformers (Gavin et al., 2006), which may 
increase the rate of protein misfolding and sequestration into toxic aggregates, thus 
resulting in accelerated neuropathology and premature death in larval and adult stages. 
Interestingly, MoPrP expression had no toxic effects on normal aging (Figure S18A, 
Supplemental information IV) and development (Figure S18C and D, Supplemental 
information IV) of wild-type background flies, while affecting their long-term survival 
(Figure S18B, Supplemental information IV).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Expression of murine prion protein exacerbates disease-relevant phenotypes in 
HD transgenic flies. (A) Expression of either wild-type (WT) or mutated (P101L) PrP caused an increased 
in neuronal loss of 93QHTTex1 transgenic flies. Data are represented as the number of rhabdomeres per 
ommatidium (mean ± SEM). (B) Expression of P101L PrP decreased lifespan of HD flies by ~2.5 days and 
WT PrP did not alter survival rate. GFP + HTT (mean = 7.5 days), WT PrP + HTT (mean = 8 days), P101L 
PrP + HTT (mean = 5 days). Murine P101L PrP (D) impairs fly viability during development as observed by 
the increased eclosion deficit of pan-neuronal 93QHTTex1 expressing flies. Comparisons are versus GFP + 
HTT, *p<0.05. 
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Rnq1 interacts and forms inclusions with mutant huntingtin in living mammalian cells 
 It is widely accepted that Rnq1 modulates polyQ aggregation in yeast cells 
(Kantcheva et al., 2014, Meriin et al., 2002), but the molecular mechanisms underlying 
this effect are unclear. Whether Rnq1 prion formation precedes polyQ aggregation serving 
as a nucleation-promoting factor for amyloid replication, or indirectly acts on polyQ 
aggregation after it has already been established needs to be clarified. The BiFC assay is 
commonly used for studying protein-protein interactions in living cells and serves as a 
robust tool to visualize the initial steps of aggregate formation, including the dimerization 
or oligomerization of misfolding-prone proteins (Goncalves et al., 2010). To further 
explore the role of Rnq1 on mutant HTT aggregation, we employed our recently developed 
HTTex1 BiFC cellular model, based on the fusion of two non-fluorescent halves of the 
Venus fluorescent reporter to HTTex1 constructs (Herrera et al., 2011, Herrera and 
Outeiro, 2012). Different combinations of wild-type (19Q) or mutant (97Q) HTTex1, as 
well as RNQ1-Venus BiFC plasmids (Figure 30A) were transfected into mammalian cells 
and the recovered emitting fluorescence was assessed by flow cytometry as an indication 
of direct protein interactions. Similar to our previous reports (Herrera et al., 2011), 
97QHTTex1-Venus BiFC pairs caused increased levels of fluorescence in comparison to 
19QHTTex1-Venus BiFC pairs (Figure 30B and C), suggestive of higher rates of 
dimerization/oligomerization. Co-transfection of RNQ1- and 97QHTTex1-Venus plasmids 
produced fluorescence as measured by the number of fluorescent cells (Figure 30B) and 
average fluorescence intensity (Figure 30C), suggesting a direct physical interaction 
between the two proteins, though much reduced in comparison to 97QHTTex1-Venus 
BiFC pairs. Analysis of 97QHTTex1-transfected cells by fluorescence microscopy 
confirmed the presence of both cytosolic oligomeric species and large aggregates, 
visualized as homogenously distributed fluorescence and very bright foci, respectively 
(Figure 30D) (Herrera et al., 2011). When co-transfected with RNQ1, 97QHTTex1 
changed its subcellular localization, accumulating as oligomeric species in all cell 
compartments, including the nucleus (Figure S19, Supplemental information IV). 
Moreover, Rnq1 co-aggregated with 97QHTTex1 generally altering its aggregation pattern 
towards the formation of fewer but larger aggregates in the cytosol (Figure 30E). These 
aggregates were often visualized as amorphous intracellular inclusions with no defined 
boundaries, suggesting that Rnq1 might alter aggregate morphology to facilitate toxic 
interactions (Duennwald et al., 2006a, Giorgini et al., 2005).  
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In spite of the increased propensity of heterogeneous polyQ aggregates formed by 
unrelated Q-rich proteins to translocate to the nucleus in mammalian cells (Preisinger et 
al., 1999), no RNQ1/97Q aggregates were observed within the nucleus (Figure 30E and 
Figure S19, Supplemental information IV). The biophysical properties of forming 
aggregates were then analyzed by means of filter trap assays. We found that the amount of 
large SDS-insoluble aggregates composed of mutant HTT was significantly enhanced in 
cells transfected with both RNQ1 and 97QHTTex1 BiFC constructs (Figure 30F and H). 
This effect is even more notable if we consider that only one copy of 97QHTTex1 was 
being expressed in the RNQ1/97Q group (Figure 30G and I). Unexpectedly, we were 
unable to detect Rnq1 protein levels by standard immunoblot procedures using an anti-
Rnq1 antibody (Santa Cruz Biotechnology Inc., Dallas, Texas, USA) (data not shown), 
suggesting that Rnq1 might adopt a different conformation once expressed in mammalian 
cells, masking the epitopes recognized by the antibodies. To overcome this, we carried out 
immunocytochemistry (ICC) in RNQ1 and 97QHTTex1 co-transfected cells, which was 
more sensitive, allowing the detection of Rnq1 throughout the cell and within BiFC 
aggregates (Figure 30J). In total, these results suggest that Rnq1 likely associates with 
HTT and accelerates polyQ aggregation. However, mutant HTT appears to be more prone 
to dimerize/oligomerize than to interact with Rnq1, indicating that this interaction is likely 
rather transient - consistent with the occurrence of highly stable Rnq1 prion conformations 
(Patel and Liebman, 2007). 
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Figure 30. Rnq1 interacts with mutant HTT and alters its aggregation in living cells. (A) 
Schematic representation of HTTex1 and RNQ1 BiFC constructs. (B-E) Cells were transfected with the 
indicated pairs of BiFC constructs, and analyzed for fluorescence levels (B, C) and formation of large 
inclusions (D-J) by flow cytometry or widefield fluorescence microscopy, respectively. Co-transfection of 
RNQ1-Venus and 97QHTTex1-Venus plasmids causes an increased number of fluorescent cells (B) and 
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similar average fluorescence to the 19Q/19Q control, indicating the generation of RNQ1/97Q dimers (C). 
The 97QHTTex1 BiFC pair is mostly localized in the cytosol as both diffuse fluorescence and large 
inclusions (D). Co-transfection of RNQ1-Venus and 97QHTTex1-Venus plasmids results in the cytosolic 
accumulation of larger insoluble species (E). (F) Representative filter trap assay and (G) immunoblotting 
(SDS-PAGE) of total protein extracts under native conditions. (H) Quantification of HTT SDS-insoluble 
species and (I) corresponding HTT protein expression levels. (J) Rnq1 antibody (1:500, Santa Cruz 
Biotechnology Inc., Dallas, Texas, USA) (in red) localizes to RNQ1/97Q BiFC inclusions (in green) (white 
arrows). Data is mean ± SD. *significant versus 19Q/19Q, #significant versus 97Q/97Q, p< 0.05. Scale bars, 
20 µm. AU, arbitrary units. 
 
Kynurenine pathway metabolism contributes to Rnq1 neurotoxicity in Drosophila  
 We were next interested in exploring the mechanisms downstream of Rnq1 
expression that contribute to the neurotoxicity observed. We have previously shown that 
dysregulation of kynurenine pathway (KP) metabolism contributes to neurodegeneration in 
flies expressing mutant HTT, α-syn, and Aβ (Breda et al., 2016, Campesan et al., 2011). 
The KP is the primary route of tryptophan degradation in mammals, and contains several 
potent neuroactive and immunomodulatory intermediates – e.g. kynurenic acid (KYNA), 
3-hydroxykynurenine (3-HK), and quinolinic acid (QUIN) - which have been implicated in 
numerous neurodegenerative disorders, including HD. Genetic or pharmacological 
inhibition of kynurenine 3-monooxygenase (KMO) modulates the levels of these 
neuroactive metabolites, thereby ameliorating disease-relevant phenotypes in models of 
HD, PD and AD (Breda et al., 2016, Campesan et al., 2011, Giorgini et al., 2005, Giorgini 
et al., 2008, Maddison and Giorgini, 2015, Zwilling et al., 2011). Since Rnq1 expression 
enhanced HD-relevant phenotypes in Drosophila, we hypothesized that KP dysfunction 
may also be involved in prion-like-mediated toxicity.  
 In order to address this question, we used RNAi to silence cinnabar (cn), the fly 
homolog for the KMO gene, in Rnq1-expressing flies. Since cn is located on the 2nd 
chromosome, we first characterized two transgenic lines encoding RNQ1 on the 3rd 
chromosome (RNQ1-2M and RNQ1-3M) in order to simplify the genetic crosses. In 
agreement with the experiments described above (Figure 25 and 26), pan-neuronal Rnq1 
expression caused neurodegeneration (Figure S20A, Supplemental information IV) and 
climbing impairments (Figure S20B, Supplemental information IV) in both RNQ1-2M and 
RNQ1-3M transgenic flies. Additionally, expression of Rnq1 in motor neurons using the 
c164 driver resulted in abnormal larvae crawling behavior (Figure S20C and D, 
Supplemental information IV). Although rhabdomere degeneration in these transgenic 
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lines is more modest (Figure 31A and Figure S21A, Supplemental information IV), we 
found that cn downregulation was able to rescue the observed neuronal loss in aged 
RNQ1-2M (Figure 31A) and RNQ1-3M flies (Figure S21A, Supplemental information 
IV). KMO inhibition also significantly ameliorated climbing performance of Rnq1 
expressing flies compared with the corresponding controls (Figure 31B and Figure S21B, 
Supplemental information IV). These observations suggest the KP plays a role in Rnq1 
toxicity, indicating a possible overlap between the mechanisms of mutant HTT and Rnq1 
toxicity. 
 
 
Figure 31. KMO genetic inhibition ameliorates neurodegeneration and locomotor 
impairments of RNQ1 transgenic flies. (A) Average number of rhabdomeres per ommatidium. 
Downregulation of the Drosophila KMO gene cinnabar (cn) rescues neuronal loss exhibited by aged elav-
driven Rnq1 expressing flies. (B) Climbing deficits are significantly rescued when cn is knocked down in 
pan-neuronal Rnq1 expressing flies. All data are mean ± SEM. *significant versus 3M + RNQ1-2M, 
#significant versus elavGAL4 and UAS 3M + RNQ1-2M controls, p<0.05. 
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Discussion 
 
 Misfolding of specific proteins into pathological conformations and their 
accumulation in the brain is a common feature of nearly all neurodegenerative disorders. 
As such, developing therapeutic approaches have focused on treating these disorders by 
preventing the formation and deposition of amyloid peptides. However, neuronal toxicity 
is not always associated with protein aggregation and may depend on the proteome 
composition and particular cellular environments. Recent studies have suggested prion-like 
proteins as co-factors in the misfolding of other aggregation-prone proteins and subsequent 
extracellular spreading of toxic aggregates (Salazar and Strittmatter, 2017, Urrea et al., 
2017), which is thought to precede neurodegeneration and the appearance of clinical 
symptoms (Brundin et al., 2010). Thus, in addition to directly blocking amyloid formation, 
a better understanding on how these molecular species contribute to neurotoxicity may aid 
in the development of more effective therapies.  
 The Rnq1 prion is central to mutant HTT-mediated toxicity in yeast (Mason and 
Giorgini, 2011) and the yeast Sup35 prion domain has been found to modulate polyQ 
toxicity in flies (Li et al., 2007), suggesting that abnormal expression of proteins 
containing Q/N-rich regions could be involved in HD pathogenesis. Here, we have 
extended these findings by generating transgenic Drosophila lines that express Rnq1 which 
may induce the formation of molecules with prion-like properties. We show that Rnq1 
elicits several disease-relevant phenotypes throughout the Drosophila lifecycle, ultimately 
leading to premature neuronal loss in aging flies. We propose that Rnq1 enhances mutant 
HTT-induced toxicity by altering the morphology of polyQ-containing aggregates, making 
them more accessible to toxic interactions. 
 Behavioral assessments showed that Rnq1 expression caused an early and rapid 
decline in adult motor function and enhanced sleep, which did not parallel the degeneration 
of fly photoreceptors (Figure 25 and Figure S16, Supplemental information IV). Indeed, 
significant neuronal loss was only detected in advanced stages of aging, indicating that 
Rnq1 may induce functional defects that occur prior to neuronal death. As mitochondrial 
function is found to be impaired in models of prion disease (Sikora et al., 2009, Siskova et 
al., 2010), it is possible that the low locomotor performance of Rnq1 expressing flies is 
due to early neuronal dysfunction involving altered mitochondrial metabolism that 
ultimately leads to neurodegeneration. In addition, as the flies age, Rnq1 molecules could 
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undergo prion-like conformational changes accumulating as pathogenic amyloids and/or 
amplifying misfolded forms of other molecules, thereby increasing neuronal vulnerability. 
This is supported by the high infectious potential of brain homogenates from aged Rnq1 
expressing flies (Figure 24). Our interpretation is in accordance with reports from other 
Drosophila models of protein misfolding-related disorders showing that pre-fibrillar 
protein conformations cause altered locomotor activity and sleep disturbances in young 
flies prior to neuronal degeneration (Gajula Balija et al., 2011, Karpinar et al., 2009), 
suggesting that these phenotypes may be caused by early impairment of neuronal function 
rather than neuronal death. 
 Although Rnq1 expression did not compromise viability of wild-type flies (Figure 
S17, Supplemental information IV), their normal development was affected as indicated by 
abnormal larval crawling phenotypes (Figure 26). In the context of protein misfolding 
disorders, differences in crawling phenotypes have been associated with protein-specific 
patterns of aggregation and distribution throughout neurons (Jakubowski et al., 2012). For 
example, expression of α-syn causes larvae to crawl shorter distances (Breda et al., 2015), 
whereas mutant HTT expressing larvae typically exhibit weaker exploratory crawling 
behavior, but greater crawling distances when compared to wild-type larvae (Steinert et al., 
2012). Rnq1 expression resulted in greater larval crawling activity, which is in accordance 
with a previous report on the murine prion-expressing larvae (Robinson et al., 2014), and 
may indicate a possible similarity between prion- and polyQ-like patterns of aggregation, 
and downstream consequences of these events.  
 The presence of Rnq1 prion conformers has been linked to cytotoxicity of polyQ 
aggregates (Duennwald et al., 2006a, Meriin et al., 2002). This toxicity may arise from the 
recruitment of essential proteins during prion amyloidogenesis or alternatively, through 
direct interaction between prion-like proteins and polyQ aggregates which could convert 
each to novel toxic conformations. Our experiments in Drosophila indicate that Rnq1 
enhances mutant HTT toxicity (Figure 27 and 28), perhaps via direct interactions between 
these proteins and consequent alteration in aggregation and cellular distribution (Figure 
30). Similarly, previous studies in yeast demonstrate that Rnq1 co-localizes with mutant 
HTT, facilitating the translocation of soluble HTT into the nucleus (Douglas et al., 2009), 
and leading to the formation of distinct types of polyQ aggregates in the cytoplasm 
(Duennwald et al., 2006a). While the accumulation of HTT in the nucleus is directly 
related with cytotoxicity (Douglas et al., 2009), the combination of mutant HTT with other 
Q-rich proteins can lead to toxic and non-toxic outcomes, depending on the interacting 
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protein and on the nature of this interaction (Duennwald et al., 2006b, Duennwald et al., 
2006a, Kayatekin et al., 2014, Ripaud et al., 2014). Nevertheless, there are likely common 
features of misfolding and aggregation that would determine the toxicity of polyQ 
aggregates.  
Interactions between Rnq1 and mutant HTT resulted in the formation of large 
aggregates, whose appearance was different from the aggregates formed exclusively by 
mutant HTT. In addition, cells expressing both Rnq1 and mutant HTT often exhibited an 
amorphous structure forming at a single location in the cytoplasm. Interestingly, we noted 
that some of these large heterogeneous structures were visualized as a condensed 
collection of many small aggregates (Figure S19, Supplemental information IV), which 
could explain the increased amount of SDS-insoluble species seen in filter traps. Thus, one 
may speculate that prion-like proteins might contribute to the formation of toxic polyQ 
aggregates through two complementary mechanisms of action. First, they could increase 
the rate of polyQ aggregation by acting as mediators for highly efficient conversion of 
mutant HTT misfolding. Therefore, the rapid production of aggregation-prone misfolded 
molecules may exceed the capacity of cellular defense mechanisms (Johnston et al., 1998), 
resulting in accumulation into amorphous aggregates with larger surface areas, hence 
potentially becoming more susceptible to toxic interactions with other cellular factors or 
organelles (Duennwald et al., 2006a, Giorgini et al., 2005). In addition, prion-like proteins 
impair autophagy in the context of HD (Park et al., 2011), which could account for 
enhanced polyQ aggregation and toxicity. Second, it is possible that the unique properties 
of Rnq1 would allow the fragmentation of co-aggregates promoting their assembly into 
small aggregates organized in highly compacted structures.  
The de novo prion formation in yeast underlies aggregate fragmentation mediated 
by molecular chaperones. In particular, Hsp104 is required for prion maintenance and 
seeding of polyQ aggregates (Meriin et al., 2002), suggesting that molecular chaperones 
may intercalate into co-aggregated structures via Rnq1 to control the release of “seeds” 
that would trigger prion-like spreading of toxic misfolded forms to neighboring cells. 
Evidence suggesting that Rnq1 contains a site for Sis1 binding, and that the Hsp40-Sis1 
complex is essential for prion propagation (Douglas et al., 2008), supports such a role for 
Rnq1 in polyQ aggregate propagation. Notably, Drosophila has a homolog for Sis1 
(DROJ1) (Lopez et al., 2003), suggesting that a similar mechanism might occur in our 
Drosophila HD model upon expression of Rnq1 to facilitate prion-like transmission of 
HTT aggregates in the fly brain (Babcock and Ganetzky, 2015, Pearce et al., 2015), and 
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would at least partially account for the enhanced neurotoxicity observed. Although small 
polyQ aggregates consisting of β-sheet structures are more likely to bind to cell surfaces, 
and therefore to be transferred between cells (Trevino et al., 2012), we cannot exclude the 
possibility that toxicity may also derive from the difficulty to eliminate such stable 
aggregates (Douglas et al., 2009) via the ubiquitin-proteasome system (Collinge and 
Clarke, 2007). 
 We observed that both types of aggregates formed in our mammalian cell system 
were usually localized adjacent to the nucleus. Prion-like proteins are found to co-
aggregate with mutant HTT in specific yeast subcellular locations (Kayatekin et al., 2014), 
known as quality control compartments for the deposition of misfolded proteins 
(Kaganovich et al., 2008), and more recently, suggested as potential maturation sites for 
the de novo prion induction (Tyedmers et al., 2010b). This latter study proposed a model in 
which aggregated proteins are concentrated and converted to highly fragmented prions at 
the perivacuolar insoluble protein deposit (IPOD) – a yeast cellular compartment for 
sequestration of protein aggregates - therefore suggesting a novel site for cross-seeding 
activity. Because these compartments are conserved from yeast to mammals (Kaganovich 
et al., 2008), it is likely that similar processes involving prion-like misfolding events may 
also occur in mammalian cells and higher eukaryotes. 
 Importantly, we found that KMO inhibition by RNAi completely reversed 
behavioral defects of Rnq1 expressing flies (Figure 31 and Figure S21, Supplemental 
information IV). Altered levels of KP metabolites have been implicated in the pathogenesis 
of several neurodegenerative disorders, including HD (Maddison and Giorgini, 2015). 
Since the identification of the yeast gene encoding KMO as a potent loss of function 
suppressor of mutant HTT toxicity (Giorgini et al., 2005), many studies have shown the 
efficacy of KMO inhibition in other protein misfolding neurodegeneration models (e.g. α-
syn, Aβ) (Breda et al., 2016, Campesan et al., 2011, Zwilling et al., 2011). Here we 
observed that knocking down cn ameliorated climbing impairments and age-dependent 
neurodegeneration of Rnq1 expressing flies, suggesting that alterations in KP metabolism 
may contribute to prion-mediated toxicity in manner similar to other misfolded proteins, 
suggesting convergent downstream pathways contributing to disease phenotypes. 
 Compelling evidence for a relevant role of prion-like proteins in the pathogenesis 
of neurodegenerative disorders has come from recent studies linking progressive 
misfolding and neurotoxicity with cross-seeding activity of otherwise unrelated proteins 
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(Ferreira et al., 2017, Katorcha et al., 2017, Salazar and Strittmatter, 2017). The current 
study strongly supports a trans effect of prion-like proteins on mutant HTT toxicity 
(Duennwald et al., 2006a), and opens novel avenues for understanding the underlying 
mechanisms of neurodegeneration. 
 
Materials and methods IV 
 
Yeast experiments 
Yeast strains and growth conditions 
 The [PIN+][psi-] and [pin-][psi-] variants carrying a premature nonsense mutation 
(ade1-14) in the ADE1 gene were derivatives of the wild-type yeast strain 74D-694 (MATa 
ade1-14 trp1-289 his3-200 ura3-52 leu2-3,112). The plasmid p6442 (CUP1, SUP35NM-
GFP, URA3 selectable marker) was used in prion co-transformation experiments for the de 
novo induction of [PSI+]. Stains were grown overnight at 30ºC with constant shaking at 
200 rpm in yeast extract peptone dextrose (YEPD) complete medium (2% w/v glucose, 2% 
w/v bactopeptone, 1% w/v yeast extract) or minimal yeast nitrogen base (YNB) medium 
(0.67% w/v YNB without amino acids, 2% w/v glucose) supplemented with appropriate 
amino acids and bases, but lacking one or more defined components. For prion 
elimination, guanidine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was added to 
a final concentration of 5 mM.  
 
Preparation of yeast and Drosophila protein extracts 
 Total yeast cell extracts were obtained from a [PIN+][psi-] variant strain. Briefly, 
cells were harvested by centrifugation at 2500 rpm for 10 min at RT. The resulting cell 
pellet was resuspended in 50 μl yeast buffer (1X PBS, 100 mM NaCl, 2 mM PMSF, 0.1 
mM pepstatin A) supplemented with EDTA-free protease inhibitor cocktail (Roche 
diagnostics, Mannheim, Germany), and cell extracts were collected using glass bead lysis 
and stored at -80ºC. Drosophila protein extracts were obtained as described in Material and 
methods II. Briefly, heads of 56-day-old flies were isolated and homogenized using 
standard procedures (Campesan et al., 2011). The homogenate was centrifuged at 
maximum speed for 10 min at 4ºC, and total protein lysate transferred into a new tube. 
Crude and pellet fly extracts were separated by centrifugation at 80,000 rpm for 60 min at 
4ºC. The resulting supernatant was taken as the crude fraction and the remaining pellet 
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(pellet fraction) was resuspended in 10 μl yeast buffer containing protease inhibitors. 
Protein concentration was measured using Bradford’s Reagent (Sigma-Aldrich, St. Louis, 
MO, USA) and 300 μg of each sample was used for co-transformation experiments in 
yeast spheroplasts. 
 
Yeast transformation and analysis of prion formation  
 Spheroplasts of [pin-][psi-] cells were used as hosts for measuring the infectivity 
protein extracts prepared from the [PIN+][psi-] yeast strain and either elavGAL4 or RNQ1 
transgenic flies. Briefly, spheroplasts of the [pin-][psi-] yeast were generated using lyticase 
as described previously (Tanaka et al., 2004a) and maintained at 4 ºC in STC buffer (1.2 M 
sorbitol, 10 mM CaCl2, 10 mM Tris-HCl pH 7.5). Protein extracts and p6442 plasmid were 
co-transfected into yeast sphaeroplasts using a transformation mix containing 40% PEG-
(4000) and 100 μg salmon sperm DNA. Plasmid uptake was selected by incubation for 3 
days at 30 ºC on a uracil (Ura)-lacking sorbitol medium. Subsequently, one hundred Ura+ 
colonies were induced for SUP35 overexpression by overnight growth in -Ura selective 
YNB medium supplemented with 50 μM copper sulphate. The de novo formation of [PSI+] 
was scored following incubation for 3 weeks at room temperature on adenine (Ade)-
lacking YNB medium. Forty-eight Ade+ white transformants were further tested for [PSI+] 
conversion by guanidine curability (Tuite et al., 1981). [PSI+] formation was calculated 
based on the mean of three independent experiments. Thirty fly heads per genotype were 
used for each experiment, in a total of 90 fly heads per genotype.  
 
Drosophila experiments 
Fly stocks and genetics 
 Fruit flies were maintained on standard maize food at 25ºC in a light/dark cycle of 
12:12 h. The elavGAL4 (c155), daGAL4 (55849) and UAS-eGFP (5431) stocks were 
obtained from the Bloomington Drosophila Stock Center (Indiana University, 
Bloomington, IN, USA). The c164GAL4 driver was a gift from Juan Botas (Baylor College 
of Medicine, Houston, TX, USA) (Torroja et al., 1999). The UAS-93QHTT exon 1 flies 
were a gift from J. Lawrence Marsh and Leslie Thompson (University of California, 
Irvine) (Steffan et al., 2001). For the generation of UAS-RNQ1 lines, the full-length gene 
encoding RNQ1 was amplified and cloned into the pTW vector using Gateway Cloning 
Technology (Invitrogen, ThermoFisher Scientific, Carlsbad, CA, USA). The resulting 
pTW-UASRNQ1 construct was confirmed by DNA sequencing, and then injected into w1118 
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embryos by means of P-element transformation (BestGene Inc, Chino Hills, CA, USA). 
Two UAS transgenic lines carrying RNQ1 targeted randomly in the 2nd chromosome 
(RNQ1-1M and -6M lines) were generated and further confirmed for the presence of 
RNQ1 transgene by PCR-based genotyping using the following primers: 
5’CCACAGTGATGACACACTC3’ and 5’CTGACCCTGTTGTTGATG3’ (Sigma-
Aldrich, St. Louis, MO, USA). Expression of RNQ1 was confirmed for both RNQ1-1M 
and RNQ1-6M lines by QPCR. The UAS-MoPrPWT and UAS-MoPrPP101L lines, referred to 
in Figure 29 as WT PrP or P101L PrP, respectively, were kindly provided by Prof. Patrick 
J. Dolph (Dartmouth College Hanover, USA) (Gavin et al., 2006). For analysis of MoPrP-
mediated toxicity in HD flies, a recombined line carrying both P101L PrP and 
93QHTTex1 transgenes in the 3rd chromosome was generated by meiotic recombination 
(Sherizen et al., 2005) upon crossing of UAS-MoPrPP101L males with UAS-93QHTTex1 
female virgins. The UAS-MoPrPP101L UAS-93QHTTex1 homozygous line was validated by 
PCR-based genotyping for the presence of both transgenes. For all experiments, the UAS-
eGFP and UAS-3M flies were used as titration controls, unless otherwise stated. 
 
Quantitative reverse transcription PCR 
  The RNQ1-1M and RNQ1-6M lines were crossed to the daGAL4 driver line for 
ubiquitous expression of the RNQ1 transgene in the F1 progeny. Samples of 30 flies per 
genotype were then collected and processed for RNA extraction by means of the TRIzol 
reagent (Invitrogen, ThermoFisher Scientific, Carlsbad, CA USA), following 
manufacturer’s instructions. RNA samples were purified by genomic DNA removal using 
Turbo DNAse (Ambion, ThermoFisher Scientific, Waltham, MA, USA) according to the 
manufacturer’s protocol. cDNA was synthesized by reverse transcription reaction using the 
QuantiTect Reverve Transcription kit (Qiagen, Hilden, Germany). Samples were then 
prepared for quantitative PCR reactions using Maxima SYBR Green Master Mix 
(ThermoFisher Scientific, Waltham, MA, USA). Two pairs of primers were used for 
cDNA quantification of either RNQ1 or the fly rpl32 housekeeping gene: 
5’TTCCATGGCAAGTTCCTACC3’ and 5’CATTCTGTTGCGGTCTACCA3’ for RNQ1; 
5’AGCATACAGGCCCAAGATCG3’ and 5’TGTTGTCGATACCCTTGGGC3’ for 
rpl32. Primers were analyzed for efficiency and specificity by melting curve analysis using 
several dilutions of genomic DNA in triplicate. Total reaction volume was 20 μl, including 
12.5 μl SYBR Green, 13.5 ng cDNA and 0.3 μM of each primer. Control reactions without 
reverse transcriptase were included to ensure that genomic DNA was efficiently removed 
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from RNA. Reactions were run in 96-well plates using a LightCycler 480 Real-Time PCR 
System (Roche diagnostics, Mannheim, Germany). Four biological replicates were used 
for each genotype and qPCR reactions were performed in quadruplicate. The amplification 
efficiency of each reaction was calculated using the qpcR package in R Studio (Ritz and 
Spiess, 2008) by fitting sigmoidal curves to the raw fluorescence data, using the pcrbatch 
function. Rnq1 expression lines were normalized to each corresponding UAS control, 
calculated using the ratiobatch function with the Cp value of rp49 used as an internal 
control for each sample. Statistical significance of relative expression levels was tested 
using a pairwise-reallocation test based upon that used by REST software (Pfaffl et al., 
2002), where Cp and efficiency values were permutated within control and treatment 
groups. 
 
Quantification of photoreceptor neurons 
 Neuronal loss was determined using the pseudopupil assay as described in 
Materials and methods I. For analysis of prion-mediated toxicity in wild-type background, 
elavGAL4>UAS-RNQ1 was examined over 8 weeks, being handled for pseudopupil 
analysis once per week. To assess the effects of prion protein expression upon HTT 
toxicity, flies expressing either RNQ1 or MoPrP and 93QHTTex1 in the nervous system 
were scored for rhabdomere number at day 1 and day 7 post-eclosion. Pan-neuronal RNQ1 
expressing flies carring cn RNAi were examined at 1 day-, 42 days- and 56 days-old. A 
minimum number of 12 flies were examined per condition. 
 
Larval crawling and climbing assays 
 Motor behavior of 3rd instar larvae was assayed by means of larval crawling assays 
as previously described (Steinert et al., 2012). Briefly, crosses were set up on standard 
maize food mixed with 0.05% bromophenol blue (FisherBiotech, Loughborough, UK). 3rd 
instar larvae stage were distinguished by the deep blue color of their intestines (Maroni and 
Laurie-Ahlberg, 1983). Young, deep blue-colored wandering larvae were selected, washed 
in distilled water and placed on a 145 mm petri dish containing solidified 0.8% agarose. 
Larvae were allowed to crawl for 2 min at 25ºC. Larval tracks and number of turns were 
manually monitored, and the distance crawled by each larva was calculated by measuring 
track length using Image J software (http://rsbweb.nih.gov/ij/). The log number of turns 
[log10(n + 1)], where “n” represents the actual number of turns performed by the larva, was 
calculated to ensure a normalized distribution of the data. At least 30 larvae were analyzed 
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for each genotype. Motor function of adult flies was analyzed via negative geotaxis 
response assays as previously described (Breda et al., 2015). Briefly, 50-60 female flies 
carrying the desired genotypes were placed in groups of 10 into 18.4 cm length-empty 
tubes, and left to acclimatize for 10 min at 25ºC. Flies were then gently tapped to the 
bottom of the tube and allowed to fly or climb the sides of the tube for 10 sec. The 
climbing pass rate was measured as the number of flies that passed an 8 cm height 
threshold line. Climbing tests were repeated 10 times for each tube, with 5-6 tubes 
containing 10 flies each analyzed per genotype. The same groups of flies were scored for 
climbing activity at days 7, 14 and 28 post-eclosion. 
 
Eclosion and longevity assays 
 Eclosion and longevity assays were performed as detailed in Materials and methods 
II.   
 
Motor and sleep activity 
 Motor activity was monitored using the Drosophila Activity Monitoring (DAM) 
system (Trikinetics, Waltham, MA, USA), as described (Mason et al., 2013). Briefly, male 
flies expressing RNQ1 in the motor neurons were collected upon eclosion and placed 
individually into the DAM activity tubes. The DAM system contains 32 channels, with 
each connected to a single tube, in which the activity of individual flies is measured when 
movement breaks an infrared beam that bisects the tube. The activity of thirty-two flies per 
genotype was individually recorded over 7 days in 12 h light/dark cycles. Only flies 
surviving for at least 5 days in the activity tubes were analyzed. Total motor activity was 
assayed as the average number of infrared beam crossings per 30 min of recording interval 
(bin) over the 7 days. Sleep activity was measured in parallel with locomotor activity for 
the same groups of flies, as described in (Joiner et al., 2006). For sleep analysis, 
movements were recorded in 5 min bin length and rest was defined as a bout of 5 or more 
minutes of complete inactivity.  
 
In vitro experiments 
BiFC constructs and cell cultures 
 The generation of HTTex1-Venus BiFC constructs have been described in detail 
elsewhere (Herrera et al., 2011). RNQ1-Venus BiFC constructs were produced by PCR-
based subcloning of RNQ1 full-length gene into the Venus BiFC vectors. Briefly, an 
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expression plasmid for untagged RNQ1 was used as template to extract the RNQ1 open 
reading frame. The resulting PCR-amplified RNQ1 was integrated into AflII and XhoI sites 
of pCS2 plasmids containing the Venus N-terminal (Venus 1, amino acids 1-158) or C-
terminal (Venus 2, amino acids 159-238) sequences. RNQ1-Venus 1 and RNQ1-Venus 2 
plasmid sequences were confirmed by DNA sequencing (LIGHTrun sequencing, GATC 
Biotech, Constance, Germany). The mouse CAD neuronal cell line was purchased from 
Sigma-Aldrich (St. Louis, MO, USA) and HT22 mouse hippocampal cells were kindly 
provided by David Schubert (The Salk Institute for Biological Studies, CA, USA). Cells 
were maintained in Dulbecco’s minimum essential medium (DMEM) (Lonza, Basel, 
Switzerland) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) (Gibco, 
TermoFisher Scientific, Carlsbad, CA, USA), 2 mM glutamine and 1X commercial 
penicillin/streptomycin solution (Sigma-Aldrich, St. Louis, MO, USA) and grown under 
undifferentiated conditions in an incubator with controlled atmosphere at 37ºC and 5% 
CO2. For flow cytometry, protein extraction or microscopy analyses, cells were seeded at a 
constant density of 7500 cells/cm2 in 6-well plates, 100 mm dishes (Corning-Costar, 
Tewksbury, MA, USA) or 35 mm glass bottom dishes (ibidi, Munich, Germany) 
respectively. Twenty-four hours after seeding, cells were co-transfected with different 
combinations of Venus BiFC plasmids using the Lipofectamine 2000 transfection reagent 
(Invitrogen, ThermoFisher Scientific, Carlsbad, CA, USA), following manufacturer’s 
instructions. Twenty-four hours after transfection, cells were collected and processed 
according to the requirements of each analytical method. 
 
Flow cytometry 
 The BiFC interaction analysis, i.e. dimerization/oligomerization, was performed by 
means of flow cytometry as described in Materials and methods I with minor 
modifications. Samples were analyzed using a BD FACSCalibur flow cytometer (Beckton 
Dickinson, Franklin Lakes, NJ, USA), and graphs prepared in FlowJo software (Tree Star 
Inc., Ashland, OR, USA). 
 
Cell imaging and immunocytochemistry 
 For co-aggregation and co-localization studies, living cell cultures were imaged 
using a Nikon Eclipse TE2000-S high throughput microscope equipped with a Hamamatsu 
Flash 2.8 sCMOS camera (Bridgewater, NJ, USA) and pictures analyzed by means of the 
Image J free software (http://rsbweb.nih.gov/ij/). For immunocytochemistry, cells were 
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prepared as described in (Steffan et al., 2001). Briefly, cells were washed and fixed for 10 
min with 4% (w/v) paraformaldehyde PBS solution. Samples were then washed three times 
and incubated for 5 min in PBST (0.1% Triton X-100, PBS 1X) to allow permeabilization 
of cell membranes. After three wash steps, cells were incubated for 45 min in blocking 
buffer (1% BSA, PBST), and exposed overnight at 4ºC to anti-RNQ1 primary antibody 
(1:500, Santa Cruz Biotechnology Inc., Dallas, Texas, USA), previously diluted in 
blocking buffer. Subsequently, cells were washed three times, incubated for 1 h at RT with 
anti-goat TRITC-conjugated secondary antibody in blocking buffer, and washed again 
three times. Nuclei were stained by incubation for 5 min with 0.1% Hoesch in PBS 
solution and samples subjected to a final wash step before microscopy fluorescence 
analysis. All procedure was carried in the dark and all wash steps were performed in PBS 
1X. The secondary antibody used was kindly provided by Florence Janody (Instituto 
Gulbenkian de Ciência, Oeiras, Portugal). 
 
Immunoblotting and filter retardation assay 
 Total protein lysates were obtained in native conditions and processed for 
immunoblotting or filter retardation assay as described in Materials and methods I. 
Immunoblotting was performed according to standard methods and membranes were 
probed against HTT (1:500, Millipore, Billerica, MA, USA) and GAPDH (1:30000, 
Ambion, Austin, TX, USA). Insoluble HTT levels were determined by means of filter 
retardation assay as described in Materials and methods I. Briefly, aggregates that are 
insoluble in SDS and larger than 0.22 μm are retained in cellulose acetate membranes and 
can then be detected using standard immunoblotting procedures. HTT insoluble species 
were immunoblotted with anti-HTT antibody. Analyses and quantification of relative 
intensity signal of protein blots were performed by means of the Image J software.   
 
Statistics 
 Graphs and statistical analyses were performed with Prism 6 Software (GraphPad 
Software Inc., La Jolla, CA, USA). Results from the yeast and mammalian experiments are 
shown as average ± standard deviation (SD) of at least three independent experiments, 
unless specified otherwise. For statistical analysis of the yeast data, background [PSI+] 
events in respective controls were subtracted from the Rnq1-expressing flies or [PIN+] 
yeast lysates and comparisons were made using single sample t-tests versus the predicted 
value of 0. Analyses of the mammalian results were performed using one-way ANOVA 
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followed by the Tukey test for comparison of mean values, aside from the filter 
blot/immunoblot experiments where a one-sample t-test was employed post-normalization. 
Drosophila data are represented as the average ± standard error (SEM), and analyses were 
carried out by ANOVA with the Tukey post-hoc test, with the exception of longevity 
experiments that were analyzed by means of a Log-rank test. Statistical significance was 
accepted when p<0.05. 
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 Neurodegenerative diseases (NDs) affect millions of people worldwide. The 
economic and social costs are extremely high, and are estimated to increase over time 
owing to the growing size of the elderly population. Although the vast majority of cases 
are observed in older people, these disorders can affect any age group, and they start likely 
years or decades before the first clear symptoms appear. Because of the long latency period 
and lack of early symptoms, NDs are generally diagnosed in very advanced phases of the 
pathology. This issue makes very difficult the search for treatments that modify the course 
of the disease, as any experimental therapy arrives when a majority of neurons is already 
death and the ageing brain has a very limited regenerative capacity. Thus, available 
treatments still act at a symptomatic level only. A common pathological hallmark among 
NDs is the formation of misfolded protein aggregates accompanied by neuronal 
dysfunction and death. Therapeutic options that target different steps of protein 
aggregation and degradation are currently being explored. However, the events leading to 
aberrant protein accumulation, and the particular cellular contexts influencing the 
formation of toxic aggregates remain unclear.  
 HD is relatively easy to model because, unlike most PD and AD cases, it has a 
monogenetic origin, and there is a direct association between the presence of mutant HTT 
and the development of the disease. HD is thus proving useful for the study of common 
molecular mechanisms underlying neurodegeneration, as well as for the identification of 
potential disease-modifying targets in NDs. Here, we used mammalian cell and Drosophila 
models of HD to study intra- and intermolecular factors involved in the oligomerization, 
aggregation and toxicity of mutant HTT. Although the expanded polyQ tract in HTT is the 
critical determinant of HD pathogenesis, the precise disease manifestations and their 
timing are clearly influenced by additional factors. We and others have found that the 
aggregation propensity of mutant HTT is indeed modulated by secondary events such as 
PTMs and/or aberrant interactions with a wide range of proteins and other cellular 
components, which may vary between neuronal populations and individuals. Advancing 
our understanding of these phenomena should precede any potential therapeutic approach 
for HD, and would provide relevant information about the normal function of HTT, a 
protein essential for normal development and cell survival. 
 
Huntingtin phosphorylation is relevant to HD pathology 
 The lower levels of HTT phosphorylation in the cortex and striatum from HD mice 
compared to other regions of the brain (Warby et al., 2005) suggests a role for 
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phosphorylation/dephosphorylation events in disease pathogenesis, and may indicate the 
existence of altered phosphorylation-modifying pathways in HD-affected neurons that 
could be potentially targeted against neurotoxicity. A significant number of studies 
demonstrate the neuroprotective potential of constitutive serine phosphorylation of mutant 
HTT in several models of HD (Atwal et al., 2011, Di Pardo et al., 2012, Gu et al., 2009, 
Humbert et al., 2002, Thompson et al., 2009), and point at specific kinases (Atwal et al., 
2011, Di Pardo et al., 2012, Thompson et al., 2009, Warby et al., 2005) and phosphatases 
(Ermak et al., 2009, Metzler et al., 2010, Pardo et al., 2006, Pineda et al., 2009, 
Rosenstock et al., 2011) as promising targets for drug development. We expanded this list 
by identifying PP1 as a modulator of HTTex1 aggregation and toxicity (Chapter III, 3.1). 
The fact that PP1 is the first protein phosphatase to be described in the literature (Branco-
Santos et al., 2017) as being involved in mutant HTTex1 behavior is of potential 
therapeutic significance, since the amount of HTTex1-containing fragments is likely to be 
increased in HD-affected neurons (Li et al., 2000) as a result of increased caspase activity 
(Hermel et al., 2004).  
 
PP1 in the context of HD and other neurodegenerative disorders 
 PP1 belongs to a family of threonine/serine specific protein phosphatases and is 
highly enriched in the brain, particularly in MSNs (da Cruz e Silva et al., 1995b). This 
phosphatase is composed of one catalytic subunit that exists in three distinct isoforms 
(PP1α, β and γ). The single PP1 catalytic subunit can form holoenzyme complexes with 
more than 200 regulatory partners, which target PP1 to specific subcellular locations 
whereby influencing its substrate specificity and function (Bollen et al., 2010, Chatterjee 
and Kohn, 2013).  PP1 is thus involved in a multiplicity of cellular signaling events and, 
together with PP2A, it accounts for more than 90% of the protein phosphatase activity in 
eukaryotes (Virshup and Shenolikar, 2009). Its precise role in NDs is not well defined and 
varies between different experimental models and conditions. Selective inhibition of a PP1 
regulatory subunit involved in ER stress protects cells from misfolded protein toxicity and 
prevents disease development in mouse models of amyotrophic lateral sclerosis (Das et al., 
2015). In AD, PP1 inhibition leads to secretion of non-amyloidogenic APP fragments (da 
Cruz e Silva et al., 1995a). Exposure to Aβ toxic peptides affects PP1 expression 
differentially, depending on the cell type (Amador et al., 2004). Tau directly interacts with 
PP1 in normal conditions, targeting PP1 to the microtubules. In turn PP1 plays a role in 
maintaining microtubule stability by regulating Tau phosphorylation and possibly other 
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microtubule-associated proteins (Liao et al., 1998). A potent inhibitor of PP1 is found to be 
upregulated in patient and mouse AD brains, wherein specifically co-localizes with Tau 
neurofibrillary tangles (Raha-Chowdhury et al., 2005). PP1 inhibition correlates with Tau 
hyperphosphorylation and memory impairment in AD rats (Sun et al., 2003), while 
inefficient inhibition of PP1 by DARPP-32 is associated with reduced synaptic plasticity 
and memory loss (Cho et al., 2015). Tau hyperphosphorylation leads to PP1 
overstimulation, which could represent an attempt of the cell to restore normal levels of 
Tau phosphorylation. Instead, increased PP1 activity leads to activation of GSK3, a kinase 
associated with fibrillar Tau pathology and axonal deficits (Braithwaite et al., 2012). These 
studies suggest that both inhibition and overstimulation of PP1 may account for neuronal 
dysfunction, while minimal repression seems to be necessary for normal cognition. 
Notably, PP1 exerts differential control of neuronal viability when activated in different 
brain regions. While PP1 potentiates synaptic activity and promotes cell survival in the 
hippocampus, it exacerbates NMDAR-induced pathways in response to excitotoxicity and 
other stress stimuli in cortico-striatal connections (Arias et al., 2002, Mansuy and 
Shenolikar, 2006). Loss of the PP1 inhibitor DARPP-32 in HD mice results in decreased 
serine-421 HTT phosphorylation and reduced neuroprotection against excitotoxicity 
(Metzler et al., 2010). Excitotoxicity involved a positive feedback loop mechanism, in 
which overstimulation of NMDAR triggered GSK3 activation via PP1, resulting in 
amplification of PP1-mediated signaling and subsequent inhibition of CREB transcription 
(Szatmari et al., 2005). However, in physiological conditions, loss of PP1 leads to CREB 
hyperphosphorylation, followed by proteosomal degradation (Taylor et al., 2000). These 
observations indicate that the precise role of PP1 depends on its interaction with particular 
regulatory subunits, which may vary between cell types and pathophysiological or 
experimental conditions. In fact, PP1 holoenzyme complexes are highly selective 
(Chatterjee and Kohn, 2013). Therefore, if PP1 is to be considered a therapeutic target in 
NDs, it is essential to identify specific regulatory partners that associate with the PP1 
catalytic subunit in particular cellular environments and/or in response to specific insults.  
 
The putative relationship between PP1 and N17 phosphorylation 
  We showed that single N17 phosphorylation of mutant HTTex1 reduces its 
aggregation, while having no effect on oligomerization (Chapter III, 3.1). Consistently, 
treatment of mammalian cells with PP1 inhibitors prevented the formation of large 
HTTex1 aggregates but did not alter the levels of oligomers. A similar effect was observed 
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in Drosophila dopaminergic neurons, with genetic downregulation of PP1 resulting in 
decreased number of HTTex1 large aggregates. However, specific downregulation of PP1 
in photoreceptor neurons led to their premature death. Since each parameter was better 
studied in different cell populations, we cannot establish a direct connection between 
HTTex1 aggregation, toxicity and PP1 downregulation. Our interpretation is that decreased 
PP1 activity in HD cells might result in increased levels of HTTex1 phosphorylation, 
which induce conformational changes that interfere with the ability of HTTex1 oligomers 
to assembly into large insoluble species, thereby increasing their availability to engage in 
toxic interactions. Ultimately, this would lead to neuronal degeneration via direct or 
indirect activation of apoptotic signaling pathways (Saudou et al., 1998). This is in 
agreement with the “toxic oligomer hypothesis”, which argues that neuronal protection 
might be conferred either by preventing the initial oligomer formation or accelerating their 
sequestration into forming neutral inclusion bodies (Arrasate et al., 2004, Bodner et al., 
2006, Kuemmerle et al., 1999, Slow et al., 2005). In line with this hypothesis, T3D fly 
mutants displayed an impressive phenotype of motor dysfunction (data not shown) in spite 
of the low deposition of inclusion bodies in their brains. Together with the striatal-
enrichment of PP1 in healthy brains (da Cruz e Silva et al., 1995b), the decreased levels of 
T3 phosphorylation in pre-manifested disease models of HD (Cariulo et al., 2017b) 
suggests that an imbalance of PP1 activity and T3 phosphorylation levels could trigger a 
series of pathological events and instigate the development of HD. The modulatory role of 
T3 phosphorylation on HTTex1 α-helicity (Ansaloni et al., 2014, Chiki et al., 2017) and 
the demonstrated impact of this modification on mutant HTT aggregation propensity 
(Chapter III, 3.1) (Cariulo et al., 2017b) lead us to speculate that phosphorylation of T3 
might attenuate the effect of expanded polyQ on HTTex1 conformation. An increased 
content of HTTex1 phosphorylated fragments within forming oligomeric structures would 
affect their structural stability, thereby preventing further stages of the aggregation process. 
Indeed, T3 phosphorylation decreases conformational rigidity of mutant HTTex1, while 
having no effect on soluble wild-type HTT (Cariulo et al., 2017b). 
However, it is important to note that our results may not imply a direct action of 
PP1 on N17 residues. It is also plausible that PP1 downregulation could have an indirect 
effect on mutant HTTex1 aggregation, while promoting downstream events of toxicity. For 
example, the deleterious effect of PP1 downregulation may be due to a potential role of the 
Drosophila PP1α-87B isoform in maintaining structural integrity of photoreceptor neurons 
(Bennett et al., 2006, Dombradi et al., 1990, Kirchner et al., 2007a, Kirchner et al., 
IV!|!Conclusions!and!Future!perspectives!
 155 
2007b). In this scenario, expression of mutant HTT would converge to determine cellular 
collapse thereby accelerating neurodegeneration. The two hypotheses are not mutually 
exclusive, and further studies will clarify whether PP1 directly regulates N17 
phosphorylation and whether there are N17-specific PP1 regulatory subunits. Such 
findings could open new venues for the development of drugs with a high degree of 
specificity. We also proposed that T3 phosphorylation plays a dominant effect over S13 
and S16 modifications on mutant HTTex1 aggregation (discussed on Chapter III, 3.1). 
Thus, future investigations should also focus on deciphering the molecular pathways that 
influence T3 phosphorylation in the context of polyQ expansion, as they could provide 
more effective therapeutic targets for promoting the formation of species with lower 
cytotoxicity. Finally, it could be interesting to further explore the role of PRL-3 on HD 
pathogenesis. In our cell BiFC-based phosphatase inhibitor screen, PRL-3 showed to be a 
strong modulator of mutant HTTex1 aggregation, with its inhibition leading to a dramatic 
increase of HTT insoluble species. PRL-3 is a tyrosine phosphatase, fact that allowed us to 
exclude any direct modulation of N17 phosphorylation by this phosphatase, but it would be 
interesting to understand the underpinnings of a pathway that seems to enhance HTT 
aggregation. 
 
The role of AGEs in huntingtin aggregation and toxicity 
 PP1 activation has been repeatedly proposed as a potential approach to treat 
Diabetes mellitus type 2 (Kuehnen et al., 2011, Reither et al., 2013, Sato et al., 1998), one 
of the most debilitating peripheral complications of HD (Carroll et al., 2015, van der Burg 
et al., 2009). Downregulation of PP1 activity in human pancreatic β cells is associated with 
impairment of glucose-induced insulin secretion through a mechanism involving decreased 
calcium influx into cells (Kuehnen et al., 2011). In HD, the progressive accumulation of 
mutant HTT in pancreatic β cells results in age-dependent decrease of insulin production 
and disruption of glucose intake (Andreassen et al., 2002, Bjorkqvist et al., 2005, Hurlbert 
et al., 1999). Glucose is the major energy supply of neurons. However, imbalance of 
glucose metabolism drives the formation of glycation agents, which aberrantly interact 
with functional proteins inducing the formation of AGEs, and AGEs have deleterious 
effects on proteins associated with NDs (Chen et al., 2006b, Choi et al., 2004, Li et al., 
2013, Vicente Miranda et al., 2017). In the current work, we established a relationship 
between mutant HTTex1 glycation and neurotoxicity in vivo (Chapter III, 3.2). 
Accumulation of AGEs can induce inflammatory responses and oxidative stress via RAGE 
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(Vicente Miranda and Outeiro, 2010). Upregulation of RAGE promotes Tau 
hyperphosphorylation and aggregation, and impairs synaptic transmission through 
activation of GSK3 and MAPKs. Conversely, glycated Tau induces RAGE-mediated ROS 
production and subsequent Aβ secretion in AD models (Kulkarni et al., 2013). Inhibiting 
or suppressing AGE-RAGE aberrant signaling is a promising therapeutic strategy against 
age-related diseases, but so far they have failed to demonstrate safety and efficacy in phase 
1 clinical trials (Galasko et al., 2014). A threonine/serine kinase, the p58-
regulated/activated protein kinase (PRAK), was recently identified as a novel binding 
partner of the RAGE cytoplasmic domain, regulating downstream autophagic signaling in 
response to Aβ-RAGE interaction (Kim et al., 2016). Since a complex kinase/phosphatase 
signaling is likely involved in RAGE mediated-processes, it would be interesting to 
investigate a possible link between PP1 malfunction and glycation-related toxicity in HD. 
We previously found that the autophagy lysosome pathway (APL) is activated in the 
presence of glycated mutant HTT (Vicente Miranda et al., 2016b). Phosphatase activity is 
required for APL induction in cell stress conditions (Wong et al., 2015b). We think it 
could be important to measure the activity levels of specific kinases and phosphatases 
involved in HTT aggregation and toxicity, as well as HTT phosphorylation levels, under 
glycation conditions. Would an increase in AGEs trigger PP1 activation as a first line of 
defense against the accumulation of toxic species? Could a continuous exposure to 
reducing sugars result in chronic reactions and overstimulation of PP1, ultimately leading 
to dephosphorylation of HTT species and their subsequent aggregation, to the point where 
cell loss is irreversible? Would such AGE-RAGE signaling transduction occur specifically 
in striatal neurons thus constituting a novel mechanism of striatal vulnerability in HD? 
Achieving a tight control of PP1 activity in glycation-affected CNS, in addition to 
peripheral tissues, could be of extreme clinical importance since it would mean the use of a 
single drug to treat multiple symptoms of HD. 
 Another potential approach to overcome glycation-induced stress and cytotoxicity 
is to reduce the accumulation of AGEs. Increased levels of glycation exacerbated mutant 
HTT-induced defects in young flies, suggesting that the deposition of glycated HTT 
species may occur in early stages of HD development (Chapter III, 3.2). However, several 
questions remain to be answered. For example, it is not yet clear whether the toxicity seen 
in HD models subjected to glycating conditions is a direct consequence of enhanced 
HTTex1 aggregation or just a result of the high reactivity of glycated species. Likewise, 
the specific HTTex1 residues where AGEs are formed remain to be identified, and 
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therefore we are still unable to know whether such modifications would be sufficient to 
initiate aggregate formation. Mounting evidence suggests that HTTex1 accumulation 
might occur as a secondary event promoted by disruption of the proteostasis network by 
age-associated glycation. Although glycation is reported to induce chaperone activity 
(Nagaraj et al., 2003, New et al., 1998, Oya-Ito et al., 2006) and to stimulate the APL 
system in a cell model of HD (Vicente Miranda et al., 2016b), glycated HTTex1 fragments 
could be more difficult to degrade thus leading to their accumulation in a time-dependent 
manner. This is demonstrated by a reduced capacity of the cells to clear mutant HTTex1 
when treated with glycation agents (Vicente Miranda et al., 2016b). A recent study from 
our laboratory shows that glycation promotes α-syn oligomerization, while blocking 
ubiquitin-mediated proteasome degradation and autophagy (Vicente Miranda et al., 2017). 
Protein aggregation and decay of the protein quality control system could therefore 
constitute concomitant events in glycation-related toxicity. An important question arising 
from these observations is how interplay between glycation and other PTMs can influence 
HTT aggregation propensity and clearance. Since lysines are the preferential targets of 
glycation (Vicente Miranda and Outeiro, 2010), and because modifications in HTT lysine 
residues are known to regulate protein degradation and clearance (Jeong et al., 2009), 
glycation agents could compete with acetyltransferases, ubiquitin or SUMO for HTT 
lysine residues thus playing a role in modulating these processes. Notably, phosphorylation 
of S13 and S16 by IKK regulates modifications on adjacent lysine residues (Thompson et 
al., 2009). It would be interesting to investigate the influence of N17 
phosphorylation/dephosphorylation events upon lysine-targeting glycation. 
 While a direct relationship between diabetes and NDs is yet to be clearly 
established, the studies discussed above indicate protein glycation as an environmental risk 
factor for disease development and progression. Anti-glycation agents may prove 
beneficial for HD patients, at least for those suffering from hyperglycemia and diabetic 
complications. In addition, preventive approaches based on dietary restriction may also 
delay the onset of disease, as well as improve the quality-of-life of symptomatic HD 
patients. Dietary energy restriction in a mouse HD model protects against mutant HTT-
related neurodegeneration while preserving BDNF levels in cortico-striatal synapses. 
Importantly, glucose metabolism of these animals was improved, motor deficits were 
delayed, and their lifespan was increased (Duan et al., 2003). Aerobic exercise is also 
known to positively impact glucose levels and improve insulin sensitivity, and may 
therefore constitute a good complementary therapy. Wheel-running HD mice exhibited 
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delayed onset of motor and cognitive deficits (Pang et al., 2006). In the future, it will be 
important to understand the nature of the link between AGEs, peripheral pathology and 
neurodegeneration. Furthermore, since there is evidence for the presence of mutant HTT in 
cerebrospinal fluid (Wild et al., 2015), the detection of AGEs in circulating HTT could 
constitute a potential biomarker for premanifest and early progression of HD. 
 
Protein-protein interactions as modifiers of huntingtin aggregation and toxicity 
 The observation of heterologous aggregates composed by apparently unrelated 
proteins in patient brains has opened up a new chapter of research regarding the 
mechanisms underlying differential progression of NDs. An age-dependent increase of 
protein misfolding as result of proteasome decay is a view widely acknowledged in the 
field, and is pointed as a possible explanation for the appearance of mixed aggregates. 
Such theory reasons that the accumulation of certain misfolded proteins, such polyQ-
containing proteins, can compromise the entire proteostatic network, thereby triggering the 
misfolding of unrelated proteins that would otherwise fold normally. Increased levels of 
misfolded proteins in the cellular environment would facilitate the occurrence of co-
aggregation processes and accelerate disease progression. However, in addition to 
increased protein concentrations, other factors may determine co-aggregation propensity 
and its outcomes (Kostylev et al., 2015, Sarell et al., 2013, Shattuck et al., 2017, Stewart 
and Radford, 2017). The presence of aggregation-prone proteins itself in a particular 
subcellular location can initiate co-aggregation events. Intrinsic properties of aggregation-
prone proteins may dictate its fate in cross-seeding interactions. Further supporting this 
notion, we showed that HTTex1 co-aggregates with other disease-causing proteins, in 
some cases depending on its phosphorylation state (Chapter III, section B). The ability of 
phosphorylated HTTex1 molecules to co-assemble into large insoluble structures appears 
to be highly selective. In particular, N17 phosphorylation prevents further co-aggregation 
processes between mutant HTT and α-syn, while having no effect upon HTT-Tau 
interactions. As such, specific PTMs in HTT might constitute interesting targets for 
controlling efficiency of cross-seeding and should be object of further study. Since 
different cell types may comprise different pools of HTT molecules, this could explain 
why the spread of HD pathology is facilitated in certain types of neurons, and leads to the 
intriguing possibility that PTMs might affect the location and timescale of disease 
progression. It has also been postulated that sequence similarity between aggregation-
prone proteins increases the chance for cross-seeding events. We showed that Rnq1, a 
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yeast prion that is highly enriched in Q/N domains, interacts with mutant HTT in human 
living cells (Chapter III, 3.4). Although not naturally present in mammalian systems, Rnq1 
was able to promote dramatic changes in mutant HTT aggregation profile, raising the 
possibility that human proteins with similar properties could function as modifiers of HTT 
aggregation.  
 Once demonstrated that specific aggregation-prone proteins interact with mutant 
HTT and affect its aggregation properties, it is important to understand whether such 
aberrant interactions can impact on mutant HTT toxicity and thus influence disease 
development and/or progression. While our collaborators explored the downstream 
consequences of mutant HTT interactions with α-syn (Pocas et al., 2015) or Tau (Blum et 
al., 2015) in Drosophila and mouse models, respectively (discussed in Chapter III, 3.3), we 
sought to determine the effect of Rnq1 expression in Drosophila, during normal aging or in 
HD-like context (Chapter III, 3.4). We showed that expression of Rnq1 is sufficient to 
cause neuronal dysfunction and degeneration in aging flies. The relevance of this finding 
stems from the fact that human cells express many proteins enriched with Q/N domains 
(Alberti et al., 2009, King et al., 2012). Furthermore, such proteins with prion-like 
properties are abundant in nature and may serve as critical environmental risk factors in 
predisposed individuals with ND (Lundmark et al., 2005). Westermark and colleagues 
show that naturally occurring amyloid-like fibrils act as seeds to accelerate 
amyloidogenesis in mice (Lundmark et al., 2005). Our data here offer an important proof-
of-concept demonstration of the role of Q/N-rich proteins as enhancers of mutant HTT 
aggregation and toxicity. We propose that these proteins may function as HTT amyloid 
precursors together with co-chaperones, although additional experiments are needed to 
prove the involvement of chaperones in such cross-seeding phenomena. Expression of 
polyQ peptides in C. elegans perturbs protein-folding homeostasis and causes co-
aggregation with Q/N-rich proteins associated with developmental deficits (Satyal et al., 
2000). A specific molecular chaperone that modulates seeding and formation of polyQ 
aggregates (Meriin et al., 2002) was able to reduce aggregation and improve development, 
while expression of other chaperones had no effect (Satyal et al., 2000). Indeed, 
subsequent studies have shown that specific chaperones can function in early stages of 
protein aggregation and alter the toxic properties of oligomers by promoting their assembly 
into fewer but larger insoluble species (Douglas et al., 2008, Mannini et al., 2012, Sajjad et 
al., 2014). However, such mechanisms of action of molecular chaperones remain unclear 
with the existence of conflicting data (Muchowski et al., 2000). The balance between 
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molecular chaperones and factors that enhance protein misfolding and aggregation may 
determine the final outcome. Chaperones associate with co-chaperones to mediate seeding 
and propagation of prion proteins (Arslan et al., 2015, Telling et al., 1995). Genetic 
manipulation of the Drosophila cellular co-factor DROJ1 with chaperone-like activity may 
help to establish such prion model of aggregation in HD (Davis and Sindi, 2016, Lopez et 
al., 2003). In addition to deregulation of the proteostasis network, it is important to 
investigate whether exposure to Q/N-rich proteins can trigger early mechanisms of cellular 
dysfunction thus contributing to enhanced cell vulnerability to mutant HTT. 
Downregulation of the Drosophila KMO gene in Rnq1 expressing flies ameliorated motor 
defects and neurodegeneration, suggesting that impaired KP metabolism may contribute to 
neuronal dysfunction and toxicity observed in these flies. We are currently performing 
measurements of overall mitochondrial metabolism and transcription in our Rnq1 flies, 
which will provide further insight into the underlying mechanisms of Rnq1-mediated 
toxicity.  
 
Final remarks  
 Resolving the biochemical properties of different molecules in the total HTT 
population, in a particular set of neurons (e.g. MSNs in the striatum), could be crucial to 
understand their relative contribution to HD pathology. In the future, monitoring the 
amount of Q/N-rich and other aggregation-prone proteins in humans, in the context of both 
physiological aging and disease, may provide opportunities for the development of 
sensitive predictive tools of HD progression. 
 In summary, the results discussed here suggest that i) pathway-modifying PTMs in 
HTT (e.g. phosphorylation and glycation), ii) the presence of specific factors in the cell 
environment (e.g. PP1, Q/N-rich proteins), and iii) the recruitment of proteins essential for 
normal cell function (e.g. α-syn and Tau) may affect significantly disease development and 
progression, and constitute areas of research of particular interest for advancing our 
knowledge of HD pathogenesis. The next big challenge will be to integrate current 
findings into meaningful pathways. Only a comprehensive approach of the putative 
molecular targets could push forward the rational development of therapeutics against a 
monogenetic disorder with as much interindividual variability as HD. 
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Table S1. Name, concentration, description, toxicity and effect on HTTex1 expression of the phosphatase 
inhibitor library. 
Code Name Concentration Compound description Toxic Inhibits HTTex1 expression 
B1 Cantharidic acid 1 µM PP1 and PP2A No No 
B2 Cantharidin 1 µM PP1 and PP2A No No 
B3 Endothall 5 µM PP2A No No 
B4 Benzylphosphonic acid 5 µM Tyrosine phosphatases No No 
B5 L-p-Bromotetramisole oxalate 10 µM Tyrosine phosphatases No No 
B6 RK-682 10 µM Tyrosine phosphatases Yes Yes 
B7 RWJ-60475 5 µM CD45 tyrosine phosphatase No Yes 
B8 RWJ-60475 (AM)3 5 µM CD45 tyrosine phosphatase (cell permeable) No No 
B9 Levamisole HCl 10 µM Mammalian alkaline phosphatase No No 
B10 Tetramisole HCl 10 µM Mammalian alkaline phosphatase No No 
B11 Cypermethrin 1 µM Calcineurin (PP2B) No No 
B12 Deltamethrin 1 µM Calcineurin (PP2B) No No 
C1 Fenvalerate 5 µM Calcineurin (PP2B) No No 
C2 Tyrphostin 8 10 µM Calcineurin (PP2B) No No 
C3 CinnGel 5 µM PTP1B No No 
C4 NSC-95397 5 µM Cdc25 No No 
C5 BN-82002 5 µM Cdc25 No No 
C6 Shikonin 10 µM PTP1B Yes No 
C7 NSC-663284 1 µM CDC25 No No 
C8 Cyclosporin A 1 µM Calcineurin (PP2B) No No 
C9 Pentamidine 10 µM PRL1 No No 
C10 BVT-948 5 µM Tyrosine phosphatases No No 
C11 B4-Rhodanine 1 µM PRL3 No No 
C12 Alexidine·2HCl 1 µM PTPMT1 No No 
D1 9,10-Phenanthrenequinone 10 µM CD45 tyrosine phosphatase Yes No 
D2 BML-260 10 µM JSP-1 No No 
D3 Sanguinarine chloride 10 µM PP2C Yes No 
D4 BML-267 10 µM PTP1B No No 
D5 BML-267 Ester 10 µM PTP1B (cell permeable) No No 
D6 OBA 10 µM Tyrosine phosphatases No No 
D7 OBA Ester 10 µM Tyrosine phosphatases (cell permeable) No No 
D8 Gossypol 10 µM Calcineurin (PP2B) No Yes 
D9 Alendronate 10 µM Tyrosine phosphatases No No 
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Figure S1. Single N17 phosphoresistant mutations do not alter HTTex1 aggregation pattern. 
Graphic representations from microscopy data of H4 cells transfected with the corresponding HTTex1-Venus 
BiFC pairs. Single phosphoresistant mutations did not change significantly the number of aggregates per cell 
(A), the distribution and number of aggregates per cell (B) or the size of aggregates (C). 
 
Supplemental!information!I!
166 
Figure S2. N17 phopho-mutations do not affect HTTex1 oligomerization. (A) Flow cytometry 
charts of H4 cells transfected with the indicated HTTex1-Venus BiFC pair. Y axis represents the side scatter 
(SSC) signal, and the X axis represents the signal in the FITC channel. Both scales are logarithmic. (B and C) 
Graphic representation of quantitative flow cytometry results. *significant versus 19QHTTex1 pair, p<0.05. 
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Figure S3. Relative contribution of N17 phosphorylatable residues towards HTTex1 
aggregation. (A) Representative pictures of H4 cells transfected with different combinations of 
phosphomimics with non-mutated 97QHTTex1-Venus constructs. These combinations produced mixed 
phenotypes in terms of aggregation. Quantitative analyses of microscopy pictures confirmed that expression 
of T3D/97Q resulted in a total absence of cells with inclusions (B). (C) Average number of aggregates per 
cell. (D) Percentage of cells showing less than 10, between 10 and 25, and more than 25 aggregates. (E) 
Percentage of aggregates smaller than 1 µm, larger than 1 µm but smaller than 3 µm, and larger than 3 µm. *, 
significant versus 97Q/97Q, p<0.05. Scale bar, 20 µm. 
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Figure S4. Combinations of phosphomimics and non-mutated 97QHTTex1 produce similar 
levels of fluorescence. (A) Representative flow cytometry profiles of cells co-transfected with different 
combinations of phosphomimic mutants and non-mutated 97QHTTex1 BiFC constructs. (B) Quantitative 
analysis of flow cytometry data. *significant versus 19QHTTex1 pair, p<0.05. 
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Figure S5. LDH activity of T3 phosphomutants measured over 24 h intervals. LDH release was 
measured in the supernatants of cells expressing non-mutated 97QHTTex1 (black bars), T3A (red bars) or 
T3D (blue bars) pairs, at different time points after transfection. Expression of T3D pair was protective at 24 
h post-transfection, but no significant differences were observed at 48 h or 72 h comparing to the non-
mutated 97QHTTex1. *significant versus 97Q/97Q, p<0.05.  
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Figure S6. Aggregation patterns of HTTex1 phosphomutants in 3rd instar larval eye imaginal 
discs. Confocal microscopy images of eye imaginal discs in larvae expressing HTTex1-mCherry under the 
control of GMRGAL4. HTTex1-mCherry is shown in red, and photoreceptors (anti-Elav) are shown in blue. 
Wild-type 19QHTTex1 showed a diffuse pattern of expression (A), whereas non-mutated 97QHTTex1 
produced high number of inclusions (B). Mutations in the N17 phosphorylatable residues reduced 
97QHTTex1-mCherry aggregation in larvae (C-E and G-H), with the exception of S13D (F), which showed 
increased number of aggregates versus non-mutated 97QHTTex1 (B). (I) Quantitative analyses of confocal 
pictures. Average number of aggregates and standard deviations were calculated for at least 5 imaginal discs 
per genotype. *significant versus GMRGAL4>UAS-97QHTTex1-mCherry, p<0.05. Scale bar, 10 µm. 
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Figure S7. Effect of phosphatase inhibitors on HTTex1 expression. Representative blots of total 
protein extracts from H4 cells transfected with non-mutated 97QHTTex1-Venus BiFC constructs and 
incubated with the indicated phosphatase inhibitors for 24 h. Membranes were probed with anti-HTT and 
anti-GAPDH antibodies, as indicated. Corresponds to Table S1. D, DMSO. 
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Figure S8. Knockdown of 
PP2A or string does not 
affect 97QHTTex1 
aggregation or toxicity in 
Drosophila. (A) Imaging of 
adult dopaminergic neurons 
in RNAi transgenic flies 
expressing 97QHTTex1 
under the control of 
THGAL4. PP2A-29B or 
string RNAi knockdown 
flies showed no overt 
phenotype in terms of 
aggregation when compared 
to 97QHTTex1 no RNAi 
control. (B) Quantitative 
analyses of confocal 
pictures. Data are average 
number of aggregates ± 
SEM. Scale bar, 10 µm. 
PP2A-29B (C) or string (D) 
downregulation did not 
affect progressive 
photoreceptor loss observed 
in 97QHTTex1 flies. 
*significant versus 97Q, 
#significant versus 97Q at 
day 1 and day 8, p<0.05. ns, 
no significant versus 97Q at 
day 15. 
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Figure S9. Double UAS control flies do not exhibit changes in aggregate phenotypic responses 
to THGAL4>UAS-97QHTTex1-mCherry expression. Quantification of average (±SEM) number of 
aggregates per brain in flies expressing both UAS-97QHTTex1-mCherry and UAS-lacZ constructs (97Q + 
lacZ), in comparison to single UAS-97QHTTex1-mCherry transgenic flies (97Q). 
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Figure S10, related to Figure 20 
Figure S11 
Figure S12 
Figure S13 
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Figure S10. Control flies do not exhibit neuronal loss when treated with MGO. Quantification 
of mean rhabdomeres (± SEM) per ommatidium in driver and UAS control flies. Flies expressing a WT 
version of HTT (20QHTTex1) were also analyzed. The pseudopupil assay was performed in untreated flies (-
) at the day of pupae hatching (day 0) and following 7 days (day 7). A group of at least 30 flies per genotype 
were separated upon eclosion and treated with the highest dose of MGO used in this study (300 µg). After 7 
days of treatment, flies were handled for rhabdomere quantification. 
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Figure S11. Knockdown of Glo1 or Tpi causes increased protein glycation and accumulation 
of AGEs in HD flies. One hundred heads from flies expressing 93QHTTex1 and knocked down for Tpi, 
Glo1 or 3M (as control) were lysed and immunoprecipitated (IP) with anti-HTT antibody (bottom panels). 
The whole protein lysates (WPL) (n = 3) and IP samples (n = 2) were probed for AGEs (left panels) or HTT 
(right panels). Arrow indicates 93QHTTex1 MW. Corresponding loading controls (α-tubulin) are shown. 
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Figure S12. Knockdown of Glo1 or Tpi does not induce neurotoxicity in WT background 
flies. Number of rhabdomeres per ommatidium in WT flies with pan-neuronal knockdown of Glo1 or Tpi is 
presented at day 0 and 7 post-eclosion, with no neurodegeneration observed. Control flies expressing 3M or 
GFP also do not exhibit degeneration of rhabdomeres. Data is mean ± SEM. 
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Figure S13. Pan-neuronal expression of 93QHTTex1 causes a dramatic decrease in lifespan. 
Survival curves of flies expressing 20QHTTex1 or 93QHTTex1 under the control of elavGAL4. Data is 
presented as mean ± SEM.  
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Figure S14, related to Figure 22 
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Figure S14. Alpha-synuclein interacts with HTT in living cells. H4 cells were transfected with 
different combinations of 19Q, 97Q and/or Syn-Venus BiFC plasmids (A). Twenty-four hours post-
transfection, cells were analysed by means of flow cytometry (B and C). Co-expression of mutant HTT and 
α-syn produces similar levels of oligomerization in comparison to the 97Q/97Q control, as indicated by flow 
cytometry measurements of number of fluorescence cells (B) and total average fluorescence (C). Data is 
mean ± SD. *significant versus 19Q/19Q, p<0.05. AU, arbitrary units. 
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Figure S15 
Figure S16, related to Figure 25D 
Figure S17 
Figure S18 
Figure S19, related to Figure 30E 
Figure S20 
Figure S21, related to Figure 31 
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Figure S15. Quantification of RNQ1 mRNA levels in Drosophila transgenic lines. Expression 
levels of daGAL4>UAS-RNQ1-1M and daGAL4>UAS-RNQ1-6M lines were compared to white background 
(w1118), driver (daGAL4) and UAS controls, by means of QPCR. Levels of Rnq1 mRNA are increased ~3-4 
fold in RNQ1-1M or RNQ1-6M expressing flies versus UAS controls. Data are represented as mean ± SEM 
of mRNA levels of RNQ1 transgene relative to rpl32 housekeeping gene. N = 30 flies per genotype. 
*significant versus respective UAS control, p<0.05. 
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Figure S16. Rnq1 expressing flies exhibit increased sleep-like behavior during nighttime. Total 
rest was assayed in newly-emerged flies using Trikinetics Drosophila activity monitors. Activity data was 
recorded over 7 days in 12 h light/dark cycles and collected in 5 min time bins. Total sleep like-behavior is 
expressed as the average number of 5 min intervals with 0 activity counts. Flies expressing Rnq1 in the 
motor neurons show an increased number of rest periods throughout the night in comparison to controls. N = 
26 - 32 flies per genotype. Data are mean ± SEM. *significant versus c164GAL4 and UAS controls, p<0.05. 
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Figure S17. Rnq1 expression does not affect longevity or viability of WT background flies. 
Lifespan (A, B) and eclosion ratio (C, D) were evaluated in flies expressing RNQ1-1M or RNQ1-6M 
transgenes via the elav promotor. (A) elavGAL4 (mean = 70 days), UAS RNQ1-1M (mean = 73 days), 
RNQ1-1M (mean = 67.5 days). (B) elavGAL4 (mean = 66 days), UAS RNQ1-6M (mean = 75 days), RNQ1-
1M (mean = 68 days). No differences were observed versus controls. Data are mean ± SEM. 
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Figure S18. Expression of murine prion protein does not induce neurotoxicity in WT 
background flies. (A) Quantification of rhabdomeres per ommatidium in flies expressing wild-type (WT 
PrP) or a mutated version (P101L PrP) of the murine prion over 56 days post-eclosion. Pan-neuronal 
expression of PrP did not induce age-dependent neuronal loss (A) but decreased lifespan in WT background, 
as determined by percentage of surviving flies (B). Mean survival values are: elavGAL4 (mean=69 days), 
WT PrP (mean=57 days), P101L PrP (mean=47 days). (C and D) Percentage of eclosion was calculated by 
the mean ratio between emerging PrP expressing females versus control males hatching out of pupal case. 
Eclosion ratio was not affected in elav-driven PrP expressing flies. All data are mean ± SEM. 
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Figure S19. Rnq1 changes subcellular localization of mutant HTT and alters its aggregation 
in living cells. HT22 cells in (A) and (B) were co-transfected with RNQ1-Venus and 97QHTTex1-Venus 
plasmids. (A) 97QHTTex1 localizes to the nucleus in the presence of Rnq1. (B) Small cytosolic puncta 
formed upon interaction of Rnq1 with 97QHTTex1 are deposited together near the nucleus. Scale bar, 20 
µm. 
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Figure S20. Phenotypic characterization of Drosophila lines carrying RNQ1 transgene in the 
3rd chromosome. Additional UAS-RNQ1 transgenic lines (RNQ1-2M and RNQ1-3M) were analyzed for 
age-dependent neurodegeneration (A) and locomotor defects in both adults (B) and larvae (C, D). RNQ1-2M 
or RNQ1-3M expressing flies produced similar disease-relevant phenotypes exhibited by RNQ1-1M and 
RNQ1-6M lines. All data are mean ± SEM. *significant versus elavGAL4 or c164GAL4, p <0.05. Scale bar, 
10 mm. 
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Figure S21. cn silencing improves disease-related phenotypes in the RNQ1-3M line. (A) 
Average number of rhabdomeres per ommatidium in aging flies. (B) Mean climbing pass rate at different 
post-eclosion ages. All data are mean ± SEM. *significant versus 3M + RNQ1-3M, #significant elavGAL4 
and UAS 3M + RNQ1-3M control, p<0.05. 
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Protein phosphatase 1 regulates huntingtin exon 1
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Abstract
Huntington’s disease is neurodegenerative disorder caused by a polyglutamine expansion in the N-terminal region of the
huntingtin protein (N17). Here, we analysed the relative contribution of each phosphorylatable residue in the N17 region
(T3, S13 and S16) towards huntingtin exon 1 (HTTex1) oligomerization, aggregation and toxicity in human cells and Drosophila
neurons. We used bimolecular fluorescence complementation to show that expression of single phosphomimic mutations
completely abolished HTTex1 aggregation in human cells. In Drosophila, mimicking phosphorylation at T3 decreased HTTex1
aggregation both in larvae and adult flies. Interestingly, pharmacological or genetic inhibition of protein phosphatase 1 (PP1)
prevented HTTex1 aggregation in both human cells and Drosophilawhile increasing neurotoxicity in flies. Our findings
suggest that PP1 modulates HTTex1 aggregation by regulating phosphorylation on T3. In summary, our study suggests that
modulation of HTTex1 single phosphorylation events by PP1 could constitute an efficient and direct molecular target for
therapeutic interventions in Huntington’s disease.
Introduction
Huntington’s disease (HD) is characterized by the loss of me-
dium spiny neurons in the striatum. The main histopathologi-
cal hallmark of HD is the misfolding and subsequent
intracellular aggregation of a mutant form of huntingtin (HTT)
(1). HTT is a very large protein ("350kDa), but expression of
exon 1 is sufficient to produce HD-like features in various cellu-
lar and animal models (2–4). HTT exon 1 (HTTex1) contains a
polyglutamine (polyQ) tract that, in normal conditions, is con-
stituted by 6–35 glutamine residues. An expansion of the polyQ
tract beyond 35 glutamines induces the misfolding and
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aggregation of mutant HTT and causes HD (5,6). Mutant HTT
with longer polyQ expansions is more prone to aggregate, and
leads to earlier onset of the disease (2,7,8).
The polyQ tract is preceded by an N-terminal sequence of
17 amino acids (N17 domain) that is highly conserved, suggest-
ing that this domain plays an important role in the function of
HTT (9–15). The N17 domain plays a key role in the aggregation
pathway of HTT, where the protein associates first into alpha-
helical oligomers and acts as a seed to concentrate and facilitate
the formation of larger aggregates and fibrils (16–20). Deletion or
posttranslational modifications such as phosphorylation, ubiq-
uitination and SUMOylation in the N17 produce striking effects
in the stability and aggregation of HTT, as well as in cell viability
(21–34). The N17 domain has three phosphorylatable amino
acid residues—threonine at position 3 (T3), and serine residues
at positions 13 and 16 (S13 and S16). Constitutive phosphoryla-
tion of T3 enhances mutant HTT aggregation, but its role in HTT
toxicity remains unclear (29). Previous studies have focused on
double S13/S16 phosphorylation (30,31,35–38), despite the fact
that double S13/S16 phosphorylation is less frequent than single
T3 or S13 phosphorylation (39,40), and that overexpression of
particular kinases is required in order to achieve double S13/S16
phosphorylation (30).
Single phosphorylation and phosphomimetic modifications
in S13 or S16 modulates the formation of HTT fibrils and redu-
ces the oligomerization rate in cell-free systems, just as the
double S13/S16 phosphorylation does, both in vitro and in vivo
(26,28,30,31). Casein kinase 2 (CK2) inhibitors reduce S13/S16
phosphorylation and enhance toxicity (37), while GM1 ganglio-
side induces S13/S16 phosphorylation and restores motor and
molecular deficits in HD mice (36). IKK, a kinase involved in in-
flammatory responses, also regulates T3 and S13/S16 phosphor-
ylation and modulates HTT aggregation (30,37,39,41). While
several protein phosphatases control HTT dephosphorylation
beyond exon 1 and modulate its toxicity (42–46), it is not known
which protein phosphatases, if any, regulate phosphorylation of
the N17 domain.
Here, we elucidate the contribution of single N17 phosphoryla-
tion events towards HTTex1 oligomerization, aggregation and tox-
icity. We screened a collection of protein phosphatase chemical
inhibitors to identify modulators of HTTex1 oligomerization and
aggregation in human cells. Inhibition of PP1 prevents HTTex1 ag-
gregation but not oligomerization in human cells. In addition,
downregulation of PP1 in Drosophila neurons reduces HTTex1 ag-
gregation and increases its toxicity. In total, our findings point to a
critical role of T3 phosphorylation in HTTex1 aggregation and sup-
port the targeting of PP1 for therapeutic interventions in HD.
Results
Single N17 phosphomutants modulate HTTex1
aggregation in human cells
In order to investigate the contribution of each phosphorylat-
able residue within the N17 region (T3, S13 and S16) towards
HTTex1 aggregation, we used the bimolecular complementation
assay (BiFC) system for the visualization of both oligomeric spe-
cies and inclusion bodies of HTTex1 in living cells, which we
have previously described (47–49). In this system, wild-type
(19Q) or disease-causing (97Q) HTTex1 are fused to non-
fluorescent halves of the Venus fluorescent protein (Fig. 1A).
Thus, upon dimerization of HTTex1 fragments, the Venus
halves are brought together and reconstitute the functional flu-
orophore. Therefore, fluorescence is proportional to the extent
of HTTex1 dimerization/oligomerization. We introduced point
mutations in each of the phosphorylatable residues within the
N17, changing these amino acids to either alanine (A mutants,
which cannot be phosphorylated—phosphoresistant) or to as-
partic acid (D mutants, which mimic the phosphorylated
state—phosphomimic). Importantly, these phosphomutants be-
have like phosphorylated peptides in terms of their aggregation
in cell-free systems and primary neuronal cultures (26,28).
We had previously shown that 97QHTTex1-Venus BiFC pairs
oligomerize and aggregate more readily than wild-type
19QHTTex1-Venus BiFC pairs (49). Strikingly, all single phospho-
mimic mutations of 97QHTTex1-Venus BiFC constructs (T3D,
S13D, S16D) completely abolished the formation of inclusion
bodies in human cells (Fig. 1B and C) while the phosphoresist-
ant mutants (T3A, S13A, S16A) behaved similarly to non-
mutated 97QHTTex1-Venus BiFC pairs (Fig. 1B and C and
Supplementary Material, Fig. S1). These phenotypes were fur-
ther confirmed by filter trap assays, where non-mutated
97QHTTex1 and phosphoresistant pairs appear as large SDS-
insoluble aggregates, as opposed to wild-type 19QHTTex1 and
phosphomimic pairs [Fig. 1D, filter trap (FT)]. No differences in
oligomerization/fluorescence levels were observed between the
phosphomutants, and non-mutated 97QHTTex1, as determined
by flow cytometry (Supplementary Material, Fig. S2). Native-
PAGE analyses confirmed that all phosphomutants formed olig-
omeric species (Fig. 1D). These results are consistent with a re-
cent report where expanded HTTex1 was shown to exist as
tetramers but not monomers (50).
Owing to its dynamic nature, phosphorylation usually af-
fects only a fraction of the total pool of any given protein. Thus,
we hypothesized that subpopulations or pools of 97QHTTex1
with different extents of phosphorylation may co-exist in cells.
In order to determine whether 97QHTTex1 fragments with dif-
ferent phosphorylation status interacted in living cells, we took
advantage of the unique features of our BiFC system to screen
all possible pairwise combinations of phosphomutants and
non-mutated 97QHTTex1 control (Table 1). Combinations of
phosphomimic with non-mutated 97QHTTex1 oligomerized to
the same extent as the non-mutated 97QHTTex1 pair, as deter-
mined by flow cytometry (Supplementary Material, Fig. S3).
However, phosphomimic pairs did not form inclusions, inde-
pendently of the mutated residue (Table 1). Combinations of
phosphomimics with non-mutated 97QHTTex1 (Table 1 and
Fig. 2A and B) or phosphoresistant mutants (Table 1) resulted in
intermediate aggregation phenotypes, depending on which resi-
due was mutated. Combinations including T3D, S13D or S16D
resulted in 0%, 14.1–22.0% or 19.8–29.1% of cells with inclusions,
respectively (Table 1), which is significantly less than the per-
centage of cells with inclusions observed with the non-mutated
97QHTTex1 pair (36.1%). In contrast, phosphoresistant pairs
generally resulted in an increased percentage of cells displaying
inclusions (43.5–48.5% cells with inclusions), with the exception
of the S13A/S16A combination (35.3%) (Table 1).
Importantly, the effect of phosphomimic mutants on
97QHTTex1 aggregation appears to be protein-specific (Fig. 2).
We and others have recently shown that HTTex1 co-aggregates
with alpha-synuclein (a-syn) and Tau, and that these interac-
tions change the aggregation profile of HTTex1 (47,48,51,52).
Combinations of phosphomimic 97QHTTex1 with a-syn BiFC
constructs resulted in a residue-dependent reduction in the per-
centage of cells with inclusions, with the T3D/Syn showing no
inclusions (Fig. 2A and C). On the other hand, combinations of
Tau-Venus plasmids showed the same aggregation pattern in-
dependently of the mutated residue (Fig. 2A and D). These
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observations further support that single N17 phosphomutants
modulate HTTex1 aggregation, and that the T3D is the most re-
strictive modification in preventing HTTex1 aggregation.
Increased dynamics of 97QHTTex1 inclusions
containing S13 or S16 phosphomimic mutants
We next analysed the dynamics of 97QHTTex1 inclusions using
fluorescence recovery after photobleaching (FRAP). We observed
a faster fluorescence recovery in inclusions formed by pairs con-
taining phosphomimic mutants (S13D or S16D) and non-mutated
97QHTTex1 in comparison to inclusions formed exclusively by
non-mutated 97QHTTex1 (Fig. 3A and B; Supplementary Material,
Videos S1–S3). The phosphoresistant (T3A or S13A)/97QHTTex1
pairs, but not the S16A/97QHTTex1, presented slower fluorescence
recovery in inclusions (Fig. 3C). Phosphomimic-containing inclu-
sions often had less defined boundaries, appearing rather continu-
ous with the cytosolic fluorescence, consistent with areas of more
dynamic exchange of HTT protein. Inclusions formed by the S13D/
97QHTTex1 combination (Fig. 3D and Supplementary Material,
Video S4) showed a fluid-like behaviour as opposed to the more
rigid behaviour of the inclusions formed by combinations contain-
ing phosphoresistant mutants (Supplementary Material, Video S5)
or non-mutated 97QHTTex1 BiFC pairs (Supplementary Material,
Video S6).
Overall, the results suggest that single phosphorylation
events within N17 domain prevent HTTex1 aggregation but not
its oligomerization, and that phosphorylation at the T3 residue
might play a critical role in modulating HTTex1 aggregation. In
addition, our observations support the idea that inclusions
might be composed of non-phosphorylated HTT or mixtures of
non-phosphorylated and phosphorylated pools of molecules,
consistent with data indicating that disease-causing HTT is
hypophosphorylated in the N17 region (29,37).
Protein phosphatases regulate HTTex1 aggregation in
human cells
The results above indicate that single N17 phosphorylation can
modulate HTTex1 aggregation, which is consistent with the idea
that N17 phosphorylation might be enhanced by the activation of
kinases (30,37,39) or, alternatively, by the inhibition of phospha-
tases. In order to identify protein phosphatases that might medi-
ate HTTex1 dephosphorylation, we screened a library of 33
phosphatase chemical inhibitors for their effect on HTTex1 aggre-
gation and oligomerization, using our 97QHTTex1-Venus BiFC
Figure 1. Single N17 phosphomimic mutations modulate 97QHTTex1 aggregation but not oligomerization in human H4 glioma cells. (A) HTTex1 (grey bars) was fused
to two non-fluorescent halves of the Venus protein. When HTTex1 dimerizes, Venus recovers fluorescence. The three N17 phosphorylatable residues were mutated to
mimic phosphorylation or dephosphorylation. (B) Cells transfected with phosphoresistant BiFC pairs resemble the non-mutated 97QHTTex1 phenotype in terms of ag-
gregation, while phosphomimic pairs showed a total absence of aggregates. (C) Quantitative analyses of microscopy pictures. *Significant versus 97Q/97Q, P<0.05.
(D) Filter trap assays (FT) were consistent with microscopy results. Phosphomimic pairs did not produce insoluble aggregates (FT), but showed similar levels of oligo-
meric species (Native-PAGE) comparing to non-mutated 97QHTTex1. Expression levels of each pair were evaluated by SDS-PAGE. Scale bar, 20 mm.
3765Human Molecular Genetics, 2017, Vol. 26, No. 19 |
Downloaded from https://academic.oup.com/hmg/article-abstract/26/19/3763/3932276
by Leicester University Library user
on 21 November 2017
Table 1. Percentage of cells containing HTT inclusions (average6SEM) when co-transfected with different combinations of HTTex1-, a-syn- or
Tau-Venus BiFC plasmids
Venus 2
T3D S13D S16D T3A S13A S16A 97Q a-syn Tau
Venus 1 T3D 0 0 0 0 0 0 0 0 15.562.2
S13D 0 0 22.063.4 17.162.3 14.561.2 14.161.3 5.661.7 15.762.2
S16D 0 27.561.5 29.163.6 19.863.0 22.961.0 10.064.8 16.561.7
T3A 46.461.3 43.563.6 45.962.5 34.562.2 N/D N/D
S13A 48.561.3 35.362.4 37.861.9 N/D N/D
S16A 48.262.6 36.666.1 N/D N/D
97Q 36.162.2 39.363.9 16.261.3
N/D, not determined.
Figure 2. Effect of phosphomimic mutants on 97QHTTex1 aggregation is protein-specific. (A) Combinations of 97QHTTex1-Venus 1 BiFC constructs with synuclein- or
tau-Venus 2 BiFC constructs revealed different co-aggregation responses to phosphomimic constructs. 97QHTTex1 (B) and synuclein (C) showed similar patterns of ag-
gregation in the presence of single phosphomimic mutations, with T3D being the most restrictive for decreasing aggregation. (D) Tau co-aggregated with 97QHTTex1
regardless of the N17 mutation. *Significant versus 97Q/97Q (B) or 97Q/Syn (C), P<0.05. Scale bar, 20 mm.
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system (Fig. 4 and Supplementary Material, Table S1). We found
that inhibitors of PP1/PP2A, CD45, and Cdc25 prevented
97QHTTex1 aggregation as determined by filter trap assay
(Fig. 4A). These results were confirmed by fluorescence micros-
copy, where we observed that inhibitors for those phosphatases
significantly decreased the percentage of cells with inclusions
(Fig. 4B). Interestingly, the decrease in oligomerization upon treat-
ment with these phosphatase inhibitors was much less dramatic
than the reduction observed in aggregation levels (B01, B02, B07,
B08 and C04). Although a slight reduction in fluorescence/oligo-
merization was observed for 28 out of the 33 inhibitors assayed,
the few exceptions where a striking decrease was observed (C06,
D01 and D03) were owing to cytotoxicity (Supplementary Material,
Table S1). Importantly, cells treated with CD45 inhibitors showed
reduced levels of HTTex1 expression and increased toxicity
(Supplementary Material, Table S1), and were therefore excluded
from the study.
Single N17 phosphomutants modulate HTTex1
aggregation in Drosophila
To further investigate the role of N17 phosphorylation on
HTTex1 aggregation, we expressed single phosphoresistant or
phosphomimic versions of 97QHTTex1 in Drosophila and as-
sessed for the formation of inclusions. We generated flies ex-
pressing different phosphomutant versions of 97QHTTex1
fused to mCherry in adult dopaminergic neurons, under the
control of tyrosine hydroxylase (TH)-GAL4 (Fig. 5, columns 1–3),
or in larval imaginal discs using the eye-specific glass multiple
reporter (GMR)-GAL4 driver (Supplementary Material, Fig. S4).
Both T3A (Fig. 5B) and T3D (Fig. 5E) mutants formed fewer inclu-
sions than non-mutated 97QHTTex1 (Fig. 5A), while S13D
(Fig. 5F) and S16D (Fig. 5G) mutants showed a significantly larger
number of aggregates (quantification in Fig. 5O). S13A (Fig. 5C)
and S16A (Fig. 5D) showed no difference in the number of
Figure 3. Phosphomimic-containing inclusions of 97QHTTex1 are more dynamic. (A) Time lapse of FRAP experiments on aggregates containing non-mutated
97QHTTex1 alone or in combination with phosphomimic mutant in H4 glioma cells. T3D mutants produced no aggregates under any circumstance. (B) Aggregates con-
taining S13D or S16D mutants recovered significantly faster than the non-mutated 97QHTTex1. (C) Aggregates combining non-mutated 97QHTTex1 with T3A or S13A
recovered more slowly than aggregates made only of non-mutated 97QHTTex1, with the exception of the S16A/97Q combination. (D) Time lapse of aggregates formed
by non-mutated 97QHTTex1 and S13D (Supplementary Material, Video S4). Aggregates containing phosphomimic versions are highly dynamic and flexible, and move
(arrow indicates moving aggregate in each frame) through the cell with more freedom than non-mutated 97QHTTex1 aggregates (Supplementary Material, Video S1).
Scale bars, 20 mm.
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inclusions in comparison with non-mutated 97QHTTex1
(Fig. 5O). In the larval eye imaginal discs, all phosphomutants
showed decreased aggregation, with the exception of the S13D
mutant that formed more inclusions than the non-mutated
97QHTTex1 (Supplementary Material, Fig. S4).
These findings indicate that expression of N17 phosphomu-
tants can modulate 97QHTTex1 aggregation in Drosophila, de-
pending on the developmental stage and cellular context.
PP1 regulates HTTex1 aggregation and neurotoxicity
in Drosophila
In order to test if protein phosphatases also regulate HTTex1 ag-
gregation in Drosophila, we performed RNAi knockdown experi-
ments for the homologues of PP1, PP2A and Cdc25 in flies
expressing 97QHTTex1 in dopaminergic neurons (Fig. 5, col-
umns 4–6, and Supplementary Material, Fig. S5). These three
phosphatases caused the stronger decrease in HTTex1 aggrega-
tion in mammalian cells, upon chemical inhibition. PP1 knock-
down flies showed a significant decrease in 97QHTTex1
aggregation (Fig. 5H), while PP2A or string (Cdc25 homologue)
downregulation had no effect on 97QHTTex1 aggregation
(Supplementary Material, Fig. S5A and B). PP1 downregulation
prevented 97QHTTex1 aggregation in the presence of serine-
phosphoresistant mutants (S13A or S16A) (Fig. 5J and K), but not
T3A, where we did not observe any statistically significant
change in the number of aggregates when compared with T3A
in the absence of PP1 RNAi (Fig. 5O). These results indicate that
the effect of PP1 RNAi on 97QHTTex1 aggregation might be
mostly mediated by T3 phosphorylation. On the other hand, PP1
knockdown caused an increased number of aggregates in T3D
background, and a reduction in the number of aggregates in
S13D and S16D backgrounds (Fig. 5O). Since HTTex1 does not
contain any phosphorylatable residue beyond N17 domain, the
increased aggregation observed in the T3D background upon
PP1 inhibition suggests that S13 and/or S16 might also be target
for phosphorylation to modulate 97QHTTex1 aggregation, in
our Drosophilamodel.
We next analysed the effect of PP1, PP2A or string RNAi
knockdown on HTTex1 toxicity in the Drosophila eye photorecep-
tor neurons (Fig. 6 and Supplementary Material, Fig. S5).
Importantly, genetic inhibition of PP1 did not compromise rhab-
domere viability in flies expressing wild-type (19Q) HTTex1 un-
der the control of rhodopsin 1 (Rh1)-GAL4 [Fig. 6A (column 4)
and D]. However, PP1 knockdown significantly enhanced
97QHTTex1 toxicity, further reducing the number of rhabdo-
meres in an age dependent manner [Fig. 6A–C (column 5) and C].
PP2A or string RNAi had no effect in the number of rhabdomeres
upon co-expression with 19QHTTex1 or 97QHTTex1
(Supplementary Material, Fig. S5C and D).
Discussion
Protein misfolding and aggregation are intimately involved in
the pathogenesis of HD and other neurodegenerative disorders.
Despite extensive research in the field, the precise molecular
mechanisms by which misfolded proteins aggregate and form
toxic species remain elusive. Increasing evidence suggests that
targeting phosphorylation events in the N17 domain of mutant
HTT can influence the pathological function of the protein
(28,30,36–38). However, the significance of single N17 phosphor-
ylation events in HTT oligomerization, aggregation and toxicity
is still poorly understood.
Here, we report that single N17 phosphorylation can prevent
HTTex1 aggregation, but not oligomerization. We propose that
each residue has a different ‘strength’ in modulating HTTex1
aggregation. Importantly, we found that protein phosphatase 1
can control HTTex1 aggregation and toxicity, suggesting that
N17 phosphorylation might be mediated by this protein phos-
phatase. The fact that single N17 phosphorylation events are
sufficient to abolish HTTex1 aggregation could be very impor-
tant from an HD therapeutic perspective, since a single N17
Figure 4. Protein phosphatases regulate HTTex1 aggregation in mammalian cells. (A) Representative filter trap of protein extracts from cells transfected with non-mu-
tated 97QHTTex1 BiFC constructs and treated with chemical inhibitors of protein phosphatases. The graph shows oligomerization levels as determined by flow cytom-
etry (black bars) and aggregation levels as determined by optic density of filter trap dots (white bars). The names of phosphatase inhibitors (Enzo Life Sciences) and the
concentrations used are described in Supplementary Material, Table S1. (B) Selected inhibitors PP1/PP2A (B01 and B02) and Cdc25 (C04 and C05) also reduced the per-
centage of H4 cells with large HTTex1 inclusions as determined by quantitative analyses of microscopy pictures. *Significant versus DMSO, P<0.05.
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phosphorylation could provide a simpler molecular target than
double phosphorylation.
We show that single phosphomimic mutation in T3, S13 or
S16 allow 97QHTTex1 to oligomerize but not to form large
inclusions in human cells (Fig. 1 and Supplementary Material,
Fig. S2). Double S13/S16 phosphorylation prevents aggregation
both in vitro and in vivo, and toxicity in vivo (22,26). However,
double S13/S16 phosphorylation is less abundant than single
phosphorylation events (39), and may require the overexpres-
sion of specific kinases (30), which may confound therapeutic
efforts based on this approach. Although some studies reported
on the effect of single S13 or S16 phosphorylation events on
HTTex1 intracellular localization, they did not focus on HTTex1
oligomerization, aggregation or toxicity (28,37). Results from
cell-free systems indicate that single S13- or S16-
phosphorylated HTTex1 behave similarly to double S13/S16-
phosphorylated HTTex1 in terms of aggregation, being unable
to form mature fibrils (26). Our findings in living human cells
provide additional biological support for those in vitro studies.
The unique properties of our BiFC cellular model allowed us
to analyse the relative contribution of each phosphorylatable
residue towards HTTex1 oligomerization and aggregation. We
found that T3D completely abolished 97QHTTex1 aggregation in
the presence of any other phosphomutant or non-mutated
97QHTTex1 molecules, while S13D or S16D only had a partial re-
duction effect (Fig. 2 and Table 1). These results, together with
the higher abundance of T3-phosphorylated pools (39,40), high-
light the relevance of this residue in modulating the aggregation
of HTTex1, and strongly support T3 as a promising target for HD
intervention (29). Our results also suggest that, HTTex1 might
be predominantly unphosphorylated under pathological condi-
tions (29,37), as phosphoresistant combinations behave more
similarly to the non-mutated 97QHTTex1 pair than to the phos-
phomimics, regarding their aggregation pattern (Fig. 1 and
Table 1).
Previous in vitro studies demonstrate that N17 phosphoryla-
tion inhibits b-sheet conformation of mutant HTTex1 and sup-
presses its fibrillization, stabilizing the a-helical structure of the
N17 domain which could led to altered aggregation dynamics
(41,53). In FRAP experiments, we show that combinations of
phosphomimic and non-mutated 97QHTTex1 induced the for-
mation of inclusions that were more dynamic, diffuse and fluid
than regular 97QHTTex1 aggregates, resembling an intermedi-
ate stage between oligomers and mature inclusions (Fig. 3,
Supplementary Material, Videos S1–S4 and S6). Additionally,
non-mutated 97QHTTex1 pairs did not aggregate to the same
extent as the phosphoresistant combinations (Fig. 1C and
Table 1). Thus, we propose a model where unphosphorylated
HTTex1 fragments oligomerize and form inclusions that grow
into mature fibrils until enough phosphorylated HTTex1 mole-
cules are intercalated in the structure to interfere with the pro-
cess, acting as a ‘brake’. This could explain the existence of
aggregates of various sizes and morphologies.
Genetic and pharmacological inhibition of PP1 resulted in
lower 97QHTTex1 aggregation and increased toxicity (Figs 4–6).
Protein phosphatases PP2B/3 (Calcineurin), PP2C and PP1/PP2A
have been also shown to regulate HTT phosphorylation at several
residues beyond exon 1, as well as HTT toxicity (42–46). It is im-
portant to note that HTTex1 does not contain any phosphorylat-
able residue beyond the N17 domain and, therefore, any direct
effect of protein phosphatases should happen on T3, S13 or S16.
Our results indicate that PP1 affects 97QHTTex1 aggregation by
regulating T3 phosphorylation. In Drosophila dopaminergic neu-
rons, PP1 knockdown in serine-phosphomutant backgrounds
leads to a decrease in 97QHTTex1 aggregation, regardless the
phosphorylation-like state of these residues (Fig. 5O). Moreover,
PP1 RNAi does not cause any further reduction of 97QHTTex1 ag-
gregation when co-expressed with T3A mutant. Together, these
data suggest that the effect of PP1 inhibition on HTTex1 aggrega-
tion is primarily mediated by T3 phosphorylation. However, an
Figure 5. PP1 knockdown prevents 97QHTTex1 aggregation in Drosophila.
Confocal microscopy images of dopaminergic neurons in adult Drosophila brains
expressing non-mutated 97QHTTex1-mCherry or the different phosphomutants
(A–G) under the control of TH-GAL4. (H–N) Co-expression of PP1a-96A RNAi to-
gether with 97QHTTex1-mCherry or phosphomutants. 97HTTex1-mCherry is
shown in red (columns 1 and 4), and dopaminergic cells (columns 2 and 5, anti-
TH) are shown in blue. T3A (B) and T3D (E) prevented 97HTTex1-mCherry aggre-
gation, while phosphomimic mutations at S13 or S16 produced a significant in-
crease of 97HTTex1-mCherry inclusion bodies (F and G). PP1a-96A RNAi
decreased the number of 97HTTex1-mCherry inclusions, with the exception of
T3A (I), where no change was observed, and T3D (L) expressing flies, which
showed a significant increase in 97HTTex1-mCherry aggregation, all in compari-
son to the respective no RNAi expressing genotype. (O) Quantification of average
number of aggregates (6SEM) in each brain. *Significant versus TH-
GAL4>97QHTTex1, #Significant versus their ‘no RNAi’ transgenic control (white
bars), †significant versus TH-GAL4>97QHTT/PP1a-96A RNAi, P<0.05. Scale bar,
10 mm.
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increase in 97QHTTex1 aggregation is observed when PP1 RNAi is
co-expressed with T3D mutant (Fig. 5L and O), indicating that S13
and S16 might also be target for PP1 regulation. Since S13D or
S16D increase 97QHTTex1 aggregation (Fig. 5F, G and O), we hy-
pothesize that PP1 modulates S13 or S16 phosphorylation upon
T3 phosphorylation. In fact, it is likely that different N17 muta-
tions may contribute to subsequent phosphorylation events in
other residues. For example, IKK-mediated S16 phosphorylation
is facilitated by previous phosphorylation of S13 (30).
Interestingly, the striking decrease in 97QHTTex1 aggrega-
tion observed when PP1 RNAi was co-expressed with S13D or
S16D mutants versus S13D or S16D alone (no RNAi) (Fig. 5O),
suggests that T3 phosphorylation is dominant over S13 or S16
phosphorylation. Our human cell data also supports this hy-
pothesis, since S13D or S16D BiFC combinations with non-
mutated 97QHTTex1 still shows aggregates, while T3D BiFC
combinations with any other mutant completely abolishes ag-
gregation (Fig. 2 and Table 1).
Figure 6. Downregulation of PP1 potentiates HTTex1 neurotoxicity in adult fly photoreceptor neurons. (A–C) Representative pictures of photoreceptors observed by wa-
ter immersion live imaging of the retinas. Wild-type flies, HD flies and flies expressing PP1a-87B RNAi together with 19QHTTex1 or 97QHTTex1 were analysed at Day 1,
8 and 15 post-eclosion. Wild-type and 19QHTTex1 expressing flies showed normal retinal morphology as the six outer photoreceptors were visible per ommatidium
(columns 1 and 2). Flies expressing 97QHTTex1 exhibited age-dependent neurodegeneration with progressive loss of rhabdomeres from 8 to 15 days after eclosion
(B and C, column 3). PP1a-87B downregulation caused an increase of neurotoxicity in flies expressing 97QHTTex1 (B and C, column 5) and did not affect photoreceptor
integrity of 19QHTTex1 flies (column 4). Visualization of the rhabdomeres was done using Rh1-Gal4>UAS-GFPninaC, as described in Materials and Methods.
(D) Quantification of mean rhabdomeres (6SEM) per ommatidium. *Significant versus 97Q, #Significant versus 97Q at days 1 and 8, P< 0.05. Scale bar, 10 mm.
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HTT N17 phosphorylation modulates neurotoxicity in sev-
eral HD models by preventing HTT aggregation (31). However,
this finding remains controversial (29,30,37). Currently, there is
still debate on whether large, insoluble aggregates are the cause
of neuropathology or a byproduct of accumulated misfolded
HTT. Though these aggregates were originally thought to be
neurotoxic, accumulating evidence suggests that the formation
of large aggregates might be part of a protective cellular mecha-
nism to sequester soluble toxic species (54–57). Our data here
suggest that N17 phosphorylation modulation of HTTex1 neuro-
toxicity and the appearance of large aggregates are not neces-
sarily related. Interestingly, polyQ-dependent toxicity varies
widely depending on the cellular environment and cell-type
specificity, indicating that additional factors may contribute to
HTTex1 toxicity (58). Moreover, studies on other post-
translational modifications in the N17 region reveal a complex
cross-talk among these different modifications in modulating
aggregation, and suggest that neurotoxicity may be owing to
different mechanisms dependent upon the modifier site (30,33).
Altered PP1 activity has been linked to a variety of diseases,
including several neurodegenerative disorders, such as
Parkinson’s and Alzheimer’s diseases (59–61). In fact, PP1 is nor-
mally highly expressed in the brain, and is particularly abun-
dant in medium spiny neurons, known to be significantly
affected in HD (62). Based on these findings, it is possible that
PP1 malfunction increases the susceptibility of certain types of
neurons to mutant HTTex1-induced degeneration. Not surpris-
ingly, inhibition of PP1 resulted in increased age-dependent
neuronal loss in our Drosophila HD model, suggesting that PP1
activity imbalance might precede HTTex1 neurotoxicity.
Despite considerable efforts to develop specific chemical activa-
tors of PP1 (63,64), further investigations will be necessary to
clarify the relationship between PP1 activity impairment, aggre-
gation and neurotoxicity in the context of HD and other polyQ
misfolding disorders.
In summary, our results support a strong role for single N17
phosphorylation events on HTTex1 aggregation, dynamics and
toxicity, and uncover the regulatory role of PP1 in these events.
Ultimately, our study opens novel avenues for the therapeutic
targeting of PP1 and N17 phosphorylation in HD.
Materials and Methods
Cell culture, plasmids and treatments
Human H4 glioma cells (ATCC HTB-148, LGC Standards,
Barcelona, Spain) were maintained in OPTI-MEM I culture me-
dium (Gibco, Invitrogen, Barcelona, Spain) supplemented with
10% (v/v) fetal bovine serum and 1% (w/v) of a penicillin/strepto-
mycin commercial antibiotic mixture (Gibco), under controlled
conditions of temperature and humidity (37 !C, 5% CO2).
Different types of cell culture dishes were used for cell seeding
depending on the application. For flow cytometry and toxicity
assays, cells were grown on 6-well plates (35mm diameter,
Techno Plastic Cultures AG, Switzerland). For microscopy, cells
were seeded on glass-bottom 35mm dishes (10mm glass surface
diameter, MatTek Corporation, Ashland, MA, USA). And, for pro-
tein extraction (PAGE and filter trap assays), cells were seeded on
100mm dishes (Techno Plastic Cultures AG, Switzerland). For all
experiments, cells were counted and seeded at a density of
10000cells/cm2 regardless dish size. Generation of HTTex1- and
tau-Venus BiFC constructs was described in detail elsewhere
(47,49). Alpha-synuclein-Venus BiFC plasmids were a kind gift
from Pamela J. McLean (Department of Neurology, Alzheimer’s
Disease Research Unit, Massachusetts General Hospital, MA,
USA). Phosphomimic (T3, S13 or S16 mutated to aspartic acid)
and phosphoresistant (T3, S13 or S16 mutated to alanine) con-
structs were produced by PCR-based site-directed mutagenesis
using 97QHTTex1-Venus plasmids as templates. Plasmid trans-
fection was performed by means of the X-tremeGene 9 reagent
(Roche diagnostics, Mannheim, Germany), following manufac-
turer’s instructions. Twenty-four hours after transfection, cells
were collected and analysed for oligomerization, aggregation
and toxicity as described below. Pharmacological inhibition of
protein phosphatases was performed using a phosphatase in-
hibitor library (Enzo Life Sciences, Lausen, Switzerland). Briefly,
cells were treated with 33 different phosphatase inhibitors upon
transfection of 97QHTTex1 BiFC constructs. Phosphatase inhibi-
tors were dissolved in DMSO and added to culture medium at
variable concentrations, according to the IC50 described in man-
ufacturer’s instructions (Supplementary Material, Table S1).
Flow cytometry
Cells were washed with Ca2þ and Mg2þ free phosphate buffer
saline (PBS) (Gibco) and collected by trypsinization (0.05% w/v
trypsin, 5min, 37 !C) into BD Falcon Round-Bottom tubes (BD
Biosciences, San Jose, CA, USA). Cell pellet was resuspended in
PBS and analysed by means of a LSR Fortessa flow cytometer
(Beckton Dickinson, Franklin Lakes, NJ, USA). Ten thousand
cells were examined per experimental group. The FlowJo soft-
ware (Tree Star, Inc., Ashland, OR, USA) was used for data analy-
ses and representation.
Fluorescence microscopy and FRAP experiments
Images of living H4 cells were acquired using an Axiovert 200M
widefield fluorescence microscope equipped with a CCD camera
(Carl Zeiss MicroImaging GmbH, Germany). Pictures of a total of
100–150 cells per sample were scored for aggregate quantifica-
tion using the ImageJ free software (http://rsbweb.nih.gov/ij/).
FRAP experiments were performed using a META LSM 510 con-
focal microscope. Briefly, protein aggregates were focused at the
central focal plane and adjusted to avoid pixel saturation.
Experiments lasted for 70–150 s, taking one picture every sec-
ond. After establishing the basal signal, aggregates were
bleached using the 488nm laser line at 100% laser transmission
on a circular region of interest with a diameter of 30 pixels
(1.31 mm radius) for 5 s (10 iterations). Fluorescence recovery
was then monitored for 60–140 s with LSM software. Images
were analysed and prepared for publication by means of the
ImageJ free software.
Immunoblotting
Proteins were extracted in native or denaturing conditions accord-
ing to the requirements of each technique. Briefly, cells were
washed with PBS 1# and collected by scraping. Cells were incu-
bated with lysis buffer and sonicated for 10s at 5mA using a
Soniprep 150 sonicator (Albra, Milano, Italy). For denaturalizing
conditions, the lysis buffer was 1% Triton X-100, 150mM NaCl,
50mM Tris pH 7.4, supplemented with a protease inhibitor cock-
tail (Roche diagnostics). For native conditions, the lysis buffer was
173mM NaCl, 50mM Tris pH 7.4, 5mM EDTA, also supplemented
with protease inhibitor cocktail. Proteins were collected after cell
lysate centrifugation at 10000g for 10min at 4 !C and quantified
by means of the BCA Protein Assay Reagent Kit (Thermo Fisher
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Scientific, Inc., Rockford, IL, USA), following manufacturer’s in-
structions. For SDS- or Native-PAGE immunoblotting, 15lg of total
protein extracts were prepared and separated by electrophoresis
using a 12% SDS-polyacrylamide gel or a 5% SDS-free-
polyacrylamide gel, respectively. For denaturing conditions, sam-
ples were boiled in standard loading buffer (200mM Tris–HCl pH
6.8, 8% SDS, 40% glycerol, 6.3% b-mercaptoethanol, 0.4% bromo-
phenol blue) for 5min at 95 !C. For native conditions, extracts
were mixed with SDS- and mercaptoethanol free loading buffer
(200mM Tris–HCl pH 6.8; 40% glycerol; 0.4% bromophenol blue)
and the boiling step was omitted. Proteins were transferred onto
PVDF membranes and blocked with 5% (w/v) non-fat dry milk in
Tris–HCl buffer saline-Tween solution (TBS-T) (150mM NaCl,
50mM Tris pH 7.4, 0.5% Tween-20) for 1h at room temperature.
Membranes were incubated with primary antibodies against HTT
(1:500, Millipore, Billerica, MA, USA) and GAPDH (1:30000, Ambion,
Austin, TX, USA) as specified. A secondary mouse IgG Horseradish
Peroxidase-linked antibody (1:10000, GE Healthcare Life Sciences,
Uppsala, Sweden) was used for 1h incubation at room tempera-
ture. Immunoblots were developed with enhanced chemilumines-
cence reagents (Millipore) and exposed to X-ray films.
Filter trap assays
Cells were pelleted by centrifugation at 700 g for 10min and cell
lysates collected in native conditions as described above. One
hundred micrograms of native protein extracts were mixed
with SDS to a final concentration of 0.4% (w/v). Samples were
loaded on a dot-blotting device and filtered by vacuum through
cellulose acetate membranes (0.22 lm pore; GE Water & Process
Technologies, Fairfield, CT, USA), previously incubated with 1%
(w/v) SDS solution in PBS. After filtration, membranes were
washed two times and processed for immublotting detection of
HTT, as described above. In these conditions, only large SDS-
insoluble aggregates are retained in the filter and therefore HTT
signal is proportional to the presence of large insoluble species.
Analyses and quantification of blots signal were performed us-
ing ImageJ software. HTTex1 aggregation levels (Fig. 4) were cal-
culated by densitometry analyses and normalized to total HTT
expression levels and GAPDH loading control.
Drosophila stocks, genetics and crosses
Flies were maintained at 25 !C and raised on standard cornmeal
medium in a light/dark cycle of 12h. We generated eight con-
structs encoding for different versions of HTTex1 fused to
mCherry: a wild-type version with a polyQ tail containing 19 gluta-
mines, a mutant version with 97 glutamines, and 6 constructs
encoding phosphomutant versions (T3A/D, S13A/D and S16A/D)
with 97 glutamines. To establish transgenic UAS-HTTex1-
mCherry lines, our constructs were cloned into pWalium10-roe by
the Gateway cloning technology (Thermo Fisher Scientific), and
then injected into y1w1118 embryos using phiC31 integrase-
mediated DNA recombination (BestGene strain #9723, attP landing
site at 2L-28E7). For genetic knockdown experiments in Drosophila,
we employed UAS-RNAi-targeted lines of four phosphatases: string
(homolog of cdc25 phosphatase, BL34831, HMS00146), PP1a-96A
(alpha-1 isoform of PP1 catalytic subunit, BL42641, HMS02477),
PP1a-87B (alpha-2 isoform of PP1 catalytic subunit, BL32414,
HMS00409), and PP2A-29B (PP2A regulatory subunit, BL43283,
HMS01921). RNAi stocks were obtained from the TRiP (Transgenic
RNAi Project) library (65,66), courtesy of the Bloomington
Drosophila Stock Center (Indiana University, Bloomington, IN,
USA). Three different driver lines were used: TH-GAL4 (active in
dopaminergic neurons, under the control of the TH promotor),
GMR-GAL4 (active in the eye) and Rh1-GAL4 (active in the photore-
ceptors R1-R6, under the control of Rh1 promotor). To analyse the
effect of RNAi downregulation of specific phosphatases upon
HTTex1 aggregation and toxicity, UAS-97QHTTmCherry/
CyO;THGAL4/TM6B was crossed with UAS-RNAi-targeted lines.
Adult flies carrying UAS-97QHTTmCherry/þ;TH-GAL4/UAS-
stringRNAi, UAS-97QHTTmCherry/þ;TH-GAL4/UAS-PP1a-87BRNAi,
UAS-97QHTTmCherry/UAS-PP1a-96A;TH-GAL4/þand UAS-97QHT
TmCherry/þ;TH-GAL4/UAS-PP2A-29BRNAi were selected and ana-
lysed. Unless specified otherwise, flies carrying UAS-lacZ targeted
to the same location were used as controls. For deep pseudopupil
(DPP) analysis, Rh1-GAL4;UAS-green fluorescent proteinninaC
(GFPninaC)/UAS-19QHTTmCherry;UAS-PP1-87BRNAi/þand Rh1-GA
L4;UAS-GFPninaC/UAS-97QHTTmCherry;UAS-PP1-87BRNAi/þadult
flies were selected and analysed. Rh1-GAL4;UAS-GFPninaC, Rh1-GA
L4;UAS-GFPninaC/UAS-19QHTTmCherry;UAS-GFP and Rh1-GAL4;
UAS-GFPninaC/UAS-97QHTTmCherry;UAS-GFP were used as
controls.
Immunohistochemistry and confocal microscopy
For confocal imaging of adult brains, 10-day-old flies were dis-
sected and brains prepared as previously described (51). Briefly,
adult flies were anesthetized with CO2 and brains isolated in PBS
1# from the head cuticles before being fixed in 4%
paraformaldehyde-containing PBS. Dopaminergic neurons were
stained by incubation for 48h at 4 !C with mouse anti-TH anti-
body (1:100, Immunostar, Hudson, WI, USA) in PBST (1# PBS,
0.3% Triton X-100) containing 5% (v/v) normal goat serum.
Samples were washed three times for 15min in PBST. Mouse
anti-Cy5 (1:200, Jackson ImmunoResearch, West Grove, PA, USA)
was diluted in PBST-containing 5% (v/v) normal goat serum and
used as secondary antibody by incubation for 24h at 4 !C. For
larva immunohistochemistry, eye imaginal discs of third instar
larvae were dissected in PBS 1# and fixed for 1h in 4% parafor-
maldehyde as described (67). Samples were then washed three
times for 15min in PBST and incubated overnight at 4 !C with rat
anti-Elav antibody (1:100, Developmental Studies Hybridoma
Bank, University of Iowa, USA). Imaginal discs were washed
three times for 15min in PBST and incubated for 2h with rat
anti-Cy5 secondary antibody (1:200, Jackson ImmunoResearch).
Finally, all samples were submitted to a last step of washing and
mounted in 80% glycerol PBS solution, followed by confocal mi-
croscopy analyses. Z-stack images were acquired using a LSM
710 Meta Zeiss confocal microscope (resolution of 1024# 1024,
slice thickness of 1 mm, frame average of 2). Z-projections were
generated and merged using ImageJ free software and images
were prepared on Adobe Photoshop CS6 (Adobe Systems
Incorporated, San Jose, CA, USA). For quantification of aggre-
gates, mCherry Z-stack images were analysed by means of the
Fiji software (68) and aggregation was measured using 3D
Objects Counter plugin (69). The minimum threshold value was
defined as 0.144 mm3 to exclude signal from soluble HTT in the
count. Volume (mm3) occupied per each aggregate, average num-
ber of aggregates and standard error were calculated for at least
five imaginal discs or adult brains per genotype.
Live imaging of adult Drosophila eye
DPP analysis was performed in living animals as previously de-
scribed (51,70). Briefly, flies at age of 1, 8 or 15 days were
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anaesthetized with CO2 and then placed on a 50-mm petri dish,
previously poured with 2% (w/v) agarose at 40 !C. Once the aga-
rose was solidified, the anesthetized flies were covered with
cool water to keep anaesthetic conditions. Adult compound eye
integrity of at least five flies per genotype was examined by fluo-
rescence microscopy with a water immersion objective (HC APO
L40X/0.80W U-V-I, Leica Microsystems, Wetzlar, Germany).
Images were obtained using a Leica DM5500 B microscope (Leica
Microsystems) and an Andor Luca R DL-604M camera (Andor
Technology Ltd., Belfast, UK). Images were analysed using
Image J free software and number of fluorescing rhabdomeres
was scored for>15 ommatidia per fly.
Statistical analyses
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) or
Sigmaplot software (Systat Software, Inc., San Jose, CA, USA)
were used to perform the statistical analysis and graphical rep-
resentation of data. In vitro results are shown as the aver-
age6 standard deviation (SD) of at least three independent
experiments and Drosophila results as the average6 standard
error (SEM), unless specified otherwise. Cell culture data were
analysed by means of a one-way ANOVA followed by a post hoc
Tukey test for average comparison. Aggregates quantification in
Drosophila was analysed by means of a one-way ANOVA with
Newman–Keuls post hoc test. DPP assays were analysed by
means of a two-way ANOVA followed by a Bonferroni post hoc
test. Results were in all cases considered significant only when
P< 0.05.
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Glycation potentiates 
neurodegeneration in models  
of Huntington’s disease
Hugo Vicente Miranda1,2, Marcos António Gomes2, Joana Branco-Santos3,4, Carlo Breda3, 
Diana F. Lázaro5, Luísa Vaqueiro Lopes2, Federico Herrera4, Flaviano Giorgini3 & 
Tiago Fleming Outeiro1,5,6
Protein glycation is an age-dependent posttranslational modification associated with several 
neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. By modifying amino-
groups, glycation interferes with folding of proteins, increasing their aggregation potential. Here, we 
studied the effect of pharmacological and genetic manipulation of glycation on huntingtin (HTT), the 
causative protein in Huntington’s disease (HD). We observed that glycation increased the aggregation 
of mutant HTT exon 1 fragments associated with HD (HTT72Q and HTT103Q) in yeast and mammalian 
cell models. We found that glycation impairs HTT clearance thereby promoting its intracellular 
accumulation and aggregation. Interestingly, under these conditions autophagy increased and the 
levels of mutant HTT released to the culture medium decreased. Furthermore, increased glycation 
enhanced HTT toxicity in human cells and neurodegeneration in fruit flies, impairing eclosion and 
decreasing life span. Overall, our study provides evidence that glycation modulates HTT exon-1 
aggregation and toxicity, and suggests it may constitute a novel target for therapeutic intervention  
in HD.
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder affecting 5–10 per 100 000 
individuals1–3. Its clinical features include progressive motor dysfunction, cognitive impairment, and psychiatric 
disturbance and dementia4. HD is caused by a CAG triplet repeat expansion in exon 1 of the HTT gene, which 
encodes a polyglutamine (polyQ) stretch in huntingtin (HTT) protein. The number of CAG repeats varies from 
16 to 35 in healthy individuals, while expansions of > 35 CAG repeats are found in HD patients1. The length of the 
polyQ tract in the protein modulates HTT aggregation, thereby causing cytotoxicity by mechanisms that are still 
not fully understood, with medium spiny neurons in the striatum particularly affected5.
Glucose is the major energy supply of neurons and is essential for their survival. However, impaired glucose 
metabolism can also damage neurons and lead to neurodegeneration. For example, diabetic patients who neglect 
their circulating glucose levels frequently develop severe neuropathy that results in the amputation of limbs6,7. 
Glucose metabolism drives the formation of by-products that are highly reactive with free amino-groups of pro-
teins. This non-enzymatic reaction, named glycation, induces the formation of advanced glycation end-products 
(AGEs) that frequently have deleterious effects on proteins8,9. For example, glycation has been reported in several 
neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, where it potentiates the aggregation 
and toxicity of proteins such as amyloid-β (Aβ ) and α -synuclein, respectively8,9.
Methylglyoxal (MGO) is an unavoidable by-product of glycolysis and the most reactive glycation agent. It is 
mainly produced by the non-enzymatic decomposition of the phosphate group of the triose phosphates (glycer-
aldeyde 3-phosphate and dihydroxyacetone phosphate)8. MGO can also arise from the interconversion between 
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glyceraldeyde 3-phosphate and dihydroxyacetone phosphate by the triose phosphate isomerase (Tpi), where the 
enediolate intermediate may leak from the active site of Tpi in a paracatalytical reaction10. Moreover, decreased 
Tpi activity results in an accumulation of dihydroxyacetone phosphate and MGO11,12. MGO is detoxified by the 
glyoxalase system [glyoxalases I (Glo1) and II (Glo2)] and by aldose reductases13. In particular, we previously 
showed that Glo1 inactivation induces a strong increase in MGO levels in yeast14. TPI1 deficiency increases 
the levels of DHAP15 and, consequently, increases the levels of MGO16,17. Notably, TPI deficiency in humans 
results in increased levels of MGO18. We recently demonstrated that glycation of α -synuclein - a central player 
in Parkinson’s disease - potentiates its aggregation and toxicity (submitted manuscript). Thus, we hypothesized 
that glycation might act as a common cellular mechanism modulating pathogenesis in several neurodegenerative 
diseases. Although HD is a genetic disorder, both genetic and environmental factors have been found to modulate 
the age of disease onset and severity of HD19–22. Although no direct correlation between glycation and the patho-
genesis of HD has been established thus far, the levels of the receptors for AGEs (RAGE) are increased in HD 
brains23 and in mouse models24. In addition, we also found that DJ-1 - an enzyme with glyoxalase and deglycase 
activity - modulates HTT toxicity25. Here, we show that glycation potentiates HTT aggregation, impairs protein 
clearance and increases neuronal loss in various established models of HD.
Results
Glycation induces HTT aggregation in yeast cells. We started by investigating the effects of MGO in a 
highly tractable yeast model of HD based on the expression of GFP-tagged HTT exon 1 fragments26 with normal 
(HTT25Q) or expanded (HTT72Q and HTT103Q) polyQ stretches, which lead to HTT aggregation and toxic-
ity27,28. Interestingly, we observed that glycating conditions (using MGO as the glycating agent) potentiated the 
formation of HTT72Q and HTT103Q inclusions in a dose-dependent manner, an effect that was potentiated by 
genetic deletion of Tpi (Fig. 1a,b).
We also modulated MGO levels genetically using Glo1 (∆ glo1) or Tpi (∆ tpi) knockout strains. Deletion of 
these genes increases the intracellular levels of MGO and promotes the accumulation of AGEs14,16,17. Remarkably, 
in protein extracts from ∆ glo1 and ∆ tpi strains, HTT was retained in the wells of SDS-PAGE gels (Fig. 1c), 
further demonstrating that glycation promotes aggregation of mutant HTT. HTT aggregation is also a func-
tion of HTT intracellular concentration, as overexpression of normal 25QHTT can also lead to aggregation29. 
Consistently, MGO also increased the intracellular HTT levels in a dose-dependent manner (Fig. 1c,d).
MGO increases HTT levels, aggregation, and toxicity in human cells. To further investigate the 
effects of glycation on HTT, we used transfected human H4 cells with variants of GFP-tagged HTT exon 1 frag-
ments encoding for 25 (HTT25Q) or 104 (HTT104Q) glutamines. To increase protein glycation, cells were treated 
with 0.5 mM of MGO, a working concentration widely used in various studies30–32. We found that this treatment 
increased protein glycation without increasing overall cytotoxicity (submitted manuscript). We confirmed that 
MGO treatment increased overall glycation levels of cells expressing either HTT25Q or HTT104Q (Fig. 2a). 
Moreover, using immunoprecipitation, we detected a consistent increase in the levels of AGEs in both HTT25Q 
and HTT104Q (Fig. 2a). Treatment with MGO induced a significant increase in the percentage of cells displaying 
HTT inclusions (1.33 fold) (Fig. 2b,c) and SDS-insoluble aggregates (1.5 fold), as assessed by filter trap assays 
(Fig. 2d,e). The levels of both HTT25Q and HTT104Q increased significantly under glycating conditions (1.33 
and 1.95 fold, respectively) (Fig. 2f,g). Notably, treatment of cells with MGO also specifically increased HTT104Q 
toxicity (1.5 fold) (Fig. 2h) and decreased cell viability of both HTT25Q and HTT104Q expressing cells (Fig. S1).
MGO impairs HTT clearance. Since MGO increased the intracellular levels of HTT, we next investigated 
the possible involvement of protein clearance pathways. First, we monitored the rate of clearance of the different 
HTT variants upon blocking de novo protein synthesis using cycloheximide (CHX). Interestingly, clearance of 
both HTT25Q (Fig. 3a,b) and HTT104Q (Fig. 3c,d) was impaired under MGO-induced glycating conditions.
Second, we assessed the effect of MGO in the autophagy lysosome pathway (ALP). For this, we blocked the 
ALP system with ammonium chloride (NH4Cl) in vehicle or MGO-treated cells, and evaluated the activation 
of ALP by measuring the accumulation of LC3-II levels33. Treatment of cells expressing HTT25Q with MGO 
reduced the activation of ALP (0.4 fold) (Fig. 3e,f). In contrast, in cells expressing HTT104Q we observed 
increased activation of ALP (6.6 fold) in response to MGO (Fig. 3g,h).
Third, we evaluated the effects of MGO on the UPS system using an unstable version of GFP (GFPu) that 
indicates the overall activity of the UPS34. Briefly, when the UPS is functioning properly, low levels of GFPu accu-
mulation are expected. As a positive control, we blocked the proteasome function with MG132 and observed a 
dose-dependent increase in the fluorescence levels, indicating proteasome inhibition (Fig. S2). The levels of GFPu 
were not altered in cells expressing either HTT25Q or HTT104Q upon MGO treatment (Fig. 3i,j).
Finally, we asked whether glycating conditions affected the cellular release of different HTT exon 1 vari-
ants. Conditioned media from HTT104Q-expressing cells treated with MGO showed a significant reduction 
in the total amount of HTT (less than 0.5 fold), but no changes were observed in the conditioned media from 
HTT25Q-expressing cells (Fig. 3k,l).
These results suggest that glycation impairs HTT clearance, causing it to accumulate and aggregate within 
cells.
Glycation enhances toxicity in Drosophila models of HD. Given that MGO increased HTT aggre-
gation and toxicity in cell models, we next investigated whether glycation also affected neuronal loss in vivo, 
employing a Drosophila model of HD based upon the pan-neuronal expression of a HTT exon 1 fragment 
with 93 or 20 glutamines (HTT93Q or HTT20Q) via the GAL4/UAS system35. HTT93Q flies exhibit a vari-
ety of HD-relevant phenotypes, including decreased lifespan, locomotor defects, degeneration of photoreceptor 
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Figure 1. Glycation increases HTT levels and inclusion formation in yeast. (a) Fluorescence micrographs of 
BY4741 (Ctrl), glo1∆ and tpi∆ yeast strains transformed with HTT 25Q, 72Q or 103Q variants fused to GFP 
(scale bar 20µ m). (b) % of yeast cells displaying HTT inclusions (at least n = 3 per condition). (c) Yeast protein 
extracts were immunoblotted with an anti-GFP antibody. Arrow indicates HTT aggregates. (d) Corresponding 
HTT levels are presented in arbitrary units (at least n = 3 per condition). Data in all panels are average ± SD, 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. For (D), unpaired two-tailed t-test with equal SD.
www.nature.com/scientificreports/
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Figure 2. MGO induces HTT aggregation and toxicity in H4 cells. (a) Human H4 cells expressing HTT 25Q 
or 104Q were treated with vehicle (Ctrl) or MGO (0.5 mM) for 16 h. Cells were lysed and immunoprecipitated 
(IP) with GFP-trap (bottom panels). The whole cell lysates (WCL) and IP samples were probed for AGEs (left 
panels) or GFP (right panels). Arrow indicates HTT 25Q and HTT 104Q MW. Corresponding loading controls 
(β -actin) are presented (n = 3). (b) H4 cells expressing HTT 25Q or 104Q fused with GFP were treated with 
vehicle (Ctrl) or MGO (0.5 mM) for 16 h. After treatment, cells were probed with Hoechst and imaged in vivo. 
Fluorescence micrographs and (c) corresponding % of cells with HTT inclusions are presented. Scale barm 
50 µ m. (d) Representative filter trap assay and (e) corresponding HTT levels of cells expressing HTT 104Q 
treated with vehicle or MGO for 16 h and immunoblotted with an anti-GFP antibody. (f) Protein extracts were 
immunoblotted with an anti-GFP antibody. (g) The corresponding HTT levels are presented (at least n = 3 per 
condition). (h) Toxicity of vehicle (Ctrl) or MGO measured by LDH release (n = 3) and normalized to 25Q. 
Data in all panels are average ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. For (c,e,g,h), unpaired 
two-tailed t-test with equal SD.
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Figure 3. Glycation impairs HTT clearance. H4 cells expressing HTT 25Q (a,b) or 104Q (c,d) for 24 h were 
pre-treated with vehicle (Ctrl) or MGO (0.5 mM) for 16 h. Cells were treated with vehicle or MGO for 24 h 
together with CHX. Protein extracts were probed for GFP and β -actin, for normalization, and protein levels are 
presented (at least n = 3). HTT 25Q (e,f) and 104Q (g,h) expressing cells were pre-treated with vehicle (Ctrl) 
or MGO (0.5 mM) for 16 h. Cells were treated with vehicle or MGO for 2 h together with vehicle (− ) or NH4Cl 
(+ ). Protein extracts were probed for LC3 (I and II) and β -actin. LC3-II levels (lower band) were normalized 
to β -actin and as a metric for autophagy induction, the difference between NH4Cl and vehicle treatments was 
calculated. The ratio between MGO and Ctrl is presented as autophagy induction ratio (at least n = 3). (i) HTT 
25Q and GFPu 104Q and GFPu cells were treated with vehicle (− ) or MGO (0.5 mM) (+ ) for 16 h. Protein 
extracts were probed for GFP and β -actin (at least n = 3). Arrow indicates GFPu. (j) Normalized GFPu levels are 
presented. (k) HTT 25Q or 104Q were treated with vehicle (− ) or MGO (0.5 mM) (+ ) for 16h. Fresh media was 
conditioned for 6 h in the same cells (− ) or (+ ) and probed in a dotblot system for GFP (n = 3). (l) Normalized 
Htt released levels are presented. Data in all panels are average ± SD, *p < 0.05, **p < 0.01. For (b,d,f,h,j), 
unpaired two-tailed t-test with equal SD.
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neurons (rhabdomeres), and impaired emergence of the adult fly from the pupal case (eclosion)36,37. We manip-
ulated glycation in fruit flies either via MGO administration or genetic knockdown of either Glo1 or Tpi. 
Importantly, silencing of Tpi or Glo1 in flies expressing HTT93Q displayed an overall increase in glycation and an 
increase in the levels of AGEs (Fig. 4a). Adult HTT93Q-expressing flies displayed a dose-dependent reduction in 
the number of rhabdomeres per ommatidium when treated with MGO for 7 days (Fig. 4b). Moreover, we found 
that treatment of HTT93Q larvae during development with MGO resulted in a significant reduction in the num-
ber of rhabdomeres upon eclosion (Fig. 4c). RNAi knockdown of either Glo1 or Tpi in WT flies did not modulate 
neurodegeneration (Fig. S3). However, in HTT93Q expressing flies, knockdown of either Glo1 or Tpi caused a 
significant increase in neurodegeneration of rhabdomeres at both 0 and 7 days after eclosion (Fig. 4d,e) when 
compared to their relative titration controls. Remarkably, we observed a significant reduction in the percentage 
of eclosion in both Glo1 and Tpi knockdown lines (Fig. 5a,b) and a 6-day reduction in the lifespan in the Glo1 
knockdown line (Fig. 5c,d). These results strongly suggest that glycation can act as an important environmental 
modifier of HTT toxicity and HD.
Figure 4. Knockdown of Glo1 or Tpi induces neurotoxicity and decreases lifespan and survival in HTT93Q 
expressing flies. (a) 100 heads of flies expressing Htt93Q and knocked down for Tpi, Glo1 or 3 M (as control) 
were lysed and immunoprecipitated with anti-HTT antibody (bottom panels). The whole protein lysates (WPL) 
(n = 3) and IP samples (n = 2) were probed for AGEs (left panels) or HTT (right panels). Arrow indicates 
HTT93Q MW. Corresponding loading controls (α -tubulin) are shown. (b) Adult flies expressing HTT93Q 
were treated with different concentrations of MGO. Quantification of mean rhabdomeres per ommatidium 
is presented. (c) Flies were treated during development with MGO. Quantification of rhabdomeres per 
ommatidium upon eclosion is presented. Number of rhabdomeres per ommatidium in HTT expressing flies 
with pan-neuronal knockdown of Glo1 (d) or Tpi (e) is presented at day 0 or 7 post-eclosion. 3M + Htt93Q and 
GFP + Htt93Q were used as titration controls for Glo1 and Tpi silencing lines, respectively. Data in all panels are 
mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Newman-Keuls post-
hoc test.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:36798 | DOI: 10.1038/srep36798
Figure 5. Knockdown of Glo1 or Tpi impairs development and reduces lifespan in flies. RNAi silencing of Glo1 
(a) or Tpi (b) caused a reduction in the percentage of flies emerging from the pupal case. Flies carrying a single 
copy of the driver (elavGAL4) are shown as a control. Data in panels (a,b) are mean ± SEM. Survival rate was 
evaluated in flies with pan-neuronal knockdown of Glo1 (c) or Tpi (d) in mutant HTT backgrounds (n = 100–150 
flies per genotype). 3M + Htt93Q and GFP + Htt93Q were used in experiments as titration controls for GloI 
and Tpi silencing lines, respectively. Htt93Q + Glo1 RNAi (mean = 6); Htt93Q + 3M (mean = 12); Htt93Q + Tpi 
a RNAi (mean = 12); Htt93Q + Tpi b RNAi (mean = 11.5); Htt93Q + GFP (mean = 13). *p < 0.05, **p < 0.01, 
****p < 0.0001; for (a,b) Ordinary one-way ANOVA with Newman-Keuls multiple comparisons test; for (c,d) 
Log-rank (Mantel-Cox) test.
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Discussion
The precise mechanisms through which HTT mutations cause HD are still unknown. However, accumulation of 
HTT plays an important role in the disease and strategies aimed at reducing its levels constitute attractive strate-
gies for therapeutic intervention and are currently being explored in ongoing clinical trials38.
Different posttranslational modifications (PTMs) are known to modulate the levels, aggregation propensity 
and clearance of HTT, and could play a role in the development of HD39–41. For example, phosphorylation of HTT 
on Ser13 and Ser16 is protective in mouse models of HD42 enhancing the clearance of HTT via the proteasome 
and chaperone-mediated autophagy43. Acetylation of Lys9 and Lys444 promotes HTT clearance via the autophagy 
lysosome pathway (ALP)44. On the other hand, SUMOylation leads to HTT accumulation and translocation into 
the nucleus45.
Using established yeast, mammalian cell and fly models of HD, we found that both pharmacological and 
genetic induction of glycation plays a deleterious role in HD models by decreasing HTT clearance, increasing 
the intracellular levels of HTT and enhancing its aggregation and toxicity, either directly or indirectly (through 
the increase in the levels of HTT). Impaired clearance of HTT via the proteasome was previously associated with 
HD2. Strikingly, we observed different effects of glycation on normal (25Q) vs. mutant (104Q) HTT variants. 
While glycation impaired the activation of the ALP system in cells expressing HTT25Q, we observed increased 
activation of the ALP system in cells expressing HTT104Q. Although we cannot completely exclude an indirect 
effect of general protein glycation, we clearly observed distinct phenotypes between 25Q and 104Q HTT. The 
increased ALP activation suggests a compensatory mechanism for the cell to cope with aggregated HTT that is 
normally cleared via the ALP system46,47.
Diabetes is a risk factor for neurodegenerative diseases such as Alzheimer’s and Parkinson’s8,9. A major con-
sequence of diabetes is glucose metabolism imbalance and consequent hyperglycemia. Glucose and its byprod-
ucts have the ability to react with amino groups, forming AGEs that can impact the function of target proteins. 
Glycation exacerbates the accumulation, aggregation and toxicity of Aβ and α -synuclein8,48. Therefore, it is rea-
sonable to hypothesize that glycation might constitute a common mechanism contributing to the development of 
neurodegenerative diseases by acting as a “second hit” that tips the proteostasis balance of cells, causing dysfunc-
tion of multiple essential cellular pathways, and leading to premature death. Interestingly, and in agreement with 
our hypothesis, drugs used for the treatment of diabetes were already shown to be protective in HD. For example, 
metformin was shown to prolong the survival of HD male mice49. In addition, exendin-4 decreased HTT aggrega-
tion, suppressed cellular pathology in both brain and pancreas, improved motor function, and extended survival 
in a mouse model of HD50. In fact, the prevalence of diabetes is higher in HD patients51,52. Mouse models of HD 
develop hyperglycemia53,54, possibly due to the accumulation of intranuclear HTT inclusions in pancreatic β cells 
that produce insulin55,56. Consistently, HD brains differentially express several proteins linked to type-2 diabe-
tes57. However, whether diabetes is a contributing factor to pathogenesis or a consequence of HD is still unclear, 
as is the role of HTT glycation.
Although activation of autophagy could clear aggregated proteins and is considered an important therapeutic 
approach for several neurodegenerative disorders58, autophagy could also lead to neuronal death. Overactivation 
of ALP can lead to apoptosis or autophagic cell death59. Therefore, promoting glycation in HTT104Q expressing 
cells might account for the observed increase in HTT cytotoxicity by overactivating the ALP.
We did not observe alterations in the UPS, suggesting that, under the conditions tested, glycation does 
not affect HTT clearance by the proteasome. Interestingly, we observed that glycation reduces the release of 
HTT104Q, which may account for the observed intracellular accumulation of HTT104Q, increased aggregation 
and toxicity.
In vivo, feeding of mutant HTT exon-1-expressing flies with MGO, reduced the number of rhabdomeres 
per omatidium, demonstrating a dose-dependent and selective effect. The deleterious effect of MGO was also 
observed in a reduction of eclosion, suggesting that glycation exacerbates HTT-toxicity during development. 
Importantly, genetic manipulation of pathways controlling MGO levels, through Glo1 or Tpi1 knockdown, also 
resulted in increased neurotoxicity of mutant HTT93Q, and reduced survival. In Tpi RNAi flies, we observed 
a significant reduction in eclosion, and in Glo1 RNAi flies we observed a significant reduction in eclosion and 
survival rate. Altogether, our data clearly suggest that increased glycation exacerbates the toxicity of mutant HTT, 
and that this can occur already during developmental stages.
In this study we demonstrate for the first time that glycation plays an important role in HTT homeostasis, 
contributing to its neurotoxicity, accumulation and aggregation, as well as potentiating several disease-relevant 
phenotypes in a Drosophila model of HD (Fig. 6). Therefore, we hypothesize that hyperglycemia, and the una-
voidable glycation of proteins including HTT, may not only be a consequence but also a contributing factor in 
HD pathogenesis.
Interestingly, we recently showed that DJ-1 overexpression protects against HTT toxicity in yeast and fruit 
flies25. Although mutations in the DJ-1 gene are associated with recessive forms of Parkinson’s disease, DJ-1 was 
recently described as an anti-MGO enzyme with glyoxalase activity60. Moreover, DJ-1 was also suggested to act 
as a protein deglycase that repairs MGO-glycated proteins61. These findings are consistent with our study, further 
supporting a connection between protein glycation and HD. Altogether, our study suggests that glycation might 
contribute to HTT dysfunction and that modulation of glycation may constitute a novel target for therapeutic 
intervention in HD.
Materials and Methods
HTT protein levels and aggregation in yeast. The parental Saccharomyces cerevisiae strain BY4741 
(MAT a, his3∆ , leu2∆ , met15∆ , ura3∆ ), and deletion mutants glo1∆ and tpi∆ strains were used (Euroscarf 
collection). Cells were grown and transformed as in ref. 13 using GFP fusion constructs with a mutant HTT 
fragment with an expanded polyQ stretch of either 25, 72 or 103 in p416 vector under the regulation of the GPD 
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promoter as in ref. 26. Protein extraction was performed as in ref. 13. Fluorescence microscopy was performed 
using a Zeiss Axiovert 200 M.
MGO purification. MGO was produced as described in ref. 14.
Immunoprecipitation, microscopy, immunoblotting, toxicity, viability and aggregation assays. 
H4 neuroglioma cells were maintained, grown and transfected with HTT exon-1 fragments with a polyQ expan-
sions of either 25 or 104 fused to GFP as in ref. 26. Twenty-four hours after HTT25Q or HTT104Q transfection, 
cells in 35 mm imaging dishes (Ibidi), 60 mm or 100 mm dishes (Corning) were treated with vehicle (PBS) or 
MGO (0.5 mM) for 16 h. Total protein lysates were obtained as in ref. 13. Htt was immunoprecipitated using 
GFP-trap (Chromotek) according to the manufacturer instructions. Widefield fluorescent microscope Zeiss 
Axiovert 200 M (Carl Zeiss MicroImaging) or point scanning confocal microscope Zeiss LSM 710 (Carl Zeiss 
MicroImaging) were used to visualize HTT inclusions. Immunobloting was performed according to stand-
ard procedures as in ref. 13 using the following antibodies: anti GFP (NeuroMab, P42212, 1:3000); anti AGEs 
(Cosmobio, KAL-KH-001, 1:500); anti LC3 (Nano Tools, 0260-100/LC3-2G6, 1:2000) and anti β -actin (Ambion, 
AM4302, 1:5000). Cytotoxicity was measured by means of the LDH kit (Clontech), following manufacturer´s 
instructions. Cell viability was determined using the MTT assay according to standard procedures. Evaluation of 
HTT aggregation profiles by filter retardation assay was performed as in ref. 62. Briefly, cellulose acetate mem-
branes retain aggregates that are not soluble in SDS (1%) and that are larger than 0.22 µ m.
HTT clearance assay. For CHX chase experiments, H4 cells were transfected as previously13 with either 
HTT25Q or HTT104Q. After 24 h, cells were treated with vehicle (PBS) or MGO (0.5 mM) for 16 h. Media was 
renewed and cells re-challenged with vehicle or MGO for 24 h in the presence of CHX (100 µ M, added at given 
time points). Protein extracts were immunobloted. Proteasome impairment was assessed as the amount of GFPu 
accumulation. H4 cells were cotransfected with E.V. with GFPu; HTT25Q with GFPu or HTT104Q with GFPu. 
24 h post transfection, media was renewed and cells treated with vehicle (PBS) or MGO (0.5 mM) for 16 h and 
processed for immunobloting with anti-GFP antibody (NeuroMab, P42212). As positive control, H4 cells were 
transfected with GFPu and treated with increasing concentrations of MG132 for 24 hours. GFPu average fluo-
rescence level was analyzed by epifluorescence microscopy. For autophagy impairment studies, H4 cells were 
transfected with HTT25Q or HTT104Q. 24 h post transfection, media was renewed and cells treated for 16 h with 
vehicle (PBS) or MGO (0.5 mM). Media was again renewed and cells were re-challenged with vehicle or MGO 
during autophagy blockage with ammonium chloride (20 mM) for 2 h. Autophagy activity was measured as the 
amount of accumulated LC3-II after treatment with autophagy blockers33. For HTT release studies, H4 cells, 
transfected with HTT25Q or HTT104Q for 24 h were treated with MGO (0.5 mM) for 16 h. Media was renewed, 
and cells were again treated with MGO (0.5 mM) for 6 h, media collected, applied onto nitrocellulose membranes 
(0.22 µ m, Millipore) using a dot blot apparatus, and immunobloted with anti-GFP by standard procedures.
Drosophila lines. Flies were raised at 25 °C in LD12:12 on standard maize food. The elav-GAL4 (c155) and 
w; UASeGFP; + (5431) lines were obtained from the Bloomington Stock Center (Bloomington, Indiana). The w; 
+ ; UASHTT93Q and w; + ; UASHTT20Q transgenic line was kindly provided by J. Lawrence Marsh and Leslie 
Thompson (University of California, Irvine)35. RNAi transgenic lines were obtained from the Vienna Drosophila 
RNAi Center (VDRC). For Glo1 knockdown, the 101560 line from the KK Library (phiC31-based transgenes at 
Figure 6. Schematic representation of the effects of MGO glycation in models of HD. Glycation increases 
HTT intracellular levels and inclusion formation in yeast and H4. Ultimately, it increases HTT-dependent 
toxicity, leading to neurodegeneration and reduced viability and lifespan in flies.
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a single, defined site) was used. For Tpi knockdown, two lines were employed from the GD Library (P-element 
based, random insertion sites): 25643 and 25644. The UASeGFP and w; 3M; + (carrying an empty vector located 
in the KK site) lines were used in the experiment as titration controls.
Immunoprecipitation of HTT expressed in flies. Flies were processed for IP 7 days post-eclosion. 
Briefly, heads were separated using standard procedures, and protein extracts prepared by vigorous homogeniza-
tion with a tissue grinder followed by liquid nitrogen freeze and thaw cycles. 750 µ g of protein were used for IP, as 
we previously described63. 10 µ l per IP of anti Htt antibody was used (Millipore, MAB5374). IP and whole protein 
lysate (WPL) were probed using anti AGEs (Cosmobio, KAL-KH-001, 1:500); anti-Htt (Millipore, MAB5374, 
1:1000) and anti α -tubulin (Sigma, T5168, 1:15000).
Drosophila eclosion and longevity assays. Eclosion of fly lines was assessed as previously described in 
ref. 64. Male flies carrying the elavGAL4 driver were crossed to virgin females carrying the UASHTT93Q trans-
gene in order to generate females expressing HTT93Q and control males in the F1 generation. 10–35 crosses were 
set up in separate vials for each condition and parental flies were removed 5 days after mating. The number of 
female or male progeny emerging was scored over 10 days post-eclosion and the percentage of eclosion per vial 
was calculated using the following ratio: (number of female/number of male flies) × 100. For longevity assays, 
newly emerged female flies of the desired genotype were collected and kept in groups of 10 in separate vials. Flies 
were moved to fresh food every 2–3 days and the number of dead individuals scored daily.
Treatment of Drosophila with MGO. MGO was dissolved in H2O and added to standard maize media at 
the required doses (10, 30, 100 or 300 µ M). For treatment during development, crosses were set up and flies were 
grown on standard maize media previously supplemented with MGO. Flies expressing the desired genotype were 
collected upon eclosion and analyzed for both eclosion percentage and rhabdomere number. For adult feeding 
experiments, newly emerged flies were transferred to MGO-supplemented food and moved daily to fresh vials 
with appropriate MGO treatment concentration. Rhabdomeres were scored in flies fed with different concentra-
tions of MGO during 7 days, newly emerged untreated flies and 7 days-old untreated flies.
Pseudopupil analysis. The number of visible rhabdomeres per ommatidium was measured as described 
in ref. 37. Briefly, the number of rhabdomeres was scored for a minimum of 50 ommatidia per fly, in at least 
12 flies per condition at day 0 or 7 post-eclosion. Heads from adult flies were removed and fixed to glass slides 
using clear fingernail polish and rhabdomeres were examined at 500X magnification using an Olympus BH2 light 
microscope.
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Abstract
Protein misfolding and aggregation is a major hallmark of neurodegenerative disorders such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Huntington’s disease (HD). Until recently, the consensus was that each aggregation-prone protein
was characteristic of each disorder [α-synuclein (α-syn)/PD, mutant huntingtin (Htt)/HD, Tau and amyloid beta peptide/AD].
However, growing evidence indicates that aggregation-prone proteins can actually co-aggregate and modify each other’s
behavior and toxicity, suggesting that this process may also contribute to the overlap in clinical symptoms across different
diseases. Here, we show that α-syn and mutant Htt co-aggregate in vivowhen co-expressed in Drosophila and produce a
synergistic age-dependent increase in neurotoxicity associated to a decline in motor function and life span. Altogether, our
results suggest that the co-existence of α-syn andHtt in the sameneuronal cells worsens aggregation-related neuropathologies
and accelerates disease progression.
Introduction
The presence of protein aggregates in the brain is a commonhall-
mark for several neurodegenerative diseases, such as Alzhei-
mer’s disease (AD), Parkinson’s disease (PD) and Huntington’s
disease (HD). The speciﬁc subcellular location and composition
of protein aggregates are characteristics for each disorder. PD
hallmarks are the formation of Lewy bodies, intracytoplasmic in-
clusions of misfolded proteins containing mainly α-synuclein
(α-syn) and the demise of dopaminergic neurons in the substan-
tia nigra. In AD, deposits of amyloid-beta and tau proteins in the
brain lead to hippocampal degeneration, cognitive impairment
and dementia. In HD, mutant huntingtin (Htt) with polygluta-
mine (polyQ) repeat expansion accumulates in cytoplasmic and
intranuclear aggregates leading to neurodegeneration in the stri-
atum (1).
Although each neurodegenerative disorder has its characteris-
tic pathophysiology, current evidence indicates that there is also
signiﬁcant overlap between apparently different disorders. For
example, α-syn is the protein that characteristically aggregates
in PD, but it was originally discovered as a constituent of amyloid
plaques in AD (2) and, later on, was found in protein aggregates in
diverse pathologies of the central nervous system, such as HD, tri-
somyof chromosome21, progressive supranuclear palsy and fron-
totemporal dementia (3–7). Tau, an AD-associated protein, was
detected in protein aggregates in patients with PD, sporadic
dementia with Lewy bodies and multiple system atrophy, as well
as in some animal models for synucleinopathies (8–14).
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This apparent convergence of themolecular and cellular phe-
nomena is accompanied by an overlap in the symptoms. For
instance, patients suffering from diseases that affect movement
control and coordination, as is the case of PD and HD, may also
exhibit dementia in more advanced stages of disease (15). Con-
versely, patients afﬂicted by dementia can also show PD- or
HD-like motor symptoms (16).
There is growing evidence that co-occurrence of aggregate-
prone proteins may decisively inﬂuence the pathophysiology
and severity of neural disorders. Tau and α-syn interact and co-
aggregate, and this is associated with an increase in neurotox-
icity in cellular and Drosophila models (17,18). Htt has been
recently shown to co-aggregate with proteins associated with
synucleinopathies and tauopathies (19–22). Mutant Htt induces
Tau hyperphosphorylation and aggregation, preventing its asso-
ciation to themicrotubular network and producing large ring-like
aggregates close to the microtubular network (19,20). DJ-1, which
is associated with familial PD, interacts and co-aggregates with
α-syn and Htt, modulating their toxicity in models of PD and
HD (20,22).
We have previously shown that α-syn modiﬁes the dynamics
and aggregation pattern of mutant Htt in cells in culture (23).
Here, we expand those studies and report that co-existence of
α-syn and mutant Htt in vivo strongly enhances PD- and HD-
related neuropathology in Drosophila melanogaster, suggesting
that the interplay between the two proteins deserves further
investigation in the context of HD and PD.
Results
Co-expression of mutant Htt and α-syn alters Htt
aggregation pattern
Expression of normal (25Q) Htt or α-syn bimolecular ﬂuorescence
complementation (BiFC) pairs in human (H4) cells produced
mostly homogeneous ﬂuorescence, Htt being more often re-
stricted to the cytosol and α-syn spreading both through nucleus
and cytosol (Fig. 1A). On the other hand, mutant (103Q) Htt BiFC
pairs produced protein aggregates. The combination of mutant
Htt/α-syn also produced aggregates, but they seemed fewer and
larger than pure 103Q aggregates. This was conﬁrmed quantita-
tively (Fig. 1B–D), as the number of aggregates per cell was
reduced 2-fold in mutant Htt/α-syn combinations (Fig. 1B), and
the number of cells with <10 aggregates grew at the expense
of cells with >25 aggregates (Fig. 1C). Finally, the percentage of
aggregates larger than 3 µm increased in mutant Htt/α-syn com-
binations at the expense of aggregates smaller than 1 µm
(Fig. 1D). The proportion of cells with 10–25 aggregates and of ag-
gregates between 1 and 3 µm remained unchanged.
Both mutant Htt and α-syn increased cell death 24 h after
transfection of H4 cells with the corresponding combinations of
BiFC constructs (Fig. 1E). However, and in spite of the clear
changes induced by α-syn on mutant Htt aggregation pattern,
we did not observe changes at the viability level, even 72 h after
transfection (data not shown). Longer experiments are extremely
difﬁcult to carry out in this experimental setup.
Htt103Q-mCherry and α-syn-EGFP co-localize
and co-aggregate in dopaminergic neurons
and in photoreceptors
In order to conﬁrm our results with human cells in culture and to
be able to measure neurotoxic effects of Htt/α-syn combinations
during longer periods of time, we performed assays using trans-
genic overexpression in Drosophila. Co-expression of a mutant
version of Htt containing 103 glutamines (Htt103Q-mCherry)
and wild-type α-syn-EGFP in dopaminergic neurons (TH-GAL4)
showed co-localization and co-aggregation of these two proteins
(Fig. 2), conﬁrming our results in cultured human cells. In terms of
subcellular location, we found that these α-syn-EGFP/Htt103Q-
mCherry aggregates accumulate both in cell bodies (Fig. 2A) and
neurites (Fig. 2B) of dopaminergic neurons. In contrast, ﬂies
co-expressing α-syn-EGFPwith awild-type version of Htt (Htt25Q-
mCherry) do not show aggregates (Fig. 2C), suggesting that only
mutant Htt stimulates the deposition of α-syn in these aggregates.
Flies expressing α-syn-EGFP or wild-type Htt25Q-mCherry alone
did not show aggregates (Fig. 2D and E).
Using sGMR-GAL4 we induced the co-expression of Htt103Q-
mCherry and α-syn-EGFP in eye imaginal discs of third instar
larvae (Fig. 3). We observed co-localization and co-aggregation
of α-syn and mutant Htt in the cytoplasm of the photoreceptors
(Fig. 3A and A′), and also in the axonal projections of the photo-
receptors in the larval brain (Fig. 3B).
Htt103Q-mCherry and α-syn-EGFP are physically
interacting
Mutant Htt103Q-mCherry was co-immunoprecipitated with
α-syn-EGFP, using an antibody against the green ﬂuorescent pro-
tein (GFP) tag, further demonstrating that mutant Htt103Q-
mCherry and α-syn-EGFP interact and co-aggregate in Drosophila
cells (Fig. 4A). In order to analyze the solubility status of these
proteins when they are co-expressed, we performed a Triton-X
solubility experiment using protein extracts from 8 days old
adult heads. We found that the levels of α-syn-EGFP and
Htt103Q-mCherry in the Triton insoluble fraction increased when
these proteins are co-expressed, in comparison when they are
expressed alone (Fig. 4B). This result indicates that co-expression
of α-syn-EGFP and Htt103Q-mCherry causes an increase in the
formation of insoluble aggregates containing these two proteins.
Co-expression of Htt103Q-mCherry and α-syn-EGFP
produces premature and severe degeneration in the
photoreceptors
Next, we expressed Htt103Q-mCherry and α-syn-EGFP in the eye
using sGMR-GAL4 and analyzed the external morphology of the
adult eye in 8 days old ﬂies (Fig. 5A–D). Expression of the GFP tag
alone had no effect on eye development or viability as the eyes
looked normal (Fig. 5A). Flies expressing α-syn-EGFP alone also
developed a normal eye, identical to control ﬂies (Fig. 5B). On
the other hand, ﬂies expressing mutant Htt103Q-mCherry,
alone or in combinationwith α-syn-EGFP, showed striking retinal
degeneration, producing a strong rough eye phenotype (Fig. 5C
and D). Co-expression of mutant Htt103Q-mCherry and α-syn-
EGFP did not worsen the rough eye phenotype in comparison
with Htt103Q-mCherry alone. However, co-expression of
Htt103Q-mCherry and α-syn-EGFP speciﬁcally in the photorecep-
tors R1–R6, using Rh1-GAL4, showed a stronger and premature
degeneration phenotype (Fig. 5G) in comparison with Htt103Q-
mCherry alone (Fig. 5H). In this case, control GFP or α-syn-EGFP
alone did not show any degeneration phenotype (Fig. 5E and F).
These results indicate that co-expression of α-syn-EGFP and
mutant Htt103Q-mCherry enhances neurodegeneration of the
Drosophila photoreceptors in vivo.
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Figure 1. Co-expression of mutant Htt and α-syn alters Htt aggregation pattern. (A) H4 cells transfected with different combinations of α-syn- and Htt-Venus BiFC
constructs. Cells transfected with a Htt25Q-Venus BiFC pair of plasmids show homogeneous ﬂuorescence indicative of oligomeric species, while a Htt103Q-Venus
BiFC pair produces both oligomeric species and large intracellular ﬂuorescent aggregates with variable size and morphology. Htt location is primarily cytosolic. α-Syn-
Venus BiFC pair produces homogeneous ﬂuorescence distributed throughout all cellular compartments, including the nucleus. When α-syn and Htt103Q BiFC
constructs were combined, there is a change in the aggregation pattern of both proteins, quantiﬁed in B–D. Co-transfection of Htt103Q with α-syn BiFC constructs
decreases the average number of aggregates per cell (B and C) and increases the average size of aggregates (D). (E) The α-syn pair or the Htt103Q pair are more toxic
than the wild-type Htt pair and combining α-syn with Htt103Q does not enhance toxicity in this model. *Signiﬁcant versus 103Q/103Q, P < 0.01; #Signiﬁcant versus
25Q/25Q, P < 0.001. Scale bar, 20 µm. AU, arbitrary units.
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Figure 2. Htt103Q-mCherry and α-syn-EGFP co-localize and co-aggregate when expressed in dopaminergic neurons. (A) Co-localization of Htt103Q-mCherry and α-syn-
EGFP aggregates in cell bodies of dopaminergic neurons (arrows). (B) Co-localization of Htt103Q-mCherry and α-syn-EGFP aggregates in neurites of dopaminergic neurons
(arrows). (C)Wild-typeHtt (Htt25Q-mCherry) does not form aggregateswith α-syn-EGFP. (D and E) The expression of α-syn-EGFP alone or Htt25Q-mCherry does not induce
the formation of aggregates. The images inA–E showdopaminergic neurons in the paired posterior lateral 1 (PPL1) clustermarked byan anti-TH antibody (against tyrosine
hydroxylase). Genotypes: (A, B) TH-GAL4, UAS-α-syn-EGFP/ UAS-Htt103Q-mCherry, (C) TH-GAL4, UAS-α-syn-EGFP/UAS-Htt25Q-mCherry, (D) TH-GAL4, UAS-α-syn-EGFP
and (E) TH-GAL4, UAS-Htt25Q-mCherry. Scale bars represent 10 µm.
Human Molecular Genetics, 2015, Vol. 24, No. 7 | 1901
Downloaded from https://academic.oup.com/hmg/article-abstract/24/7/1898/596093
by Universidade Nova de Lisboa user
on 26 April 2018
Co-expression of Htt103Q-mCherry and α-syn-EGFP
in the nervous system causes severe motor dysfunction
and a decrease in life span
We evaluated themotor function and life span of ﬂies co-expres-
singmutantHtt103Q-mCherry and α-syn-EGFP in the central ner-
vous system, using nSyb-GAL4 (Fig. 6). To test motor function we
used ‘climbing assays’, where ﬂies of different genotypes were
tapped to the bottom of the vial and allowed to climb up the
walls (Fig. 6A). We recorded the climbing time when ﬁve ﬂies
crossed a 15-cm ﬁnish line. Eight days old ﬂies co-expressing
Htt103Q-mCherry and α-syn-EGFP took, on average, four more
seconds to reach the ﬁnish line than the other genotypes tested.
The motor ability of ﬂies co-expressing Htt103Q-mCherry/α-syn-
EGFP deterioratedmore and faster than the other genotypes,with
the difference in climbing times reaching 32 s by day 30.
Flies co-expressing Htt103Q-mCherry and α-syn-EGFP also
showed a dramatic decrease in life span, with 44 days of max-
imum survival (Fig. 6B). Flies co-expressing Htt25Q-mCherry
and α-syn-EGFP had a maximum survival of 71 days. Maximum
survival of ﬂies expressing GFP, α-syn-EGFP, Htt25Q-mCherry or
Htt103Q-mCherry alone ranged from 59 to 83 days. Interestingly,
neurotoxicity, motor dysfunction and ﬂy death started around
days 8–15 and their increase occurred in parallel, indicating an
association between these events. These results suggest that
co-expression of α-syn and mutant Htt synergistically enhances
each other’s toxicity, eventually accelerating the progression of
the disorder.
Discussion
Here, we show that α-syn and mutant Htt, two proteins asso-
ciated with PD and HD, respectively, can interact and co-aggre-
gate in vivo. Furthermore, their co-expression produced a
synergistic deterioration of neural tissue, motor function and
life span in Drosophila. The effects of α-syn/Htt co-expression
under the different promoters are summarized in Table 1.
While co-expression of other proteins associated with human
neurodegenerative diseases has also shown deleterious effects
in different models (17,18,23,24), this is the ﬁrst demonstration
that co-expression of α-syn and mutant Htt can enhance neuro-
degeneration in Drosophila.
Our results support the idea that the co-occurrence of these
two different aggregation-prone proteins in neural cells can pro-
duce striking changes in the pathology, symptoms and disease
progression. Moreover, our study may give some clues why
some patients suffering with a speciﬁc neuropathology may
Figure 3. Htt103Q-mCherry and α-syn-EGFP co-localize and co-aggregate in the eye discs of third instar larvae. (A) Third instar larval eye disc from double transgenics
stained with the pan-neuronal marker anti-elav. α-Syn-EGFP co-localized and co-aggregated with Htt103Q-mCherry aggregates in the cytoplasm of larval
photoreceptors. (A′) Magniﬁed area delimited by the box in (A). Arrows indicate foci of co-aggregated proteins. (B) Htt103Q-mCherry and α-syn-EGFP co-localized in
the photoreceptors’ axonal projections in the larval brain. Genotype: sGMR-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-mCherry. Scale bars represent 10 µm.
Figure 4. Htt103Q-mCherry and α-syn-EGFP are physically interacting. (A)
Immunoprecipitation of α-syn-EGFP with an antibody against the EGFP tag pulled
down Htt103Q-mCherry from dopaminergic neurons, showed by immunoblotting
analysis. (B) Immunoblotting of Total, Triton-X soluble and Triton-X insoluble
fractions of α-syn-EGFP and Htt103Q-mCherry from adult heads of ﬂies
co-expressing these two proteins. The levels of α-syn-EGFP and Htt103Q-mCherry
in the insoluble fraction are higher when these proteins are co-expressed.
Genotypes: (A) TH-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-mCherry. (B) α-Syn:
sGMR-GAL4, UAS-α-syn-EGFP. Htt103Q: sGMR-GAL4, UAS-Htt103Q-mCherry.
α-Syn/Htt103Q-mCherry: sGMR-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-mCherry.
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show, at the symptomatic level, a signiﬁcant overlap between dif-
ferent human neurodegenerative diseases. It is possible that a
HD patient containing a mutant version of the Htt gene (expan-
sion of the trinucleotide CAG) and thereby suffering from the
consequences of mutant Htt aggregation and toxicity may be
also in risk of developing aggregation of α-syn and therefore
being affected by some of the symptoms associated with PD.
This could occur as a consequence of the propensity of mutant
Htt and α-syn to interact, co-aggregate and interfere with their
normal biological roles in cells. In addition, the twomost affected
brain regions in patients with PD and HD, the substantia nigra
and striatum, respectively, are anatomically and functionally
interconnected, reinforcing the interest of studying the crosstalk
between these two neuropathologies. Finally, the models estab-
lished in this work may constitute useful tools to screen and
discover new candidate drugs against PD and HD.
Figure 5. Co-expression of Htt103Q-mCherry and α-syn-EGFP produces premature and severe degeneration in the photoreceptors. (A–D) Externalmorphology of the adult
eye. (A and B) Expression of GFPor α-syn-EGFP does not affect external eyemorphology. (C andD) Co-expression ofHtt103Q-mCherry and α-syn-EGFP produces a rough eye
phenotype identical to the one induced by the single expression of Htt103Q-mCherry. (E–H) Photoreceptors neurodegeneration in the adult eye, analyzed by water
immersion microscopy assay of the retinas. (E) Expression of GFP did not induce degeneration of the photoreceptors, with the six photoreceptors being present in the
ommatidial clusters; (F, G) ﬂies expressing α-syn-EGFP or Htt103Q-mCherry showed progressive degeneration of the photoreceptors. (H) Co-expression of Htt103Q-
mCherry and α-syn-EGFP induced severe and early degeneration of the photoreceptors. Genotypes are indicated in the boxes on top and lateral of the ﬁgures: (A)
sGMR-GAL4, UAS-GFP, (B) sGMR-GAL4, UAS-α-syn-EGFP, (C) sGMR-GAL4, UAS-Htt103Q-mCherry, (D) sGMR-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-mCherry, (E) Rh1-
GAL4, UAS-GFP, (F) Rh1-GAL4, UAS-α-syn-EGFP, (G) Rh1-GAL4, UAS-Htt103Q-mCherry and (H) Rh1-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-mCherry. Scale bars represent
50 µm (A–D) and 10 µm (E–H).
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Material and Methods
Cell culture and BiFC plasmids
Maintenance of H4 human glioma cells and Htt and α-syn BiFC
constructs were previously described in detail (23,25). Brieﬂy, in
our BiFC systems, Htt and α-syn were fused to two non-ﬂuores-
cent halves of the Venus protein (Venus 1, amino acids 1–157;
and Venus 2, amino acids 158–239). When the Htt and α-syn di-
merize, the Venus halves get together and reconstitute a func-
tional ﬂuorophore. Fluorescence is therefore proportional to the
Figure 6. Co-expression of Htt103Q-mCherry and α-syn-EGFP in the nervous system causes severe motor dysfunction and a decrease in life span. (A) Flies co-expressing
Htt103Q-mCherry and α-syn-EGFP under the control of nSyb-GAL4 showa strong impairment of themotor abilities comparedwith the rest of the genotypes tested. The Y-
axis represents the time (in seconds), it took for ﬁvemales to climb 15 cm (mean ± SEM). Statistically signiﬁcant values, comparing each of genotypes, were calculated by
doing two-way ANOVA with Bonferroni post-test. With very few exceptions, all the differences detected between the genotypes tested in this assay were statistically
signiﬁcant with a P < 0.001 (except the difference between the genotypes Htt25Q-mCherry and α-Syn-EGFP/Htt25Q-mCherry which is signiﬁcant for a P < 0.01). The
differences not statistically signiﬁcant (P > 0.05) were GFP versus Htt25Q-mCherry at day 13; α-Syn-EGFP versus Htt103Q-mCherry at day 13; α-Syn-EGFP versus α-Syn-
EGFP/Htt25Q-mCherry at days 24 and 30; Htt103Q-mCherry versus α-Syn-EGFP/Htt25Q-mCherry at day 8. (B) Flies co-expressing Htt103Q-mCherry and α-syn-EGFP
under the control of nSyb-GAL4 have a life span signiﬁcantly shorter in comparison with the rest of the genotypes tested. Values on the Y-axis represent the
percentage of ﬂies alive at each time point analyzed. The maximum survival (in days) is indicated for each genotype (the mean values indicate the number of days it
took for half of the ﬂies to die): control (nSyb-GAL4) 83 (mean = 70), GFP (nSyb-GAL4, UAS-GFP) 77 (mean = 64), α-syn-EGFP (nSyb-GAL4, UAS-α-syn-EGFP) 68
(mean = 45), Htt25Q-mCherry (nSyb-GAL4, UAS- Htt25Q-mCherry) 74 (mean = 56), Htt103Q-mCherry (nSyb-GAL4, UAS-Htt103Q-mCherry) 59 (mean = 44), α-syn-EGFP/
Htt25Q-mCherry (nSyb-GAL4, UAS-α-syn-EGFP/UAS-Htt25Q-mCherry) 71 (mean = 50) and α-syn-EGFP/Htt103Q-mCherry (nSyb-GAL4, UAS-α-syn-EGFP/UAS-Htt103Q-
mCherry) 44 (mean = 25). Statistical signiﬁcance is indicated in the graph (log-rank, Mantel–Cox test).
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amount of Htt/α-syn dimers and oligomers. H4 cells were trans-
fected with the corresponding BiFC pairs and 24 h later pictures
were taken on a Zeiss Axiovert 200M. A total of 150 cells from
three independent experiments were analyzed. Graphs of
Figure 1 show mean ± SD of three independent experiments.
Drosophila stocks
To generate UAS-α-Syn-EGFP, we fused α-syn with EGFP and
cloned into pUAST using the BglII and Acc65I restriction sites.
The transgenic ﬂies were generated by BestGene, USA.We gener-
ated two different UAS-Htt-mCherry lines, one encoding a wild-
type version of Htt (exon 1) with a 25 polyQ tail and the other
encoding a mutant version of Htt with a 103 polyQ tail. These
two constructs were cloned into pWalium10-roe and transgenic
lines were generated using phiC31 integrase-mediated DNA
integration (BestGene Strain #9723, attP acceptor site in 28E7).
Four different drivers were obtained from the Bloomington
Stock Center (Indiana University, Bloomington, IN, USA): nSyb-
GAL4 (active in the entire nervous system, under the control of
the Synaptobrevin promoter), TH-GAL4 (active in dopaminergic
neurons, under the control of the tyrosine hydroxylase pro-
moter), GMR-GAL4 (active in the eye, under the control of the
glass multiple reporter) and Rh1-GAL4 (active in the photorecep-
tors R1–R6, under the control of the rhodopsin1 promoter). Dros-
ophila stocks were maintained at 25°C on standard cornmeal
media in an incubator with a 12 h light/dark cycle.
Immunohistochemistry and microscopy
Brain preparations for confocalmicroscopy imagingwere done as
previously described (26). Brieﬂy, adult ﬂies were anesthetized
with CO2 and the brains were isolated from the head cuticles
and ﬁxed in phosphate buffered saline (PBS) containing 4%
paraformaldehyde.
Dopaminergic neurons were stained by incubation for 48 h at
4°C with mouse anti-TH antibody (Immunostar, Hudson, WI,
USA) diluted 1:50 in PBST (1× PBS + 0.3% Triton X-100) containing
5% (v/v) normal goat serum. Three 10-min washes with PBST
were done before incubation with a secondary anti-mouse Cy5
(Jackson ImmunoResearch), also diluted in PBST-containing 5%
(v/v) normal goat serum.
Brain sampleswere analyzed and imageswere collected using
a LSM 710Meta Zeiss confocal microscope. Images were acquired
with a resolution of 1024 × 1024, with a slice thickness of 1 µm
and a line-average of 4. Z-projections were generated using Ima-
geJ and the images were processed using Adobe Photoshop.
The degenerative effects caused by co-expression of α-syn
and mutant Htt were assessed in the photoreceptors of adult
eyes. To analyze external eye morphology, we used a Leica Z16
APOmacroscope and a Leica DFC 420C camera. To analyze photo-
receptor degeneration, we performed water immersion micros-
copy as previously described (27). Images were obtained using a
Leica DM5500 B microscope and an Andor LucaR camera.
Immunoprecipitation, Triton-X solubility and
immunoblotting analysis
Flies were transferred to 50-ml tubes, frozen in liquid nitrogen
and immediately decapitated by vigorous vortexing. Isolated
heads were collected to 1.5-ml tubes and maintained in dry
ice. Proteins were extracted in lysis buffer supplemented with
Complete Protease Inhibitor Cocktail tablets from Roche (Basel,
Switzerland). Total protein was quantiﬁed using the DC Protein
Assay, from Bio-Rad (CA, USA). In the immunoprecipitation ex-
periments, α-syn-EGFP was pulled down from 1 mg of total pro-
tein extract, using GFP-Trap_A beads or blocked agarose beads
(No Ab, no antibody negative control), following manufacturer’s
instructions (Chromotek, Munich, Germany). α-syn-EGFP pull-
down and Htt103Q-mCherry co-immunoprecipitation were
analyzed by immunoblotting using anti-GFP (3H9) and anti-RFP
(5F8) antibodies from Chromotek, both diluted 1:1000 in PBS.
Input lane corresponds to 30 µg of total protein extract and co-
IP lane corresponds to one-ﬁfth of the immunoprecipitated
material.
The Triton-X solubility experiment was performed as previ-
ously described (28). Brieﬂy, 200 µg of total protein extract was
incubated with 1% Triton X-100 on ice during 30 min. Triton sol-
uble and insoluble proteins fractions were separated by a 60-min
centrifugation step at 15 000g at 4°C. The supernatant, containing
the soluble proteins fraction (Triton-X soluble), was carefully
collected and the pellet, containing the insoluble proteins fraction
(Triton-X insoluble), was resuspended in 40 µl of 2% sodium
dodecyl sulfate Tris–HCl buffer pH 7.4 by pipetting and sonication
for 10 s. For the immunoblotting analysis, equal volumes of
each fraction were loaded and the presence of α-syn-EGFP and
Htt103Q-mCherry in the total, soluble and insoluble fractions
wasdetectedusing anti-GFP (3H9) andanti-RFP (5F8).Additionally,
anti-α-tubulin (AA4.3) from Developmental Studies Hybridoma
Bank (IA, USA), diluted 1:500 in PBS, was used as loading control.
Climbing assays and survival assays
Motor function was analyzed by startle-induced locomotion and
negative geotaxis response assays, commonly called climbing as-
says, as previously described (29). Brieﬂy, groups of 10 males of
the same age of each genotype of interest were placed into
18-cm-long vials, at room temperature for environmental accli-
matization, and 30 min later they were gently tapped to the bot-
tomof the vial (aminimumnumberof 30males per genotypewas
tested).We recorded the climbing timewhen ﬁveﬂies crossed the
15-cm ﬁnish line. For each genotypewe tested three independent
groups of males and performed ﬁve trials for each time point.
Results are the average climbing time ± SEM of these independ-
ent experiments.
For survival assays, ﬂies were maintained in a humid incuba-
tor at 25°C under a 12 h light/dark cycle. Thirty adult females of
the same agewere placed in three vials (10 ﬂies per vial) contain-
ing fresh food. Each 3 days the ﬂies were transferred into vials
with fresh food and the number of living ﬂies was registered.
Table 1. GAL4 lines used in this study and respective phenotypes
GAL4 line Tissue Phenotype (co-expression of α-syn and mutant Htt)
TH-GAL4 Dopaminergic neurons Co-localization, interaction and co-aggregation of α-syn and Htt
nSyb-GAL4 Nervous system Impairment of motor abilities and reduced life span
sGMR-GAL4 Eye Co-localization, co-aggregation and retinal degeneration
Rh1-GAL4 Photoreceptors R1-R6 Premature degeneration of the photoreceptors
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Statistical analysis
Statistical analyses were done using GraphPad Prism software
version 5 (San Diego, CA, USA). For BiFC we performed a one-
way ANOVA followed by a post-hoc Tukey test for average com-
parison. For climbing assays, we performed a two-way ANOVA
followed by a Bonferroni post-test. For the survival assays, we
performed a Log-rank (Mantel–Cox) test.
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INTRODUCTION
Protein–protein interactions are at the root of all biologic 
processes in both physiologic and pathologic conditions. 
Our ability to study such interactions relied for a long time 
on biochemical assays such as immunoprecipitation or 
immunocytochemistry, performed on cell or tissue lysates 
or fixed cells or tissue. While these assays are extremely 
informative, accurate and widely used, they do not enable 
the study of the dynamics of protein–protein interactions 
in living cells and organisms. Additionally, they are not 
well suited for high-throughput screens because they are 
usually rather laborious and time consuming. Advances in 
the last two decades have made it possible to characterize 
the full interactome of a single protein, visualize multiple 
protein–protein interactions in living organisms, or carry 
out high-throughput genetic and pharmacologic screens for 
the identification of modifiers of protein interactions [1–4]. 
Such technologies include fluorescence, bioluminescence 
and protein complementation assays, and hold the promise 
for a more complete understanding of normal and aberrant 
protein–protein interactions in health and disease.
In this chapter, we focus on the bimolecular fluorescence 
complementation assay and its application to the study 
of aberrant protein oligomerization in neurodegenerative 
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disorders such as Alzheimer’s disease, Parkinson’s disease 
and Huntington’s disease.
An online video is linked to this chapter (see Online 
video 1).
NEURODEGENERATIVE DISORDERS  
AND PROTEIN MISFOLDING
Neurodegenerative disorders are a family of age-related 
pathologies caused by a progressive loss of neurons in 
specific areas of the nervous system. Therefore, clinical 
symptoms are characteristic of each disorder (Table 12.1). 
However, they share several molecular, cellular and histo-
pathologic features such as inflammation, oxidative stress, 
mitochondrial dysfunction and the accumulation of β-sheet-
rich proteinaceous inclusions [5]. These events are closely 
interrelated, but the initial trigger of neurodegenerative dis-
orders remains unclear in most cases.
A great deal of evidence supports the idea that protein 
misfolding is the initial trigger of neurodegenerative disor-
ders [6–8]. Single-gene mutations have been identified as the 
primary cause of some neurodegenerative disorders, such 
as familial Parkinson’s disease (PD), familial Alzheimer’s 
disease (AD), familial amyotrophic lateral sclerosis (ALS) 
or Huntington’s disease (HD) [8–15]. These mutations 
lead invariably to protein misfolding, aggregation and neu-
rotoxicity in cell and animal models. Point mutations in 
α-synuclein, parkin, and LRRK2, among a few other genes, 
cause PD [8,10–12]. α-Synuclein is the main component of 
the Lewy bodies, proteinaceous inclusions characteristic of 
the disorder. Presenilin mutations cause the accumulation of 
β-amyloid peptide in AD [8]. Mutations in superoxide dis-
mutase, TDP-43 or FUS induce the aggregation and toxic-
ity of these proteins in familial ALS [13–15]. Elongation of 
the polyglutamine tract of the huntingtin protein beyond 35 
glutamines is the cause of HD, where huntingtin inclusions 
are also present [9,16]. Protein aggregation and toxicity is 
also dependent on protein concentration because duplica-
tions and triplications of the genes encoding α-synuclein or 
amyloid precursor protein (APP) cause PD and AD, respec-
tively [17–19].
PROTEIN OLIGOMERIZATION, 
AGGREGATION AND TOXICITY
The large proteinaceous deposits found in cells and tissues 
were originally thought to be the toxic forms. However, the 
formation of large amyloid structures has also been hypoth-
esized as a natural mechanism for storing peptidic hor-
mones and factors to be released to the medium [20] or for 
scavenging dysfunctional proteins before they are degraded 
by the ubiquitin–proteasome and lysosome–autophagy sys-
tems [21,22]. Current evidence strongly indicates that large 
amyloid deposits constitute an attempt by cells to neutralize 
the toxicity of smaller, more soluble aggregated species 
known as dimers and oligomers [16,23,24]. (For the sake 
of simplicity, we will refer to both species as oligomers or 
oligomeric species throughout the text.) While large aggre-
gates occupy specific cellular sites and do not move sub-
stantially, oligomeric species are able to move more freely 
within cells and across membranes. Their solubility and 
dynamic properties should, in theory, allow them to inter-
fere with biologic processes more effectively than larger, 
more static, protein inclusions. Soluble oligomeric species 
could even spread throughout tissues and act as seeds for 
the generation of protein aggregates and toxicity in different 
areas of the brain, as happens in prion disorders [25–27].
Large protein inclusions are easily observed by classic 
microscopy and protein labeling procedures. However, the 
dynamics and behavior of oligomeric species remain poorly 
understood due, at least in part, to the lack of suitable exper-
imental models for the study of oligomeric species in living 
cells. We and others have recently used protein complemen-
tation approaches for the visualization of oligomers in liv-
ing cells [27–32].
PROTEIN COMPLEMENTATION ASSAYS: 
HISTORY AND LATEST DEVELOPMENTS
Protein complementation was discovered by Frederic M 
Richards as early as 1958 [33]. He realized that a ribo-
nuclease digested with subtilisin produced two fragments 
without activity when they were isolated, but recov-
ered activity when they were mixed together. In the mid 
1960s, Agnes Ullmann and Nobel Prize winners François 
Jacob and Jacques Monod used this principle to produce 
β-galactosidase fragments which would complement in bac-
teria [34]. Many proteins have since been shown to display 
this property and have been used with different purposes 
(Table 12.2). Johnsson and Varshavsky pioneered the yeast 
two-hybrid system based on split-ubiquitin for the detec-
tion of protein–protein interactions between both soluble 
and membrane-bound proteins [35]. In 2000, Ghosh et al 
described for the first time a complementation assay with 
a fluorescent protein, the green fluorescent protein (GFP) 
(Fig. 12.1A), when they studied the interaction of artificial 
peptides in bacteria [36]. Nagai et al used the complementa-
tion properties of the green and yellow fluorescent proteins 
to develop genetically-encoded calcium sensors [37–39]. 
Kerppola and colleagues then used fluorescence comple-
mentation for the analysis of protein–protein interaction in 
mammalian cells and named the method bimolecular fluo-
rescence complementation (BiFC) assay (Fig. 12.1) [40].
In the following decade, BiFC systems evolved con-
siderably. There are currently BiFC systems with virtually 
every fluorescent protein in the spectrum (Table 12.2), and 
their advantages and disadvantages have been extensively 
analyzed. Probably the greatest advantage of BiFC assays 
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TABLE 12.1 Selected Protein Misfolding Disorders
Neurologic disorders
Disease Location Aggregate Types
Major protein  
components References
Parkinson’s disease Substantia nigra;
Cerebral cortex
Cytoplasmic
Lewy bodies
α-synuclein
Ubiquitin
LRRK2
6, 8, 11, 12, 56
Alzheimer’s disease Neocortex
Limbic region
Extracellular amyloid  
plaques and intracellular  
Tau tangles
β-amyloid
HSP90
tau protein
Ubiquitin
7, 8, 18, 57
Huntington’s disease Striatal and cortical  
areas
Nuclear and cytoplasmic  
aggregates
Huntingtin
Ubiquitin
7, 9, 16
Spinocerebellar  
ataxias
Cerebellum, spinal  
cord and brainstem
Cytoplasmic or  
intranuclear inclusions
Ataxins
CACNA1A
tau protein
TBP
ATN1
58–61
Friedreich ataxia Dentate nucleus,
dorsal root ganglia
Cytoplasmatic inclusions  
in neurons
Frataxin 62
ALS Motor neurons Cytoplasmatic aggregates  
in neurons and astrocytes
SOD I
TDP-43
FUS/TLS
Ubiquitin
13, 63, 64
Alexander’s disease Astrocytes Rosenthal fibers GFAP
CRYAB
HSP27
Plectin
65–67
Fragile X syndrome Neocortex
Hippocampus
Intranuclear inclusions FMRP
Ubiquitin
68
Transmissible  
spongiform  
encephalopathy  
(TSEs)
Cerebral cortex Fibrillar amyloid deposits Prion protein  
(PrP)
MAP2
Tau protein
22, 69
Familial amyloid  
polyneuropathy
Sensory and motor  
nerve fibers
Autonomic ganglions
Amyloid deposits Transthyretin 70
Prolactinomas Pituitary gland Amyloid deposits Prolactin 71
Non-neurologic disorders
Disease Location Aggregate types Composition References
Aortic medial amyloid Circulatory system Amyloid deposits Medin 72
Atherosclerosis Circulatory system Amyloid deposits Apolipoprotein AI 73
Cardiac arrhythmias,  
isolated atrial  
amyloidosis
Circulatory system Atrial amyloid deposits Atrial natriuretic  
factor
74
Cerebral amyloid  
angiopathy
Circulatory system Amyloid deposits Beta amyloid,  
Cystatin
75
Continued
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TABLE 12.1 Selected Protein Misfolding Disorders—cont’d
Non-neurologic disorders
Disease Location Aggregate types Composition References
Diabetes mellitus
type 2
Pancreas Amyloid deposits Amylin 76
Dialysis related  
amyloidosis
Systemic Amyloid deposits in  
osteoarticular structures
Beta 2  
microglobulin
77
Finnish amyloidosis Systemic Amyloid deposits Gelsolin 78
Hereditary non- 
neuropathic systemic  
amyloidosis
Systemic Amyloid deposits Lysozyme 79
Lattice corneal  
dystrophy
Eye Amyloid deposits Keratoepithelin 80
Medullary carcinoma  
of the thyroid
Thyroid gland Nuclear, cytoplasmic  
and extracellular amyloid  
deposits
Calcitonin 81
Rheumatoid arthritis Bones and joints B and T cell aggregates Serum amyloid A 82
Sporadic inclusion  
body myositis
Muscle Multiprotein aggregates:  
Aβ42, Tau, α-synuclein
S-IBM 83
Systemic AL  
amyloidosis
Systemic Amyloid deposits Immunoglobulin  
light chain AL
84
over other complementation assays is the fact that the signal 
is produced and visualized simply by the reconstitution of 
the fluorescent protein, without adding any substrate. First- 
and second-generation fluorescent proteins reconstitute the 
fluorophore much more efficiently at temperatures below 
30°C, and were therefore suitable for studies in plants, 
worms, Xenopus and in vitro assays with purified proteins 
[3,41,42]. However, mammalian cells do not respond well 
to temperatures below 37°C. This limitation was overcome 
by the development of third-generation fluorescent pro-
teins, such as Venus and Cerulean, which are brighter and 
able to efficiently reconstitute the fluorophore at 37°C (Fig. 
12.1B). On the other hand, third-generation fluorophores 
often show lower signal-to-noise ratios because they have 
higher levels of spontaneous binding of the split proteins, 
i.e. binding not mediated by the interaction of the proteins 
of interest [42–44]. Point mutations in these proteins, or 
different partitions of the fluorophore, are able to improve 
signal-to-noise ratios by decreasing spontaneous binding 
and background signal, but there is still room for further 
improvement [42,43,45,46]. Another major limitation of 
some BiFC systems is that they are fundamentally irre-
versible once the functional fluorophore is formed, unlike 
complementation systems based on luciferase, β-lactamase 
or DHFR [36]. This feature complicates the visualization of 
reversible interactions, but it can be useful for trapping and 
visualization of rare complexes, or to test the effect of the 
accumulation of oligomers in living cells and organisms. 
There is a delay between the actual interaction between the 
proteins of interest and the reconstitution of the fluorophore, 
probably in the range of minutes. This makes it difficult to 
monitor phenomena that occur in the range of miliseconds 
or seconds in real time. Finally, original BiFC systems were 
limited to the study of the interaction between two proteins 
simultaneously, but current multicolor BiFC systems allow 
the analysis of multiple alternative protein–protein interac-
tions simultaneously (Fig. 12.1C) [3,4]. Multicolor BiFC is 
based on the fact that different N-terminal fragments from 
different GFP-derived proteins have different excitation/
emission spectra when combined with the same C-terminal 
fragment (Fig. 12.1C). For instance, N-terminal fragments 
of mLumin, Cerulean, or Venus can be used to identify three 
protein–protein interactions simultaneously in the same 
cell, using them in combination with the C-terminal frag-
ment from ECFP. BiFC systems can be also combined with 
FRET/FLIM platforms to analyze the interaction between 
more than two proteins simultaneously [47].
ADVANTAGES OF BiFC SYSTEMS FOR 
STUDYING PROTEIN INTERACTIONS
BiFC systems have many advantages over other methods 
for the visualization of protein–protein interactions. First, 
they enable the visualization of actual protein–protein 
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TABLE 12.2 Proteins Used for Complementation Studies and Their Applications. We have Focused Mostly on Those 
Reports of Protein Complementation Systems Aimed at Studying Protein–Protein Interactions. For an Extensive 
Review of the Current Uses and Future Potential of Protein Complementation Assays, Please See Shekhawat and 
Ghosh (2011) [36]
Protein Partitions Aim Reference
Ribonuclease A 20/21 First description of protein  
complementation
33
Beta-galactosidase 147/148 Protein–protein interaction 34, 85
Ubiquitin 35/36 Protein–protein interaction 35
Dihydrofolate reductase  
(DHFR)
107/108 Protein–protein interaction 86
Tobacco etch virus  
(TEV)-protease
118/119 Protein–protein interaction 87
Beta-lactamase 196/197 Protein–protein interaction
DNA methylation
88, 89
Chorismate mutase 21/22 Protein–protein interaction 90
DnaE (intein) 123/124 Protein–protein interaction 91
Herpes Simplex Virus 1  
(HSV1)-Thymidine  
kinase
265/266 Protein–protein interaction  
in vivo (combined with PET)
92
Kills cells in the presence of  
ganciclovir
93
Luciferases Firefly 437/438 Protein–protein interaction 94
Gaussia 105/106 Protein–protein interaction 95
Renilla 229/230 Protein–protein interaction 96
Fluorescent proteins GFP 155/156
213/214
Protein–protein interaction 3, 51
EGFP 157/158 Protein–protein interaction 97
BFP 172/173 Protein–protein interaction 3
ECFP 154/155, 172/173 Protein–protein interaction
Production of genetically  
encoded calcium sensors
4, 38
Cerulean 154/155, 172/173 Protein–protein interaction 53
EYFP 154/155, 172/173 Protein–protein interaction 4
Venus 144/145, 154/155, 
158/159, 172/173,
210/211
Protein–protein interaction
Production of genetically  
encoded calcium sensors
37–39, 42, 43, 45, 
46, 53
mCitrine 154/155, 172/173 Protein–protein interaction 53
Kusabira  
Orange
– Protein–protein interaction Su et al 2006, oral 
communicationa
mRFP1 154/155, 168/169 Protein–protein interaction 3, 98
mCherry 159/160 Protein–protein interaction 99
mKate 151/152,
165/166
Protein–protein interaction 100
mLumin 151/152, 165/167 Protein–protein interaction 100
ahttp://www.dmphotonics.com/PW2011/PW2011BiFC.htm
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FIGURE 12.1 The principle of bimolecular fluorescence complementation 
(BiFC) assays. (A) Proteins from the family of the green fluorescent protein can 
be split in two non-fluorescent fragments. In the appropiate conditions, these 
fragments can physically interact and reconstitute the functional fluorophore. 
The fragments are not necessarily sequential. For example, the N-terminal 
fragment comprising amino acids 1–172 can be combined successfully with 
a C-terminal fragment comprising amino acids 155–238. (B) In single-
color BiFC assays, the non-fluorescent fragments are fused to two proteins 
of interest. If the proteins dimerize, the non-fluorescent fragments are close 
enough to each other to reconstitute the fluorophore and emit fluorescence. 
(C) Interactions between more than two proteins can be studied by multicolor 
BiFC. In multicolor BiFC, the proteins of interest are fused to the N-terminal 
fragments of fluorophores with compatible excitation/emission spectra or to 
the C-terminal fragment of one of the fluorophores. Because the excitation/
emission spectrum is determined by the largest fragment (N-terminal), each 
protein interaction will produce a different type of fluorescence.
interactions in the cell. This is an advantage over micros-
copy techniques that use co-localization of signals as an 
indication of protein–protein interaction. Microscopic 
co-localization does not necessarily mean that there is an 
interaction between the proteins of interest, as most light 
microscopy techniques do not afford enough resolution. 
Co-localization has a spatial resolution above 250 nm, and 
therefore proteins can co-localize and actually be very far 
from each other or in different planes. FRET-FLIM tech-
niques enable the determination of whether two proteins 
actually interact, because the transfer of energy can occur 
only if the distance between the proteins is less than 10 
nm. However, the distance between the two interactors is 
calculated based on the difference between the life-time 
of the two fluorophores and, therefore, the identification 
of the interaction between the proteins of interest is not 
as direct as in BiFC assays. Second, BiFC systems allow 
studies in living cells. Immunoprecipitation and immu-
noblotting techniques are excellent as biochemical proofs 
of interaction and/or oligomerization, but they cannot 
be used on living cells. The same happens with immu-
nocytochemistry when samples are fixed and exposed to 
antibodies, procedures that introduce several additional 
artifacts and sources of bias in the experimental design. 
FRET-FLIM is also possible for studies in living cells. 
Finally, BiFC systems are much more suitable for high-
throughput analyses than are immunoprecipitation, immu-
nocytochemistry or FRET-FLIM methods. There are a 
few examples of FRET-based high-throughput screening 
of compounds that modify the interaction between two 
proteins, but their setup is far more complex, expensive 
and time-consuming than BiFC models [48,49]. Although 
the design and development of BiFC systems may be 
time-consuming, once it is established it can greatly save 
time and resources in large-scale analyses. Most of the time 
required would correspond to the cloning for the generation 
of the system (1–3 months), although there are now new 
tools available that could make this task easier, such as the 
Gateway BiFC vectors [50]. Preparation of samples for flow 
cytometry and their analysis can take as little as 2 hours 
(30–50 samples at a good cell concentration), and are also 
amenable to automation. If the analyzer is a fluorescence 
microscope, samples may not need any further handling 
(living cells) or just fixation (dead cells), but data acquisi-
tion, analysis and interpretation is not as straightforward as 
it is in flow cytometry analyses. This is also the main advan-
tage of BiFC over FRET/FLIM assays. The same screening 
by immunoprecipitation or immunocytochemistry would 
greatly increase the costs due to the requirement of antibod-
ies, and would require much more time for the processing of 
samples. Thus, the larger the study, the more cost-effective 
becomes a BiFC system.
Further toxicity and biochemical assays should comple-
ment results of the initial BiFC screening in order to char-
acterize both the nature and toxicity of oligomeric species 
and the levels of expression of the constructs. If insoluble 
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aggregates are formed, Triton-X-soluble and -insoluble 
fractions, sucrose gradients or filter trap assays can be used 
to more accurately characterize larger inclusions [27,28].
PROTEIN COMPLEMENTATION ASSAYS FOR 
THE STUDY OF NEURODEGENERATIVE 
DISORDERS
We have recently developed BiFC models for the visualiza-
tion of α-synuclein and huntingtin oligomerization in liv-
ing cells [27–29]. Other groups developed similar models 
for the study of the oligomerization of APP, tau protein and 
huntingtin [30–32]. The principle of the success of these 
systems is the simplicity of the technique and the fact that 
we know a priori that the proteins of interest oligomerize 
and, therefore, finding the optimal combination of BiFC 
constructs is just a matter of time.
In BiFC models, monomers are not fluorescent, and 
only dimers, oligomers and larger inclusions – if they 
are formed – produce fluorescence (Fig. 12.2). This 
‘all or nothing’ difference makes it possible to monitor 
closely the first steps of aggregation, i.e. oligomerization, 
because cells pass from a non-fluorescent to a fluorescent 
state progressively over time. Additionally, oligomers 
and large inclusions can be observed on a microscope 
as relatively different entities. Fluorescence from oligo-
mers is homogeneously distributed, while large inclu-
sions are foci of concentrated, intense fluorescence (Fig. 
12.2). This allows the determination of the number, size 
and subcellular location of large inclusions [28] and the 
assessment of the dynamics of oligomeric species and 
inclusions of different sizes over time, for example. We 
have also used successfully our huntingtin BiFC system 
to show cell-to-cell transmission of huntingtin in living 
cells by flow cytometry [27]. In that study, two indepen-
dent populations of cells were transfected with each of 
the BiFC constructs. When these cell populations were 
isolated, they did not display fluorescence, as determined 
by flow cytometry. However, when cell populations were 
mixed, some fluorescent cells appeared, demonstrating 
the traffic of mutant huntingtin between cells. Another 
possible, but yet unexplored use for these systems would 
be to include a localization signal in one of the BiFC con-
structs, such as a nuclear import signal or a mitochondrial 
localization signal, and study the dynamics of proteins 
between organelles and cytoplasm.
FIGURE 12.2 BiFC models of neurodegenerative disorders. (A) In these models, monomers do not show fluorescence. Dimers and oligomers show a 
homogeneously distributed fluorescence in the subcellular compartment where they are formed; larger inclusions are observed as brighter regions with 
different morphologies that ‘scavenge’ fluorescence from the rest of the cell. The localization of the oligomers and aggregates depends on the protein of 
interest and the particular experimental conditions. (B) In the huntingtin BiFC model, fluorescence is mostly restricted to the cytoplasm and aggregates 
are very frequent. Scale bar: 20 µm.
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METHODS
Design
The first step for the design of a BiFC system is to choose 
the reporter protein. As mentioned before, basically 
every fluorescent protein can be split and used for BiFC 
(Table 12.2). However, they behave differently in many 
aspects that could be relevant to each particular experimen-
tal paradigm. First- and second-generation fluorophores, 
such as GFP, YFP, EGFP and EYFP, are less bright and 
fold with decreased efficiency at temperatures over 30°C. 
Although there is a BiFC system with a superfolder ver-
sion of GFP, it is not clear whether this version is able to 
reconstitute the fluorophore at 30°C [51]. Third-generation 
fluorophores overcome the temperature issue but they pro-
duce more nonspecific background. Some point mutations 
in Venus, such as V150A or I152L, can improve signal-
to-noise ratios of third-generation fluorophores in differ-
ent experimental paradigms [42,46](Table 12,2). A recent 
report described a new partition of Venus (Aa 1–210 and 
Aa 210–238) that shows lower levels of spontaneous bind-
ing and higher signal-to-noise ratios [43]. Interestingly, the 
superfolder GFP BiFC also uses a partition in this interval 
(Aa 1–213 and Aa 214–238) [51].
While the lower brightness of first- and second-generation 
fluorophores is a disadvantage if the interaction is very 
weak, the higher brightness of third-generation fluoro-
phores can also be a problem if interactions are strong. The 
former may produce a signal which is too low, masking 
the effect of conditions that inhibit oligomerization; the 
latter may produce saturating signals close to the upper 
limit of detection of the analyzers, thus masking conditions 
that enhance oligomerization. In theory, this could be com-
pensated for by the use of stronger or weaker promoters 
or by transfecting cells with higher or lower numbers of 
plasmids.
There are additional particular properties specific for each 
fluorophore that could be of interest – or a disadvantage –  
for our BiFC system. For example, mCherry is more resis-
tant to low pH than are the green proteins, a property that 
has been used to develop reporter systems in lysosomal 
and autophagy-related proteins [52]. On the other hand, 
mCherry and other fluorescent proteins have a strong 
tendency to aggregate themselves into tetramers, which is 
not desirable when analyzing protein–protein interactions.
The excitation and emission wavelengths of the fluores-
cent proteins can also pose limitations, especially when the 
BiFC system is to be used in combination with other fluo-
rochromes or in multicolor BiFC. The C-terminal fragment 
is shorter and extremely similar among the different fluo-
rescent proteins, while the N-terminal region is responsible 
for the excitation and emission properties of the final fluo-
rophore. Multicolor BiFC takes advantage of this feature. 
In multicolor BiFC, one protein of interest is fused to a 
C-terminal fragment, and the other two (or more, in theory) 
are fused to two N-terminal fragments from different fluo-
rescent proteins (Fig. 12.2B). The most popular combina-
tion for multicolor BiFC is Cerulean and Venus (amino acids 
1–172, N-terminal) with the C-terminal region of ECFP 
(amino acids 155–238). While the combination of Cerulean 
with ECFP emits in the blue spectrum (max. ex. 439 nm; max. 
em. 479 nm), Venus with ECFP displays yellow/green fluo-
rescence (max.ex. 504 nm; max. em. 513 nm) [4,53].
The optimal relative orientation of the protein of interest 
and the reporter protein cannot be currently predicted from 
their amino acid sequence or tertiary structure. Therefore, 
it has to be determined empirically by testing all possible 
combinations (Fig. 12.3). Producing and testing the different 
combinations of constructs is time-consuming and adds to the 
costs involved. However, testing can be very often restricted 
to two or three combinations on the basis of the properties of 
the protein of interest. This is illustrated by the following two 
examples. Proteins such as caspases, or the amyloid precur-
sor protein, suffer post-translational cleavage. If the goal is to 
study the interaction of one of the cleavage fragments, then 
it is important to make sure that the reporter protein remains 
fused to the fragment of interest after cleavage. Other pro-
teins are not functional when tags are located in their terminal 
regions. For example, some intermediate filaments, such as 
desmin or GFAP, may form aberrant aggregates or lose their 
ability to generate functional oligomers when tags are fused 
to their C-terminal side [54,55]. If the objective is to produce 
a BiFC system with intermediate filaments, the combinations 
should be therefore restricted to N-terminal fusions.
A series of controls should be included in the cloning 
plan and experimental design, especially to have an esti-
mate of binding specificity and background (noise) signal 
caused by spontaneous binding of the halves of the reporter 
protein. Ideal controls would be fusion proteins that are 
unable to interact, such as versions of the proteins of interest 
which lack the interacting region or have a substitution in it. 
According to the original developers of BiFC and to our own 
experience, the non-fluorescent fragments of any fluorescent 
protein cannot be used as negative controls without being 
fused to a protein as they might produce higher background 
due to non-specific assembly (http://people.pharmacy.pur-
due.edu/∼hu1/). In spite of these measures,  researchers 
should expect some degree of noise, even with the least 
bright fluorescent proteins. This is especially enhanced when 
fusion proteins are overexpressed, because their higher intra-
cellular concentration will increase the chance that the two 
non-fluorescent halves will meet and bind spontaneously. 
It is expected that physiologic promoters or less potent pro-
moters would give lower background signals. Nevertheless, 
the very potent cytomegalovirus (CMV) promoter is still the 
most common promoter used in mammalian BiFC systems.
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In the case of BiFC models of neurodegenerative disor-
ders, it can be relevant to compare wild type versus mutant, 
disease-related proteins. For example, in the case of our 
huntingtin BiFC model, we and others compare the oligo-
merization of HD-related mutant huntingtin (with a 103Q 
glutamine tract) versus the oligomerization of a wild type 
form of the protein (with a 25Q glutamine tract) [27,30].
In summary, the design of a BiFC system is not trivial 
and should be considered thoroughly before starting the 
production of constructs. Spending some time elaborating 
the best strategy for our experimental paradigm can prove 
advantageous in the development of the BiFC system.
Development
One of the most appealing features of BiFC systems is that they 
can be developed and optimized with reagents and equipment 
found in virtually every laboratory suited to cell and molecu-
lar biology, or in the core facilities of most institutions. This 
is further facilitated by the fact that research laboratories and 
some plasmid repositories have made available to the scientific 
community a few BiFC constructs where any protein of inter-
est can be cloned (http://people.pharmacy.purdue.edu/∼hu1/; 
http://www.addgene.org). Additionally, there are Gateway 
BiFC vectors available that can accelerate the cloning [50].
If the available constructs are not suitable for the par-
ticular experimental conditions, it is relatively easy to 
make home-made BiFC systems. The sequences of the 
protein of interest and the reporter protein, a vector, and 
cloning reagents and equipment are enough to produce the 
constructs. In order to test and optimize the BiFC system, 
needs are reduced to common cell culture materials and 
equipment such as simple flow cytometry analyzers and/or 
a wide-field/confocal fluorescence microscope that can be 
currently found in most laboratories. Detailed protocols of 
these sets of techniques are common knowledge and their 
explanation is beyond the scope of this chapter.
Troubleshooting
No Signal
A biologic cause for this is highly unlikely because (a) the pro-
tein of interest is known to interact with itself to form oligomers 
(in the case of protein misfolding disorders), and (b) there is 
always some background derived from the spontaneous bind-
ing of the halves of the reporter protein. Therefore, the cause of 
this problem should be of a technical nature. One could:
 1.  Check the DNA sequence of your constructs for pos-
sible frameshift mutations. Frameshift mutations, due to 
errors during cloning, will convert part of the reporter 
protein into a totally different protein unable to reconsti-
tute a functional fluorophore.
 2.  Confirm that both BiFC constructs are efficiently trans-
fected. Some cells are reluctant to be efficiently trans-
fected with more than one plasmid, e.g. primary neurons 
or astrocytes. Cells transfected with only one BiFC con-
struct will not give any signal.
 3.  Test other possible combinations of constructs, includ-
ing molecular linkers of different size between the pro-
tein of interest and the reporter protein. The molecular 
linkers will increase the flexibility of the protein and 
improve the chances that the non-fluorescent halves will 
reconstitute the fluorophore.
FIGURE 12.3 Basic constructs for the development of a BiFC system. They are represented from the N-terminal end (top) to the C-terminal end (bot-
tom). The protein of interest is represented by the green rectangles, and the fluorophore fragments are represented by three-dimensional protein structures 
(blue, C-terminal fragment; yellow, N-terminal fragment). (A) Both fluorophore fragments fused to the C-terminal region of the proteins of interest. 
(B) Both fluorophore fragments fused to the N-terminal region of the proteins of interest. (C) The N-terminal fragment of the fluorophore fused to the 
C-terminal end of the proteins of interest, and the C-terminal fragment fused to the N-terminal end of the proteins of interest. (D) The reverse of option C.
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Low Signal
The fluorescence of the BiFC system is, in theory, propor-
tional to the oligomerization of the protein. However, there 
are many factors that could affect the amount of signal. In 
this case, one should:
 1.  Check transfection efficiency.
 2.  Verify the effect of temperature. Although it is not the 
optimal temperature for mammalian cells, reconstitution 
of the fluorophore is more efficient at lower temperatures.
 3.  Confirm that cultures are reasonably viable. If the pro-
tein of interest is very toxic it can kill those cells that 
express it and therefore give a lower signal. The situa-
tion could be improved by transfecting lower amounts 
of BiFC constructs or putting the fusion proteins under 
a less potent promoter. It could also be avoided by using 
cells more resistant to the toxicity of the protein.
 4.  Verify the time-frame for flurophore maturation. We 
detect fluorescent cells as soon as 4–6 hours after trans-
fection by flow cytometry, but we need at least 8 hours 
to see a few fluorescent cells by microscopy.
 5.  Test combinations of constructs, including molecular 
linkers, in order to improve the chances that the fluoro-
phore will be reconstituted.
If none of these measures improve the signal, the protein 
of interest may be interfering with the reconstitution of the 
fluorophore. This must be determined empirically, and may 
have no easy solution.
Low Signal-to-Noise Ratio (High Background)
In order to have an estimate of the spontaneous reconstitu-
tion of the BiFC fragments, a series of controls should be 
included in the experimental design.
 1.  Ideally, constructs containing a mutant protein of inter-
est that is deficient for interaction should be used to 
establish the background line.
 2.  If available, inhibitors or activators of the interaction 
could be helpful to establish the specificity of the inter-
action as well as the upper and lower limits of signal.
 3.  If the background is still very high, one may need to 
change the fluorophore, modify the partition of the 
fluorophore, or look for point mutants that reduce its 
spontaneous reconstitution and thus improve the signal-
to-noise ratio. Such partitions and mutations have been 
described for several fluorophores, Venus being prob-
ably the most studied in this sense.
NOTE: BiFC halves of the fluorophore should not be 
used without being fused to a protein of interest as back-
ground controls. They frequently show higher levels of fluo-
rescence than when they are fused to proteins. The use of 
constructs containing third proteins, known to interact or not 
interact with the proteins of interest as a reference or basal 
line, is possible but not recommended. Each protein–protein 
interaction has a particular fluorescence pattern that can be 
altered by many factors, such as intracellular localization.
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